<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>739</serviceExecutionTime><Drug id="10045"><DrugName>metalloprotease inhibitor, Glycomed</DrugName><DrugSynonyms><Name><Value>ECE inhibitor, Glycomed</Value></Name><Name><Value>metalloprotease inhibitor, Glycomed</Value></Name><Name><Value>endothelin converting enzyme inhibitor, Glycomed</Value></Name><Name><Value>162550-05-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17809">Glycomed Inc</CompanyOriginator><CompaniesSecondary><Company id="17809">Glycomed Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17809" type="Company"><TargetEntity id="4296020874" type="organizationId">Glycomed Inc</TargetEntity></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"/><TargetEntity id="10028245" type="MEDDRA"/><TargetEntity id="D009103" type="MeSH"/><TargetEntity id="-1241225595" type="omicsDisease"/><TargetEntity id="112" type="siCondition"/></SourceEntity><SourceEntity id="230" type="ciIndication"><TargetEntity id="10028980" type="MEDDRA"/><TargetEntity id="D009369" type="MeSH"/><TargetEntity id="1855" type="siCondition"/></SourceEntity><SourceEntity id="246" type="ciIndication"><TargetEntity id="10031282" type="MEDDRA"/><TargetEntity id="D010024" type="MeSH"/><TargetEntity id="-1487907849" type="omicsDisease"/><TargetEntity id="965" type="siCondition"/></SourceEntity><SourceEntity id="28" type="ciIndication"><TargetEntity id="10003246" type="MEDDRA"/><TargetEntity id="D001168" type="MeSH"/><TargetEntity id="-1504014133" type="omicsDisease"/><TargetEntity id="720" type="siCondition"/></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"/><TargetEntity id="10037153" type="MEDDRA"/><TargetEntity id="D011565" type="MeSH"/><TargetEntity id="-1735788310" type="omicsDisease"/><TargetEntity id="490" type="siCondition"/></SourceEntity><SourceEntity id="372" type="ciIndication"><TargetEntity id="10045285" type="MEDDRA"/><TargetEntity id="D014456" type="MeSH"/><TargetEntity id="413" type="siCondition"/></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"/><TargetEntity id="D002318" type="MeSH"/><TargetEntity id="-1500764314" type="omicsDisease"/><TargetEntity id="182" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="780" type="Action"><TargetEntity id="423" type="Mechanism">Endothelin-Converting Enzyme (ECE) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="253" type="Action"><TargetEntity id="451" type="Mechanism">Matrix Metalloproteinase Inhibitors</TargetEntity><TargetEntity id="1087" type="Mechanism">Metalloprotease Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="213">Multiple sclerosis</Indication><Indication id="230">Neoplasm</Indication><Indication id="246">Osteoporosis</Indication><Indication id="28">Arthritis</Indication><Indication id="281">Psoriasis</Indication><Indication id="372">Ulcer</Indication><Indication id="57">Cardiovascular disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="780">Endothelin converting enzyme inhibitor</Action><Action id="253">Matrix metalloprotease inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="15184">Systemic antipsoriatic product</Action><Action id="1545">Anticancer</Action><Action id="2657">Antihypertensive</Action></ActionsSecondary><Technologies><Technology id="667">Peptidomimetic</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C2</Code><Name>ANTIHYPERTENSIVES</Name></Ephmra><Ephmra><Code>C</Code><Name>CARDIOVASCULAR SYSTEM</Name></Ephmra><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra></EphmraCodes><LastModificationDate>2004-03-24T23:48:00.000Z</LastModificationDate><ChangeDateLast>2004-03-24T23:48:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Glycomed was investigating an endothelin peptide analog which is a hydroxamic acid matrix metalloproteinase inhibitor for the potential treatment of cardiovascular disorders and other indications [&lt;ulink linkType="reference" linkID="176095"&gt;176095&lt;/ulink&gt;]. No development has been reported by the company since 1997 [&lt;ulink linkType="reference" linkID="438902"&gt;438902&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Laboratory tests showed that the lead compound acted as an endothelin receptor antagonist. It blocked the pressor response to Big-ET in anesthetized rats [&lt;ulink linkType="reference" linkID="176095"&gt;176095&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Researchers at Glycomed performed structure-activity relationship studies to determine the structural requirements for inhibitors of MMPs. They discovered three key constituents for optimal activity. Work was undertaken on broad-spectrum MMPIs to produce more potent and more selective compounds [&lt;ulink linkType="reference" linkID="275910"&gt;275910&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="230">Neoplasm</Indication><StatusDate>2002-02-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>2002-02-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="246">Osteoporosis</Indication><StatusDate>2002-02-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="372">Ulcer</Indication><StatusDate>2002-02-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="28">Arthritis</Indication><StatusDate>2002-02-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><StatusDate>2002-02-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>2002-02-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="230">Neoplasm</Indication><StatusDate>1998-02-02T00:00:00.000Z</StatusDate><Source id="275910" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="246">Osteoporosis</Indication><StatusDate>1998-02-02T00:00:00.000Z</StatusDate><Source id="275910" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="28">Arthritis</Indication><StatusDate>1998-02-02T00:00:00.000Z</StatusDate><Source id="275910" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="213">Multiple sclerosis</Indication><StatusDate>1998-02-02T00:00:00.000Z</StatusDate><Source id="275910" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate>1998-02-02T00:00:00.000Z</StatusDate><Source id="275910" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="372">Ulcer</Indication><StatusDate>1998-02-02T00:00:00.000Z</StatusDate><Source id="275910" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17809">Glycomed Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="57">Cardiovascular disease</Indication><Source id="176095" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00658"><Name>Endothelin converting enzyme</Name><SwissprotNumbers/></Target><Target id="PTGT-01318"><Name>Matrix metalloprotease</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=190931" linkType="reference" linkID="190931"&gt;190931&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="101186"><DrugName>melatonin (perinatal asphyxia), Chiesi Farmaceutici</DrugName><DrugSynonyms><Name><Value>melatonin (perinatal asphyxia), Chiesi Farmaceutici</Value></Name><Name><Value>melatonin (perinatal asphyxia), University College London</Value></Name></DrugSynonyms><CompanyOriginator id="23505">University College London</CompanyOriginator><CompaniesPrimary><Company id="15381">Chiesi Farmaceutici SpA</Company></CompaniesPrimary><CompaniesSecondary><Company id="23505">University College London</Company></CompaniesSecondary><CrossReferences><SourceEntity id="15381" type="Company"><TargetEntity id="4296558863" type="organizationId">Chiesi Farmaceutici SpA</TargetEntity></SourceEntity><SourceEntity id="23505" type="Company"><TargetEntity id="4296335971" type="organizationId">University College London</TargetEntity></SourceEntity><SourceEntity id="2524" type="ciIndication"><TargetEntity id="R09.01" type="ICD10"/><TargetEntity id="799.01" type="ICD9"/><TargetEntity id="10003497" type="MEDDRA"/><TargetEntity id="D001237" type="MeSH"/><TargetEntity id="-353078630" type="omicsDisease"/><TargetEntity id="3123" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><IndicationsPrimary><Indication id="2524">Asphyxia</Indication></IndicationsPrimary><ActionsSecondary><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2016-11-25T11:04:30.000Z</LastModificationDate><ChangeDateLast>2016-08-31T00:00:00.000Z</ChangeDateLast><AddedDate>2016-03-08T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15381" linkType="Company"&gt;Chiesi Farmaceutici&lt;/ulink&gt; under license from &lt;ulink linkID="23505" linkType="Company"&gt;University College London&lt;/ulink&gt;, is investigating melatonin, for the potential treatment of perinatal asphyxia. In June 2014, development was ongoing [&lt;ulink linkID="1741233" linkType="Reference"&gt;1741233&lt;/ulink&gt;], [&lt;ulink linkID="1741234" linkType="Reference"&gt;1741234&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In April 2012, the EMA granted Orphan Drug status to the drug for the treatment of perinatal asphyxia [&lt;ulink linkID="1741233" linkType="Reference"&gt;1741233&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15381">Chiesi Farmaceutici SpA</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2524">Asphyxia</Indication><StatusDate>2014-06-10T00:00:00.000Z</StatusDate><Source id="1741234" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23505">University College London</Company><Country id="GB">UK</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2524">Asphyxia</Indication><StatusDate>2014-06-10T00:00:00.000Z</StatusDate><Source id="1741234" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23505">University College London</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2524">Asphyxia</Indication><StatusDate>2012-04-02T00:00:00.000Z</StatusDate><Source id="1741233" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="15381">Chiesi Farmaceutici SpA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20607">University of London</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="1">Drug - Discovery/Design</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="159106" title="Chiesi and UCL to develop and test a novel melatonin formulation as a brain protective medicine for babies with birth asphyxia "/></Deals><PatentFamilies><PatentFamily id="4200172" number="WO-2018167162" title="Therapeutic dosage and regimen for melatonin"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chiesi Farmaceutici SpA" id="15381"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="101431"><DrugName>HIF-2a inhibitors (cancer), IntelliSyn Pharma</DrugName><DrugSynonyms><Name><Value>HIF-2a inhibitors (cancer), IntelliSyn Pharma</Value></Name></DrugSynonyms><CompanyOriginator id="1113048">IntelliSyn Pharma</CompanyOriginator><CompaniesPrimary><Company id="1113048">IntelliSyn Pharma</Company></CompaniesPrimary><CrossReferences><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><IndicationsPrimary><Indication id="651">Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action id="9686">Hypoxia inducible factor-2 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-19T11:36:54.000Z</LastModificationDate><ChangeDateLast>2019-06-20T00:00:00.000Z</ChangeDateLast><AddedDate>2016-03-30T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1113048" linkType="Company"&gt;IntelliSyn Pharma&lt;/ulink&gt; is investigating hypoxia inducible factor-2 alpha inhibitors (HIF-2a) for the potential treatment of cancer. In March 2016, preclinical data were presented [&lt;ulink linkID="1741264" linkType="Reference"&gt;1741264&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2016, preclinical data were presented at the 251st ACS meeting in San Diego, CA. Inhibition of HIF-2a-induced release was reported with the test compound at 100 microM after incubation. Excellent physical properties and drug like characteristics were observed with each of the designed scaffolds [&lt;ulink linkID="1741264" linkType="Reference"&gt;1741264&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1113048">IntelliSyn Pharma</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2016-03-16T00:00:00.000Z</StatusDate><Source id="1741264" type="OTHER"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-02235"><Name>Hypoxia inducible factor-2</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="102542"><DrugName>CSD-125</DrugName><DrugSynonyms><Name><Value>CSD-125</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1004360">Sun Yat-Sen University</CompanyOriginator><CompaniesPrimary><Company id="1004360">Sun Yat-Sen University</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1004360" type="Company"><TargetEntity id="4297781695" type="organizationId">Sun Yat-sen University</TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity><SourceEntity id="1901" type="Action"><TargetEntity id="917" type="Mechanism">Cathepsin K Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2462" type="Action"><TargetEntity id="453" type="Mechanism">MMP-9 (Gelatinase B) Inhibitors</TargetEntity><TargetEntity id="4054" type="Mechanism">Anti-MMP-9</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="2461" type="Action"><TargetEntity id="4055" type="Mechanism">Anti-MMP-2</TargetEntity><TargetEntity id="452" type="Mechanism">MMP-2 (Gelatinase A) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00373" type="ciTarget"><TargetEntity id="174797251836843" type="siTarget">Integrin alpha-M</TargetEntity><TargetEntity id="4513" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01320" type="ciTarget"><TargetEntity id="14426426643133" type="siTarget">72 kDa type IV collagenase</TargetEntity><TargetEntity id="499" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01323" type="ciTarget"><TargetEntity id="67502082943183" type="siTarget">Matrix metalloproteinase-9</TargetEntity><TargetEntity id="4125" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><IndicationsPrimary><Indication id="291">Rheumatoid arthritis</Indication></IndicationsPrimary><ActionsPrimary><Action id="2461">Metalloprotease-2 inhibitor</Action><Action id="2462">Metalloprotease-9 inhibitor</Action><Action id="1901">Cathepsin K inhibitor</Action><Action id="5054">CD11b antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="12596">Osteoclast inhibitor</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-18T11:59:35.000Z</LastModificationDate><ChangeDateLast>2019-06-19T00:00:00.000Z</ChangeDateLast><AddedDate>2016-06-22T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1004360" linkType="Company"&gt;National Sun Yat-Sen University&lt;/ulink&gt; is investigating CSD-125, a soft coral-derived anti-inflammatory compound, for the potential treatment of rheumatoid arthritis (RA). In June 2016, preclinical data were presented [&lt;ulink linkID="1767999" linkType="Reference"&gt;1767999&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2016, preclinical data were presented at the 17th EULAR Annual European Congress of Rheumatology in London, UK. In type II collagen-induced arthritis rat models, CSD-125 significantly attenuated RA progression and decreased the expression of osteoclast-related proteins and also triggered receptor on myeloid cells 2 in multinucleated cells. In addition, CSD-125 reduced the number of cells with positive expression of IL-17 alpha, IL-1 beta and TNF-alpha, phospho-ERK, phospho-JNK and phospho-p38 in the synovial tissue and the levels of M-CSF and IL-17 alpha were also decreased. Overall, CSD-125 attenuated joint destruction through inhibition of osteoclast activation in a type II collagen-induced arthritis rat model [&lt;ulink linkID="1767999" linkType="Reference"&gt;1767999&lt;/ulink&gt;]. &lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1004360">Sun Yat-Sen University</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-06-09T00:00:00.000Z</StatusDate><Source id="1767999" type="OTHER"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-00373"><Name>CD11b</Name><SwissprotNumbers><Swissprot>P05555</Swissprot><Swissprot>P11215</Swissprot><Swissprot>P11578</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01320"><Name>Metalloprotease-2</Name><SwissprotNumbers><Swissprot>P08253</Swissprot><Swissprot>P33434</Swissprot><Swissprot>P33436</Swissprot><Swissprot>P50757</Swissprot><Swissprot>Q90611</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01323"><Name>Metalloprotease-9</Name><SwissprotNumbers><Swissprot>O18733</Swissprot><Swissprot>P14780</Swissprot><Swissprot>P41245</Swissprot><Swissprot>P41246</Swissprot><Swissprot>P50282</Swissprot><Swissprot>P52176</Swissprot></SwissprotNumbers></Target><Target id="PTGT-05560"><Name>Cathepsin K</Name><SwissprotNumbers><Swissprot>O35186</Swissprot><Swissprot>P43235</Swissprot><Swissprot>P43236</Swissprot><Swissprot>P55097</Swissprot><Swissprot>P61276</Swissprot><Swissprot>P61277</Swissprot><Swissprot>Q3ZKN1</Swissprot><Swissprot>Q5E968</Swissprot><Swissprot>Q90686</Swissprot><Swissprot>Q9GLE3</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1767999" linkType="reference" linkID="1767999"&gt;1767999&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="10398"><DrugName>CGS-30440</DrugName><DrugSynonyms><Name><Value>CGS-30440</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>169319-62-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="24452">Ciba-Geigy Corp</CompanyOriginator><CompaniesSecondary><Company id="24452">Ciba-Geigy Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="10398" type="Drug"><TargetEntity id="226041" type="siDrug">CGS-30440</TargetEntity></SourceEntity><SourceEntity id="24452" type="Company"><TargetEntity id="5000062743" type="organizationId">Ciba Geigy Corp</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"/><TargetEntity id="D006973" type="MeSH"/><TargetEntity id="-369992864" type="omicsDisease"/><TargetEntity id="240" type="siCondition"/></SourceEntity><SourceEntity id="18" type="Action"><TargetEntity id="381" type="Mechanism">Angiotensin-I Converting Enzyme (ACE) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00039" type="ciTarget"><TargetEntity id="55189613116363" type="siTarget">Angiotensin-converting enzyme</TargetEntity><TargetEntity id="2465" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="178">Hypertension</Indication></IndicationsSecondary><ActionsPrimary><Action id="18">ACE inhibitor</Action><Action id="80">Endopeptidase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2657">Antihypertensive</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C9A</Code><Name>ACE INHIBITORS, PLAIN</Name></Ephmra><Ephmra><Code>C2</Code><Name>ANTIHYPERTENSIVES</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-17T10:07:05.000Z</LastModificationDate><ChangeDateLast>2002-03-21T17:19:08.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt; (formerly Ciba-Geigy) has discontinued its evaluation of &lt;ulink linkID="10398" linkType="Drug"&gt;CGS-30440&lt;/ulink&gt; [&lt;ulink linkID="347827" linkType="reference"&gt;347827&lt;/ulink&gt;], a dual inhibitor of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) that was under investigation for the potential treatment of hypertension [&lt;ulink linkID="179237" linkType="reference"&gt;179237&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Oral administration of &lt;ulink linkID="10398" linkType="Drug"&gt;CGS-30440&lt;/ulink&gt; to normotensive rats inhibited the pressor response to angiotensin I and potentiated the diuretic and natriuretic effects of exogenous atrial natriuretic peptide (ANP). In a rat renovascular model of hypertension, &lt;ulink linkID="10398" linkType="Drug"&gt;CGS-30440&lt;/ulink&gt; decreased blood pressure and cardiac and aortic hypertrophy [&lt;ulink linkID="225832" linkType="reference"&gt;225832&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Results of a preclinical study of &lt;ulink linkID="10398" linkType="Drug"&gt;CGS-30440&lt;/ulink&gt; in rats were presented at Protease Inhibitors symposium, in Baltimore, Maryland in November 1996 [&lt;ulink linkID="225995" linkType="reference"&gt;225995&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24452">Ciba-Geigy Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="178">Hypertension</Indication><StatusDate>1999-11-18T00:00:00.000Z</StatusDate><Source id="347827" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24452">Ciba-Geigy Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="178">Hypertension</Indication><StatusDate>1995-06-22T00:00:00.000Z</StatusDate><Source id="179237" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00039"><Name>ACE</Name><SwissprotNumbers><Swissprot>P09470</Swissprot><Swissprot>P12820</Swissprot><Swissprot>P12821</Swissprot><Swissprot>P12822</Swissprot><Swissprot>P47820</Swissprot><Swissprot>Q10714</Swissprot><Swissprot>Q10715</Swissprot><Swissprot>Q10751</Swissprot><Swissprot>Q50JE5</Swissprot><Swissprot>Q6Q4G4</Swissprot><Swissprot>Q9GLN7</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00656"><Name>Endopeptidase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="12731"><DrugName>tipranavir</DrugName><DrugNamesKey><Name id="42826529">Aptivus</Name><Name id="43061292">Elodius</Name><Name id="42749901">tipranavir</Name></DrugNamesKey><DrugSynonyms><Name><Value>PNU-140690</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>tipranavir</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>U-14069</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>PNU 140690E</Value></Name><Name><Value>U-140690</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Aptivus</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Elodius</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>174484-41-4</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>191150-83-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="22006">Pharmacia &amp; Upjohn Inc</CompanyOriginator><CompaniesPrimary><Company id="14881">Boehringer Ingelheim International GmbH</Company></CompaniesPrimary><CompaniesSecondary><Company id="22006">Pharmacia &amp; Upjohn Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="12731" type="Drug"><TargetEntity id="240094" type="siDrug">Tipranavir</TargetEntity></SourceEntity><SourceEntity id="14881" type="Company"><TargetEntity id="4298428312" type="organizationId">Boehringer Ingelheim International GmbH</TargetEntity></SourceEntity><SourceEntity id="22006" type="Company"><TargetEntity id="5036162624" type="organizationId">Pharmacia &amp; Upjohn LLC</TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity></SourceEntity><SourceEntity id="768" type="Action"><TargetEntity id="4056" type="Mechanism">HIV-1 Protease Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00939" type="ciTarget"><TargetEntity id="5563997851553483" type="siTarget">Reverse Transcriptase Human immunodeficiency virus type 1</TargetEntity><TargetEntity id="17809854121553483" type="siTarget">Integrase Gag-Pol polyprotein</TargetEntity><TargetEntity id="-312403773" type="omicsTarget"/><TargetEntity id="-213884076" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>HIV-1 infection - South America - Feb-2003</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="159">HIV-1 infection</Indication></IndicationsPrimary><ActionsPrimary><Action id="768">HIV-1 protease inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="746">Solution</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology><Technology id="776">Oral gel formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2018-08-22T11:51:21.000Z</LastModificationDate><ChangeDateLast>2018-08-22T00:00:00.000Z</ChangeDateLast><AddedDate>1996-07-10T16:24:35.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="22546" linkType="Company"&gt;Boehringer Ingelheim&lt;/ulink&gt; has developed and launched tipranavir (Aptivus; Elodius; U-140690), an oral third-generation non-peptidic HIV-1 protease inhibitor (PI), for the treatment of HIV infection [&lt;ulink linkID="213396" linkType="reference"&gt;213396&lt;/ulink&gt;], [&lt;ulink linkID="353777" linkType="reference"&gt;353777&lt;/ulink&gt;].  In June 2005, the FDA granted the drug accelerated approval for use in combination with &lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt; in treatment-experienced patients and it was launched in the same month [&lt;ulink linkID="609056" linkType="Reference"&gt;609056&lt;/ulink&gt;], [&lt;ulink linkID="609257" linkType="Reference"&gt;609257&lt;/ulink&gt;], [&lt;ulink linkID="636373" linkType="Reference"&gt;636373&lt;/ulink&gt;];  in October 2007, the FDA granted the drug full 'traditional' approval for HIV infection [&lt;ulink linkID="836731" linkType="Reference"&gt;836731&lt;/ulink&gt;].  In July 2005, the drug was approved and presumed launched in Mexico [&lt;ulink linkID="615027" linkType="Reference"&gt;615027&lt;/ulink&gt;]. In August 2005, it was approved and presumed launched in Switzerland [&lt;ulink linkID="630730" linkType="Reference"&gt;630730&lt;/ulink&gt;], and  in October 2005, it was approved by the EMEA [&lt;ulink linkID="630730" linkType="Reference"&gt;630730&lt;/ulink&gt;], [&lt;ulink linkID="630750" linkType="Reference"&gt;630750&lt;/ulink&gt;]; by that time, the drug had been approved and launched in Germany [&lt;ulink linkID="1342720" linkType="Reference"&gt;1342720&lt;/ulink&gt;]. In October 2005, the drug was approved in Denmark and Latvia and  subsequently launched in both the countries [&lt;ulink linkID="1456896" linkType="Reference"&gt;1456896&lt;/ulink&gt;], [&lt;ulink linkID="1454583" linkType="Reference"&gt;1454583&lt;/ulink&gt;],  [&lt;ulink linkID="1425335" linkType="Reference"&gt;1425335&lt;/ulink&gt;]. At that time, the drug was approved in the Netherlands [&lt;ulink linkID="1434389" linkType="Reference"&gt;1434389&lt;/ulink&gt;] and was subsequently launched [&lt;ulink linkID="1434391" linkType="Reference"&gt;1434391&lt;/ulink&gt;]. In November 2005, the drug was approved in Spain and by January 2013, it had been launched [&lt;ulink linkID="1364290" linkType="Reference"&gt;1364290&lt;/ulink&gt;]. In December 2005, the capsule formulation of the drug was launched in Sweden and France [&lt;ulink linkID="1407166" linkType="Reference"&gt;1407166&lt;/ulink&gt;], [&lt;ulink linkID="1350089" linkType="Reference"&gt;1350089&lt;/ulink&gt;]. In March 2007, the drug was launched in Portugal [&lt;ulink linkID="1390336" linkType="Reference"&gt;1390336&lt;/ulink&gt;]. In April 2008, the drug received full EC approval [&lt;ulink linkID="900081" linkType="Reference"&gt;900081&lt;/ulink&gt;]. By March 2014, tipranivir had been launched in Canada [&lt;ulink linkID="2059784" linkType="Reference"&gt;2059784&lt;/ulink&gt;]. The drug had been launched in Australia by  October 2016 [&lt;ulink linkID="2059795" linkType="Reference"&gt;2059795&lt;/ulink&gt;]. In July 2006, the company reported that tipranavir may increase the risk of intracranial hemorrhage in HIV patients included in clinical trials. Boehringer  would work with outside investigators to establish  intracranial hemorrhage frequency and was also in discussions with regulatory authorities over updating product labelling and patient package insert [&lt;ulink linkID="676886" linkType="Reference"&gt;676886&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In October 2004, Boehringer submitted an NDA to the FDA  for tipranavir for the treatment of HIV-1 infection. Priority Review was requested in the US [&lt;ulink linkID="566729" linkType="Reference"&gt;566729&lt;/ulink&gt;], [&lt;ulink linkID="566397" linkType="Reference"&gt;566397&lt;/ulink&gt;]. In May 2005, the FDA's Antiviral Drugs Advisory Committee recommended approval of tipranavir [&lt;ulink linkID="602657" linkType="Reference"&gt;602657&lt;/ulink&gt;]. In June 2005, the FDA granted the drug accelerated approval for use in combination with ritonavair in treatment-experienced patients. Longer-term data would be needed before traditional approval could be granted.  The company expected to launch the drug within 2 weeks of approval. The drug was launched later that month [&lt;ulink linkID="609056" linkType="Reference"&gt;609056&lt;/ulink&gt;], [&lt;ulink linkID="609257" linkType="Reference"&gt;609257&lt;/ulink&gt;].   In October 2007, the FDA granted the drug full 'traditional' approval for HIV infection  in treatment-experienced adults [&lt;ulink linkID="836731" linkType="Reference"&gt;836731&lt;/ulink&gt;]. In June 2008, the FDA approved the drug for treatment-experienced  HIV-1 infected patients  aged between  2 and 18 years [&lt;ulink linkID="919777" linkType="Reference"&gt;919777&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In October 2004, Boehringer submitted NDA to the EMEA  for tipranavir for the treatment of HIV-1 infection [&lt;ulink linkID="566729" linkType="Reference"&gt;566729&lt;/ulink&gt;], [&lt;ulink linkID="566397" linkType="Reference"&gt;566397&lt;/ulink&gt;]. In July 2005, the UK Committee for Medicinal Products for Human Use issued a positive opinion about the drug [&lt;ulink linkID="615027" linkType="Reference"&gt;615027&lt;/ulink&gt;]. In August 2005 it was approved in Switzerland [&lt;ulink linkID="630730" linkType="Reference"&gt;630730&lt;/ulink&gt;], and  in October 2005, it was approved by the EMEA [&lt;ulink linkID="630730" linkType="Reference"&gt;630730&lt;/ulink&gt;], [&lt;ulink linkID="630750" linkType="Reference"&gt;630750&lt;/ulink&gt;]; by that time, the drug had been  approved in Germany [&lt;ulink linkID="1342720" linkType="Reference"&gt;1342720&lt;/ulink&gt;]. In October 2005, the drug was approved in Denmark and Latvia and  subsequently launched in both the countries [&lt;ulink linkID="1456896" linkType="Reference"&gt;1456896&lt;/ulink&gt;], [&lt;ulink linkID="1454583" linkType="Reference"&gt;1454583&lt;/ulink&gt;],  [&lt;ulink linkID="1425335" linkType="Reference"&gt;1425335&lt;/ulink&gt;].  At that time, the drug was approved in the Netherlands [&lt;ulink linkID="1434389" linkType="Reference"&gt;1434389&lt;/ulink&gt;] and was subsequently launched [&lt;ulink linkID="1434391" linkType="Reference"&gt;1434391&lt;/ulink&gt;]. In November 2005, the drug was approved in Spain and by January 2013, it had been launched [&lt;ulink linkID="1364290" linkType="Reference"&gt;1364290&lt;/ulink&gt;].  In December 2005, the capsule formulation of the drug was launched in Sweden and France [&lt;ulink linkID="1407166" linkType="Reference"&gt;1407166&lt;/ulink&gt;], [&lt;ulink linkID="1350089" linkType="Reference"&gt;1350089&lt;/ulink&gt;]. In March 2007, the drug was launched in Portugal [&lt;ulink linkID="1390336" linkType="Reference"&gt;1390336&lt;/ulink&gt;]. In April 2008, the drug received full EC approval [&lt;ulink linkID="900081" linkType="Reference"&gt;900081&lt;/ulink&gt;]. In April 2009, the EMEA's CHMP recommended extension of the drug's indication to include highly pretreated children and adolescents [&lt;ulink linkID="1002924" linkType="Reference"&gt;1002924&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;In July 2005, the drug was approved in Mexico [&lt;ulink linkID="615027" linkType="Reference"&gt;615027&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2013, the drug had been approved in Brazil and presumed launched as Elodius [&lt;ulink linkID="1647989" linkType="Reference"&gt;1647989&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase IV&lt;/subtitle&gt;In July 2007, Boehringer expected to begin a phase IV trial of tipranavir for HIV infection in August 2007. The open-label, randomized, multinational, POTENT (prospective evaluation of tipranavir versus darunavir in treatment experienced patients) study would enroll 800 patients previously treated with three classes of antiretrovirals and resistant to more than one protease inhibitor. Patients would receive with 500 mg of tipranavir plus 200 mg of ritonavir twice-daily or 600 mg of darunavir plus 100 mg of ritonavir twice-daily. Both agents would be administered with an optimized background regimen and patients would be followed-up for 48 weeks. The primary endpoint was time to virologic failure and the secondary endpoint was virological response, defined as less than 50 copies/ml, following 48 weeks of treatment. The company expected to report results in 2010 [&lt;ulink linkID="815559" linkType="Reference"&gt;815559&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In February 2007, a multicenter, randomized, open-label phase IIIb study (NCT00440271;  1182.98) began. The SPRING study would  examine the safety, efficacy and pharmacokinetics of the drug in a racially diverse group of 400 treatment-experienced patients in North America, Germany, Italy, Spain and Mexico. Half the patients would receive 500 mg of  tipranavir boosted with 200 mg of &lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt; twice-daily in combination with an optimized background regimen for 48 weeks. The remaining patients would be included in a randomized pilot study to evaluate the effect of therapeutic drug monitoring on the drug's efficacy. The primary endpoint was response at 48 weeks, defined as a viral load of less than 50 copies/ml. Secondary endpoints included reduction in viral load from baseline, treatment failure, time to AIDS/AIDS related progression or death, pill counts, pharmacokinetics, safety and lab changes [&lt;ulink linkID="805074" linkType="Reference"&gt;805074&lt;/ulink&gt;]. Enrollment in the trial began   in June 2007 [&lt;ulink linkID="804866" linkType="Reference"&gt;804866&lt;/ulink&gt;]. This study has been terminated in Spain.&lt;/para&gt;&lt;para&gt;In September 2006, clinical safety data on tipranavir were presented at the 46th ICAAC meeting in San Francisco, CA. In the study, hepatic events associated with ritonavir-boosted tipranavir therapy were assessed  versus  comparators. The results showed that treatment with tipranavir resulted in a greater risk of elevated LFTs. Of the 74  patients who developed grade 3/4 LFTs, 4 experienced a hepatic serious adverse event, with one patient dying from  multi-organ failure due to increased bilirubin levels. The  majority (77%) of    grade 3/4 LFT patients  were able to continue therapy, with hepatic monitoring recommended throughout [&lt;ulink linkID="688574" linkType="Reference"&gt;688574&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2006, the company reported that tipranavir may increase the risk of intracranial hemorrhage after receiving 14 reports of intracranial hemorrhage, including 8 fatalities, in 13 of 6,480 subjects  included in  clinical trials. The rate of intracranial hemorrhage events was 0.2% of patient exposure years. A case-by-case analysis showed that other medical conditions, including CNS lesions, head trauma, recent neurosurgery, hypertension or alcohol abuse, may have contributed to these events. Boehringer Ingelheim was to work with outside investigators to establish  intracranial hemorrhage  frequency and was also in discussions with regulatory authorities regarding the updating of product labelling and patient package insert [&lt;ulink linkID="676886" linkType="Reference"&gt;676886&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2003, Boehringer launched its phase III program. Two pivotal trials, known as RESIST-1 and -2, were to evaluate triple class-experienced HIV patients at 280 sites worldwide and compare the safety and efficacy of tipranavir boosted with low-dose &lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt;  to a comparator PI, also boosted with a low-dose ritonavir. RESIST-1 was to enroll over 500 patients in the US, Canada and Australia, while RESIST-2 was to enroll more than 800 patients in Europe and South America. All participants were to receive resistance testing at baseline to determine the optimal drug combination. The phase III program was also to include two companion trials, study 1182.51 and RESIST-3, for patients with limited treatment options who did not qualify for the pivotal trials [&lt;ulink linkID="478159" linkType="reference"&gt;478159&lt;/ulink&gt;]. The 500 mg dose of tipranavir boosted with 200 mg of ritonavir was selected for the trials [&lt;ulink linkID="485143" linkType="reference"&gt;485143&lt;/ulink&gt;]. Patient enrollment began in Atlanta for the RESIST phase III studies in April 2003 [&lt;ulink linkID="486791" linkType="reference"&gt;486791&lt;/ulink&gt;]. Data were presented in April 2004, at the HIV and Women's Health meeting in Los Angeles, CA. The compound appeared to be enhanced when taken with a high fat meal and delivered through a self-emulsifying drug delivery system [&lt;ulink linkID="534945" linkType="reference"&gt;534945&lt;/ulink&gt;]. Additional data from the RESIST-1 trial were presented at the  44th ICAAC meeting in Washington DC. 620 HIV positive patients (already on antiretroviral treatment ) were randomized to receive either tipranavir/ritonavir (500 mg/200 mg) or comparator PI/ritonavir (PIs used were lopinavir (61%), saquinavir (21%), amprenavir (14%) or indinavir (4%)) over a 24-week period. Results showed that the baseline characteristics for the two arms were similar; median viral load (VL) in the tipranavir/ritonavir  or comparator PI/ritonavir groups were 4.81 and 4.84 log10 copies/ml. Tipranavir/ritonavir was superior to comparator PI/ritonavir in proportion of those patients with VL &amp;lt; 400 copies/ml (34.7% vs 16.5%) and those with VL &amp;lt; 50 copies/ml (25.1% vs 10%). Adverse events profiles were similar, although the tipranavir/ritonavir arm had a higher rate of ALT and lipid elevations, but most of these were asymptomatic and transient [&lt;ulink linkID="569091" linkType="Reference"&gt;569091&lt;/ulink&gt;], [&lt;ulink linkID="567875" linkType="Reference"&gt;567875&lt;/ulink&gt;]. In November 2004, data from the pivotal phase III study (RESIST-2) were presented at the 7th International Congress on Drug Therapy in HIV Infection which showed that a greater percentage of HIV-positive patients taking a regimen of Boehringer Ingelheim AG's tipranavir with a boost of low dose ritonavir (tipranavir/r) achieved a treatment response compared to those taking a regimen containing one of several comparator marketed protease inhibitors with a low-dose boost of ritonavir (CPI/r). RESIST-2 enrolled 863 patients with advanced HIV disease who, on average, had received 12 antiretroviral drugs, were experiencing virologic failure, and had documented protease inhibitor resistance. Treatment response, defined as 1 log10 or greater decrease in viral load from baseline, was achieved by 41% of patients who received tipranavir/r compared to 14.9% of patients in the CPI/r group. At 24 weeks, 33.6% of participants in the tipranavir/r group and 13.1% of participants in the CPI/r group achieved viral loads of less than 400 copies/ml, and 22.5% versus 8.6% achieved less than 50 copies/ml. Patients taking tipranavir/r also experienced greater increases in their CD4+ cell count than those taking a CPI/r with CD4+ increases of 31 cells/mm3 and 1 cell/mm3, respectively. The tipranavir/r adverse event profile was similar to events observed in the CPI group through 24 weeks, although the tipranavir/r group experienced a higher rate of liver enzyme and lipid elevations, but most laboratory abnormalities were asymptomatic. A subset of the study population received enfuvirtide as part of their treatment regimen. For these patients, who were generally more immunocompromized, 38.5% in the tipranavir/r arm versus 13.0% in the CPI/r arm achieved a viral load of less than 400 copies/ml and 23.1% versus 4.3% achieved less than 50 copies/ml [&lt;ulink linkID="571679" linkType="Reference"&gt;571679&lt;/ulink&gt;]. Similar data were presented in February 2005 at the 12th Conference on Retroviruses and Opportunistic Infections in Boston, MA [&lt;ulink linkID="587466" linkType="Reference"&gt;587466&lt;/ulink&gt;]. Similar data were presented at the 3rd IAS Conference on HIV Pathogenesis and Treatment in Rio, Brazil [&lt;ulink linkID="615027" linkType="Reference"&gt;615027&lt;/ulink&gt;]. Similar 24-week data were published in November 2006 [&lt;ulink linkID="743918" linkType="Reference"&gt;743918&lt;/ulink&gt;]. In November 2005, data from the RESIST trials presented at the 10th European AIDS conference in Dublin, Ireland, showed that tipranavir outperformed several protease inhibitor drugs through 48 weeks of HIV treatment [&lt;ulink linkID="636072" linkType="Reference"&gt;636072&lt;/ulink&gt;], [&lt;ulink linkID="636373" linkType="Reference"&gt;636373&lt;/ulink&gt;], [&lt;ulink linkID="636375" linkType="Reference"&gt;636375&lt;/ulink&gt;]. In December 2005, similar data  were presented at the 45th ICAAC meeting in Washington DC [&lt;ulink linkID="641151" linkType="Reference"&gt;641151&lt;/ulink&gt;]. In February 2006, combined analyses of the two studies were reported at the 13th Conference on Retroviruses and Opportunists Infections (CROI) in Denver, CO [&lt;ulink linkID="649574" linkType="Reference"&gt;649574&lt;/ulink&gt;]. In September 2006, the results of a RESIST dataset,  PhenoSense assay analysis were presented at the 46th ICAAC meeting in San Francisco, CA. In the study, the lower and upper phenotypic clinical cutoffs (LCCO; UCCO), for tipranavir/ritonavir, lopinavir/ritonavir, saquinavir/ritonavir and amprenavir/ritonavir  were defined as 2.0/8.0, 9.0/55.0, 2.3/12.0 and 4/11.5, respectively. The proportion of RESIST study samples fully susceptible to tipranavir/ritonavir, lopinavir/ritonavir, saquinavir/ritonavir and amprenavir/ritonavir were 53%, 18%, 17% and 26% [&lt;ulink linkID="688530" linkType="Reference"&gt;688530&lt;/ulink&gt;]. In a further analysis, the impact of HIV PR mutations L33F/I, V82A, I84V and L90M on resistance to tipranavir/ritonavir, lopinavir/ritonavir, saquinavir/ritonavir, amprenavir/ritonavir and atazanavi/ritonavir  was evaluated. In the presence of one or more of the mutations the percentage of resistant isolates was lowest for tipranavir/ritonavir (range 5.9%-69.4%), compared to reference compounds lopinavir/ritonavir (range 14.4%-82.3%), saquinavir/ritonavir (range 30.9%-97.6%), amprenavir/ritonavir (range 16.2%-96.0%) and atazanavi/ritonavir (range 21%-91.7%) [&lt;ulink linkID="688552" linkType="Reference"&gt;688552&lt;/ulink&gt;]. In November 2006, 96-week data were presented at the 8th International Congress on Drug Therapy in HIV Infection in Glasgow, Scotland. At 96-weeks more than twice the percentage of patients in the tipranavir/r arm responded to treatment with 26.9% achieved a viral load below 400 copies/ml and 20.4% achieved a viral load of less than 50 copies/ml. The effects of the drug were enhanced by co-administration of enfuvirtide, 34.7% of patients achieved an undetectable viral load of less than 50 copies/ml [&lt;ulink linkID="742786" linkType="Reference"&gt;742786&lt;/ulink&gt;]. In July 2007, further data from the ongoing RESIST trials showed that common tipranavir-associated side effects included diarrhoea, nausea, vomiting, abdominal pain, fever, fatigue, headache, bronchitis, depression and rash. Tipranavir-treated patients also had more gastrointestinal symptom disorders and elevated transaminase, cholesterol and triglyceride levels, compared with patients in the ritonavir group [&lt;ulink linkID="815559" linkType="Reference"&gt;815559&lt;/ulink&gt;]. In October 2007, new combined data was presented at the 11th European AIDS Conference  in Madrid, Spain. The 156-week treatment data showed that tipranavir/ritonavir, produced 20.9% response rate when compared with 7.5% for the ritonavir-boosted comparator protease inhibitors (low dose ritonavir boosted lopinavir, amprenavir, saquinavir and indinavir). Among the patients taking enfuvirtide for the first time, the tipranavir and ritonavir group produced 20.9% response rate compared with 7.5% for the comparator group.The tipranavir and ritonavir group within this arm also has twice as many patients achieving less than 50 copies/ml viral load [&lt;ulink linkID="844300" linkType="Reference"&gt;844300&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2006, data from an  international, multi-center, open-label, randomized, phase II dose finding study in 115 HIV-1 infected children aged between 2 and 18 years were reported. Those children receiving tipranavir/ritonavir as part of combination antiretroviral therapy achieved virological response (decrease in viral load to &amp;lt;400 copies/ml or &amp;lt;50 copies/ml for undetectable) and immunological improvements (increase in CD4+ cell count) at 48 weeks of therapy. Patients received tipranavir/ritonavir  at 290/115 mg/m2 or 375/150 mg/m2 bid. At the lower dose, 39.7%  and 34.5% respectively achieved virological response and undetectable viral loads. At the higher dose, 45.6%  and 35.1% achieved virological response and undetectable viral loads. The drug was well tolerated [&lt;ulink linkID="685078" linkType="Reference"&gt;685078&lt;/ulink&gt;]. Similar data were reported in August 2008 at the International AIDS conference in Mexico City, Mexico. New 100-week data showed the drug to have long-term efficacy and safety in treatment-experienced children [&lt;ulink linkID="931544" linkType="Reference"&gt;931544&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2004, Boehringer reported interim findings from the phase IIb study, BI 1182.51, at the XV International AIDS Conference in Bangkok, Thailand. The international, multicenter, randomized, open-label study evaluated tipranavir boosted with low-dose &lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt; (TPV/r) alone or in combination with boosted &lt;ulink linkID="4259" linkType="Drug"&gt;saquinavir&lt;/ulink&gt; (SQV/r), &lt;ulink linkID="7867" linkType="Drug"&gt;amprenavir&lt;/ulink&gt; (APV/r) or &lt;ulink linkID="14681" linkType="Drug"&gt;lopinavir&lt;/ulink&gt; (LPV/r) in highly treatment-experienced patients. Primary endpoints of the analysis examined the safety and pharmacokinetics of tipranavir. Secondary endpoints included evaluation of virologic response. All dual-boosted protease inhibitor (PI) combinations with tipranavir were well tolerated and the frequency of adverse events was similar among all four treatment arms. Safety data were comparable in the first 2 weeks when all patients were taking single ritonavir-boosted PI regimens, and were comparable between weeks 2 and 4 when the dual-boosted PI regimens were administered. Reductions in plasma PK parameters of SQV, APV and LPV were observed when boosted PIs were co-administered with TPV/r. The minimum drug levels of SQV, APV and LPV decreased by 81%, 56% and 55%, respectively, from weeks 2 to 4 with the addition of TPV/r [&lt;ulink linkID="548723" linkType="Reference"&gt;548723&lt;/ulink&gt;], [&lt;ulink linkID="551751" linkType="Reference"&gt;551751&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2003, further data from the phase II, randomized, multicenter, open-label study, BI 1182.2, were presented at the 9th European AIDS Conference in Warsaw, Poland. 41 non-nucleoside reverse transcriptase inhibitor (NNRTI)-naive patients who had clinically failed two or more PI-containing regimens were randomized to receive either low- or high-dose tipranavir boosted with &lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt;, plus &lt;ulink linkID="10172" linkType="Drug"&gt;efavirenz&lt;/ulink&gt; and one new nucleoside reverse transcriptase inhibitor (NRTI), twice daily. Of the 61% of patients who completed 80 weeks of treatment, the median viral load decreased by 2.55 log and 2.43 log, and the CD4+ cell count increased by 175 cells/mm3 and 143 cells/mm3 in the low- and high-dose arms, respectively [&lt;ulink linkID="511068" linkType="reference"&gt;511068&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2003, data were presented on a dose-finding phase II, multicenter, randomized, blinded study. The study recruited 216 treatment-experienced patients and was to determine the MTD and resistance profile of the drug for use in the phase III RESIST trials. Patients were dosed with tipranavir and boosted with &lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt;, at doses of 500/100 mg, 500/200 mg and 750/200 mg for 2 weeks. The levels of virus in participants decreased by 0.9 log, 1.0 log and 1.2 log, respectively; however, the 500/200 mg dose was the most favorable as far as safety and pharmacokinetic profile were concerned. This study showed that tipranavir was active against HIV that had a reduced sensitivity to commercially available PIs. In the same study 157 samples of HIV-1 were taken from the total study population at baseline and tested for sensitivity to tipranavir. These isolates showed resistance to all the available PIs, but not to tipranavir. After 2 weeks of treatment there was a 1.24 log drop in virus levels, for patients who had a reduction in sensitivity to these existing PIs at baseline. It was found that tipranavir remained active against virus with 16 or more PI mutations [&lt;ulink linkID="478945" linkType="reference"&gt;478945&lt;/ulink&gt;], [&lt;ulink linkID="479770" linkType="reference"&gt;479770&lt;/ulink&gt;], [&lt;ulink linkID="485143" linkType="reference"&gt;485143&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Additional data from phase II trials were presented in July 2003, at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment in Paris, France. Data from study 1182.52, showed a high inhibitory quotient calculated from patients with drug-resistant HIV-1 infection, which suggested that tipranavir/&lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt; may be active in the majority of triple class-experienced HIV-positive patients. Additional data suggested that a 500/200 mg dose of tipranavir/&lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt; could induce a robust viral load response in previously-treated patients with up to 20 protease gene mutations [&lt;ulink linkID="497596" linkType="reference"&gt;497596&lt;/ulink&gt;], [&lt;ulink linkID="499539" linkType="reference"&gt;499539&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2002, Boehringer was planning a phase IIb study in nine countries, which was underway by July 2002 [&lt;ulink linkID="444225" linkType="reference"&gt;444225&lt;/ulink&gt;], [&lt;ulink linkID="446521" linkType="reference"&gt;446521&lt;/ulink&gt;], [&lt;ulink linkID="457259" linkType="reference"&gt;457259&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In September 2007, clinical data on tipranavir were presented at the 47th ICAAC meeting in Chicago, IL. An investigation into the effect of once-daily &lt;ulink linkID="10172" linkType="Drug"&gt;efavirenz&lt;/ulink&gt; (600 mg) on the pharmacokinetics of twice-daily tipranavir (500 mg) plus ritonavir (200 mg; tipranavir/r) in healthy subjects (n = 16) established that efavirenz had no clinically relevant effect on tipranavir/r; it was concluded that tipranavir/r plus efavirenz could be safely coadministered without any need for dose adjustment [&lt;ulink linkID="829911" linkType="Reference"&gt;829911&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2007, clinical data on tipranavir were presented at the 47th ICAAC meeting in Chicago, IL, from a single-center, double-blind trial. In investigation into the ECG effects observed with therapeutic (500/200 mg) and supra-therapeutic (750/200 mg) doses of twice-daily tipranavir/r healthy subjects (n = 80) found that tipranavir/r did not relevantly prolong the QTc interval or exhibit QT prolongation or clinically important ECG effects at either dose [&lt;ulink linkID="829912" linkType="Reference"&gt;829912&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2006, an open-label, non-randomized, parallel-assigned, phase I trial (&lt;ulink linkID="212980" linkType="Protocol"&gt;NCT02259855&lt;/ulink&gt;; 1182.59) to evaluate the pharmacokinetics of tipranavir/ritonavir and steady state ribavirin and pegylated Interferon alfa 2a in HIV negative, HCV Infected subjects (n = 36) with mild hepatic impairment. In October 2008, the study was completed [&lt;ulink linkID="1601834" linkType="Reference"&gt;1601834&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2004, phase I data on tipranavir were presented at the 44th ICAAC meeting in Washington DC. In one study, the pharmacokinetic (PK) effects of steady-state tipranavir/ritonavir (500 mg/200 mg) on single doses of rifbutin (150 mg) were evaluated in 24 healthy volunteers (mean age = 32.8 +/- 8.5 years; male:female ratio = 20:4). Co-administration of tipranavir/ritonavir with rifabutin caused statistically significant increases in primary PK parameters (AUC, Cmax, Cp (12 h)) for both rifabutin and its metabolite 25-O-desacetyl-rifabutin (contributes to 10% of rifabutin's antimicrobial activity). The AUC ratio of 25-O-desacetyl-rifabutin to rifabutin after rifabutin dosing alone and after co-administration with tipranavir/ritonavir increased from 0.086 to 0.65, respectively, suggesting  potential  CYP3A4-dependent mechanism for  the metabolism of  25-O-desacetyl-rifabutin (CYP3A4 metabolizes both tipranavir/ritonavir and rifabutin). Rifabutin did not affect the steady-state PK of tipranavir/ritonavir. No unexpected adverse effects were observed in this trial [&lt;ulink linkID="568926" linkType="Reference"&gt;568926&lt;/ulink&gt;]. In another study, the effect of  tipranavir/ritonavir (500 mg/200 mg) on the PKs of clarithromycin (500 mg; bid) was examined in24 healthy volunteers (mean age = 33.2 +/- 9.2 years; male:female ratio = 17:7) . In general, tipranavir/ritonavir treatment with clarithromycin was well-tolerated in this study with no unexpected adverse effects observed. The study recommended that the fact that tipranavir/ritonavir   use would have an effect (almost complete inhibition) on  the active metabolite, 14-OH-clarithromycin (twice as active  against H influenzae, but 4 to 7 times less active against M avium and M intracellular complex), a dose adjustment  may be  in patients with renal impairment [&lt;ulink linkID="568927" linkType="Reference"&gt;568927&lt;/ulink&gt;]. The mass excretion balance and metabolite profile of tipranavir when co-administered with ritonavir in 12 subjects was determined; the main route of elimination was via feces (82.3%) compared with urine (4.4%). Tipranavir steady-state concentration was achieved after 7 days administration of  tipranavir/ritonavir (500 mg/200 mg) [&lt;ulink linkID="568925" linkType="Reference"&gt;568925&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2001, clinical data on tipranavir were presented at the First International AIDS Society Conference on HIV Pathogenesis and Treatment, in Buenos Aires, Argentina. The open-label, dose-finding study evaluated 41 NNRTI-naive patients who had clinically failed two or more PI-containing regimens. In total, 19 patients were randomized to receive tipranavir, 500 mg bid (group A) and 22 patients were randomized to receive tipranavir, 1000 mg bid (group B) in combination with &lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt;, &lt;ulink linkID="10172" linkType="Drug"&gt;efavirenz&lt;/ulink&gt; and one NRTI. In an intent-to-treat analysis at 48 weeks, 79% of patients in group A and 50% of patients in group B achieved HIV levels in the blood below the limit of detection (&amp;lt; 400 copies/ml). The proportion of patients with HIV RNA at less than 50 copies/ml was 68% in group A and 41% in group B. This represents a mean reduction from baseline in HIV RNA of 2.34 log(10) copies/ml and 1.71 log(10) copies/ml in groups A and B, respectively. The mean CD4+ cell count increased by 184 cells/mm3 (baseline = 258) in Group A and by 149 cells/mm3 (baseline = 274) in group B [&lt;ulink linkID="414885" linkType="reference"&gt;414885&lt;/ulink&gt;]. Similar data, presented at the 9th Conference on Retroviruses and Opportunistic Infections in Seattle, WA, in February 2002, showed that patients with virus resistant to multiple HIV/AIDS drugs achieved and maintained viral suppression with tipranavir. The phase II trial involved 41 patients who had decreased susceptibility to a mean of 1.6 NRTIs and 2.9 PIs at baseline. Of these, 85% remained fully susceptible to tipranavir throughout the study [&lt;ulink linkID="444225" linkType="reference"&gt;444225&lt;/ulink&gt;]. In July 2002, these data were also presented at the 11th International HIV Drug Resistance Workshop in Seville, Spain. A separate study, also presented at the meeting, showed that development of decreased susceptibility to tipranavir in vitro was slow and complex, involving multiple mutations. Six mutations emerged sequentially, L33F, I84V, K45I, I13V, V32I and V82L, but none were individually responsible for decreased susceptibility to tipranavir [&lt;ulink linkID="457259" linkType="reference"&gt;457259&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2000, clinical data on tipranavir were presented at the 5th International Congress on Drug Therapy in HIV Infection in Glasgow, UK. Two weeks of twice-daily dosing of 300 mg and 1200 mg of tipranavir, co-administered with 200 mg of &lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt;, produced median tipranavir trough concentrations of 21 and 67 microM, respectively, and reductions in HIV RNA of 1.4 and 1.6 log(10) copies/ml, respectively [&lt;ulink linkID="391121" linkType="reference"&gt;391121&lt;/ulink&gt;]. Tipranavir also retained in vitro activity against HIV-1 isolates derived from PI-naive and -experienced patients [&lt;ulink linkID="391593" linkType="reference"&gt;391593&lt;/ulink&gt;], [&lt;ulink linkID="448225" linkType="reference"&gt;448225&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Phase II trials had been initiated, under &lt;ulink linkID="18937" linkType="Company"&gt;Pharmacia&lt;/ulink&gt; by the end of 1998 [&lt;ulink linkID="326900" linkType="reference"&gt;326900&lt;/ulink&gt;] and were ongoing, under Boehringer, in March 2001 [&lt;ulink linkID="402711" linkType="reference"&gt;402711&lt;/ulink&gt;]; at this time, the company was predicting launch during 2003 [&lt;ulink linkID="407161" linkType="reference"&gt;407161&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 1998, a phase I/II trial commenced involving patients with viral loads over 5000 RNA copies/ml after taking &lt;ulink linkID="5321" linkType="Drug"&gt;indinavir&lt;/ulink&gt;  or &lt;ulink linkID="7310" linkType="Drug"&gt;ritonavir&lt;/ulink&gt; plus two other anti-HIV medications for at least 6 months. During the trial, patients replaced their previous protease inhibitor with tipranavir for 4 weeks before also switching the remaining two drugs [&lt;ulink linkID="316808" linkType="reference"&gt;316808&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Initial dose-escalation studies of this compound were completed by 1997 and a dose of 1500 mg tid selected for further study. By May 1998, &lt;ulink linkID="18995" linkType="Company"&gt;Pharmacia &amp;amp; Upjohn&lt;/ulink&gt; was developing a 300 mg pill and exploring formulations that increased absorption of the compound in order to reduce the pill burden [&lt;ulink linkID="316808" linkType="reference"&gt;316808&lt;/ulink&gt;], [&lt;ulink linkID="308038" linkType="reference"&gt;308038&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2000, data on tipranavir were presented at the 40th ICAAC meeting in Toronto, Canada. Using site directed mutagenesis and in vitro drug selection studies, it appeared that there were no obvious common combinations of known PI mutations that clearly conferred tipranavir resistance. It was pointed out that although it is possible for HIV-1 to develop resistance to tipranavir, the genetic changes responsible for this are likely to be multiple and complex [&lt;ulink linkID="383135" linkType="reference"&gt;383135&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 1999, results of an in vitro study presented at the 3rd International Workshop on HIV Drug Resistance and Treatment Strategy, suggested that tipranavir is active against strains of HIV that are highly resistant to all four protease inhibitors approved for use at the time of the study. Of the highly resistant isolates, 90% were completely sensitive to tipranavir [&lt;ulink linkID="329013" linkType="reference"&gt;329013&lt;/ulink&gt;], [&lt;ulink linkID="448422" linkType="reference"&gt;448422&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In November 2004, Boehringer  opened its tipranavir expanded access program  in the US, which would provide tipranavir to HIV patients who were not enrolled in ongoing tipranavir trials, were triple-antiretroviral class-experienced, had  two or more PI regimens, were PI-resistant and were over 18  [&lt;ulink linkID="573469" linkType="Reference"&gt;573469&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 1998, Deutsche Bank predicted potential sales of $25 million in 2001 rising to $50 million in 2002 [&lt;ulink linkID="316769" linkType="reference"&gt;316769&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Richard MW Hoetelmans, Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;30 March 1999&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="12731"&gt;Tipranavir&lt;/ulink&gt; is a potent, non-peptide inhibitor of HIV protease. Inhibition of the viral protease enzyme leads to the production of non-infectious virions, which have the morphological features of immature particles. The use of protease inhibitors in combination with two nucleoside reverse transcriptase (RT) inhibitors has led to dramatic improvements in the treatment of individuals infected with HIV-1. The currently licensed HIV protease inhibitors are transition state analogs of peptide substrates of HIV protease. &lt;ulink linkType="Drug" linkID="12731"&gt;Tipranavir&lt;/ulink&gt; is a non-peptidic HIV protease inhibitor, but with a different structure from currently licensed protease inhibitors.&lt;br/&gt; &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="12731"&gt;Tipranavir&lt;/ulink&gt;, a sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrone, inhibits HIV protease by binding to its active site [&lt;ulink linkType="reference" linkID="251330"&gt;251330&lt;/ulink&gt;]. A broad screening program identified phenprocoumon as a molecular template for HIV protease inhibitors. Subsequent modification of this lead through repeated cycles of structure-based design, led to activity enhancements through pyrone and dihydropyrone ring systems and amide-based substitution. Finally, incorporation of sulfonamide substitution provided a series of highly potent HIV protease inhibitors. Crystallographic studies provided information on binding interactions responsible for high enzymatic binding and have led to the development of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="300460"&gt;300460&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="225273"&gt;225273&lt;/ulink&gt;]. The drug is synthesized by a convergent approach amenable to large-scale preparation in a pilot plant environment. The key step is the aldol addition of a nitroaromatic ester to an aldehyde. The two stereocenters present in the target molecule are each set independently by resolution of enantiomers [&lt;ulink linkType="reference" linkID="315131"&gt;315131&lt;/ulink&gt;].&lt;br/&gt; &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;The inhibition constants (Ki) of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; for the HIV-1 and HIV-2 proteases are &amp;lt; 0.01 nM and &amp;lt; 0.1 nM, respectively [&lt;ulink linkType="reference" linkID="315133"&gt;315133&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="12731"&gt;Tipranavir&lt;/ulink&gt; inhibits the acute infection of H9 cells with HIV-1 III-B with a mean IC90 of 0.16 +/- 0.07 microM. The observed IC90 for the inhibition of infection of peripheral blood mononuclear cells (PBMCs) by clinical isolates ranges from 0.07 to 0.8 microM [&lt;ulink linkType="reference" linkID="251330"&gt;251330&lt;/ulink&gt;]. An HIV-1 NL4-3 strain resistant to &lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt; (after 37 passages of the strain in the presence of this protease inhibitor) showed a 47-, 80-, 125- and &amp;gt; 125-fold decrease in susceptibility to &lt;ulink linkType="Drug" linkID="5321"&gt;indinavir&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="4259"&gt;saquinavir&lt;/ulink&gt;, and &lt;ulink linkType="Drug" linkID="8255"&gt;nelfinavir&lt;/ulink&gt;, respectively, but only a 6-fold decrease in susceptibility to &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; (defined as increase in IC90) [&lt;ulink linkType="reference" linkID="251330"&gt;251330&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;At a dose of 10 mg/kg, &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; produce plasma levels above the IC90 value for several hours in both rats and dogs. It also lacks cross-resistance to &lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt; and blocked protease activity in &lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt;-resistant clinical isolates [&lt;ulink linkType="reference" linkID="213396"&gt;213396&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="12731"&gt;Tipranavir&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt; have been studied in combination against the replication of HIV-1 clinical isolates in PBMCs. A &lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt;-sensitive and -resistant isolate pair derived from an individual before and after monotherapy with &lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt; were used. These isolates showed no significant difference in sensitivity to &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt;, but the resistant isolate was more than 50-fold less sensitive to &lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt; than the sensitive isolate. Further analysis showed that the combination of various concentrations of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; with &lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt; yielded additive to moderately synergistic antiviral effects against the &lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt;-sensitive isolate and stronger synergy against the &lt;ulink linkType="Drug" linkID="7310"&gt;ritonavir&lt;/ulink&gt;-resistant isolate. The mechanism of synergy was not investigated, but the results suggested that both the virological and the observed in vitro pharmacological effects may have contributed to the observed synergy [&lt;ulink linkType="reference" linkID="307998"&gt;307998&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The effects of human plasma albumin and alpha1-acid glycoprotein on the antiretroviral activity of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; were assessed with HIV-1 IIIB in H9 cell culture and HIV-1JR-CSF in PBMC culture. Increases in IC90 ranged from 1.7- to 6.2-fold, with the largest increase observed in the presence of 2 mg of alpha1-acid glycoprotein/ml [&lt;ulink linkType="reference" linkID="251330"&gt;251330&lt;/ulink&gt;]. The specific pattern of resistance to &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; has not yet been elucidated [&lt;ulink linkType="reference" linkID="315133"&gt;315133&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;The steady-state pharmacokinetics of orally administered &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; have been assessed in healthy volunteers aged 19 to 55 years [&lt;ulink linkType="reference" linkID="320114"&gt;320114&lt;/ulink&gt;]. Groups of eight volunteers received 300, 600, 900, 1200, 1600 or 2000 mg of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; (as disodium salt capsules) as a single dose on day one, followed by tid dosing on days 3 to 12. The exposure to &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; was lower after multiple dosing, compared to single doses, most likely due to the induction of metabolizing enzymes. In the two lowest dose-groups the apparent oral clearance increased by approximately 2-fold after multiple dosing, compared to a single dose. For the higher-dose groups, the increases in the apparent oral clearance were smaller and ranged from 2 to 41%. For dose regimens of 900 mg tid or more, the average steady-state trough concentrations were above the predicted IC90 of 1 microM [&lt;ulink linkType="reference" linkID="320114"&gt;320114&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The effects of food and elevated gastric pH were investigated in 12 healthy volunteers (aged 20 to 51 years) in a randomized, cross-over, single-dose study (900 mg) [&lt;ulink linkType="reference" linkID="320116"&gt;320116&lt;/ulink&gt;]. The volunteers ingested &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; either on an empty stomach, with a high-fat breakfast, or 10 min after 20 ml of Maalox TC. Blood samples for pharmacokinetic evaluation were drawn over a 48-h period. After the administration of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; with a high-fat breakfast, exposure to the drug (as measured by the AUC) was approximately 2-fold higher (p = 0.0001), the maximum concentration was 55% higher (p = 0.0001) and the time to the maximum concentration was delayed by approximately 1 h (p = 0.02) compared to administration on an empty stomach. When taken with the antacid, the AUC was 33% lower (p &amp;gt; 0.05) and the maximum concentration was 41% lower (p = 0.015) compared to administration on an empty stomach. In this case, the time to the maximum concentration was unchanged. Thus, the absorption of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; is enhanced when taken with a meal, and may be decreased at higher pH values of the gastric contents, when compared to the administration on an empty stomach [&lt;ulink linkType="reference" linkID="320116"&gt;320116&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In an open-label, multiple-dose study, &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; (900, 1200, and 1500 mg po tid) was administered to 24 protease inhibitor-naive HIV-1-infected individuals with pharmacokinetic evaluation after 10 days of therapy [&lt;ulink linkType="reference" linkID="320117"&gt;320117&lt;/ulink&gt;]. The average steady-state trough concentrations of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; in plasma were 1.2, 1.9 and 2.8 microM in the 900, 1200, and 1500 mg dose groups, respectively. The pharmacokinetics of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; in HIV-1-infected individuals (with two nucleoside RT inhibitors) were no different from those observed in healthy volunteers (without nucleoside RT inhibitors) [&lt;ulink linkType="reference" linkID="320117"&gt;320117&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/II&lt;/subtitle&gt;In an open-label, multiple-dose study, &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; (900, 1200 or 1500 mg tid) was administered to 24 protease inhibitor-naive, HIV-1-infected individuals [&lt;ulink linkType="reference" linkID="320117"&gt;320117&lt;/ulink&gt;]. The patients were treated with two nucleoside RT inhibitors for at least two months (median = 10 months) and had CD4 counts &amp;gt; 50 cells/microl and an HIV-1 RNA copy number of &amp;gt; 4000/ml. The addition of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; to the dual nucleoside regimen resulted in a decrease of plasma HIV-1 RNA with 1.0, 1.3 and 1.2 log10 units on day 11 for the 900, 1200 and 1500 mg dose groups, respectively. After 4 weeks of therapy, the reduction in HIV-1 RNA in plasma was 0.5, 1.1 and 0.9 log10 units, respectively. At this time, no genotypic changes were observed [&lt;ulink linkType="reference" linkID="320117"&gt;320117&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;Reported primary side-effects of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; in healthy volunteers after 9.3 days of multiple dosing were mild to moderate diarrhea, and mild nausea and abdominal cramps. Two individuals reported vertigo, mood alterations, slowed thinking and movement, and lack of concentration in the highest dose group (2000 mg tid), which resolved after discontinuation of the drug [&lt;ulink linkType="reference" linkID="320114"&gt;320114&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="320116"&gt;320116&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I/II study in HIV-1-infected individuals, the primary reported side-effects after 4 weeks of treatment with 900, 1200 or 1500 mg of &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; tid were diarrhea, nausea and vomiting that could be managed by taking the drug with light snacks and by symptomatic treatment. No serious adverse events have been reported [&lt;ulink linkType="reference" linkID="320114"&gt;320114&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="320116"&gt;320116&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="320117"&gt;320117&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion&lt;/subtitle&gt;The inhibition of HIV protease has provided physicians with potent drugs that are capable of reducing the replication of HIV to undetectable levels (if administered in combination with nucleoside RT inhibitors). However, cross-resistance has been observed for all currently licensed protease inhibitors. This severely limits therapeutic options if patients fail a protease inhibitor-containing regimen. Furthermore, the long-term toxicity associated with the use of protease inhibitors (especially lipodystrophy) raises serious concerns regarding the safety of these agents. In contrast to licensed protease inhibitors, &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; is a structurally different, non-peptidic inhibitor of HIV protease, and in vitro experiments show low cross-resistance to strains of HIV that are resistant to the peptidic inhibitors of protease.&lt;/para&gt;&lt;para&gt;Due to cross-resistance within the classes of protease inhibitors and non-nucleoside RT inhibitors, therapeutic options for salvage therapy in HIV-1-infected individuals are limited, despite the increasing number of available drugs. If &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; also shows limited cross-resistance with other protease inhibitors in vivo, it will be a valuable addition to the armamentarium of antiretroviral agents. However, long-term toxicity has yet to be investigated. &lt;/para&gt;&lt;para&gt;In conclusion, &lt;ulink linkType="Drug" linkID="12731"&gt;tipranavir&lt;/ulink&gt; is a potent inhibitor of HIV protease and may be of great value if its structural difference from the currently licensed protease inhibitors leads to a distinct resistance and toxicity profile.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><Source id="1425335" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-06-30T00:00:00.000Z</StatusDate><Source id="609056" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><Source id="1454583" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><Source id="1434391" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2003-02-07T00:00:00.000Z</StatusDate><Source id="478159" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="AU">Australia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2016-10-31T00:00:00.000Z</StatusDate><Source id="2059795" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2008-04-28T00:00:00.000Z</StatusDate><Source id="900081" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2014-03-05T00:00:00.000Z</StatusDate><Source id="2059784" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2013-04-30T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-12-06T00:00:00.000Z</StatusDate><Source id="1407166" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="ES">Spain</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><Source id="1364290" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="GR">Greece</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><Source id="1438015" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="FR">France</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-12-15T00:00:00.000Z</StatusDate><Source id="1350089" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="PT">Portugal</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2007-03-21T00:00:00.000Z</StatusDate><Source id="1390336" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-08-26T00:00:00.000Z</StatusDate><Source id="630750" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-10-31T00:00:00.000Z</StatusDate><Source id="1342720" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="IT">Italy</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2007-04-30T00:00:00.000Z</StatusDate><Source id="630750" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-07-19T00:00:00.000Z</StatusDate><Source id="615027" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2002-02-01T00:00:00.000Z</StatusDate><Source id="353777" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>1996-07-10T00:00:00.000Z</StatusDate><Source id="213396" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2007-04-30T00:00:00.000Z</StatusDate><Source id="805074" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2007-04-30T00:00:00.000Z</StatusDate><Source id="805074" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="ES">Spain</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-11-02T00:00:00.000Z</StatusDate><Source id="1364290" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-10-25T00:00:00.000Z</StatusDate><Source id="1456896" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2000-02-01T00:00:00.000Z</StatusDate><Source id="353777" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2013-04-30T00:00:00.000Z</StatusDate><Source id="1647989" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-08-26T00:00:00.000Z</StatusDate><Source id="630750" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-07-19T00:00:00.000Z</StatusDate><Source id="615027" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2008-04-28T00:00:00.000Z</StatusDate><Source id="900081" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-10-31T00:00:00.000Z</StatusDate><Source id="1342720" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2003-02-07T00:00:00.000Z</StatusDate><Source id="478159" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2003-02-07T00:00:00.000Z</StatusDate><Source id="478159" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2004-10-25T00:00:00.000Z</StatusDate><Source id="566397" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-06-23T00:00:00.000Z</StatusDate><Source id="609056" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2004-10-25T00:00:00.000Z</StatusDate><Source id="566729" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>2005-10-26T00:00:00.000Z</StatusDate><Source id="630750" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>1997-10-01T00:00:00.000Z</StatusDate><Source id="287795" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22006">Pharmacia &amp; Upjohn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="159">HIV-1 infection</Indication><StatusDate>1998-05-01T00:00:00.000Z</StatusDate><Source id="316808" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="14881">Boehringer Ingelheim International GmbH</OwnerCompany><Country id="US">US</Country><Indication id="159">HIV-1 infection</Indication><AwardedIndication>Treatment of HIV-1 infection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2005-06-22T00:00:00.000Z</MileStoneDate><Source id="609257" type="PR"/></Row><Row><RegulatoryDesignation id="5">Accelerated Approval</RegulatoryDesignation><OwnerCompany id="14881">Boehringer Ingelheim International GmbH</OwnerCompany><Country id="US">US</Country><Indication id="159">HIV-1 infection</Indication><AwardedIndication>Treatment of HIV-1 infection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="3">Filed</DesignationApplicationStatus><MileStoneDate>2004-10-25T00:00:00.000Z</MileStoneDate><Source id="566729" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00939"><Name>HIV-1 protease</Name><SwissprotNumbers><Swissprot>P03366</Swissprot><Swissprot>P03367</Swissprot><Swissprot>P03369</Swissprot><Swissprot>P04585</Swissprot><Swissprot>P04586</Swissprot><Swissprot>P04587</Swissprot><Swissprot>P04588</Swissprot><Swissprot>P04589</Swissprot><Swissprot>P05959</Swissprot><Swissprot>P05960</Swissprot><Swissprot>P05961</Swissprot><Swissprot>P12497</Swissprot><Swissprot>P12498</Swissprot><Swissprot>P12499</Swissprot><Swissprot>P18802</Swissprot><Swissprot>P20875</Swissprot><Swissprot>P20892</Swissprot><Swissprot>P24740</Swissprot><Swissprot>P35963</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1003399">Laboratory Corporation of America Holdings</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14881">Boehringer Ingelheim International GmbH</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18767">Pfizer Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="115126" title="Boehringer Ingelheim to develop P&amp;U's tipranavir worldwide"/><Deal id="116159" title="Monogram to conduct data analysis for Boehringer Ingelheim"/></Deals><PatentFamilies><PatentFamily id="1014449" number="WO-09912919" title="Process to produce 4-hydroxy-2-oxo-pyrane derivates useful as protease inhibitors."/><PatentFamily id="103984" number="WO-03066564" title="Process for producing (R)-3-hydroxy-3-(2-phenylethyl)hexanoic acid and its intermediate"/><PatentFamily id="1280945" number="WO-09906024" title="Self-emulsifying formulation for lipophilic compounds"/><PatentFamily id="1282487" number="WO-00057885" title="Pharmaceutical emulsions for retroviral protease inhibitors"/><PatentFamily id="1289295" number="WO-2004087139" title="Antiviral combination of tipranavir and a further antiretroviral compound"/><PatentFamily id="1364808" number="WO-2006052373" title="Method for treating HIV infection through co-administration of tipranavir and etravirine"/><PatentFamily id="141711" number="WO-2006060175" title="Method for treating HIV infection through co-administration of tipranavir and SCH417690"/><PatentFamily id="1532817" number="WO-2004085427" title="Enantioselective hydrogenation of intermediates during tipranavir synthesis"/><PatentFamily id="1533500" number="WO-02068404" title="Method for producing optically active dihydropyrones"/><PatentFamily id="1578774" number="WO-00055150" title="Improved process for asymmetric hydrogenation"/><PatentFamily id="1619272" number="WO-2004052831" title="Method for the production of optically active dihydropyrones"/><PatentFamily id="1622358" number="WO-2006060177" title="Method for treating HIV infection through co-administration of tipranavir and GW873140"/><PatentFamily id="1709556" number="WO-2011013110" title="Unit dosage forms of HIV protease inhibitors"/><PatentFamily id="1732593" number="WO-03030871" title="Powder processing with pressurized gaseous fluids"/><PatentFamily id="1754103" number="WO-2007114978" title="Method for treating HIV infection through co-administration of tipranavir and PA-457"/><PatentFamily id="1761669" number="WO-2006055660" title="Method for treating HIV infection through co-administration of tipranavir and UK-427857 (maraviroc)"/><PatentFamily id="182882" number="WO-2007103740" title="Immunoassays, haptens, immunogens and antibodies for anti-HIV therapeutics"/><PatentFamily id="1918134" number="WO-2006055455" title="Method for treating HIV infection through co-administration of tipranavir and darunavir"/><PatentFamily id="2102465" number="WO-2007084618" title="Method for determining resistance of  HIV to protease inhibitor treatment"/><PatentFamily id="2130646" number="WO-2006006851" title="Process for the preparation of an enantiomerically enriched ester or the corresponding acid thereof"/><PatentFamily id="2175758" number="WO-00236110" title="Oral dosage self-emulsifying formulations of pyranone protease inhibitors"/><PatentFamily id="2256891" number="US-20090062346" title="Deuterium-enriched tipranavir"/><PatentFamily id="272681" number="WO-2004060370" title="Treatment of hiv infection through combined administration of tipranavir and capravirine"/><PatentFamily id="277874" number="WO-00025784" title="Method for improving the pharmacokinetics of tipranavir"/><PatentFamily id="2965651" number="RU-02543322" title="Pharmaceutical composition for treating hiv-infection, method for preparing and method of using"/><PatentFamily id="2983658" number="CN-104784179" title="Application of tipranavir in anti breast cancer drug"/><PatentFamily id="400947" number="WO-2004052883" title="Improved process for the synthesis of an antiviral compound"/><PatentFamily id="406246" number="WO-2008142090" title="Self-emulsifying formulation of tipranavir for oral administration"/><PatentFamily id="494913" number="WO-02068403" title="Continuous method for producing dihydropyrones"/><PatentFamily id="511380" number="WO-2007092802" title="Method for treating HIV infection through co-administration of tipranavir and GS 9137"/><PatentFamily id="553507" number="WO-2008112286" title="De novo synthesis of conjugates"/><PatentFamily id="565168" number="WO-2009084036" title="Composition for treatment of viral infections"/><PatentFamily id="573148" number="EC-1999SP3206" title="Method for improving the pharmacokinetics of tipranavir"/><PatentFamily id="583889" number="WO-09530670" title="Pyranone compounds useful to treat retroviral infections."/><PatentFamily id="585664" number="WO-2006060159" title="Method for treating HIV infection through co-administration of tipranavir and GW695634"/><PatentFamily id="67488" number="WO-2006055754" title="Method for treating hiv infection through co-administration of tipranavir and reverset"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="1">Analyte</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>13</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>11</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Laboratory Corporation of America Holdings" id="1003399"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chongqing University of Technology" id="1010449"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ricoh Co Ltd" id="1011930"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ark Diagnostics" id="1015191"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wells Fargo Bank NA" id="1019244"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protia LLC" id="1043660"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pharmasyntez" id="1065783"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"/><CountAsOwner>21</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>21</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Royal DSM NV" id="15823"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nektar Therapeutics" id="17221"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mylan NV" id="18439"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pfizer Inc" id="18767"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sun Pharmaceutical Industries Ltd" id="27561"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Honeywell International Inc" id="30855"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="13564"><DrugName>anti-estrogens, BioNumerik</DrugName><DrugSynonyms><Name><Value>anti-estrogens, BioNumerik</Value></Name><Name><Value>anti-estrogen compounds, BioNumerik</Value></Name></DrugSynonyms><CompanyOriginator id="14778">BioNumerik Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="14778">BioNumerik Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="14778" type="Company"><TargetEntity id="4296389143" type="organizationId">Bionumerik Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="286" type="Action"><TargetEntity id="3050" type="Mechanism">Selective Estrogen Receptor Destabilizers (SERD)</TargetEntity><TargetEntity id="3127" type="Mechanism">Estrogen Receptor (ER) Zinc Finger Inhibitors</TargetEntity><TargetEntity id="1284" type="Mechanism">Estrogen Receptor (ER) Antagonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="49">Breast tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="286">Estrogen receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2017-08-28T06:46:28.000Z</LastModificationDate><ChangeDateLast>2002-04-02T17:03:55.000Z</ChangeDateLast><AddedDate>1996-10-08T15:20:05.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;BioNumerik was investigating a series of anti-estrogen compounds for the potential treatment of breast cancer; however, investigation has been discontinued [&lt;ulink linkID="221199" linkType="reference"&gt;221199&lt;/ulink&gt;], [&lt;ulink linkID="378185" linkType="reference"&gt;378185&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14778">BioNumerik Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="49">Breast tumor</Indication><StatusDate>2000-07-28T00:00:00.000Z</StatusDate><Source id="378185" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14778">BioNumerik Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>1996-10-08T15:20:05.000Z</StatusDate><Source id="221199" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00692"><Name>Estrogen receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="14519"><DrugName>miconazole (vaginal hydrogel pessary), Core Technologies</DrugName><DrugNamesKey><Name id="42781574">Miconazole Hycore-V</Name><Name id="42750994">miconazole</Name></DrugNamesKey><DrugSynonyms><Name><Value>miconazole</Value><Types><Type>INN</Type></Types></Name><Name><Value>Miconazole Hycore-V</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Hydrogel (miconazole vaginal pessary)</Value></Name><Name><Value>Hydrogel miconazole pessary, Core Technologies</Value></Name><Name><Value>miconazole (vaginal hydrogel pessary), Core Technologies</Value></Name><Name><Value>22916-47-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="27279">CeNeS Pharmaceuticals plc</CompanyOriginator><CompaniesSecondary><Company id="27279">CeNeS Pharmaceuticals plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="27279" type="Company"><TargetEntity id="4295894867" type="organizationId">Paion Holdings UK Ltd</TargetEntity></SourceEntity><SourceEntity id="1027" type="ciIndication"><TargetEntity id="4083" type="siCondition"/></SourceEntity><SourceEntity id="1748" type="Action"><TargetEntity id="1059" type="Mechanism">Efflux Pump (Fungal) Inhibitors</TargetEntity><TargetEntity id="1508" type="Mechanism">Homoserine Dehydrogenase (Fungal) Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1027">Female genital tract infection</Indication><Indication id="53">Candida albicans infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="1748">Fungicide</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="625">Pessary</Technology><Technology id="623">Vaginal formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J2</Code><Name>SYSTEMIC AGENTS FOR FUNGAL INFECTIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-19T05:31:28.000Z</LastModificationDate><ChangeDateLast>2004-02-23T13:29:07.000Z</ChangeDateLast><AddedDate>1997-02-11T13:01:03.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Core Technologies was developing a hydrogel pessary, containing miconazole nitrate released at a controlled rate over 24 hours, for the potential treatment of vaginal candidiasis [&lt;ulink linkID="233263" linkType="reference"&gt;233263&lt;/ulink&gt;]. By March 1999, the project had been discontinued [&lt;ulink linkID="337173" linkType="reference"&gt;337173&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results from the phase III study in 1997 were disappointing compared to data from the phase II trial, although significant efficacy was observed when compared to placebo. The release rate of the drug from the delivery system was identified as the cause of this. A new applicator and retrieval net were subsequently developed, as well as a modification of the polymer properties, and a further phase III clinical trial commenced in February 1998 [&lt;ulink linkID="278990" linkType="reference"&gt;278990&lt;/ulink&gt;]. Results from this trial did not support the continued development of miconazole for Hycore-V [&lt;ulink linkID="337173" linkType="reference"&gt;337173&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Core completed preclinical development of the one-day product early in 1997 [&lt;ulink linkID="233263" linkType="reference"&gt;233263&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="27279">CeNeS Pharmaceuticals plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1027">Female genital tract infection</Indication><StatusDate>1999-04-01T00:00:00.000Z</StatusDate><Source id="337173" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27279">CeNeS Pharmaceuticals plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="53">Candida albicans infection</Indication><StatusDate>1999-04-01T00:00:00.000Z</StatusDate><Source id="337173" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27279">CeNeS Pharmaceuticals plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="53">Candida albicans infection</Indication><StatusDate>1999-04-01T00:00:00.000Z</StatusDate><Source id="337173" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27279">CeNeS Pharmaceuticals plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="53">Candida albicans infection</Indication><StatusDate>1999-04-01T00:00:00.000Z</StatusDate><Source id="337173" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="27279">CeNeS Pharmaceuticals plc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="53">Candida albicans infection</Indication><StatusDate>1998-02-24T00:00:00.000Z</StatusDate><Source id="278990" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27279">CeNeS Pharmaceuticals plc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="53">Candida albicans infection</Indication><StatusDate>1998-02-24T00:00:00.000Z</StatusDate><Source id="278990" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27279">CeNeS Pharmaceuticals plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="53">Candida albicans infection</Indication><StatusDate>1997-02-11T13:01:03.000Z</StatusDate><Source id="233263" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27279">CeNeS Pharmaceuticals plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1027">Female genital tract infection</Indication><StatusDate>1997-02-11T13:01:03.000Z</StatusDate><Source id="233263" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1057339" number="EP-00803248" title="Skin care compositions containing retinol or retinyl ester"/><PatentFamily id="1066734" number="WO-2004024120" title="Medicated skin cleansing products"/><PatentFamily id="1071125" number="WO-2007124476" title="Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them"/><PatentFamily id="1134156" number="WO-09949835" title="An Acidified Composition For Topical Treatment Of Nail And Skin Conditions"/><PatentFamily id="1139496" number="EP-01138314" title="Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues"/><PatentFamily id="1168424" number="US-08383140" title="Absorbable crystalline copolyester-based bioactive hydroforming luminal liner compositions"/><PatentFamily id="1238928" number="WO-03009800" title="Sustained-release therapeutic bioadhesive systems"/><PatentFamily id="1242656" number="CN-01357331" title="Suppository for controlling sexual spread of AIDS"/><PatentFamily id="1253157" number="WO-2011113118" title="Drug tolerance/persistence of fungal biofilms"/><PatentFamily id="1258361" number="WO-2008036292" title="Method for treating otitis externa"/><PatentFamily id="1259139" number="WO-09011754" title="Aerosolized azole antifungals."/><PatentFamily id="1328206" number="CN-101601693" title="Externally used medicine for treating acne"/><PatentFamily id="1362809" number="WO-2004028502" title="Cleansing composition containing antifungal agent and antibacterial agent"/><PatentFamily id="1385141" number="WO-03032948" title="Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity"/><PatentFamily id="1421997" number="WO-09014076" title="A preparation for the treatment of fungal infections."/><PatentFamily id="1438476" number="WO-2006010589" title="Post foaming gel mousse"/><PatentFamily id="1466076" number="CN-01712003" title="Medicinal composition for viganitis"/><PatentFamily id="1474156" number="CN-101091690" title="Combination of miconazole and ribavirin applied to hair including tioconazole"/><PatentFamily id="1495805" number="US-04988697" title="Fungicidal Compositions And Method"/><PatentFamily id="1509660" number="WO-02060404" title="Composition Of Miconazole For External Application And Skin-Whitening"/><PatentFamily id="1565470" number="WO-2012126899" title="Inhibition and treatment of biofilms"/><PatentFamily id="1566562" number="WO-08702580" title="Film-Forming, Pharmaceutical Vehicles For Application Of Medicaments To Nails, Pharmaceutical Compositions Based On Those Vehicles, And Methods Of Using Same"/><PatentFamily id="1577302" number="WO-09929301" title="Lipid Compositions And Their Use"/><PatentFamily id="1610119" number="RU-02157187" title="Dermatological remedy &quot;mikonazol&quot;"/><PatentFamily id="165271" number="EP-00277333" title="Novel Imidazole Derivatives Having Therapeutical Activity, Process For Their Preparation And Pharmaceutical Compositions Containing Them"/><PatentFamily id="1676289" number="US-20090253712" title="Aqueous solvent system for solubilization of azole compounds"/><PatentFamily id="1694668" number="CN-01682688" title="Technology for once removing chloasma and freckle and preparation of medicinal cream"/><PatentFamily id="1712099" number="WO-00057845" title="Method for removal of human horny tissues."/><PatentFamily id="1762775" number="WO-2011027246" title="A cream comprising miconazole nitrate and a biopolymer for the treatment of diaper rash"/><PatentFamily id="1869999" number="US-05514698" title="Antifungal vaginal cream composition."/><PatentFamily id="1899270" number="JP-05376889" title="Candidiasis prophylactic or therapeutic agent"/><PatentFamily id="1907843" number="WO-09531217" title="Tocopherol compositions for delivery of biologically active agents."/><PatentFamily id="1943211" number="JP-09020680" title="Antifungal Agent"/><PatentFamily id="1944396" number="WO-09418967" title="Treatments for diseases characterized by neovascularization."/><PatentFamily id="1995650" number="WO-2009129470" title="Methods for treating herpes virus infections"/><PatentFamily id="204094" number="WO-09856350" title="Aerosols"/><PatentFamily id="2060102" number="EP-01508329" title="Composition for an antifungal agent for suppressing fungal growth in an oral cavity"/><PatentFamily id="2065937" number="CN-01954813" title="Suppository for multi-infection of vagina"/><PatentFamily id="2087278" number="JP-03038522" title="Antifungal Composition"/><PatentFamily id="2096342" number="US-06080744" title="Topical antifungal treatment"/><PatentFamily id="2138063" number="KR-00659715" title="Use of bamboo concentrate for suppressing expression of cytochrome p450 3 family enzymes so as to increase medicinal efficacy of drug of which in vivo medicinal efficacy is reduced by metabolism of same enzymes"/><PatentFamily id="2250071" number="US-06281239" title="Method of treating onychomycosis."/><PatentFamily id="2334782" number="WO-2009048594" title="Multicomponent bioactive intravaginal ring"/><PatentFamily id="2335699" number="JP-2004269419" title="Miconazole -containing aqueous|water-based injection"/><PatentFamily id="2347457" number="WO-02087570" title="Composition comprising antifungal agents for treating vulvovaginitis and vaginosis"/><PatentFamily id="2369902" number="WO-09631551" title="Microgels"/><PatentFamily id="2375044" number="US-09006278" title="Controlled release systems of pluribioactive antifungal drugs and applications thereof"/><PatentFamily id="2387195" number="CN-102727800" title="Multi-purpose tinea drug and preparation method thereof"/><PatentFamily id="242621" number="WO-09418964" title="Use of omega -guanidinocarboxylic acid esters."/><PatentFamily id="2482319" number="CN-102788863" title="Detection method of compound preparation containing compound zingiber corallinum hance solution and urea miconazole ointment"/><PatentFamily id="2565420" number="WO-2013107809" title="Use of azole antifungals for the treatment of actinic keratosis"/><PatentFamily id="2696620" number="WO-2014037883" title="Topical antimicrobial formulations"/><PatentFamily id="2704842" number="CN-103520086" title="Miconazole nitrate expandable vaginal suppository, and preparation method and detection method thereof"/><PatentFamily id="2732177" number="CN-103735558" title="One anti-variation fungi ointment and a preparation method and application thereof"/><PatentFamily id="2737134" number="CN-103664527" title="One of clean in 2, 4-dichloro-alpha-chlorine methyl benzene methyl alcohol and method"/><PatentFamily id="2751366" number="CN-203506904" title="Oral ulcer care bag"/><PatentFamily id="2788872" number="WO-2014130922" title="Compositions and methods for treating fungal infections"/><PatentFamily id="279240" number="US-20050214364" title="Products and methods for treating vaginal infections"/><PatentFamily id="279722" number="EP-01031353" title="Antimycotic compositions"/><PatentFamily id="2854669" number="WO-2014205519" title="Antimicrobial compositions and methods of use"/><PatentFamily id="2870952" number="CN-104146957" title="Antifungal drug emulsion spray preparation"/><PatentFamily id="2891409" number="CN-104324039" title="A medicament for treating a human body surface fat tumor and use method"/><PatentFamily id="292078" number="WO-2006024284" title="Atrium patch"/><PatentFamily id="2931619" number="CN-104490905" title="A treating hemorrhoids cream and preparation method"/><PatentFamily id="2947225" number="CN-104548100" title="Topical combination for treating skin diseases"/><PatentFamily id="2958862" number="WO-2015088625" title="Compounds and methods of promoting myelination"/><PatentFamily id="2969658" number="CN-104706635" title="Effervescence piece of treating vaginitis and its preparation method"/><PatentFamily id="30127" number="WO-2004016245" title="Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections"/><PatentFamily id="3035497" number="WO-2015142528" title="Portable medical treatment system and method of use"/><PatentFamily id="3042696" number="CN-104906135" title="Nano-silver application in preparing synergistic agent of antifungal drugs"/><PatentFamily id="3086048" number="CN-105106329" title="Metronidazole compound miconazole nitrate vagina effervescence piece and preparation method"/><PatentFamily id="3108885" number="CN-105214052" title="Miconazole compound slow release tablet used for tinea manuum and preparation method thereof"/><PatentFamily id="3117235" number="JP-2015168615" title="The composition for washing|cleaning"/><PatentFamily id="3149445" number="GB-201600147" title="Miconazole medicine intermediate a- (2,4-dichlorophenyl) -a- (1- imidazolyl) ethanol synthesis method"/><PatentFamily id="3185532" number="GB-201602852" title="Miconazole drug intermediate 2,4- dichlorophenyl chloromethyl ketone synthesis method"/><PatentFamily id="3189787" number="CN-105535017" title="Miconazole powder for prevention of fungal disease"/><PatentFamily id="320891" number="WO-00028821" title="Therapeutic anti-fungal nail preparation"/><PatentFamily id="326600" number="WO-03039559" title="Pharmaceutical combinatons comprising a fungicide, a bacteriostatic sulphonamide and an antibacterial compound for topical application"/><PatentFamily id="3285848" number="CN-105256533" title="A preparation method of magnetic drug-loaded fabric"/><PatentFamily id="3323739" number="CN-105853300" title="A scurf-removing and itching-removing oil-removing moistening head washing cream and its preparation method"/><PatentFamily id="3444700" number="WO-2016182032" title="Administration of azole antifungal agent to eyelid skin"/><PatentFamily id="3515192" number="CN-106266037" title="Liquid gel and preparation method thereof"/><PatentFamily id="3515616" number="CN-106265486" title="Nitrate slow-release gel and preparation method thereof"/><PatentFamily id="3544325" number="CN-105439832" title="Synthesis method of miconazole intermediate 2,4-dichlorobenzene chloride methyl ketone"/><PatentFamily id="3549707" number="CN-106377631" title="A composition for preventing and treating acne"/><PatentFamily id="3553949" number="CN-105439956" title="Synthesis method of miconazole intermediate"/><PatentFamily id="3557022" number="CN-106389789" title="A western medicine composition for preventing whelks and preparation method thereof"/><PatentFamily id="3611468" number="EP-03159012" title="Nanoemulsions having reversible continuous and dispersed phases"/><PatentFamily id="3657383" number="CN-106692540" title="Pharmaceutical composition for scald"/><PatentFamily id="3721267" number="JP-2017119651" title="Composition for oral cavity"/><PatentFamily id="3749464" number="WO-2017134049" title="Implantable medical products, a process for the preparation thereof, and use thereof"/><PatentFamily id="3775844" number="CN-107089951" title="Preparation method of miconazole nitrate"/><PatentFamily id="3799402" number="WO-2017162822" title="Compositions for mucosal adhesion and uses thereof"/><PatentFamily id="3815310" number="US-20170290810" title="Anti-fungal compositions for treating nails and methods for fabricating and using thereof"/><PatentFamily id="3870073" number="CN-107365501" title="A medical silicone rubber material"/><PatentFamily id="3870074" number="CN-107365500" title="An anti-infective medical silicon rubber material and preparation method thereof"/><PatentFamily id="3901805" number="CN-107469038" title="A cream for treating beriberi and preparation method thereof"/><PatentFamily id="3911072" number="CN-107485610" title="An application of miconazole in preventing vascular rupture"/><PatentFamily id="3917192" number="CN-107510831" title="A cardiotonic venting coldness dispelling antibacterial effervescent tablet and preparation method thereof"/><PatentFamily id="3921103" number="WO-2018013625" title="Deuterated miconazole"/><PatentFamily id="4070821" number="WO-2018096405" title="Compositions and methods for the treatment of oral infectious diseases"/><PatentFamily id="4148414" number="CN-108329266" title="A miconazole crystal form and preparing method and application thereof"/><PatentFamily id="4168576" number="CN-108396040" title="A miconazole intermediates of the biosynthesis method"/><PatentFamily id="419540" number="JP-05743375" title="Candidiasis prophylactic or therapeutic agent"/><PatentFamily id="420335" number="WO-2006042059" title="Organo-gel formulations for therapeutic applications"/><PatentFamily id="4236061" number="CN-108586662" title="One kind azole antifungal medicine fragment imprinted polymer and its preparation method and application"/><PatentFamily id="4328630" number="WO-2019003098" title="Topical pharmaceutical composition comprising miconazole and luliconazole or salts thereof"/><PatentFamily id="4347264" number="CN-109106735" title="Antiphlogistic and analgesic spray agent and preparation method thereof"/><PatentFamily id="4439923" number="CN-109432110" title="A nitrate compound composite for gynae"/><PatentFamily id="4461474" number="WO-2019068862" title="Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections"/><PatentFamily id="484437" number="CN-01136866" title="External-use medicine for treating vaginitis"/><PatentFamily id="501119" number="WO-2005072774" title="Vaginal compositions for treating infections"/><PatentFamily id="52930" number="WO-09619186" title="Antifungal treatment of nails."/><PatentFamily id="541065" number="JP-2000128786" title="Miconazole-containing aqueous injection and its production"/><PatentFamily id="547336" number="WO-02098463" title="Antifungal compositions."/><PatentFamily id="656512" number="CN-01839883" title="Medicine for treating tinea pedis"/><PatentFamily id="688360" number="WO-09734599" title="Use of clotrimazole and related compounds in the treatment of diarrhea."/><PatentFamily id="692074" number="GB-01474510" title="Ointments"/><PatentFamily id="733392" number="WO-2008059258" title="Treatment of multi-drug resistant bacterial infections"/><PatentFamily id="787627" number="WO-2009132101" title="Methods of treating fungal infections"/><PatentFamily id="834681" number="US-03717655" title="1-(Beta-Aryl)Ethyl-Imidazole Derivatives"/><PatentFamily id="849083" number="WO-2008045186" title="Method of treatment of otitis externa"/><PatentFamily id="871451" number="WO-2010007381" title="Antibacterial combination therapy for the treatment of Gram positive bacterial infections"/><PatentFamily id="943837" number="WO-00030626" title="Methods and kits for treating vulvovaginal candidiasis with miconazole nitrate"/><PatentFamily id="972101" number="EP-00310122" title="Antifungal Composition"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dermatological Products Of Texas" id="1010404"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BTG plc" id="15266"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kaken Pharmaceutical Co Ltd" id="17633"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Strathclyde" id="21741"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="PAION AG" id="29493"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="29264"><DrugName>antibacterials (imidazolinones), BMS</DrugName><DrugSynonyms><Name><Value>antibacterials (imidazolinones), BMS</Value></Name><Name><Value>antibacterials (imidazolidinones), BMS</Value></Name><Name><Value>antibacterials (4-thiazolidinones), BMS</Value></Name><Name><Value>556817-31-3</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25709">Bristol-Myers Squibb Pharmaceutical Research Institute</CompanyOriginator><CompaniesSecondary><Company id="25709">Bristol-Myers Squibb Pharmaceutical Research Institute</Company></CompaniesSecondary><CrossReferences><SourceEntity id="25709" type="Company"><TargetEntity id="5035524299" type="organizationId">Bristol-Myers Squibb Pharmaceutical Research Institute</TargetEntity></SourceEntity><SourceEntity id="40" type="ciIndication"><TargetEntity id="A49.9" type="ICD10"/><TargetEntity id="10060945" type="MEDDRA"/><TargetEntity id="D001424" type="MeSH"/><TargetEntity id="-1693440076" type="omicsDisease"/><TargetEntity id="800" type="siCondition"/></SourceEntity><SourceEntity id="8498" type="Action"><TargetEntity id="1676" type="Mechanism">MurB Reductase Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="40">Bacterial infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="8498">UDP-N-Acetylmuramate dehydrogenase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="104">Bacterial cell wall synthesis inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2007-10-22T14:58:31.000Z</LastModificationDate><ChangeDateLast>2007-10-22T14:58:31.000Z</ChangeDateLast><AddedDate>2000-06-20T15:37:24.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS) was investigating a series of 4-thiazolidinones, which competitively inhibit the prokaryotic enzyme MurB, for the potential treatment of bacterial infections [&lt;ulink linkType="reference" linkID="371589"&gt;371589&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By November 2002, heterocyclic bioisosteric replacement of the thiazolidine nucleus had been investigated to improve in vitro MurB inhibitory activity. Imidazolidinone analogs were found to have similar potency, but also had whole cell antibacterial activity which thiazolidinone derivatives lacked. One of the two active compounds in this series (structure shown) that exhibited good in vitro potency against MurB enzyme had an IC50 value of 15 microM and activity against Staphylococcus aureus (MIC = 4 microg/ml) [&lt;ulink linkType="reference" linkID="484696"&gt;484696&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25709">Bristol-Myers Squibb Pharmaceutical Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2007-10-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25709">Bristol-Myers Squibb Pharmaceutical Research Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="40">Bacterial infection</Indication><StatusDate>2000-06-20T00:00:00.000Z</StatusDate><Source id="371589" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-02243"><Name>UDP-N-Acetylmuramate dehydrogenase</Name><SwissprotNumbers><Swissprot>O25963</Swissprot><Swissprot>O51544</Swissprot><Swissprot>O66805</Swissprot><Swissprot>O83128</Swissprot><Swissprot>P08373</Swissprot><Swissprot>P18579</Swissprot><Swissprot>P37417</Swissprot><Swissprot>P44605</Swissprot><Swissprot>P57153</Swissprot><Swissprot>P57952</Swissprot><Swissprot>P59450</Swissprot><Swissprot>P61431</Swissprot><Swissprot>P61432</Swissprot><Swissprot>P61433</Swissprot><Swissprot>P61434</Swissprot><Swissprot>P61435</Swissprot><Swissprot>P61616</Swissprot><Swissprot>P65460</Swissprot><Swissprot>P65461</Swissprot><Swissprot>P65462</Swissprot><Swissprot>P65463</Swissprot><Swissprot>P65464</Swissprot><Swissprot>P65465</Swissprot><Swissprot>P65466</Swissprot><Swissprot>P65467</Swissprot><Swissprot>P74529</Swissprot><Swissprot>P95837</Swissprot><Swissprot>Q1RHX1</Swissprot><Swissprot>Q313Q1</Swissprot><Swissprot>Q31U21</Swissprot><Swissprot>Q32AE8</Swissprot><Swissprot>Q38VZ2</Swissprot><Swissprot>Q39DI6</Swissprot><Swissprot>Q3A2G8</Swissprot><Swissprot>Q3AAE8</Swissprot><Swissprot>Q3BUJ8</Swissprot><Swissprot>Q3IJU8</Swissprot><Swissprot>Q3J4L9</Swissprot><Swissprot>Q3J791</Swissprot><Swissprot>Q3JVB9</Swissprot><Swissprot>Q3K0Y5</Swissprot><Swissprot>Q3K8J6</Swissprot><Swissprot>Q3KKK8</Swissprot><Swissprot>Q3SMH1</Swissprot><Swissprot>Q3STS5</Swissprot><Swissprot>Q3YV08</Swissprot><Swissprot>Q45305</Swissprot><Swissprot>Q46I41</Swissprot><Swissprot>Q46XL1</Swissprot><Swissprot>Q47K28</Swissprot><Swissprot>Q47LH5</Swissprot><Swissprot>Q47UY2</Swissprot><Swissprot>Q48L51</Swissprot><Swissprot>Q48TP5</Swissprot><Swissprot>Q493L3</Swissprot><Swissprot>Q49VT7</Swissprot><Swissprot>Q4FPK7</Swissprot><Swissprot>Q4FT57</Swissprot><Swissprot>Q4JSV7</Swissprot><Swissprot>Q4KFT1</Swissprot><Swissprot>Q4L4G3</Swissprot><Swissprot>Q4QNS0</Swissprot><Swissprot>Q4UKP0</Swissprot><Swissprot>Q4UTX4</Swissprot><Swissprot>Q4ZVY7</Swissprot><Swissprot>Q57C80</Swissprot><Swissprot>Q57H81</Swissprot><Swissprot>Q5E225</Swissprot><Swissprot>Q5F9J9</Swissprot><Swissprot>Q5FL42</Swissprot><Swissprot>Q5FUJ3</Swissprot><Swissprot>Q5GRK8</Swissprot><Swissprot>Q5H0N1</Swissprot><Swissprot>Q5HHT2</Swissprot><Swissprot>Q5HQZ1</Swissprot><Swissprot>Q5HSB7</Swissprot><Swissprot>Q5L1H7</Swissprot><Swissprot>Q5L5A3</Swissprot><Swissprot>Q5LBG5</Swissprot><Swissprot>Q5LU58</Swissprot><Swissprot>Q5LYN3</Swissprot><Swissprot>Q5M396</Swissprot><Swissprot>Q5MZH9</Swissprot><Swissprot>Q5NFD4</Swissprot><Swissprot>Q5P3R2</Swissprot><Swissprot>Q5PAK9</Swissprot><Swissprot>Q5PK78</Swissprot><Swissprot>Q5QY76</Swissprot><Swissprot>Q5SJC8</Swissprot><Swissprot>Q5WAV8</Swissprot><Swissprot>Q5WTI8</Swissprot><Swissprot>Q5X1S7</Swissprot><Swissprot>Q5XCA5</Swissprot><Swissprot>Q5YP42</Swissprot><Swissprot>Q5ZSA6</Swissprot><Swissprot>Q604V9</Swissprot><Swissprot>Q62M77</Swissprot><Swissprot>Q63WM3</Swissprot><Swissprot>Q64RZ8</Swissprot><Swissprot>Q65JX9</Swissprot><Swissprot>Q65WM5</Swissprot><Swissprot>Q660S4</Swissprot><Swissprot>Q66FR3</Swissprot><Swissprot>Q68XC1</Swissprot><Swissprot>Q6A6J8</Swissprot><Swissprot>Q6AH30</Swissprot><Swissprot>Q6AJ55</Swissprot><Swissprot>Q6DAP0</Swissprot><Swissprot>Q6FAZ1</Swissprot><Swissprot>Q6G126</Swissprot><Swissprot>Q6G2Q7</Swissprot><Swissprot>Q6GB92</Swissprot><Swissprot>Q6GIQ3</Swissprot><Swissprot>Q6LLV2</Swissprot><Swissprot>Q6MAQ1</Swissprot><Swissprot>Q71ZQ0</Swissprot><Swissprot>Q728V0</Swissprot><Swissprot>Q72JP7</Swissprot><Swissprot>Q72MQ5</Swissprot><Swissprot>Q73HL4</Swissprot><Swissprot>Q73RJ5</Swissprot><Swissprot>Q73SU8</Swissprot><Swissprot>Q74K66</Swissprot><Swissprot>Q7MGQ8</Swissprot><Swissprot>Q7MUY2</Swissprot><Swissprot>Q7MYE5</Swissprot><Swissprot>Q7NI66</Swissprot><Swissprot>Q7NXN4</Swissprot><Swissprot>Q7UA72</Swissprot><Swissprot>Q7UVF9</Swissprot><Swissprot>Q7V3P9</Swissprot><Swissprot>Q7V9C4</Swissprot><Swissprot>Q7VEJ2</Swissprot><Swissprot>Q7VJ12</Swissprot><Swissprot>Q7VPJ2</Swissprot><Swissprot>Q7VQF2</Swissprot><Swissprot>Q7W509</Swissprot><Swissprot>Q7WGH4</Swissprot><Swissprot>Q822B0</Swissprot><Swissprot>Q82DR4</Swissprot><Swissprot>Q82VS1</Swissprot><Swissprot>Q830P3</Swissprot><Swissprot>Q83F16</Swissprot><Swissprot>Q83FK5</Swissprot><Swissprot>Q83HA7</Swissprot><Swissprot>Q83PC7</Swissprot><Swissprot>Q87A76</Swissprot><Swissprot>Q87KP5</Swissprot><Swissprot>Q87YF8</Swissprot><Swissprot>Q88LM5</Swissprot><Swissprot>Q88YF4</Swissprot><Swissprot>Q890Y6</Swissprot><Swissprot>Q89FU9</Swissprot><Swissprot>Q8A806</Swissprot><Swissprot>Q8CPZ7</Swissprot><Swissprot>Q8D243</Swissprot><Swissprot>Q8DD33</Swissprot><Swissprot>Q8DLV6</Swissprot><Swissprot>Q8DUF8</Swissprot><Swissprot>Q8EK85</Swissprot><Swissprot>Q8ESR4</Swissprot><Swissprot>Q8EZC5</Swissprot><Swissprot>Q8FB88</Swissprot><Swissprot>Q8FZP4</Swissprot><Swissprot>Q8K7K5</Swissprot><Swissprot>Q8KA63</Swissprot><Swissprot>Q8P150</Swissprot><Swissprot>Q8P9R1</Swissprot><Swissprot>Q8PLJ3</Swissprot><Swissprot>Q8R8Z6</Swissprot><Swissprot>Q8RDQ3</Swissprot><Swissprot>Q8UDN0</Swissprot><Swissprot>Q8X711</Swissprot><Swissprot>Q8XNI0</Swissprot><Swissprot>Q8XWC4</Swissprot><Swissprot>Q8Y776</Swissprot><Swissprot>Q8YI64</Swissprot><Swissprot>Q8YM74</Swissprot><Swissprot>Q8Z316</Swissprot><Swissprot>Q8ZAN4</Swissprot><Swissprot>Q92BT5</Swissprot><Swissprot>Q92IT8</Swissprot><Swissprot>Q92NM1</Swissprot><Swissprot>Q97LP4</Swissprot><Swissprot>Q98KB5</Swissprot><Swissprot>Q99ZS9</Swissprot><Swissprot>Q9A5A7</Swissprot><Swissprot>Q9CB48</Swissprot><Swissprot>Q9CGD5</Swissprot><Swissprot>Q9HZM7</Swissprot><Swissprot>Q9JV28</Swissprot><Swissprot>Q9K016</Swissprot><Swissprot>Q9K9T1</Swissprot><Swissprot>Q9KV40</Swissprot><Swissprot>Q9L0L7</Swissprot><Swissprot>Q9PAE6</Swissprot><Swissprot>Q9PL89</Swissprot><Swissprot>Q9PM01</Swissprot><Swissprot>Q9RNM8</Swissprot><Swissprot>Q9RWN8</Swissprot><Swissprot>Q9X239</Swissprot><Swissprot>Q9X6Y8</Swissprot><Swissprot>Q9Z6S1</Swissprot><Swissprot>Q9ZDS7</Swissprot><Swissprot>Q9ZJJ4</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="31623"><DrugName>methylphenidate analog, Pharma-Eco</DrugName><DrugSynonyms><Name><Value>methylphenidate analog, Pharma-Eco</Value></Name></DrugSynonyms><CompanyOriginator id="22748">Pharm-Eco Laboratories Inc</CompanyOriginator><CompaniesSecondary><Company id="22748">Pharm-Eco Laboratories Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22748" type="Company"><TargetEntity id="5001141371" type="organizationId">Pharm-Eco Laboratories Inc</TargetEntity></SourceEntity><SourceEntity id="34" type="ciIndication"><TargetEntity id="F90" type="ICD10"/><TargetEntity id="10003736" type="MEDDRA"/><TargetEntity id="D001289" type="MeSH"/><TargetEntity id="-197354408" type="omicsDisease"/><TargetEntity id="87" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="34">Attention deficit hyperactivity disorder</Indication></IndicationsSecondary><ActionsSecondary><Action id="2940">Psychomodulator</Action><Action id="257">Monoamine uptake inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2008-02-20T18:07:24.000Z</LastModificationDate><ChangeDateLast>2008-02-20T18:07:24.000Z</ChangeDateLast><AddedDate>2000-11-17T16:42:35.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="22748"&gt;Pharm-Eco&lt;/ulink&gt; was investigating an analog of methylphenidate for the treatment of attention-deficit hyperactivity disorder [&lt;ulink linkType="reference" linkID="390245"&gt;390245&lt;/ulink&gt;]. This analog of the active ingredient of the marketed treatment Ritalin has an improved pharmacokinetic profile enabling less frequent dosing and a slower onset of action which reduces the compound's abuse liability [&lt;ulink linkType="reference" linkID="390245"&gt;390245&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22748">Pharm-Eco Laboratories Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="34">Attention deficit hyperactivity disorder</Indication><StatusDate>2008-02-20T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22748">Pharm-Eco Laboratories Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="34">Attention deficit hyperactivity disorder</Indication><StatusDate>2000-11-17T00:00:00.000Z</StatusDate><Source id="390245" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="33490"><DrugName>ESR-1150</DrugName><DrugSynonyms><Name><Value>ESR-1150</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>alpha 1 adrenoceptor agonist, Boehringer Ingleheim</Value></Name></DrugSynonyms><CompanyOriginator id="14881">Boehringer Ingelheim International GmbH</CompanyOriginator><CompaniesSecondary><Company id="14881">Boehringer Ingelheim International GmbH</Company></CompaniesSecondary><CrossReferences><SourceEntity id="14881" type="Company"><TargetEntity id="4298428312" type="organizationId">Boehringer Ingelheim International GmbH</TargetEntity></SourceEntity><SourceEntity id="187" type="ciIndication"><TargetEntity id="10046543" type="MEDDRA"/><TargetEntity id="D014549" type="MeSH"/><TargetEntity id="-1859456438" type="omicsDisease"/><TargetEntity id="355" type="siCondition"/></SourceEntity><SourceEntity id="31" type="Action"><TargetEntity id="50" type="Mechanism">alpha1-Adrenoceptor Agonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="187">Urinary incontinence</Indication></IndicationsSecondary><ActionsPrimary><Action id="31">Alpha 1 adrenoceptor agonist</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>G4B4</Code><Name>Urinary incontinence products</Name></Ephmra></EphmraCodes><LastModificationDate>2014-07-25T11:44:27.000Z</LastModificationDate><ChangeDateLast>2004-03-24T23:48:17.000Z</ChangeDateLast><AddedDate>2001-03-28T11:10:31.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="33490"&gt;ESR-1150&lt;/ulink&gt; is an alpha 1 adrenoceptor agonist which was under development by &lt;ulink linkType="Company" linkID="22546"&gt;Boehringer Ingelheim&lt;/ulink&gt; for the potential treatment of urinary incontinence. Phase I/II clinical trials had been initiated by March 2001 [&lt;ulink linkType="reference" linkID="403269"&gt;403269&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="407163"&gt;407163&lt;/ulink&gt;]; however, no further development has been reported since then. &lt;/para&gt;&lt;para&gt;WO-09632939 and US-06268389 claim the use of alpha 1 adrenoceptor agonists for the potential treatment of incontinence.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><StatusDate>2003-04-11T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14881">Boehringer Ingelheim International GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><StatusDate>2001-03-28T00:00:00.000Z</StatusDate><Source id="403269" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00069"><Name>Alpha 1 adrenoceptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2273405" number="WO-02060421" title="Use of 2-amino-1(4-hydroxy-2-methanesulphonamidophenyl)ethanol for treating urinary incontinence"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boehringer Ingelheim International GmbH" id="14881"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Osaka University" id="20653"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="34405"><DrugName>kallikrein inhibitors, Ferring</DrugName><DrugSynonyms><Name><Value>FE-999024</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>FE-999026</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>kallikrein inhibitors, Ferring</Value></Name><Name><Value>CH-2856</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>CH-4215</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>VA-999024</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29708">Ferring Pharmaceuticals SA</CompanyOriginator><CompaniesSecondary><Company id="29708">Ferring Pharmaceuticals SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="34405" type="Drug"><TargetEntity id="323877" type="siDrug">VA-999024</TargetEntity></SourceEntity><SourceEntity id="29708" type="Company"><TargetEntity id="4296524617" type="organizationId">Ferring Holding SA</TargetEntity></SourceEntity><SourceEntity id="250" type="ciIndication"><TargetEntity id="10033645" type="MEDDRA"/><TargetEntity id="D010195" type="MeSH"/><TargetEntity id="-883850659" type="omicsDisease"/><TargetEntity id="398" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="513" type="Action"><TargetEntity id="3285" type="Mechanism">Kallikrein Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="250">Pancreatitis</Indication></IndicationsSecondary><ActionsPrimary><Action id="513">Kallikrein inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>B2C2</Code><Name>Inhibitors of the Kallikrein-kinin-system</Name></Ephmra></EphmraCodes><LastModificationDate>2010-06-02T15:28:29.000Z</LastModificationDate><ChangeDateLast>2010-06-02T15:28:29.000Z</ChangeDateLast><AddedDate>2001-05-30T12:45:46.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="29708"&gt;Ferring&lt;/ulink&gt; was investigating  a series of selective   kallikrein inhibitors, including compounds FE-999024 (CH-2856; VA-999024) and FE-999026  (CH-4215),  for the potential treatment of pancreatitis [&lt;ulink linkType="reference" linkID="411087"&gt;411087&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="451842"&gt;451842&lt;/ulink&gt;]. By May 1996, preclinical studies had begun [&lt;ulink linkType="Reference" linkID="411089"&gt;411089&lt;/ulink&gt;]; these were ongoing in September 2002 [&lt;ulink linkType="Reference" linkID="463642"&gt;463642&lt;/ulink&gt;]. However, since that date, no further development has been reported, although in March 2008, &lt;ulink linkType="Company" linkID="1040023"&gt;Vantia Therapeutics&lt;/ulink&gt; did acquire a &lt;ulink linkType="Drug" linkID="60402"&gt;kallikrein inhibitor program&lt;/ulink&gt; from Ferring, which presumably stemmed from the program described here [&lt;ulink linkType="Reference" linkID="913854"&gt;913854&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="913802"&gt;913802&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2002, preclinical data were presented on FE-999024 at the 17th International Symposium on Medicinal Chemistry in Barcelona, Spain. The compound inhibited human tissue kallikrein 1 (hK1) with a nanomolar potency (Ki=2.2nM) and showed in vivo potency in animal models of acute pancreatitis. As of September 2002, in vivo preclinical studies were ongoing with FE-999024 [&lt;ulink linkType="reference" linkID="463080"&gt;463080&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="463320"&gt;463320&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2002, preclinical data on the compounds were presented at the Digestive Disease Week meeting in San Francisco, CA. FE-999024 and FE-999026 had Ki values of 5 nM and 6 microM for human tKK, and 1 microM and 3 nM for human pKK, respectively. In a rat model of pancreatitis induced by cerulein infusion, only FE-999024 inhibited signs of tissue damage, though both compounds were effective at preventing edema and plasma protein extravasation in the guinea pig model [&lt;ulink linkType="reference" linkID="451842"&gt;451842&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="451178"&gt;451178&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2001, animal studies were presented at Digestive Disease Week in Atlanta, GA. In a rat model of acute interstitial edematous pancreatitis, tKK activity was increased over 100-fold during pancreatitis and FE-999024 abolished kinin-mediated vascular effects [&lt;ulink linkType="reference" linkID="411087"&gt;411087&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="250">Pancreatitis</Indication><StatusDate>2004-09-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29708">Ferring Pharmaceuticals SA</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="250">Pancreatitis</Indication><StatusDate>1996-05-31T00:00:00.000Z</StatusDate><Source id="411089" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01192"><Name>Kallikrein</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1104942" linkType="reference" linkID="1104942"&gt;1104942&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="37780"><DrugName>SDX-103</DrugName><DrugSynonyms><Name><Value>indanocine analogs, Salmedix</Value></Name><Name><Value>SDX-103</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25451">University of California San Diego</CompanyOriginator><CompaniesSecondary><Company id="25451">University of California San Diego</Company><Company id="29254">Salmedix Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="37780" type="Drug"><TargetEntity id="330111" type="siDrug">SDX-103</TargetEntity></SourceEntity><SourceEntity id="25451" type="Company"><TargetEntity id="4296621839" type="organizationId">University of California San Diego</TargetEntity></SourceEntity><SourceEntity id="29254" type="Company"><TargetEntity id="4296884816" type="organizationId">Salmedix Inc</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="814">Tubulin modulator</Action></ActionsPrimary><ActionsSecondary><Action id="61">Angiogenesis inhibitor</Action><Action id="1589">Apoptosis stimulator</Action><Action id="1545">Anticancer</Action><Action id="759">Anticancer multidrug resistance inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2016-10-08T09:47:02.000Z</LastModificationDate><ChangeDateLast>2016-10-27T00:00:00.000Z</ChangeDateLast><AddedDate>2002-01-14T16:11:10.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="29254" linkType="Company"&gt;Salmedix&lt;/ulink&gt;, licensed from &lt;ulink linkID="25451" linkType="Company"&gt;University of California San Diego&lt;/ulink&gt; (UCSD), was investigating the apoptosis stimulator and angiogenesis inhibitor SDX-103, the lead in a series of indanocine analog tubulin modulators, for the potential treatment of cancer. By late 2001, preclinical studies were ongoing, and pending successful results in these, clinical trials were to be planned [&lt;ulink linkID="432315" linkType="reference"&gt;432315&lt;/ulink&gt;], [&lt;ulink linkID="448301" linkType="reference"&gt;448301&lt;/ulink&gt;]. In June 2005, preclinical studies were still ongoing [&lt;ulink linkID="607690" linkType="Reference"&gt;607690&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The University had also been  investigating a series of &lt;ulink linkID="21042" linkType="Drug"&gt;indanone derivatives&lt;/ulink&gt; that included indanocine analogs.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2002, preclinical data on SDX-103 were presented at the 93rd AACR meeting in San Francisco, CA. When tested in primary CLL cells and in tumor cell lines, SDX-103 retained a similar anti-proliferating and pro-apoptotic activity to indanocine. No toxicity was observed for SDX-103 iv and ip in athymic nude mice at doses up to 300 mg/kg. SDX-103 had antitumor activity in mice bearing P-388 leukemia dosed with 300 mg/kg ip [&lt;ulink linkID="446184" linkType="reference"&gt;446184&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2001, preclinical studies had shown that SDX-103 stimulated apoptosis in non-dividing, multi-drug resistant tumor cells at concentrations low enough not to affect healthy cells. In addition, data suggested it could be a good clinical candidate, having advantages over other tubulin modulators [&lt;ulink linkID="432315" linkType="reference"&gt;432315&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By December 2001, Salmedix had licensed SDX-103 from University of California San Diego [&lt;ulink linkID="432315" linkType="Reference"&gt;432315&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29254">Salmedix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2007-06-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25451">University of California San Diego</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2002-12-05T00:00:00.000Z</StatusDate><Source id="432315" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29254">Salmedix Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2002-12-05T00:00:00.000Z</StatusDate><Source id="432315" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-02029"><Name>Tubulin</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20547">University of California</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="118104" title="Salmedix to develop University of California San Diego's SDX-102 and SDX-103"/></Deals><hasSWOTs>N</hasSWOTs></Drug><Drug id="39122"><DrugName>palifosfamide</DrugName><DrugNamesKey><Name id="42915868">Zymafos</Name><Name id="42880040">palifosfamide</Name><Name id="42996780">palifosfamide tromethamine</Name></DrugNamesKey><DrugSynonyms><Name><Value>ifosfamide analogs, Dekk-Tec</Value></Name><Name><Value>lysine-isophosphoramide mustard (L-IPM), Dekk-Tec</Value></Name><Name><Value>4-hydroperoxyifosfamide, Dekk-Tec</Value></Name><Name><Value>lysine-isophosphoramide mustard (cancer), ZIOPHARM</Value></Name><Name><Value>ifosfamide analogs, ZIOPHARM/Dekk-Tec</Value></Name><Name><Value>ZIO-202</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ZIO-203</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>palifosfamide</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>IPM</Value></Name><Name><Value>Isophosphoramide mustard</Value></Name><Name><Value>lysine-isophosphoramide mustard</Value></Name><Name><Value>L-IPM</Value></Name><Name><Value>ZIO-201</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>palifosfamide lysine</Value></Name><Name><Value>Zymafos</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>L-IPM (cancer), ZIOPHARM</Value></Name><Name><Value>HO-IFOS, Dekk-Tec</Value></Name><Name><Value>palifosfamide-tris</Value></Name><Name><Value>palifosfamide-T</Value></Name><Name><Value>IPM-L</Value></Name><Name><Value>ZIO-201-T</Value></Name><Name><Value>palifosfamide tromethamine</Value><Types><Type>USAN</Type></Types></Name><Name><Value>31645-39-3</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>1070409-31-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15652">Dekk-Tec Inc</CompanyOriginator><CompaniesPrimary><Company id="1122803">Predictive Therapeutics</Company></CompaniesPrimary><CompaniesSecondary><Company id="1009856">ZIOPHARM Oncology Inc</Company><Company id="15652">Dekk-Tec Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="39122" type="Drug"><TargetEntity id="687337" type="siDrug">Palifosfamide tromethamine</TargetEntity><TargetEntity id="437523" type="siDrug">Palifosfamide lysine</TargetEntity></SourceEntity><SourceEntity id="1009856" type="Company"><TargetEntity id="4295902600" type="organizationId">ZIOPHARM Oncology Inc</TargetEntity></SourceEntity><SourceEntity id="1122803" type="Company"><TargetEntity id="5047750621" type="organizationId">Neotx Holdings Ltd</TargetEntity></SourceEntity><SourceEntity id="15652" type="Company"><TargetEntity id="5035523619" type="organizationId">Dekk-Tec Inc</TargetEntity></SourceEntity><SourceEntity id="1054" type="ciIndication"><TargetEntity id="C62" type="ICD10"/><TargetEntity id="186" type="ICD9"/><TargetEntity id="10061379" type="MEDDRA"/><TargetEntity id="D013736" type="MeSH"/><TargetEntity id="-1177649515" type="omicsDisease"/><TargetEntity id="648" type="siCondition"/></SourceEntity><SourceEntity id="1261" type="ciIndication"><TargetEntity id="10041056" type="MEDDRA"/><TargetEntity id="D055752" type="MeSH"/><TargetEntity id="70573" type="ORPHANET"/><TargetEntity id="-1257831198" type="omicsDisease"/><TargetEntity id="614" type="siCondition"/></SourceEntity><SourceEntity id="194" type="ciIndication"><TargetEntity id="10039491" type="MEDDRA"/><TargetEntity id="D012509" type="MeSH"/><TargetEntity id="-172901782" type="omicsDisease"/><TargetEntity id="714" type="siCondition"/></SourceEntity><SourceEntity id="203" type="ciIndication"><TargetEntity id="10025310" type="MEDDRA"/><TargetEntity id="D008223" type="MeSH"/><TargetEntity id="-386134440" type="omicsDisease"/><TargetEntity id="698" type="siCondition"/></SourceEntity><SourceEntity id="3378" type="ciIndication"><TargetEntity id="10041299" type="MEDDRA"/><TargetEntity id="3394" type="ORPHANET"/><TargetEntity id="1736" type="siCondition"/></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"/><TargetEntity id="589" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"/><TargetEntity id="10033128" type="MEDDRA"/><TargetEntity id="D010051" type="MeSH"/><TargetEntity id="-1370909262" type="omicsDisease"/><TargetEntity id="626" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="50" type="Action"><TargetEntity id="1404" type="Mechanism">DNA-Damaging Drugs</TargetEntity><TargetEntity id="1895" type="Mechanism">DNA Alkylating Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="651">Cancer</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1054">Testis tumor</Indication><Indication id="1261">Small-cell lung cancer</Indication><Indication id="194">Sarcoma</Indication><Indication id="203">Lymphoma</Indication><Indication id="3378">Soft tissue sarcoma</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="3713">Advanced solid tumor</Indication><Indication id="799">Ovary tumor</Indication></IndicationsSecondary><ActionsSecondary><Action id="803">DNA modulator</Action><Action id="50">Anticancer alkylating agent</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>L1A</Code><Name>ALKYLATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-31T13:27:57.000Z</LastModificationDate><ChangeDateLast>2016-08-31T00:00:00.000Z</ChangeDateLast><AddedDate>2002-04-08T15:38:46.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1122803" linkType="Company"&gt;Predictive Therapeutics&lt;/ulink&gt;, under license from &lt;ulink linkID="1009856" linkType="Company"&gt;ZIOPHARM Oncology&lt;/ulink&gt; (previously under license from &lt;ulink linkID="15652" linkType="Company"&gt;Dekk-Tec&lt;/ulink&gt;), is investigating palifosfamide (ZIO-201; Zymafos; isophosphoramide mustard, IPM; structure shown), the lead bifunctional DNA alkylator and cross-linker in a series of preactivated forms of &lt;ulink linkID="52416" linkType="Drug"&gt;ifosfamide&lt;/ulink&gt;, for the potential treatment of cancer [&lt;ulink linkID="1754527" linkType="Reference"&gt;1754527&lt;/ulink&gt;], [&lt;ulink linkID="1754683" linkType="Reference"&gt;1754683&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;ZIOPHARM Oncology was developing the drug for the potential iv treatment of ifosfamide-responsive tumor types, such as small-cell lung cancer (SCLC) [&lt;ulink linkID="570163" linkType="Reference"&gt;570163&lt;/ulink&gt;], [&lt;ulink linkID="1158066" linkType="Reference"&gt;1158066&lt;/ulink&gt;]. In June 2012,   an adaptive phase III trial for SCLC was initiated [&lt;ulink linkID="1299839" linkType="Reference"&gt;1299839&lt;/ulink&gt;], [&lt;ulink linkID="1299824" linkType="Reference"&gt;1299824&lt;/ulink&gt;]; in January 2013, interim analysis of the trial was expected around the end of 2013 [&lt;ulink linkID="1357284" linkType="Reference"&gt;1357284&lt;/ulink&gt;]; in March 2013, the phase III trial was converted to a phase II trial after failure of the drug to meet its primary endpoint in a phase III trial in soft tissue sarcoma (STS) [&lt;ulink linkID="1534551" linkType="Reference"&gt;1534551&lt;/ulink&gt;].  In March 2013, a phase II trial in metastatic germ cell tumors, including testicular and ovarian tumors, was initiated [&lt;ulink linkID="1389178" linkType="Reference"&gt;1389178&lt;/ulink&gt;]. In March 2013, a phase II trial was initiated in patients with breast cancer [&lt;ulink linkID="1390612" linkType="Reference"&gt;1390612&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;ZIOPHARM was previously developing the drug for the potential treatment of STS.  In July 2010,  a phase III study of the drug in combination with doxorubicin for STS began [&lt;ulink linkID="1117205" linkType="Reference"&gt;1117205&lt;/ulink&gt;]; in January 2013,   it was hoped that an NDA submission would be made toward the end of 2013 or in early 2014 [&lt;ulink linkID="1357284" linkType="Reference"&gt;1357284&lt;/ulink&gt;]. However, in March 2013, the company decided to discontinue this indication after the  primary endpoint was not met in the trial was not met [&lt;ulink linkID="1396177" linkType="Reference"&gt;1396177&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Other indications such as lymphoma and pediatric cancers were under consideration. By September 2007, trials were being planned [&lt;ulink linkID="833169" linkType="Reference"&gt;833169&lt;/ulink&gt;]; however, no development has been reported for some time.&lt;/para&gt;&lt;para&gt;ZIOPHARM is also investigating oral formulation of &lt;ulink linkID="61655" linkType="Drug"&gt;palifosfamide&lt;/ulink&gt; for ifosfamide-responsive tumor types, such as sarcomas.&lt;/para&gt;&lt;para&gt;Dekk-Tec has also investigated other preactivated forms of ifosfamide, including 4-hydroperoxyifosfamide (&lt;ulink linkID="68054" linkType="Drug"&gt;HOO-IFOS&lt;/ulink&gt;) and its synthetic stable precursor HO-IFOS, as well as isophosphoramide mustard (IPM), ZIO-202 and ZIO-203 [&lt;ulink linkID="446255" linkType="Reference"&gt;446255&lt;/ulink&gt;], [&lt;ulink linkID="570163" linkType="Reference"&gt;570163&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In October 2008, the EMEA's COMP adopted a positive opinion on granting palifosfamide Orphan Drug status for STS [&lt;ulink linkID="952731" linkType="Reference"&gt;952731&lt;/ulink&gt;]. In December 2008, the drug was granted EU Orphan status for STS [&lt;ulink linkID="970894" linkType="Reference"&gt;970894&lt;/ulink&gt;], [&lt;ulink linkID="972793" linkType="Reference"&gt;972793&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2008, the FDA awarded palifosfamide Orphan status for STS [&lt;ulink linkID="904226" linkType="Reference"&gt;904226&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;&lt;subtitle&gt;Sarcoma&lt;/subtitle&gt;In November 2007, a randomized phase III trial was planned for 2008 [&lt;ulink linkID="847709" linkType="Reference"&gt;847709&lt;/ulink&gt;]. In May 2009, a registration study was expected to start in the first half of 2010 [&lt;ulink linkID="1010257" linkType="Reference"&gt;1010257&lt;/ulink&gt;]. In October 2009, it was disclosed that the trial would start once a regulatory review had been conducted [&lt;ulink linkID="1049563" linkType="Reference"&gt;1049563&lt;/ulink&gt;]. In November 2009,  ZIOPHARM was discussing the registration trial in STS with US and international regulatory authorities. The trial was expected to begin in the first half of  2010 [&lt;ulink linkID="1055307" linkType="Reference"&gt;1055307&lt;/ulink&gt;]; [&lt;ulink linkID="1056246" linkType="Reference"&gt;1056246&lt;/ulink&gt;]. In January 2010, an end-of-phase II meeting was conducted with the FDA. At that time, the company planned to seek an SPA for the phase III trial. In June 2010, the planned randomized, double-blinded, placebo-controlled, pivotal, phase III, PICASSO 3 trial (&lt;ulink linkID="68528" linkType="Protocol"&gt;NCT01168791&lt;/ulink&gt;; IPM3001) was to treat metastatic soft tissue sarcoma patients with doxorubicin and palifosfamide. Enrollment was to start in the third quarter of 2010 [&lt;ulink linkID="1109659" linkType="Reference"&gt;1109659&lt;/ulink&gt;]. In July 2010, the 424-patient study began. The study was to be conducted in North America, Europe, South America, Australia, Israel and Korea [&lt;ulink linkID="1117205" linkType="Reference"&gt;1117205&lt;/ulink&gt;]. In November 2011, enrollment was expected to complete in the first quarter of 2012 and primary endpoint data were anticipated in  the second half of 2012 [&lt;ulink linkID="1236357" linkType="Reference"&gt;1236357&lt;/ulink&gt;]. In January 2012, the independent data monitoring committee (IDMC) recommended continuation of the trial and at that time enrollment was expected to be completed by the end of  the first quarter of 2012  [&lt;ulink linkID="1258591" linkType="Reference"&gt;1258591&lt;/ulink&gt;]. In April 2012, the company reported that  the  trial was approaching 90% completion that included the  central review of pathology and radiology of subjects before getting randomized [&lt;ulink linkID="1277090" linkType="Reference"&gt;1277090&lt;/ulink&gt;]. In June 2012, enrollment was completed [&lt;ulink linkID="1298050" linkType="Reference"&gt;1298050&lt;/ulink&gt;]; later that month, the progression-free survival data from the trial were expected in the fourth quarter of 2012; in November 2012,  the trial's IDMC meet was  to occur in  the middle of that month  [&lt;ulink linkID="1339053" linkType="Reference"&gt;1339053&lt;/ulink&gt;]. In November 2012, the IDMC recommended that the study proceed without any changes. At that time, progression-free survival data were expected in the first quarter of 2013 [&lt;ulink linkID="1340911" linkType="Reference"&gt;1340911&lt;/ulink&gt;]. In January 2013, it was reported at the 31st Annual JPMorgan Healthcare Conference in San Francisco, CA, that top-line data would be released by the end of 1Q 2013 [&lt;ulink linkID="1357284" linkType="Reference"&gt;1357284&lt;/ulink&gt;]. In February 2013, the company reported that the trial reached its target number of progression-free survival. At that time, topline data were expected to be reported in the 'last week of March 2013' [&lt;ulink linkID="1382743" linkType="Reference"&gt;1382743&lt;/ulink&gt;]. In March 2013, data were expected to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL [&lt;ulink linkID="1393258" linkType="Reference"&gt;1393258&lt;/ulink&gt;]; later that month, the company reported that the trial did not met its primary endpoint of progression-free survival, however IDMC recommended to continue with the secondary endpoint of overall survival. At that time, the company decided to discontinue the trial with STS and results were to be published in a scientific journal [&lt;ulink linkID="1396177" linkType="Reference"&gt;1396177&lt;/ulink&gt;]. In October 2013, data from the international study were presented at the 2013 European Cancer Congress in Amsterdam, The Netherlands. Patients (n = 447)  received doxorubicin (75 mg/m2 iv) plus either palifosfamide (150 mg/m2 iv) or placebo. The median PFS was 5.98 versus 5.23 months for palifosfamide + doxorubicin versus placebo plus doxorubicin group. The median overall survival was 15.91 months for palifosfamide + doxorubicin when compared with 16.89 months for placebo plus doxorubicin. At that time, subgroup analysis was ongoing [&lt;ulink linkID="1480397" linkType="Reference"&gt;1480397&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metastatic soft-tissue sarcomaPhase II&lt;/subtitle&gt;In December 2008, a multi-center, parallel group, randomized, phase II study called  'PICASSO' (2008-004856-57) was initiated  to assess the safety and efficacy of the  drug in combination with doxorubicin in     subjects with unresectable or metastatic soft-tissue sarcoma [&lt;ulink linkID="1625736" linkType="Reference"&gt;1625736&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;SCLC&lt;/subtitle&gt;In February 2012,  the company planned to initiate an adaptive phase III trial for SCLC [&lt;ulink linkID="1260404" linkType="Reference"&gt;1260404&lt;/ulink&gt;]; in May 2012, this was slated for the third quarter of 2012 [&lt;ulink linkID="1287360" linkType="Reference"&gt;1287360&lt;/ulink&gt;]. In June 2012, recruitment began in the multicenter, randomized, controlled, open-label, adaptive, phase III MATISSE study (&lt;ulink linkID="85721" linkType="Protocol"&gt;NCT01555710&lt;/ulink&gt;; IPM3002). The trial would assess palifosfamide-tris in combination with &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; and &lt;ulink linkID="3072" linkType="Drug"&gt;etoposide&lt;/ulink&gt; versus carboplatin and etoposide alone in chemotherapy-naive, extensive-stage SCLC patients (n = 548). The primary endpoint would be overall survival assessed every 12 weeks up to 1 year. At that time, the study was expected to complete in June 2015 [&lt;ulink linkID="1299839" linkType="Reference"&gt;1299839&lt;/ulink&gt;]; later that month, the first patient was dosed from the pivotal MATISSE study. The company reported that the trial would be conducted in North America, Europe, Australia and Asia. At that time, a single, pre-planned interim analysis was scheduled to occur following 125 events was to be conducted by an IDMC [&lt;ulink linkID="1299824" linkType="Reference"&gt;1299824&lt;/ulink&gt;]. By December 2012, the IDMC had recommended the trial to continue following the analysis of safety data in 20 patients [&lt;ulink linkID="1393258" linkType="Reference"&gt;1393258&lt;/ulink&gt;]. In January 2013, it was reported at the 31st Annual JPMorgan Healthcare Conference in San Francisco, CA, that the interim analysis would occur around the end of 2013 [&lt;ulink linkID="1357284" linkType="Reference"&gt;1357284&lt;/ulink&gt;]. In March 2013, the phase III trial was converted to a phase II trial after failure of the drug to meet its primary endpoint in the phase III STS trial [&lt;ulink linkID="1534551" linkType="Reference"&gt;1534551&lt;/ulink&gt;]. In May 2015,  efficacy and safety data were presented at the 51st ASCO meeting in Chicago, IL. Overall survival (primary endpoint) was 10.37 and 10.03 months; serious adverse events (SAE; secondary endpoint) were observed in 25.5 and 28.3% of patients in the carboplatin + etoposide arm and palifosfamide + carboplatin + etoposide arm, respectively [&lt;ulink linkID="1662247" linkType="Reference"&gt;1662247&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2013, &lt;ulink linkID="20593" linkType="Company"&gt;Indiana University&lt;/ulink&gt;-sponsored an open-label, single group assigned, multi-center, single-arm, efficacy, phase II trial (&lt;ulink linkID="115153" linkType="Protocol"&gt;NCT01808534&lt;/ulink&gt;; IUCRO-0403  NCI-2013-00510  1301010501) was initiated in the US, in patients (expected n = 5) with recurrent and incurable germ cell tumors, including testicular and ovarian tumors, who have relapsed on initial platinum-based therapy and high dose chemotherapy [&lt;ulink linkID="1389178" linkType="Reference"&gt;1389178&lt;/ulink&gt;], [&lt;ulink linkID="1737429" linkType="Reference"&gt;1737429&lt;/ulink&gt;]. In July 2015, the trial was terminated [&lt;ulink linkID="1737429" linkType="Reference"&gt;1737429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2012, Ziopharm planned a randomized, open label, phase II trial (&lt;ulink linkID="94278" linkType="Protocol"&gt;NCT01703754&lt;/ulink&gt;, ATI001-201), of palifosfamide-tris in combination with &lt;ulink linkID="69775" linkType="Drug"&gt;Ad-RTS-IL-12&lt;/ulink&gt; in patients (n = 65) with advanced breast cancer. At that time, the expected study start date was November 2012 [&lt;ulink linkID="1333467" linkType="Reference"&gt;1333467&lt;/ulink&gt;]. In March 2013, the two-part, multicenter study was initiated in patients with non-resectable, recurrent or metastatic breast cancer (expected n = 68). The first part of the trial would assess the safety of Ad-RTS IL-12 and palifosfamide, alone or in combination and the second part would evaluate the efficacy of Ad-RTS IL-12 alone and in combination with palifosfamide [&lt;ulink linkID="1390612" linkType="Reference"&gt;1390612&lt;/ulink&gt;]; at that time, the trial was expected to complete in February 2016 [&lt;ulink linkID="1333467" linkType="Reference"&gt;1333467&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By February 2006, the company was planning phase II trials in lymphoma [&lt;ulink linkID="652209" linkType="Reference"&gt;652209&lt;/ulink&gt;]; in June 2006, trials were in late-stage planning [&lt;ulink linkID="671540" linkType="Reference"&gt;671540&lt;/ulink&gt;]. In March 2007, a phase II trial was scheduled to start later that year [&lt;ulink linkID="777458" linkType="Reference"&gt;777458&lt;/ulink&gt;]; in July 2007, planning was in the "advanced" stage [&lt;ulink linkID="811650" linkType="Reference"&gt;811650&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Also by February 2006, the company was planning phase II trials in pediatric sarcoma [&lt;ulink linkID="652209" linkType="Reference"&gt;652209&lt;/ulink&gt;]; in June 2006, trials were in late-stage planning [&lt;ulink linkID="671540" linkType="Reference"&gt;671540&lt;/ulink&gt;]. In July 2007, planning was in the "advanced" stage [&lt;ulink linkID="811650" linkType="Reference"&gt;811650&lt;/ulink&gt;]; this was still the case in September 2007 [&lt;ulink linkID="833169" linkType="Reference"&gt;833169&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I/II&lt;/subtitle&gt;By September 2008, the company had initiated dosing in the phase II arm (&lt;ulink linkID="41891" linkType="Protocol"&gt;NCT00718484&lt;/ulink&gt;; IPM2002; PICASSO) of the phase I/II trial &lt;ulink linkID="41881" linkType="Protocol"&gt;NCT00608803&lt;/ulink&gt; in patients with STS in the US and Europe. In the study, 100 patients would be randomized to receive palifosfamide plus doxorubicin or doxorubicin alone. The primary endpoint would be progression-free survival [&lt;ulink linkID="941010" linkType="Reference"&gt;941010&lt;/ulink&gt;]. In August 2009, enrollment was ongoing [&lt;ulink linkID="1033832" linkType="Reference"&gt;1033832&lt;/ulink&gt;]. In October 2009, topline interim data from a 3-month median follow-up analysis of 58 patients showed that 13 progression-free survival events had occurred in the doxorubicin group, and 6 had occurred in the doxorubicin and palifosfamide combination group. The hazard ratio was 0.67 favoring the combination. Safety data showed palifosfamide did not increase toxicity. In the both treatment groups, the most common adverse events were neutropenia, fatigue, nausea, hypokalemia, leucopenia, anemia and alopecia. Following a positive safety and efficacy review by the data committee, enrollment in the trial was stopped. Full data would be presented at the Connective Tissue Oncology Society Annual Meeting in November 2009 [&lt;ulink linkID="1049563" linkType="Reference"&gt;1049563&lt;/ulink&gt;]. In November 2009, further data from the trial were presented at the 15th Annual Connective Tissue Oncology Society meeting in Miami, FL. As of October 05, 2009, there were 61 evaluable patients with 20 progression-free survival events; 14 in the   arm and 6 in the combination arm, leading to a hazard ratio of 0.63 favoring the combination. The median progression-free survival for doxorubicin was 4.4 months but has not been reached for the combination. The data were determined to be sufficient to proceed to a pivotal study [&lt;ulink linkID="1055307" linkType="Reference"&gt;1055307&lt;/ulink&gt;]. In June 2010, positive data from the trial were presented at the 46th ASCO meeting in Chicago, IL. A hazard ratio of 0.39 was reported for patients who received doxorubicin alone or doxorubicin and palifosfamide combination for 6 cycles or less. The RECIST response rate  for the palifosfamide arm was 23%, and for the doxorubicin arm alone was 9% [&lt;ulink linkID="1171985" linkType="Reference"&gt;1171985&lt;/ulink&gt;],  [&lt;ulink linkID="1263194" linkType="Reference"&gt;1263194&lt;/ulink&gt;]. In February 2012, positive preliminary overall survival data from the trial demonstrated a meaningfully positive trend favoring the palifosfamide arm with intent-to-treat (ITT) and modified ITT hazard ratios of 0.79 and 0.78, respectively. Approximately 40% of subjects treated with palifosfamide were alive at 2-years after starting treatment. A total of 30% in the control arm treated with doxorubicin (including those who crossed-over and received subsequent palifosfamide) were alive, compared to an expected 25% based on randomized data. At that time, final results were expected to be reported at a major medical conference in the second half of 2012 [&lt;ulink linkID="1263194" linkType="Reference"&gt;1263194&lt;/ulink&gt;]. In October 2012, Ziopharm issued a statement to address concerns over the validity of the PICASSO trial. The company maintained that the Form 483 issued to the investigator regarding study site regulation breaches had no impact on the study or the quality of the data, as reviewed by an independent  former FDA GCP auditor [&lt;ulink linkID="1333388" linkType="Reference"&gt;1333388&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By February 2008, dosing in a phase I/II trial (&lt;ulink linkID="41881" linkType="Protocol"&gt;NCT00608803&lt;/ulink&gt;; IPM1002) of palifosfamide plus doxorubicin in subjects (expected n = 30) with advanced refractory solid tumors had begun [&lt;ulink linkID="873703" linkType="Reference"&gt;873703&lt;/ulink&gt;]. In November 2008, at the 14th annual Connective Tissue Oncology Society meeting in London, UK, data were reported from the phase I part of the trial which had enrolled 13 patients to date. Of 12 evaluable patients, 3 had partial responses. Of 8 patients, 2 achieved partial responses and the remaining 6 patients were progression free with a median duration of follow-up of 15 weeks. The combination was well tolerated with no dose-limiting toxicities reported and no patients experienced encephalopathy, renal or bladder toxicity [&lt;ulink linkID="964070" linkType="Reference"&gt;964070&lt;/ulink&gt;], [&lt;ulink linkID="1046620" linkType="Reference"&gt;1046620&lt;/ulink&gt;]. In May 2009, similar data were presented at the 45th ASCO meeting in Orlando, FL [&lt;ulink linkID="1014295" linkType="Reference"&gt;1014295&lt;/ulink&gt;], [&lt;ulink linkID="1013010" linkType="Reference"&gt;1013010&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2006, the FDA approved a phase I/II trial in advanced sarcoma patients. At that time, the study was expected to start in early 2006 in the US, Canada and the UK. Completion of enrollment was expected by the end of 2006 [&lt;ulink linkID="643418" linkType="Reference"&gt;643418&lt;/ulink&gt;]. In February 2006, a phase I/II trial (&lt;ulink linkID="24295" linkType="Protocol"&gt;NCT00439686&lt;/ulink&gt;; IPM2001) began in patients (expected n = 40) with advanced sarcoma [&lt;ulink linkID="652209" linkType="Reference"&gt;652209&lt;/ulink&gt;]. In July 2007, interim results were reported at the European Society of Medical Oncology meeting in Lugano, Switzerland. Out of the first ten evaluable patients (median four prior treatments) of the 39 enrolled subjects, one partial response (21 weeks and ongoing) was seen and four exhibited stable disease. Of these five subjects, two had progressed through prior ifosfamide treatment. Palifosfamide was also shown to be well tolerated and no significant bone marrow suppression, alopecia or neurotoxicity was observed. Following the data, enrollment was expanded to include additional patients [&lt;ulink linkID="811650" linkType="Reference"&gt;811650&lt;/ulink&gt;]. In September 2007, positive interim efficacy data from an ongoing phase II sarcoma trial were presented at the 14th Annual European Cancer Conference meeting in Barcelona, Spain. The trial had enrolled 51 patients, of whom 31 were evaluable at that time. Clinically beneficial responses were seen in 14 patients, of whom one had a partial response, four had minor responses and nine had stable disease (SD). Five of the seven leiomyosarcoma patients had SD or better. The drug was well tolerated with mild to moderate gastrointestinal or renal side effects and no significant bone marrow suppression, alopecia or neurotoxicity [&lt;ulink linkID="833169" linkType="Reference"&gt;833169&lt;/ulink&gt;]. In November 2007, further data were presented at the Connective Tissue Oncology Society annual meeting in Seattle, WA. The trial was fully enrolled with 54 patients, of which 50 were in phase II. Of 44 evaluable patients, 48% had stable disease or better with a median progression-free survival of 10 weeks. Of the 11 subjects enrolled who had not previously received ifosfamide, 64% had stable disease or better and the median progression-free survival had not been reached [&lt;ulink linkID="847709" linkType="Reference"&gt;847709&lt;/ulink&gt;]. In November 2008, at the 14th Annual Connective Tissue Oncology Society meeting in London, UK, data showed that palifosfamide-treated patients with STS had a 3-month progression free rate of 45%. Ifosfamide-naive patients that received palifosfamide had a progression free rate of 55%. The 6-month free rate was 23%. No patients experienced encephalopathy, renal or bladder toxicity. In September 2009, the trial was ongoing but not recruiting patients [&lt;ulink linkID="964070" linkType="Reference"&gt;964070&lt;/ulink&gt;], [&lt;ulink linkID="1046620" linkType="Reference"&gt;1046620&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By May 2005, a phase I/II trial and two phase II cancer trials were expected to start in the second half of 2005 [&lt;ulink linkID="596444" linkType="Reference"&gt;596444&lt;/ulink&gt;], [&lt;ulink linkID="602471" linkType="Reference"&gt;602471&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I and other clinical data&lt;/subtitle&gt;In June 2011, an open-label, phase I study (&lt;ulink linkID="76751" linkType="Protocol"&gt;NCT01340547&lt;/ulink&gt;; IPM1005) was initiated in patients with advanced solid tumors (expected n = 24) in the US, to assess the safety, pharmacokinetics and preliminary efficacy of palifosfamide. At that time, the study was scheduled to complete in August 2012 [&lt;ulink linkID="1257595" linkType="Reference"&gt;1257595&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; In July 2010, a phase I trial for SCLC was to start in the fourth quarter of 2010, and be followed by a phase II trial [&lt;ulink linkID="1120135" linkType="Reference"&gt;1120135&lt;/ulink&gt;]; in November 2010, a phase I, open-label, multicenter, single arm study (&lt;ulink linkID="72298" linkType="Protocol"&gt;NCT01242072&lt;/ulink&gt;; IPM1004) was initiated to assess the safety of the drug in combination with etoposide and carboplatin, in patients (expected n=12) of age 18 years and older, with solid tumors, including non-small-cell lung cancer, SCLC, testicular cancer, ovarian cancer, osteosarcoma and  thymoma. The maximum tolerated dose would also be determined. At that time, the study was expected to be completed in July 2011 [&lt;ulink linkID="1158157" linkType="Reference"&gt;1158157&lt;/ulink&gt;]. In December 2010, the first patient was dosed  [&lt;ulink linkID="1158066" linkType="Reference"&gt;1158066&lt;/ulink&gt;].  In November 2011, data were presented from 22 patients at the 23rd AACR-NCI-EORTC International Conference in San Francisco, CA. Of the 22 patients evaluable, 5 showed partial response, 4 had stable disease, and 4 had progressive disease. Overall, the combination treatment was well tolerated and showed activity in NSCLC, SCLC, germ cell tumor and ovarian cancer. At that time, patients were being evaluated in the 130 mg/m2 palifosfamide plus 100 mg/m2 etoposide and carboplatin (AUC4) group, and a confirmatory study was planned to be performed in SCLC patients [&lt;ulink linkID="1239918" linkType="Reference"&gt;1239918&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; In September 2007, trials in ovarian cancer were in the advanced planning stage [&lt;ulink linkID="833169" linkType="Reference"&gt;833169&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2002, an IND had been submitted for ZIO-210 [&lt;ulink linkID="446255" linkType="Reference"&gt;446255&lt;/ulink&gt;]. In November 2004, phase I cancer trials began; these were expected to be completed by the first quarter of 2005 [&lt;ulink linkID="570163" linkType="Reference"&gt;570163&lt;/ulink&gt;]. In April 2005, a Detroit-based trial, in late-stage cancers, was ongoing [&lt;ulink linkID="596444" linkType="Reference"&gt;596444&lt;/ulink&gt;]. In May 2005, a second site was to be added to the trial 'soon' [&lt;ulink linkID="602471" linkType="Reference"&gt;602471&lt;/ulink&gt;]. By February 2006, the maximum tolerated dose had not been reached, and one patient had stable disease for more than a year [&lt;ulink linkID="651059" linkType="Reference"&gt;651059&lt;/ulink&gt;]. In June 2006, clinical data were presented at the 42nd ASCO meeting in Atlanta, GA. The MTD was approximately 1.5 g/m2/cycle. The trial was ongoing [&lt;ulink linkID="671540" linkType="Reference"&gt;671540&lt;/ulink&gt;]. Further phase I data were reported in November 2006 at the Connective Tissue Oncology Society meeting in Venice, Italy. By that time, the trial had expanded to Houston and Santa Monica. In the dose-ranging studies, patients received palifosfamide daily for 3 consecutive days every 4 weeks. Clinical efficacy was observed in 2 of 11 sarcoma patients and one patient with mesothelioma. No bone marrow toxicity, hemorrhagic cystitis or CNS toxicity were observed and the maximum tolerated dose was 400 mg/m2/d. The dose limiting toxicity was electrolyte imbalance [&lt;ulink linkID="738737" linkType="Reference"&gt;738737&lt;/ulink&gt;]. In July 2007, the phase I trial was ongoing, with the aim of evaluating the drug's maximum tolerated dose in alternate schedules [&lt;ulink linkID="811650" linkType="Reference"&gt;811650&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By February 2008, data had shown potent synergistic activity between palifosfamide, and doxorubicin and &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; [&lt;ulink linkID="873703" linkType="Reference"&gt;873703&lt;/ulink&gt;], [&lt;ulink linkID="895600" linkType="Reference"&gt;895600&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, preclinical data were presented at the 98th AACR meeting in Los Angeles, CA. Palifosfamide administered po to mice with P388 leukemia increased life span by 150% compared to vehicle-treated controls. Similarly, a comparison of oral and systemic administration of palifosfamide in MX-1 breast cancer xenografts showed a similar decrease in tumor growth for both routes of administration: 80% for ip and 65% for po. The maximum tolerated dose for oral administration was 5-fold that of ip, which coincided with the maximal efficacious dose [&lt;ulink linkID="783194" linkType="Reference"&gt;783194&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, data showing palifosfamide was 30-fold more active than IFOS in vitro and in vivo models of lymphoma presented at the World Congress of the International Society of Hematology in Punta del Este, Uruguay. Furthermore, palifosfamide killed IFOS-resistant lymphoma in cancer-bearing mice [&lt;ulink linkID="777458" linkType="Reference"&gt;777458&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2006, data showing palifosfamide efficacy in cyclophosphamide (CPA)-resistant pediatric sarcoma models were presented at the Connective Tissue Oncology Society meeting in Venice, Italy. Sarcoma cell lines with high intracellular aldehyde dehydrogenase 3A1 levels were killed by the drug but not by CPA. Furthermore, palifosfamide-treated mice with xenografts of CPA-resistant human sarcoma cells had over a 5-fold reduction in sarcoma growth whereas CPA therapy had no effect. The results were comparable to palifosfamide administered as a single dose or three daily doses and supported a phase I/II trial in pediatric cancers as well as other trials involving different routes of administration of the drug [&lt;ulink linkID="738147" linkType="Reference"&gt;738147&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2006, data showing that palifosfamide was active against cancers resistant to CPA and, or ifosfamide, were presented at the 2006 Bone Marrow Transplant Meetings in Honolulu, HI. The data indicated that the drug might be useful in conditioning regimens for blood cell and bone marrow transplants. Further in vitro data showed that the metabolites of cyclophosphamide and ifosfamide, chloroacetaldehyde and acrolein, killed proximal kidney tubule cells, whereas palifosfamide did not [&lt;ulink linkID="651059" linkType="Reference"&gt;651059&lt;/ulink&gt;], [&lt;ulink linkID="651367" linkType="Reference"&gt;651367&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other preactivated forms of ifosfamide&lt;/subtitle&gt;In April 2005, preclinical data on palifosfamide and IPM were presented at the 96th AACR meeting in Anaheim, CA. Palifosfamide and IPM were administered iv to adult mice, daily for 3 days. The sub-acute LD10/50 values for palifosfamide were 133 and 220 mg/kg, compared with 119 and 149 mg/kg for IPM, respectively. The dose-limiting toxicity of both drugs was hematological failure. In the MX1 human breast tumor model, palifosfamide showed greater efficacy than IPM, with a maximum tolerated dose of 93 and 40 mg/kg and tumor inhibition of 10.2 and 2.1 days, respectively, relative to controls. No CNS, kidney or bladder toxicities were noted with palifosfamide because, unlike IPM, palifosfamide is not metabolized to acrolein or acetaldehydes [&lt;ulink linkID="597318" linkType="Reference"&gt;597318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2002, preclinical data on IPM were presented at the 14th EORTC-NCI-AACR meeting in Germany, Frankfurt. IPM was administered by infusion once daily x 3 to 16 beagle dogs with dose escalation between 1 and 100 mg/kg, one bolus to two monkeys (5 mg/kg) and to ten mice (100 mg/kg). The half-life was approximately 25 min (dogs receiving a median dose of 5 mg/kg). Maximum tolerated dose was 5 mg/kg. Plasma clearance was constant between 5 and 10 mg/kg (1.40 l/h/kg) and increased at 100 mg/kg (5.7 l/h/kg). At 5 mg/kg, no IPM was detected 1.5 h post-injection, at 10 mg/kg after 2 h and at 100 mg/kg after 4 h. Toxicity noted was death at doses greater than 10 mg/kg, and at 5 mg/kg or less, transient liver and renal, bone marrow, and gastrointestinal dysfunctions, although no IPM was detectable in plasma. For mice, plasma concentrations decreased in less than 1 h, with a clearance of 8.44 l/h/kg; half-life was 3.42 min (two compartment model). In monkeys, the mean half-life-a and half-life-b values were 4.86 and 256 min, respectively. Median clearance was 1.65 l/h/kg and no IPM was detected 4 h post-dose. No major toxicities were noted. Human pharmacokinetic parameters were predicted from allometric analysis using the three species. Data predicted an starting dose of 30 mg/m2 with a clearance of 40.5 l/h, a half-life-a and half-life-b of 10 min and 1 h 45 min, respectively, for a 70 kg patient [&lt;ulink linkID="470617" linkType="Reference"&gt;470617&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002, preclinical data on &lt;ulink linkID="68054" linkType="Drug"&gt;HOO-IFOS&lt;/ulink&gt; and IPM were presented at the 93rd AACR meeting in San Francisco, CA. Both compounds had been assayed in human tumor xenograft models in which they showed favorable activity [&lt;ulink linkID="446255" linkType="Reference"&gt;446255&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Since palifosfamide in its free acid form was too unstable in solution, the company developed a hydroxymethylaminomethane (tris) salt formulation of palifosfamide (palifosfamide-tris); this formulation superseded a lysine salt of palifosfamide (L-IPM) that had safety issues [&lt;ulink linkID="659916" linkType="Reference"&gt;659916&lt;/ulink&gt;], [&lt;ulink linkID="783194" linkType="Reference"&gt;783194&lt;/ulink&gt;]. Palifosfamide is not metabolized to acrolein or chloroacetaldehyde which cause bladder or central nervous system toxicities, which are issues of the prodrug ifosfamide [&lt;ulink linkID="811650" linkType="Reference"&gt;811650&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Susanne Jung &amp;amp; Bernd Kasper, &lt;ulink linkType="Company" linkID="28348"&gt;University of Heidelberg&lt;/ulink&gt;, Department of Internal Medicine V, Germany&lt;/para&gt;&lt;para&gt;Submission date: 28 September 2009&lt;br/&gt;Publication date: 05 January 2010&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Abstract&lt;/subtitle&gt;Isophosphoramide mustard is an active metabolite of ifosfamide, a prodrug used in the treatment of several tumor entities, including bone and soft-tissue sarcoma. However, isophosphoramide mustard is chemically unstable and cannot be administered directly; additionally, other metabolites of ifosfamide are known to cause severe side effects. Palifosfamide, under development by &lt;ulink linkType="Company" linkID="1009856"&gt;ZIOPHARM Oncology Inc&lt;/ulink&gt;, is a formulation of isophosphoramide mustard stabilized with tris(hydroxymethyl)aminomethane salt (palifosfamide-tris) to enable intravenous and &lt;ulink linkType="Drug" linkID="61655"&gt;oral administration&lt;/ulink&gt;. Preclinical studies demonstrated that palifosfamide-tris had an antitumor efficiency comparable or superior to that of ifosfamide. In phase I and I/II trials of the intravenous form, patients treated with palifosfamide-tris did not display any of the neurotoxic or nephrotoxic side effects associated with ifosfamide. A phase III trial was being planned at the time of publication. Palifosfamide-tris is expected to be a safer and less toxic alternative to ifosfamide; however, considering other new approaches under investigation for sarcoma, such as molecular-based treatment strategies, it is unclear what position palifosfamide-tris might occupy on the market.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Sarcomas are a heterogeneous group of tumors arising mainly from the embryonic mesoderm, and can be localized anywhere in the body [&lt;ulink linkType="Reference" linkID="1049315"&gt;1049315&lt;/ulink&gt;]. These tumors can be classified as soft-tissue sarcomas, which comprise approximately 80% of all sarcomas, and osteosarcomas, which comprise approximately 20% of sarcomas. Soft-tissue sarcomas can arise in muscles, tendons, fat, fibrous tissue, synovial tissue, blood vessels and nerves, with the majority located in the extremities, particularly the lower extremities. Soft-tissue sarcomas are relatively rare, with approximately 10,000 cases diagnosed each year in the US; more than 40% are diagnosed in patients older than 55 years, although all age groups are affected. Complete surgical resection of the tumor is central to successful treatment. Additionally, adjuvant radiotherapy (usually 50 to 60 Gy) is used to improve local control. If patients are diagnosed at an early stage and the complete surgical removal of all tumor manifestations can be achieved, then the prognosis is excellent. In up to 50% of patients, however, distant metastases occur during the course of the disease, reducing the 5-year overall survival rate to &amp;lt; 10%. New therapeutic approaches directed against the activity of various molecules involved in growth regulation (eg, VEGF, VEGFR, IGFR, EGFR, mTOR and CDKs) are being developed for patients with distant metastases, as well as for those with primarily unresectable or advanced disease. For example, bevacizumab, a mAb against VEGF, and &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="12973"&gt;sunitinib&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="43738"&gt;pazopanib&lt;/ulink&gt;, all small-molecule tyrosine kinase inhibitors of the VEGFR, have a stabilizing effect on tumor growth [&lt;ulink linkType="Reference" linkID="1049325"&gt;1049325&lt;/ulink&gt;]. However, the most effective first-line systemic therapy consists of doxorubicin, an anthracycline antibiotic that intercalates DNA, and ifosfamide, an oxazaphosphorine-type DNA-alkylating agent [&lt;ulink linkType="Reference" linkID="1049315"&gt;1049315&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049321"&gt;1049321&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049325"&gt;1049325&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Osteosarcoma is characterized by the irregular production of osteoid or immature bone by malignant cells, and is a relatively rare disease. Approximately 750 to 900 cases are diagnosed each year in the US, with approximately half of these cases occurring in children and adolescents &amp;lt; 20 years of age [&lt;ulink linkType="Reference" linkID="945461"&gt;945461&lt;/ulink&gt;]. Historically, treatment was restricted to the local surgical removal of the tumor, and the prognosis of patients with osteosarcoma was poor, with up to an 90% mortality rate. With the use of chemotherapy, the prospects of patients have improved; currently, at least two-thirds of patients with non-metastatic extremity osteosarcoma will become long-term survivors [&lt;ulink linkType="Reference" linkID="1059193"&gt;1059193&lt;/ulink&gt;]. A standard chemotherapy regimen does not yet exist, but the most active substances are high-dose methotrexate, doxorubicin, cisplatin and ifosfamide. A combination of etoposide with high-dose ifosfamide is an effective induction therapy, particularly for patients with metastatic disease. These drugs achieve their antineoplastic effect in chemically different ways: etoposide is a topoisomerase II inhibitor and ifosfamide is an alkylating agent [&lt;ulink linkType="Reference" linkID="1049313"&gt;1049313&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049328"&gt;1049328&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Therefore, ifosfamide is an important component of standard systemic chemotherapy regimens for sarcoma [&lt;ulink linkType="Reference" linkID="1049336"&gt;1049336&lt;/ulink&gt;]. Ifosfamide is also important in the treatment of other neoplasms, such as testicular, cervical, ovarian and breast cancers, as well as lymphomas, making the drug a central element of the anticancer chemotherapeutic armamentarium [&lt;ulink linkType="Reference" linkID="1049477"&gt;1049477&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Like its structural isomer cyclophosphamide, ifosfamide is a nitrogen mustard prodrug that is part of the oxazaphosphorine class of alkylating anticancer agents. The cytotoxic effects of these agents result from intramolecular bisalkylation reactions involving electrophilic aziridinyl species intermediates. The cytotoxic effects of ifosfamide are largely exerted by the active metabolite isophosphoramide mustard, which cannot be administered directly as an anticancer drug because of extreme instability in solution. The formation of electrophilic aziridinyl species from isophosphoramide mustard is followed by nucleophilic attacks on DNA, ultimately forming a bisalkylation product and crosslinked DNA at the N(7) position of guanine on opposing strands, thereby inhibiting DNA and protein synthesis (for a review, see reference [&lt;ulink linkType="Reference" linkID="1055249"&gt;1055249&lt;/ulink&gt;]).&lt;/para&gt;&lt;para&gt;The hepatic biotransformation of ifosfamide into isophosphoramide mustard also produces acrolein and chloroacetaldehyde. These by-products are believed to be responsible for considerable side effects, such as severe hemorrhagic cystitis (acrolein) and nephro- and neurotoxic effects (chloroacetaldehyde). Hemorrhagic cystitis can be prevented in most cases by the application of &lt;ulink linkType="Drug" linkID="24142"&gt;mesna&lt;/ulink&gt; (sodium 2-mercaptoethane sulfonate), a thiol donor that binds acrolein through its sulfhydryl moieties; however, the nephro- and neurotoxicity of chloroacetaldehyde cannot be prevented and limits the use of ifosfamide in high-dose regimens [&lt;ulink linkType="Reference" linkID="1049311"&gt;1049311&lt;/ulink&gt;]. In addition to these side effects, the hepatic overexpression of aldehyde dehydrogenase (ALD) enzymes, including ALD family 1 member A1 (ALDH1A1) and family 3 member 1 (ALDH3A1), is associated with ifosfamide use and can hamper efficacy [&lt;ulink linkType="Reference" linkID="1049479"&gt;1049479&lt;/ulink&gt;]. These enzymes detoxify the products of ifosfamide metabolism into carboxyphosphamide, an inactive metabolite, and can lead to ifosfamide-resistant cancers [&lt;ulink linkType="Reference" linkID="1049479"&gt;1049479&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1009856"&gt;ZIOPHARM Oncology Inc&lt;/ulink&gt;, under license from &lt;ulink linkType="Company" linkID="15652"&gt;Dekk-Tec Inc&lt;/ulink&gt;, is developing palifosfamide, a formulation of isophosphoramide mustard that is stable in solution and is suitable for the intravenous treatment of ifosfamide-responsive tumor types, such as sarcoma [&lt;ulink linkType="Reference" linkID="652209"&gt;652209&lt;/ulink&gt;]. ZIOPHARM initially focused development on a lysine-stabilized formulation (palifosfamide-lys), but has since concentrated development on a tris(hydroxymethyl)aminomethane salt-stabilized formulation (palifosfamide-tris). As the palifosfamide formulations are based on the active metabolite of ifosfamide, they are expected to have an anticancer effect similar to that of ifosfamide, while avoiding the side effects associated with the toxic metabolites. ZIOPHARM has initiated and reported data from phase II clinical trials of palifosfamide-tris in patients with sarcoma [&lt;ulink linkType="Reference" linkID="974988"&gt;974988&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="975997"&gt;975997&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046620"&gt;1046620&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046634"&gt;1046634&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1052681"&gt;1052681&lt;/ulink&gt;]. In addition, the company has been investigating an oral formulation in preclinical studies [&lt;ulink linkType="Reference" linkID="783194"&gt;783194&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="895600"&gt;895600&lt;/ulink&gt;]. At the time of publication, a phase III, randomized clinical trial of a palifosfamide salt for sarcoma was anticipated for 2010 as a registration trial, and trials in other cancers were also being planned [&lt;ulink linkType="Reference" linkID="1010257"&gt;1010257&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049563"&gt;1049563&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;Isophosphoramide mustard (palifosfamide; N,N'-bis(2-chloroethyl)phosphorodiamidic acid) in its free acid form is susceptible to hydrolysis by water of crystallization, rendering the compound too unstable in solution to be useful for pharmaceutical purposes [&lt;ulink linkType="Reference" linkID="659916"&gt;659916&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="976000"&gt;976000&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049997"&gt;1049997&lt;/ulink&gt;]. ZIOPHARM attempted to overcome the stability issue by synthesizing and investigating various salt-stabilized formulations of isophosphoramide mustard. A lysine-salt formulation of this compound (palifosfamide-lys) was stable in solution, with enhanced solubility and stability over a wide range of pH values, improved non-deliquescence characteristics and a more favorable dissolution rate [&lt;ulink linkType="Reference" linkID="783194"&gt;783194&lt;/ulink&gt;]. However, early clinical evaluation in patients with advanced cancers detected renal toxicity, which was likely caused by the lysine component (a nephrotoxin) and exacerbated by isophosphoramide mustard [&lt;ulink linkType="Reference" linkID="1049997"&gt;1049997&lt;/ulink&gt;]. A tris-salt formulation of isophosphoramide mustard (palifosfamide-tris) was subsequently developed by ZIOPHARM to overcome the safety issues associated with palifosfamide-lys. In addition to an improved tolerability profile, palifosfamide-tris also had improved storage and reconstitution stability, and enhanced solubility characteristics, compared with the lysine-salt formulation [&lt;ulink linkType="Patent" linkID="PA3697726"&gt;WO-2008124097&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="783194"&gt;783194&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Isophosphoramide mustard was synthesized via amidation of phenyl phosphorodichloridate followed by hydrogenation. An ice-cold solution of phenyl phosphorodichloridate in acetone was treated with 2-chloroethylamine hydrochloride. Triethylamine was then added dropwise during a 1-h period, and the reaction mixture was stirred at room temperature for 16 h. The resultant phosphoroamidate and a catalytic amount of platinum oxide in ethanol were hydrogenated at 345-kPa pressure at room temperature for 5 h to yield isophosphoramide mustard [&lt;ulink linkType="Reference" linkID="1049327"&gt;1049327&lt;/ulink&gt;]. The lysine salt was prepared by slowly adding isophosphoramide mustard to a stirred solution of lysine in water at 2 to 8degC. The resulting compound, palifosfamide-lys, had a 2:1 stoichiometry of amine to isophosphoramide mustard and was prepared as a lyophilisate comprising an excipient [&lt;ulink linkType="Patent" linkID="PA3193701"&gt;WO-2006047575&lt;/ulink&gt;], [&lt;ulink linkType="Patent" linkID="PA3697726"&gt;WO-2008124097&lt;/ulink&gt;]. The tris salt was prepared by adding isophosphoramide mustard to a mixture of tris and acetonitrile and stirred overnight to produce palifosfamide-tris, which had a 1:1 stoichiometry of tris to isophosphoramide mustard. Palifosfamide-tris was then prepared as a lyophilisate comprising an excipient, preferably mannitol [&lt;ulink linkType="Patent" linkID="PA3697726"&gt;WO-2008124097&lt;/ulink&gt;]. Different preparations of salts and syntheses were also described in &lt;ulink linkType="Patent" linkID="PA3193701"&gt;WO-2006047575&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3697726"&gt;WO-2008124097&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;Preclinical studies used as evidence for the development of a clinical platform included the evaluation of isophosphoramide mustard and the stabilized palifosfamide formulations, palifosfamide-lys and palifosfamide-tris, both of which contain the same active ingredient.&lt;/para&gt;&lt;para&gt;Mechanism of action&lt;br/&gt;The intramolecular 1,3-N-alkylation reactions of isophosphoramide mustard at pH 7.4 produce electrophilic alkylating agents with aziridinyl moieties [&lt;ulink linkType="Reference" linkID="1055249"&gt;1055249&lt;/ulink&gt;]. To investigate the propensity of isophosphoramide mustard for intramolecular 1,5-N-alkylation reactions, the five-membered-ring oxaza- and diazaphospholidine products of the reaction were synthesized and characterized using 31P-NMR [&lt;ulink linkType="Reference" linkID="1055249"&gt;1055249&lt;/ulink&gt;]. In aqueous solution at pH 7.4 and 37degC, the intramolecular O-alkylation product of isophosphoramide mustard, 2-(2-chloroethylamino)-2-tetrahydro-2H-1,3,2-oxaphospholidine-2-oxide, exhibited a chemical shift (delta)with a value of 33.0 ppm and a t1/2 value of 3.3 h. The 31P-NMR resonances indicative of this product were not detected in reaction solutions of isophosphoramide mustard. The 1,5-N-alkylation product of isophosphoramide mustard, 1-(2-chloroethyl)-2-hydroxy-tetrahydro-2H-1,3,2-diazaphospholidine-2-oxide, was generated in situ, but was not isolated because of the instability of the product. The hydrolysis products derived from this compound were also undetectable in reaction solutions of isophosphoramide mustard. These data indicated that direct intramolecular O-alkylation was not involved in the chemistry of isophosphoramide mustard, and that 1,5-N-alkylation was not a significant pathway in aqueous solution [&lt;ulink linkType="Reference" linkID="1055249"&gt;1055249&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The mechanisms of bisalkylation by isophosphoramide mustard were investigated using NMR [&lt;ulink linkType="Reference" linkID="1055236"&gt;1055236&lt;/ulink&gt;]. By 1H- and 13C-NMR, the distribution of 2H in the products of a reaction of a synthesized isophosphoramide mustard-beta,beta,beta',beta'-d4 and thiosulfate (at pD 7.0) were consistent with bisalkylation through sequential aziridinyl intermediates. A hybridization value of sp2.4 to 2.5 was calculated for the C-H bonds of the reaction centers for the initial aziridine formed by isophosphoramide mustard. These data were consistent with an observed inverse isotope effect [&lt;ulink linkType="Reference" linkID="1055236"&gt;1055236&lt;/ulink&gt;]. In a further kinetic study of the mechanisms of bisalkylation activity of isophosphoramide mustard decomposition products using 31P-NMR, a pKa value of 4.28 was determined at 20degC [&lt;ulink linkType="Reference" linkID="1056294"&gt;1056294&lt;/ulink&gt;]. At pH 7.4 and 37degC, isophosphoramide mustard underwent a first and second alkylation with t1/2 values of approximately 77 and 171 min, respectively [&lt;ulink linkType="Reference" linkID="1056294"&gt;1056294&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A molecular study compared the DNA base sequence specificity for DNA interstrand guanine-guanine crosslinking of isophosphoramide mustard with that of the nitrogen mustards phosphoramide mustard (an active metabolite of cyclophosphamide) and mechlorethamine [&lt;ulink linkType="Reference" linkID="1055240"&gt;1055240&lt;/ulink&gt;]. All three agents demonstrated an equal preference for the base sequence 5'-GNC-3' over 5'-GC-3'and 5'-GNNC-3' (where N = A or T), despite a 7-atom crosslink that is produced by isophosphoramide mustard in duplex DNA versus a 5-atom crosslink that is produced by mechlorethamine and phosphoramide mustard [&lt;ulink linkType="Reference" linkID="1055240"&gt;1055240&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The protonation of isophosphoramide mustard and its aziridine derivative was investigated using 1H-, 31P-, 15N- and 17O-NMR [&lt;ulink linkType="Reference" linkID="1055230"&gt;1055230&lt;/ulink&gt;]. Single monobasic titration curves with the same pKa value of 4.31 were exhibited by isophosphoramide mustard between pH 2 and 10 by the positions of the 31P-, 15N- and 17O-NMR resonances; the results indicated that a single protonation was occurring at a nitrogen atom. The aziridine derivative also exhibited single monobasic titration curves with the same pKa value of 5.30, over the same pH range, and the results indicated that a single protonation occurred at the ring nitrogen [&lt;ulink linkType="Reference" linkID="1055230"&gt;1055230&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The chemical degradation products of isophosphoramide mustard occurring in buffered solutions were investigated at pH 1 to 13 using 31P-, 15N- and 13C-NMR [&lt;ulink linkType="Reference" linkID="1055243"&gt;1055243&lt;/ulink&gt;]. Only ionic phosphate and chloroethylammonium chloride, produced from the breakdown of two P-N bonds, were detected at pH 2.0 (defined as pathway I). After approximately 15 h in solution at pH 9.3 and 13.0, monoaziridinyl- and bisaziridinyl-isophosphoramide mustard (both products of the 1,3-cyclization of the N-chloroethyl group) were detected (defined as pathway II). All of the products of pathways I and II were detectable at intermediate pH. At pH 3.5 and 5.0, products of the P-N bond hydrolysis were most abundant, but two phosphorylated products were also detected. Ionic phosphate represented 67 and 17% of the total phosphorylated isophosphoramide mustard degradation products detected at pH 3.5 and 5.0, respectively; phosphorylethanolamine, which was likely formed by 1,5-cyclization of a transient compound to a 1,3,2-oxazaphospholidine intermediate, represented 16 and 46% of the total degradation products detected at pH 3.5 and 5.0, respectively [&lt;ulink linkType="Reference" linkID="1055243"&gt;1055243&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The abundance of monohydroxyl-isophosphoramide mustard, which was likely formed by alkylation by water of an aziridine/aziridinium intermediate, increased from approximately 5% at pH 3.5 to 28% at pH 5.0, indicating the occurrence of pathway II between these pH values. At pH 7.0 and 7.4, pathway II was initiated first, followed by 1,3-cyclization and water alkylation of the aziridines formed, although ionic phosphate and phosphorylethanolamine were the final products to be detected [&lt;ulink linkType="Reference" linkID="1055243"&gt;1055243&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A method of LC-MS/MS was developed to investigate the existence of impurities in synthesized isophosphoramide mustard [&lt;ulink linkType="Reference" linkID="1055247"&gt;1055247&lt;/ulink&gt;]. The main impurity detected, present at a concentration of 2 to 5%, was N-(2-chloroethyl)-N'-ethylphosphorodiamidic acid; this impurity was deemed to be nontoxic in animals in unreported studies [&lt;ulink linkType="Reference" linkID="1055247"&gt;1055247&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vitro antitumor activity&lt;br/&gt;The IC50 value for isophosphoramide mustard against a mouse lymphocytic leukemia cell line (L1210) was 33 microM after a 1-h exposure and 15 microM after a 4-h exposure [&lt;ulink linkType="Reference" linkID="1055228"&gt;1055228&lt;/ulink&gt;]. The IC50 values determined for isophosphoramide mustard against the human cancer cell lines U937 (lymphoma), K562 (myelogenous leukemia) and I83CLL (chronic B-cell leukemia) were 124, 1972 and 170 microM, respectively [&lt;ulink linkType="Reference" linkID="1055249"&gt;1055249&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The IC50 values obtained for increasing concentrations of palifosfamide-lys (1- or 3-day exposure) incubated with osteosarcoma (SaOS2, OS222, OS229 and OS230), Ewing's sarcoma (SKPNDW and SKES1), alveolar (RH30) and embryonal rhabdomyosarcoma (RD) cell lines ranged from 2.25 to 6.75 mM, except for the OS222 cell line (OS222), for which the IC50 value was 31.5 microM [&lt;ulink linkType="Reference" linkID="1032397"&gt;1032397&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vivo antitumor activity&lt;br/&gt;DBA/2 mice (n = 6) implanted with L1210 cells (10(5) ip, on day 0) were used to evaluate single-dose isophosphoramide mustard (100 mg/kg ip, on day 1) for antitumor activity [&lt;ulink linkType="Reference" linkID="1055229"&gt;1055229&lt;/ulink&gt;]. The survival time of mice treated with isophosphoramide mustard was increased by 111% compared with untreated control mice, and four out of six treated mice survived to the end of the study at day 60. Using the same study design, isophosphoramide mustard was evaluated for antitumor activity against cyclophosphamide-sensitive or -resistant L1210 cells (10(5) sc, on day 0) implanted into DBA/2 mice. The survival time of cyclophosphamide-sensitive L1210 cell-implanted mice treated with isophosphoramide mustard was increased by 85% compared with untreated control mice, and there were no survivors in either group at the end of the study on day 45. Isophosphoramide mustard treatment increased the survival time of cyclophosphamide-resistant L1210 cell-implanted mice by 56% compared with untreated control mice, and one out of six treated mice survived to the end of the study on day 45 [&lt;ulink linkType="Reference" linkID="1055229"&gt;1055229&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Further tumor models including C57BL/6 mice implanted with B16 melanoma tumors and B6C3F1 mice implanted with 16/C mammary or M5076 sarcoma tumors (30 to 60 mg sc of tumor fragments, 2 to 3 days before treatment) were also evaluated [&lt;ulink linkType="Reference" linkID="1055229"&gt;1055229&lt;/ulink&gt;]. Single-dose isophosphoramide mustard (100 mg/kg ip) delayed B16 melanoma tumor growth by 2.4 days and M5076 sarcoma tumor growth by 10.6 days compared with growth in untreated control mice. Multiple-dose isophosphoramide mustard (60 mg/kg ip, on days 3, 7, 11 and 15) delayed 16/C mammary tumor growth by 15.3 days. Using a delayed daily-dosing schedule for isophosphoramide mustard (18, 27 or 40 mg/kg/day sc, on days 11 to 15), the growth of M5076 sarcoma tumor was delayed by 6.1, 3.3 or 1.0 days, respectively, compared with growth in control mice [&lt;ulink linkType="Reference" linkID="1055229"&gt;1055229&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Isophosphoramide mustard was also evaluated for antitumor activity in an MX1 human breast tumor model in mice [&lt;ulink linkType="Reference" linkID="445370"&gt;445370&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="597318"&gt;597318&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="976000"&gt;976000&lt;/ulink&gt;]. In a study using a 5-day dosing protocol (ip), 4-hydroperoxyifosfamide demonstrated greater activity than isophosphoramide mustard [&lt;ulink linkType="Reference" linkID="445370"&gt;445370&lt;/ulink&gt;]. Another 5-day study in xenograft mice compared increasing doses of palifosfamide-lys, isophosphoramide mustard or ifosfamide (20 to 100 mg/kg/day ip) [&lt;ulink linkType="Reference" linkID="597318"&gt;597318&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="976000"&gt;976000&lt;/ulink&gt;]. Palifosfamide-lys was 5-fold more effective at extending the lifespan of mice with cancer than isophosphoramide mustard at comparable doses. Survival was extended by 10.2, 2.1 or 8.6 days after treatment with palifosfamide-lys, isophosphoramide mustard or ifosfamide, respectively, compared with survival in untreated control mice [&lt;ulink linkType="Reference" linkID="597318"&gt;597318&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="976000"&gt;976000&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a 5-day comparison of palifosfamide-lys, isophosphoramide mustard and ifosfamide (20 to 125 mg/kg/day ip) in mice xenografted with Lewis lung cancer, palifosfamide-lys and isophosphoramide mustard exhibited equivalent anticancer activity at doses that indicated a 2-fold higher MTD for palifosfamide-lys. The survival of mice was extended by 8.3, 12.5 and 18 days after treatment with palifosfamide-lys, isophosphoramide mustard and ifosfamide, respectively, compared with survival in untreated control mice [&lt;ulink linkType="Reference" linkID="976000"&gt;976000&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Further studies suggested that palifosfamide-lys (100 mg/kg iv, for 3 days) was significantly more active than cyclophosphamide (150 mg/kg ip, qw for 6 weeks) against tumor growth and event-free survival in cyclophosphamide-resistant (OS31; resistance defined by ALDH3A1 overexpression) and -sensitive (OS33) osteosarcoma xenograft models in SCID mice compared with untreated controls [&lt;ulink linkType="Reference" linkID="1032397"&gt;1032397&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046840"&gt;1046840&lt;/ulink&gt;]. A significant difference was noted for relative tumor volume (p = 0.002) and for event-free survival (p = 0.0009) between treated and untreated groups of OS31 tumor-bearing mice. Similarly, significance was also achieved in these parameters (p = 0.001 and 0.01, respectively) in OS33 tumor-bearing mice [&lt;ulink linkType="Reference" linkID="1032397"&gt;1032397&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046840"&gt;1046840&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A similar improvement in survival time was observed in a P388 leukemia mouse model treated with palifosfamide-lys (280 mg/kg/day po, for 1, 5 or 10 days); treatment increased survival time by 150% compared with that in untreated control mice [&lt;ulink linkType="Reference" linkID="783194"&gt;783194&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Another study compared palifosfamide-lys with its halogenated analogs (ZIO-202 and ZIO-203) and cisplatin in NCr nude athymic mice bearing human PANC01 pancreas- and DU145 prostate-derived cancers and CD2F1 mice bearing murine P388 leukemia cisplatin-resistant and -sensitive cancers [&lt;ulink linkType="Reference" linkID="659916"&gt;659916&lt;/ulink&gt;]. Palifosfamide-lys demonstrated similar anticancer activity to ZIO-202 and ZIO-203 against human-derived cancers. Furthermore, palifosfamide-lys and cisplatin were equally effective against cisplatin-sensitive P388 cancers, whereas palifosfamide-lys had an 8-fold increased anti-leukemia activity against cisplatin-resistant P388 cells [&lt;ulink linkType="Reference" linkID="659916"&gt;659916&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The mouse MX1 breast cancer xenograft model was used extensively to evaluate both the palifosfamide-lys and palifosfamide-tris formulations [&lt;ulink linkType="Reference" linkID="783194"&gt;783194&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="895600"&gt;895600&lt;/ulink&gt;]. In a comparison of the two stabilized forms of palifosfamide (normalized for isophosphoramide mustard content), palifosfamide-lys (56 mg/kg/day) and palifosfamide-tris (36 mg/kg/day) demonstrated comparable antitumor activity [&lt;ulink linkType="Reference" linkID="783194"&gt;783194&lt;/ulink&gt;]. The effects of the route of administration on anticancer efficacy were also evaluated. MTDs of oral palifosfamide-lys (81 mg/kg/day)reduced tumor growth by 65% compared with untreated control animals, whereas MTDs of intraperitoneal palifosfamide-lys (36 mg/kg/day) reduced tumor growth by 80% [&lt;ulink linkType="Reference" linkID="783194"&gt;783194&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="895600"&gt;895600&lt;/ulink&gt;]. Similarly, MTDs of oral palifosfamide-tris increased median survival by 7.5 days compared with survival in untreated control animals, and MTDs of intraperitoneal palifosfamide-tris increased survival by 9 days [&lt;ulink linkType="Reference" linkID="895600"&gt;895600&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a study of palifosfamide-tris (12 mg/kg/day ip, for 5 days) and doxorubicin (8 mg/kg/day iv, for 3 days), the synergistic activity of the combined treatment significantly reduced tumor volume and increased median survival at study completion in MX1 xenograft models compared with the activity of the single agents (p &amp;lt; 0.0001) [&lt;ulink linkType="Reference" linkID="895600"&gt;895600&lt;/ulink&gt;]. A further study with the MX1 xenograft demonstrated a similar synergistic effect of palifosfamide-tris (54 mg/kg ip, for 5 days) combined with &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; (10 mg/kg iv, every 6 days for 3 doses) compared with the single agents [&lt;ulink linkType="Reference" linkID="895600"&gt;895600&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;&lt;subtitle&gt;In vitro&lt;/subtitle&gt;Palifosfamide-lys did not reduce the viability of primary rabbit kidney proximal tubule cells in a cell culture system. In this system, chloroacetaldehyde had an LD50 value of approximately 40 microM, with complete inhibition at 75 microM, and acrolein had an LD50 value of 80 microM [&lt;ulink linkType="Reference" linkID="640635"&gt;640635&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="976001"&gt;976001&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;In vivo&lt;/subtitle&gt;The toxicology of isophosphoramide mustard was investigated in monkeys, beagle dogs and rodents. In monkeys, no major toxicities were observed following the administration of a single infusion at 5 mg/kg [&lt;ulink linkType="Reference" linkID="470615"&gt;470615&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049312"&gt;1049312&lt;/ulink&gt;]. In adult beagle dogs, causes of death after the administration of increasing doses of isophosphoramide mustard (1.0 to 100 mg/kg iv, for 3 days) were renal toxicity (100 mg/kg), bone marrow depletion (10 mg/kg), liver toxicity, hematological and gastrointestinal failure (&amp;lt;/= 5 mg/kg); the MTD of isophosphoramide mustard was 5 mg/kg [&lt;ulink linkType="Reference" linkID="1049312"&gt;1049312&lt;/ulink&gt;]. After single-acute oral and intravenous doses of isophosphoramide mustard, the LD50 values were 3560 and 428 mg/kg, respectively, in rats, and were 1432 and 688 mg/kg, respectively, in mice. In addition, an LD10 value of 93 mg/kg for a single-acute intravenous dose of isophosphoramide mustard was determined in mice [&lt;ulink linkType="Reference" linkID="1049312"&gt;1049312&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In adult mice, bone marrow failure was the DLT following a subacute once-daily infusion of palifosfamide-lys or isophosphoramide mustard for 3 days [&lt;ulink linkType="Reference" linkID="597318"&gt;597318&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049312"&gt;1049312&lt;/ulink&gt;]. The LD10 and LD50 values for palifosfamide-lys were 133 and 220 mg/kg/day, respectively, and for isophosphoramide mustard were 119 and 149 mg/kg/day, respectively [&lt;ulink linkType="Reference" linkID="597318"&gt;597318&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="976000"&gt;976000&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049312"&gt;1049312&lt;/ulink&gt;]. Complications following isophosphoramide mustard administration also included necrosis of kidney tubules and lymphoid depletion [&lt;ulink linkType="Reference" linkID="976000"&gt;976000&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049312"&gt;1049312&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In SCID mice, the MTD for intravenous palifosfamide-lys administered for 3 consecutive days was 100 mg/kg; treatment caused &amp;lt; 15% mean weight loss, with recovery to baseline occurring within 4 weeks [&lt;ulink linkType="Reference" linkID="1032397"&gt;1032397&lt;/ulink&gt;]. Palifosfamide-lys did not cause CNS, kidney or bladder toxicities in mice bearing MX1 human breast tumors; the MTD of palifosfamide-lys in MX1 xenograft mice was 93 mg/kg/day, which was greater than the MTD determined for isophosphoramide mustard (40 mg/kg/day) [&lt;ulink linkType="Reference" linkID="445370"&gt;445370&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="597318"&gt;597318&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;The stability of isophosphoramide mustard in vitro was evaluated in PBS, human plasma and RPMI 1640 tissue culture medium that contained 10% fetal bovine serum [&lt;ulink linkType="Reference" linkID="1055228"&gt;1055228&lt;/ulink&gt;]. In PBS, the degradation of isophosphoramide mustard (8 mM) was pH-dependent and followed a first-order process; the t1/2 value was 45 min in pH 7.4 at 38degC. Isophosphoramide mustard (20 microg/ml) exhibited enhanced stability in human plasma and RPMI 1640, with t1/2 values of 55 and 98 min, respectively [&lt;ulink linkType="Reference" linkID="1055228"&gt;1055228&lt;/ulink&gt;]. In an in vitro binding study, 90 and &amp;gt; 98% of isophosphoramide mustard bound to proteins in plasma obtained from humans and dogs within 5 min, respectively [&lt;ulink linkType="Reference" linkID="470617"&gt;470617&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049312"&gt;1049312&lt;/ulink&gt;]. During a 1-h assessment period, 98% of isophosphoramide mustard remained bound to proteins in dog plasma for a minimum of 30 min. In addition, the stability of isophosphoramide mustard binding to proteins in dog plasma was investigated following incubation in PBS. After incubations of 7 and 24 h, 40 and 10% of isophosphoramide mustard was recovered, respectively [&lt;ulink linkType="Reference" linkID="1049312"&gt;1049312&lt;/ulink&gt;]. In another analysis, isophosphoramide mustard (20 microg/ml) was incubated with fresh Sprague-Dawley rat plasma at 37degC; after 30 min, 55% was bound to plasma proteins [&lt;ulink linkType="Reference" linkID="1055228"&gt;1055228&lt;/ulink&gt;]. The partition of isophosphoramide mustard between plasma and RBCs was determined using fresh rat blood; a partition ratio of 4.9:1.0 in favor of plasma was determined, indicating pharmacokinetic differences for isophosphoramide mustard in plasma and blood [&lt;ulink linkType="Reference" linkID="1055228"&gt;1055228&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The pharmacokinetic profile of a single isophosphoramide mustard infusion was assessed in monkeys, dogs, mice and Sprague-Dawley rats [&lt;ulink linkType="Reference" linkID="470617"&gt;470617&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049312"&gt;1049312&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1055228"&gt;1055228&lt;/ulink&gt;]. In monkeys, isophosphoramide mustard (5 mg/kg) was measured 4 h after application. The AUC0-24 h value for isophosphoramide mustard was 3.00 mg/kg/l/h, with a clearance of 1.65 l/h/kg, elimination t1/2 value of 4.2 h, volume of distribution (Vd) of 10.1 l and Cmax of 1.5 mg/l. In the plasma of dogs, isophosphoramide mustard was undetectable 1.5 h after the administration of a 5-mg/kg dose and 2 h after a 10-mg/kg dose. Following the 10-mg/kg dose, the clearance of isophosphoramide mustard was a constant 1.01 l/h/kg, the AUC0-24 h value was 9.84 mg/kg/l/h, with an elimination t1/2 value of 0.99 h, Vd value of 1.29 l and Cmax value of 10.52 mg/l. In the plasma of mice, a 100-mg/kg dose of isophosphoramide mustard was undetectable after 1 h, with a distribution t1/2 value of 2 min, an AUC0-24 h value of 11.85 mg/kg/l/h, clearance of 8.44 l/h/kg, elimination t1/2 value of 7.53 h, Vd value of 50.62 l and Cmax value of 66.00 mg/l [&lt;ulink linkType="Reference" linkID="470617"&gt;470617&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049312"&gt;1049312&lt;/ulink&gt;]. An allometric analysis of these pharmacokinetic data from monkeys, dogs and mice predicted that a starting dose of 30 mg/m in a 70-kg patient would have an a clearance value of 39.5 l/h, a distribution t1/2 value of approximately 10 min and an elimination t1/2 value of approximately 105 min [&lt;ulink linkType="Reference" linkID="1049312"&gt;1049312&lt;/ulink&gt;]. In Sprague-Dawley rats, isophosphoramide mustard (40 mg/kg) exhibited a monoexponential decline, with a mean t1/2 value of 12.6 min, a mean total clearance of 10.99 ml/min, a mean AUC value of 1243 microg/min/ml, a mean Vd value of 220.2 ml, a mean residence time value of 17.40 min and a mean elimination constant of 0.068 min(-1) [&lt;ulink linkType="Reference" linkID="1055228"&gt;1055228&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The pharmacokinetics of palifosfamide-tris (20, 30 and 40 mg/kg) administered systemically and orally were evaluated in female Sprague-Dawley rats [&lt;ulink linkType="Reference" linkID="895600"&gt;895600&lt;/ulink&gt;]. In this study, a Tmax value of approximately 0.5 h was determined, with the elimination t1/2 value estimated to range from 0.25 to 0.64 h. Oral bioavailability of palifosfamide-tris was 48, 65 and 73% for the 20-, 30- and 40-mg/kg doses, respectively. The overall mean bioavailability was 62% in females and 41% in males [&lt;ulink linkType="Reference" linkID="895600"&gt;895600&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The pharmacokinetic profile of palifosfamide-tris (592 mg/m2/day iv) was assessed in a phase I clinical trial in patients (n = 20) with advanced cancers. The Tmax value was 13 min, the Cmax value was 24.7 to 44.7 microg/ml, the t1/2 value was 35 to 37 min and the AUC0-infinity value was 0.81 to 1.68 mgmin/ml [&lt;ulink linkType="Reference" linkID="1046841"&gt;1046841&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046902"&gt;1046902&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The pharmacokinetic profile of palifosfamide-tris (100 and 150 mg/m2) and palifosfamide-lys (413 mg/m2) were compared in a phase I/II clinical trial in patients with advanced cancers. The mean AUC0-2 h values for palifosfamide-tris were 6138 and 7023 for the 100- and 150-mg/m2 doses, respectively, and for palifosfamide-lys were 7492 (units not reported) [&lt;ulink linkType="Reference" linkID="1046620"&gt;1046620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;A phase I, dose-escalation, non-randomized, open-label, uncontrolled, single-group assignment clinical trial (ClinicalTrials.gov identifier: NCT00421135; IPM1001) investigated two dosing schedules of palifosfamide-lys (daily: 30 to 787 mg/m2/day iv, for 3 days every 3 weeks; and single-dose: 600 mg/m2 iv, every 3 weeks) until DLT, progression or six cycles in patients (n = 26) with advanced cancers after previous standard chemotherapy. Stable disease for &amp;gt; 1 year was observed in three patients, including two with sarcoma (one who had previously failed ifosfamide treatment) and one with mesothelioma [&lt;ulink linkType="Reference" linkID="1046841"&gt;1046841&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046902"&gt;1046902&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1047621"&gt;1047621&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I, dose-finding, non-randomized, open-label, uncontrolled, single-group assignment clinical trial (NCT00608803; IPM1002) assessed a combination of palifosfamide-tris (iv, for 3 days every 3 weeks) and doxorubicin (iv, on day 1 every 3 weeks) in patients with advanced, refractory tumors including sarcoma (n = 9), carcinoma (n = 3) and mesothelioma (n = 1) who were ifosfamide- and doxorubicin-naive [&lt;ulink linkType="Reference" linkID="1013010"&gt;1013010&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046620"&gt;1046620&lt;/ulink&gt;]. Three dose combinations of palifosfamide-tris/doxorubicin (100/60, 150/60 and 150/75 mg/m2) were administered. Interim efficacy data were reported from 12 evaluable patients (who had received a minimum of two cycles of treatment), including all patients with sarcoma (n = 9). A partial response was observed in two of these patients and stable disease in the other seven patients; therapy was continuing in six of these patients. Additionally, one patient with small-cell lung carcinoma exhibited a partial response [&lt;ulink linkType="Reference" linkID="1013010"&gt;1013010&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046620"&gt;1046620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I, dose-escalation, non-randomized, open-label, uncontrolled, single-group assignment clinical trial (NCT00607711) of palifosfamide-tris (&lt;ulink linkType="Drug" linkID="61655"&gt;daily capsules&lt;/ulink&gt; for 15 days followed by a 6-day rest period) in patients (expected n = 20) with advanced, refractory solid tumors after previous standard chemotherapy had been planned. However, according to the NIH clinical trials registry, this trial had been suspended by the time of publication because of the withdrawal of the IND application.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A phase I/II, non-randomized, open-label, uncontrolled, single-group assignment, safety and efficacy clinical trial (NCT00439686; IPM2001) assessed palifosfamide-lys (up to 519 mg/m2/day iv, for 3 consecutive days every 3 weeks for up to 6 months) in patients (n = 41) with advanced sarcoma after previous standard chemotherapy; a single intravenous dose of palifosfamide-tris was included to assess bioequivalence [&lt;ulink linkType="Reference" linkID="974988"&gt;974988&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="975997"&gt;975997&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046620"&gt;1046620&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046634"&gt;1046634&lt;/ulink&gt;]. The phase I dose-finding portion of the trial in four patients identified the MTD as 413 mg/m2/day, which was used in the phase II portion of the trial [&lt;ulink linkType="Reference" linkID="974988"&gt;974988&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="975997"&gt;975997&lt;/ulink&gt;]. In the phase II portion, tumor burden was reduced by 25% at 6 weeks in one patient, and another patient with chondrosarcoma exhibited stable disease for five cycles. The progression-free survival rate at 3 months was 43% (all patients were evaluable), 45% for patients with soft tissue sarcomas (n = 33) and 55% for ifosfamide-naive patients (n = 11). Additionally, the 6-month progression-free survival rate was estimated to be 23% for patients with soft-tissue sarcoma [&lt;ulink linkType="Reference" linkID="1046620"&gt;1046620&lt;/ulink&gt;]. At the time of publication, this trial was listed on the NIH clinical trials registry as ongoing.&lt;/para&gt;&lt;para&gt;A phase II, multicenter, randomized, open-label, active-control, crossover-assignment clinical trial (NCT00718484; IPM2002, PICASSO) assessed palifosfamide-tris (150 mg/m2/day iv, for 3 days every 3 weeks) in combination with doxorubicin (75 mg/m2/day iv, on day 1 every 3 weeks) versus single-agent doxorubicin (same dosage as combination) in doxorubicin-nave patients (n = 67) with unresectable or metastatic soft-tissue sarcoma [&lt;ulink linkType="Reference" linkID="1052681"&gt;1052681&lt;/ulink&gt;]. Interim data from 61 treated patients indicated that palifosfamide-tris in combination with doxorubicin significantly increased progression-free survival by at least 50%, compared with single-agent doxorubicin (the hazard ratio was 0.63 favoring the palifosfamide-tris and doxorubicin combination; p = 0.026). From the 20 documented progression-free survival events (14 events in patients treated with single-agent doxorubicin and 6 events in patients treated with the palifosfamide-tris and doxorubicin combination), the median progression-free survival time for single-agent doxorubicin was 4.4 months and had not been reached for the palifosfamide-tris and doxorubicin combination [&lt;ulink linkType="Reference" linkID="1052681"&gt;1052681&lt;/ulink&gt;]. This trial was ongoing at the time of publication.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;At the time of publication, a phase III, randomized, clinical trial was being planned as a registration trial and was anticipated to commence in 2010 [&lt;ulink linkType="Reference" linkID="1010257"&gt;1010257&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049563"&gt;1049563&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;In the phase I, dose-escalation, clinical trial (NCT00421135) that investigated two palifosfamide-lys dosing schedules in patients with advanced cancers, 445 mg/m2/day was classified as the MTD based on observations of an increased creatinine (&gt; 0.5 mg/dl) level in patients receiving the 445-mg/m2/day dose of palifosfamide-lys, but not in patients receiving lower doses [&lt;ulink linkType="Reference" linkID="1046902"&gt;1046902&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1047621"&gt;1047621&lt;/ulink&gt;]. Other adverse events that were &gt;/= grade 2 and reported by &amp;gt; 25% patients (n = 24 evaluable for safety) included nausea (50%), fatigue (42%) and anorexia (33%). The DLT exhibited by 1 out of 3 patients receiving 445 mg/m2/day and 9 out of 13 patients receiving &gt;/= 590 mg/m2/day palifosfamide-lys was renal toxicity, characterized by transient proximal renal tubular acidosis; this DLT was not exhibited by patients in the single-dose cohort. Hemorrhagic cystitis or CNS toxicity was not reported by patients receiving the single dose, but was observed in patients receiving the daily-dosing schedule [&lt;ulink linkType="Reference" linkID="1046841"&gt;1046841&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1047621"&gt;1047621&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase I clinical (NCT00608803) trial that assessed the combination of palifosfamide-tris with doxorubicin, there were no reports of bladder, renal or neurotoxicity, and the toxicity profile indicated that palifosfamide-tris was well tolerated [&lt;ulink linkType="Reference" linkID="1046620"&gt;1046620&lt;/ulink&gt;]. Of the adverse events reported by evaluable patients (n = 13), 14% were possibly palifosfamide-tris-related, 20% were possibly doxorubicin-related (12% defined as being definitely doxorubicin-related) and 54% were possibly related to the drug combination. Grade 3 to 4 adverse events included neutropenia (n = 3) and thrombocytopenia (n = 2); grade 1 to 2 adverse events included anemia (n = 4), microhematuria (n = 3), nausea (n = 4) and vomiting (n = 2) [&lt;ulink linkType="Reference" linkID="1046620"&gt;1046620&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase I, dose-finding portion of the phase I/II clinical trial (NCT00439686) of palifosfamide-lys in patients with advanced sarcoma, all patients receiving the 519-mg/m2/day dose discontinued therapy because of renal DLT, while the bone marrow toxicity observed was modest. Hemorrhagic cystitis or CNS toxicities were not reported [&lt;ulink linkType="Reference" linkID="974988"&gt;974988&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="975997"&gt;975997&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase II portion of this trial, palifosfamide-lys was well tolerated and no significant bone marrow suppression, alopecia, encelphalopathy, neurotoxicity or hematuria was observed [&lt;ulink linkType="Reference" linkID="974988"&gt;974988&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="975997"&gt;975997&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046620"&gt;1046620&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1046634"&gt;1046634&lt;/ulink&gt;]. Common adverse events were gastrointestinal and renal in nature. Grade 3 to 4 events included hypophosphatemia (17%) [&lt;ulink linkType="Reference" linkID="1046634"&gt;1046634&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase II clinical trial (NCT00718484) in patients with unresectable or metastatic soft-tissue sarcoma, palifosfamide-tris did not increase the toxicity of doxorubicin in 61 patients who were eligible for safety evaluations [&lt;ulink linkType="Reference" linkID="1052681"&gt;1052681&lt;/ulink&gt;]. Treatment-related side effects in &gt;/= 10% of the patient population, in both arms of the trial, included alopecia, anemia, diarrhea, dyspepsia, fatigue, hypokalemia, leukopenia, nausea, neutropenia, stomatitis and vomiting. Treatment-related grade &gt;/= 3 events in &gt;/= 5% of the patient population receiving palifosfamide-tris in combination with doxorubicin versus single-agent doxorubicin included febrile neutropenia (3 versus 6%), leukopenia (17 versus 16%), neutropenia (20 versus 29%), fatigue (3 versus 6%) and hypokalemia (10 versus 0%). The treatment-related serious adverse events in &gt;/= 5% of the patient population receiving palifosfamide-tris in combination with doxorubicin versus single-agent doxorubicin included dehydration (7 versus 0%) and neutropenia (0 versus 6%) [&lt;ulink linkType="Reference" linkID="1052681"&gt;1052681&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;Dekk-Tec claimed the isophosphoramide mustard analog palifosfamide-lys in &lt;ulink linkType="Patent" linkID="PA3193701"&gt;WO-2006047575&lt;/ulink&gt;, which claims salts of isophosphoramide mustard and analogs as anticancer agents (specific product claim; claim 9). At the time of publication, no regional equivalents had been granted, but pending equivalent applications in the US included &lt;ulink linkType="Patent" linkID="PA3193378"&gt;US-20060089333&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3704512"&gt;US-20080267945&lt;/ulink&gt; (both specific product claim; claim 9). These applications were made with US government support under grant number 5R44CA083552-03 awarded by the NCI, giving the US government certain rights to the invention. Both US applications comprise identical claims; however, &lt;ulink linkType="Patent" linkID="PA3193378"&gt;US-20060089333&lt;/ulink&gt; is a national filing in its own right, whereas &lt;ulink linkType="Patent" linkID="PA3704512"&gt;US-20080267945&lt;/ulink&gt; is a national registration of the PCT application (&lt;ulink linkType="Patent" linkID="PA3193701"&gt;WO-2006047575&lt;/ulink&gt;). One of these US applications will likely be abandoned. In Europe, the equivalent &lt;ulink linkType="Patent" linkID="PA3523205"&gt;EP-01805192&lt;/ulink&gt; was also pending grant.&lt;/para&gt;&lt;para&gt;In the third quarter of 2004, Dekk-Tec granted ZIOPHARM an exclusive worldwide license to palifosfamide-lys. The license included two pending US patent applications (presumably &lt;ulink linkType="Patent" linkID="PA3193378"&gt;US-20060089333&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA3704512"&gt;US-20080267945&lt;/ulink&gt;) and foreign counterparts. ZIOPHARM since filed &lt;ulink linkType="Patent" linkID="PA3697726"&gt;WO-2008124097&lt;/ulink&gt;, which claims new crystalline salts of isophosphoramide mustard and analogs, and also licensed &lt;ulink linkType="Patent" linkID="IN2750053"&gt;WO-0071134&lt;/ulink&gt; from the &lt;ulink linkType="Company" linkID="20226"&gt;Southern Research Institute&lt;/ulink&gt;, which covers other isophosphoramide mustard analogs.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;The chemotherapy for several cancer entities, most notably soft-tissue and bone sarcoma, but also lymphoma and other neoplasms, has relied heavily on DNA alkylators such as cyclophosphamide and ifosfamide. However, severe side effects associated with ifosfamide prevent the application of any high-dose regimens. When metabolized in the body, ifosfamide is processed into its active metabolite, isophosphoramide mustard, with two of the byproducts being acrolein and chloroacetaldehyde. Acrolein is believed to be the main cause of hemorrhagic cystitis, while chloroacetaldehyde is believed to be responsible for further neuro- and nephrotoxic side effects. Any attempts to use isophosphoramide mustard as a monotherapy chemotherapeutic agent were hampered by instability issues, which have prevented the pharmaceutical use of this compound. Therefore, ZIOPHARM Oncology's chemically stable salts of isophosphoramide mustard, palifosfamide-tris/-lys, have been linked with high expectations. These salts could display the antitumor activity of ifosfamide without the typical side effects associated with ifosfamide treatment.&lt;/para&gt;&lt;para&gt;Preclinical and phase I and II clinical trial data demonstrated that both salts of palifosfamide were expected to fulfill this promise. As detailed in the previous sections, palifosfamide displayed considerable antitumor activity in patients with sarcoma and, perhaps most impressively, also in patients who had previously been treated unsuccessfully with ifosfamide. In the clinical trials of both salts of palifosfamide, patients did not experience hemorrhagic cystitis or any of the neuro- and nephrotoxic side effects associated with ifosfamide. Nevertheless, in the ongoing PICASSO trial, exclusion criteria for patients include clinically evident congestive heart failure, significant cardiac arrhythmias, coronary artery disease or ischemia, serious myocardial dysfunction, HIV infection, history of nephrectomy or urinary tract obstruction, active infection, and pregnancy or lactation; these criteria would significantly limit the application of the drug if used to limit the eligible patient population outside of the trial setting. Although phase III clinical trials need to be conducted, both palifosfamide salts already appear to be a more effective and safer versions of the precursor ifosfamide. Apart from an improved toxicity and safety profile, the palifosfamide salts can also be administered orally; at the time of publication, successful oral administration of palifosfamide-tris had been demonstrated in animal models, but requires further evaluation.&lt;/para&gt;&lt;para&gt;If data from phase III clinical trials confirm the findings from preclinical studies and phase I/II trials, it is feasible that a palifosfamide salt could replace ifosfamide as a future treatment. When these stabilized salts progressed beyond the preclinical stage, the use of the compounds as a substitute for ifosfamide for the management of high-risk sarcoma was already being discussed in the scientific literature [&lt;ulink linkType="Reference" linkID="986349"&gt;986349&lt;/ulink&gt;]. Palifosfamide salts are also considered a treatment option in radiosensitization schemes that combine chemotherapy with irradiation, expanding the potential therapeutic applications of this compound [&lt;ulink linkType="Reference" linkID="986349"&gt;986349&lt;/ulink&gt;], and has also been indicated as a new chemotherapeutic agent in conditioning regimens for bone marrow transplantation [&lt;ulink linkType="Reference" linkID="976000"&gt;976000&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="976001"&gt;976001&lt;/ulink&gt;]. For several hematological malignancies, allogeneic hematopoietic stem cell transplantation offers the only possibility of a potentially curative treatment. With a combination of myeloablative high-dose radio/chemotherapy before transplantation, a strong antitumor effect can be achieved; this effect is then enhanced by the graft-versus-tumor effect of the transplant. However, the severe side effects of the high-dose conditioning before transplantation have been limiting factors of this treatment strategy, making the development of milder and more tolerable conditioning regimens, including non-myeloablative schemes, an important aim of current research in the field of bone marrow transplantation [&lt;ulink linkType="Reference" linkID="1049331"&gt;1049331&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049332"&gt;1049332&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049333"&gt;1049333&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As a consequence of the positive data acquired thus far, palifosfamide has been granted orphan drug status in Europe for the treatment of soft-tissue sarcoma [&lt;ulink linkType="Reference" linkID="970894"&gt;970894&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="972793"&gt;972793&lt;/ulink&gt;]. Although this outcome suggests that a palifosfamide salt might be an excellent chemotherapeutic alternative to ifosfamide, chemotherapy in the treatment of neoplasms such as sarcoma has limited efficiency [&lt;ulink linkType="Reference" linkID="1049325"&gt;1049325&lt;/ulink&gt;]. For patients with sarcoma diagnosed at an early stage, a first-line therapy consisting of adequate surgery is the decisive factor determining the overall outcome of the treatment. Conversely, patients with unresectable and metastatic disease have a poor prognosis, with an overall survival at 5 years of &amp;lt; 10%, even if extensive chemotherapy regimens are applied [&lt;ulink linkType="Reference" linkID="1049315"&gt;1049315&lt;/ulink&gt;]. From this perspective, the improvement of existing chemotherapeutic agents does not address the issue of an overall unsatisfactory outcome of current first-line chemotherapy regimens.&lt;/para&gt;&lt;para&gt;To improve the efficiency of chemotherapy in the systemic treatment of sarcoma in addition to local treatment with surgery and radiotherapy, new cytotoxic agents are being developed and tested. For example, &lt;ulink linkType="Drug" linkID="9112"&gt;trabectedin&lt;/ulink&gt;, a minor-groove binder that exhibited antitumor activity in preclinical studies, was associated with one complete and three partial remissions in 20 patients with sarcoma in a phase I clinical trial [&lt;ulink linkType="Reference" linkID="1049315"&gt;1049315&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049321"&gt;1049321&lt;/ulink&gt;]. Five phase II trials for the drug demonstrated long progression-free rates for several patients, although the overall response rate in these trials was relatively low. Overall, &lt;ulink linkType="Drug" linkID="9112"&gt;trabectedin&lt;/ulink&gt; has demonstrated an ability to slow tumor growth and, consequently, has been used for 2 years as a second-line systemic chemotherapeutic agent in the treatment of sarcomas [&lt;ulink linkType="Reference" linkID="1049325"&gt;1049325&lt;/ulink&gt;]. Another minor-groove binder, &lt;ulink linkType="Drug" linkID="22964"&gt;brostallicin&lt;/ulink&gt;, which is in phase II development by &lt;ulink linkType="Company" linkID="1033744"&gt;Systems Medicine Inc&lt;/ulink&gt;, has also been tested extensively and has demonstrated promising results, with 20 out of 40 patients exhibiting disease stabilization, and progression-free survival at 3 months being as high as 46% [&lt;ulink linkType="Reference" linkID="1049325"&gt;1049325&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Within the group of small molecules, the VEGFR inhibitor &lt;ulink linkType="Drug" linkID="43738"&gt;pazopanib&lt;/ulink&gt; has demonstrated antitumor activity in soft-tissue sarcoma. &lt;ulink linkType="Drug" linkID="43738"&gt;Pazopanib&lt;/ulink&gt; has been investigated in a phase II, non-randomized clinical trial in patients with refractory or relapsed soft-tissue sarcoma [&lt;ulink linkType="Reference" linkID="1024698"&gt;1024698&lt;/ulink&gt;]. For leiomyosarcoma, synovial sarcoma and other types of soft-tissue sarcoma, progression-free survival rates at 3 months were 34, 44 and 44%, respectively, and, at the time of publication, the next step in the development of &lt;ulink linkType="Drug" linkID="43738"&gt;pazopanib&lt;/ulink&gt; was a phase III, randomized, double-blind trial (NCT00753688) of &lt;ulink linkType="Drug" linkID="43738"&gt;pazopanib&lt;/ulink&gt; compared with placebo [&lt;ulink linkType="Reference" linkID="1024698"&gt;1024698&lt;/ulink&gt;]. It is not unlikely that &lt;ulink linkType="Drug" linkID="43738"&gt;pazopanib&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="22964"&gt;brostallicin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="9112"&gt;trabectedin&lt;/ulink&gt; will prove to be more efficient in the treatment of neoplasms such as sarcoma than established agents such as ifosfamide. If these newer cytotoxic agents displace the current agents in use, such as doxorubicin or ifosfamide, an improvement in the safety profile of ifosfamide provided by the development of the palifosfamide salts would lose a substantial impact.&lt;/para&gt;&lt;para&gt;In another recent development, focus in the treatment of sarcoma has begun to shift from broad-spectrum cytotoxic chemotherapy to more specific molecular-targeted therapies. Based on a more detailed classification of sarcomas using cytogenetic analysis tools, new strategies established on the biological properties of the different tumor entities are being developed. Among these novel strategies are the use of antiangiogenic and immunomodulatory drugs, growth factor inhibition, Bcl-2 antisense therapy, Raf kinase inhibition, Hsp modulation and proteasome inhibition. The combination of a molecularly based characterization of sarcoma subgroups and a specifically targeted treatment of the individual groups would be expected to considerably improve the treatment of sarcoma [&lt;ulink linkType="Reference" linkID="1049315"&gt;1049315&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049321"&gt;1049321&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1049325"&gt;1049325&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As long as the clinical trials of new anticancer agents have not reached the stage of final data evaluation, chemotherapy with anthracyclines and/or ifosfamide will remain the standard treatment. Therefore, a stable form of the active metabolite of ifosfamide without the severe side effects associated with ifosfamide will be a welcome addition to the armamentarium available for the treatment of sarcoma.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1122803">Predictive Therapeutics</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1754683" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="203">Lymphoma</Indication><StatusDate>2008-11-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2013-03-26T00:00:00.000Z</StatusDate><Source id="1396177" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2013-03-26T00:00:00.000Z</StatusDate><Source id="1396177" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1754683" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1054">Testis tumor</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1754683" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1754683" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2013-03-26T00:00:00.000Z</StatusDate><Source id="1396177" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2013-03-26T00:00:00.000Z</StatusDate><Source id="1396177" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15652">Dekk-Tec Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2003-11-10T00:00:00.000Z</StatusDate><Source id="570163" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2013-03-26T00:00:00.000Z</StatusDate><Source id="1396177" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2013-03-26T00:00:00.000Z</StatusDate><Source id="1396177" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1754683" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1754683" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1754683" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2015-11-30T00:00:00.000Z</StatusDate><Source id="1754683" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2010-11-24T00:00:00.000Z</StatusDate><Source id="1158157" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3713">Advanced solid tumor</Indication><StatusDate>2011-06-29T00:00:00.000Z</StatusDate><Source id="1257595" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-10-09T00:00:00.000Z</StatusDate><Source id="1333467" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2010-07-19T00:00:00.000Z</StatusDate><Source id="1117205" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2010-07-19T00:00:00.000Z</StatusDate><Source id="1117205" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2010-07-19T00:00:00.000Z</StatusDate><Source id="1117205" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2010-07-19T00:00:00.000Z</StatusDate><Source id="1117205" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="XD">North America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2010-07-19T00:00:00.000Z</StatusDate><Source id="1117205" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2010-07-19T00:00:00.000Z</StatusDate><Source id="1117205" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2012-06-06T00:00:00.000Z</StatusDate><Source id="1299839" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2013-03-11T00:00:00.000Z</StatusDate><Source id="1390612" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2013-03-06T00:00:00.000Z</StatusDate><Source id="1389178" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2013-03-26T00:00:00.000Z</StatusDate><Source id="1534551" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3378">Soft tissue sarcoma</Indication><StatusDate>2008-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1054">Testis tumor</Indication><StatusDate>2013-03-06T00:00:00.000Z</StatusDate><Source id="1389178" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2012-06-05T00:00:00.000Z</StatusDate><Source id="1299839" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1261">Small-cell lung cancer</Indication><StatusDate>2012-06-05T00:00:00.000Z</StatusDate><Source id="1299839" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15652">Dekk-Tec Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2002-04-08T00:00:00.000Z</StatusDate><Source id="446255" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-11-10T00:00:00.000Z</StatusDate><Source id="570163" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2007-03-22T00:00:00.000Z</StatusDate><Source id="777458" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2006-02-23T00:00:00.000Z</StatusDate><Source id="652209" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2006-02-23T00:00:00.000Z</StatusDate><Source id="652209" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009856">ZIOPHARM Oncology Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="194">Sarcoma</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="941010" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1122803">Predictive Therapeutics</OwnerCompany><Country id="EU">EU</Country><Indication id="3378">Soft tissue sarcoma</Indication><AwardedIndication>Treatment of soft tissue sarcoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2008-12-03T00:00:00.000Z</MileStoneDate><Source id="970894" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1122803">Predictive Therapeutics</OwnerCompany><Country id="EU">EU</Country><Indication id="3378">Soft tissue sarcoma</Indication><AwardedIndication>Treatment of soft tissue sarcoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2008-10-08T00:00:00.000Z</MileStoneDate><Source id="952731" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1009856">ZIOPHARM Oncology Inc</OwnerCompany><Country id="US">US</Country><Indication id="3378">Soft tissue sarcoma</Indication><AwardedIndication>Treatment of soft tissue sarcomas</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2008-05-05T00:00:00.000Z</MileStoneDate><Source id="904226" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009856">ZIOPHARM Oncology Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="1122803">Predictive Therapeutics</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15652">Dekk-Tec Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20226">Southern Research Institute</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="107454" title="ZIOPHARM Oncology to develop Dekk-Tec's ifosfamide analogs worldwide"/><Deal id="117523" title="SRI and ZIOPHARM to collaborate on isophosphoramide research"/><Deal id="132646" title="US Government to award funding to ZIOPHARM for development of palifosfamide, darinaparsin and indibulin"/><Deal id="160016" title="Predictive Therapeutics in license Palifosfamide from ZIOPHARM Oncology against multiple indications       "/></Deals><PatentFamilies><PatentFamily id="1364769" number="WO-2006047575" title="Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents"/><PatentFamily id="1531092" number="WO-2010014841" title="Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof"/><PatentFamily id="2568996" number="WO-2013116281" title="Combination therapy including isophosphoramide mustard, analogs, or salts thereof"/><PatentFamily id="997698" number="WO-2008124097" title="Salts of isophosphoramide mustard and analogs thereof"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ZIOPHARM Oncology Inc" id="1009856"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dekk-Tec Inc" id="15652"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="4471"><DrugName>saredutant</DrugName><DrugNamesKey><Name id="42756617">saredutant</Name></DrugNamesKey><DrugSynonyms><Name><Value>SR-48968</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>saredutant</Value><Types><Type>INN</Type></Types></Name><Name><Value>saredutant succinate</Value></Name><Name><Value>SR-48968C</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>142001-63-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="26494">Sanofi-Synthelabo</CompanyOriginator><CompaniesSecondary><Company id="1009547">Sanofi SA</Company><Company id="26494">Sanofi-Synthelabo</Company><Company id="26658">Sanofi Recherche SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4471" type="Drug"><TargetEntity id="183412" type="siDrug">Saredutant</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="26494" type="Company"><TargetEntity id="5000326934" type="organizationId">Sanofi Synthelabo Caraibes SARL</TargetEntity></SourceEntity><SourceEntity id="26658" type="Company"><TargetEntity id="5035524034" type="organizationId">Sanofi Recherche SA</TargetEntity></SourceEntity><SourceEntity id="187" type="ciIndication"><TargetEntity id="10046543" type="MEDDRA"/><TargetEntity id="D014549" type="MeSH"/><TargetEntity id="-1859456438" type="omicsDisease"/><TargetEntity id="355" type="siCondition"/></SourceEntity><SourceEntity id="192" type="ciIndication"><TargetEntity id="K58" type="ICD10"/><TargetEntity id="10023003" type="MEDDRA"/><TargetEntity id="D043183" type="MeSH"/><TargetEntity id="-716973018" type="omicsDisease"/><TargetEntity id="397" type="siCondition"/></SourceEntity><SourceEntity id="1937" type="ciIndication"><TargetEntity id="F41.1" type="ICD10"/><TargetEntity id="10018075" type="MEDDRA"/><TargetEntity id="32" type="siCondition"/></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="25" type="ciIndication"><TargetEntity id="10057666" type="MEDDRA"/><TargetEntity id="D001008" type="MeSH"/><TargetEntity id="-1384065283" type="omicsDisease"/><TargetEntity id="30" type="siCondition"/></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"/><TargetEntity id="D003863" type="MeSH"/><TargetEntity id="-508468160" type="omicsDisease"/><TargetEntity id="53" type="siCondition"/></SourceEntity><SourceEntity id="267" type="Action"><TargetEntity id="317" type="Mechanism">Tachykinin NK2 Antagonists</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="PTGT-01433" type="ciTarget"><TargetEntity id="42129332968653" type="siTarget">Substance-K receptor</TargetEntity><TargetEntity id="-292574261" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="187">Urinary incontinence</Indication><Indication id="192">Irritable bowel syndrome</Indication><Indication id="1937">Generalized anxiety disorder</Indication><Indication id="20">Pain</Indication><Indication id="25">Anxiety disorder</Indication><Indication id="31">Asthma</Indication><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsPrimary><Action id="267">NK2 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2941">Antidepressant</Action><Action id="2942">Anxiolytic</Action><Action id="2953">Anti-inflammatory</Action><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N5C</Code><Name>TRANQUILLISERS</Name></Ephmra><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra><Ephmra><Code>G4B4</Code><Name>Urinary incontinence products</Name></Ephmra></EphmraCodes><LastModificationDate>2017-12-28T14:44:50.000Z</LastModificationDate><ChangeDateLast>2011-05-26T09:31:22.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi-aventis&lt;/ulink&gt; (formerly &lt;ulink linkID="26494" linkType="Company"&gt;Sanofi-Synthelabo&lt;/ulink&gt;) was developing the non-peptide NK2 antagonist saredutant (SR-48968; structure shown) as saredutant succinate (SR-48968C) for the potential oral treatment of depression and generalized anxiety disorder (GAD) [&lt;ulink linkID="367094" linkType="Reference"&gt;367094&lt;/ulink&gt;], [&lt;ulink linkID="463211" linkType="Reference"&gt;463211&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By February 2007, saredutant had shown a significant advantage over placebo in two of four completed phase III depression studies [&lt;ulink linkID="765430" linkType="Reference"&gt;765430&lt;/ulink&gt;]. In July 2008, a decision on filing for depression was expected in mid-2009  following results of trials of saredutant in combination with SSRIs [&lt;ulink linkID="931778" linkType="Reference"&gt;931778&lt;/ulink&gt;]. In October 2006, phase III studies in GAD were initiated [&lt;ulink linkID="755864" linkType="Reference"&gt;755864&lt;/ulink&gt;], [&lt;ulink linkID="755865" linkType="Reference"&gt;755865&lt;/ulink&gt;]. However, by April 2009, development had been terminated, following presumed negative results from studies of saredutant plus escitalopram in depression [&lt;ulink linkID="1004352" linkType="Reference"&gt;1004352&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 1998, saredutant was under development by the company for the potential treatment of urinary incontinence and analgesia [&lt;ulink linkID="328910" linkType="Reference"&gt;328910&lt;/ulink&gt;]. However, these indications were not mentioned in the company's pipeline disclosed in June 2001 [&lt;ulink linkID="413342" linkType="Reference"&gt;413342&lt;/ulink&gt;]. Previously, it has also been investigated for the potential treatment of asthma [&lt;ulink linkID="227792" linkType="Reference"&gt;227792&lt;/ulink&gt;]. Saredutant has also been developed for irritable bowel syndrome (IBS). By February 2003, phase IIb trials had begun [&lt;ulink linkID="479170" linkType="Reference"&gt;479170&lt;/ulink&gt;], [&lt;ulink linkID="491369" linkType="Reference"&gt;491369&lt;/ulink&gt;]. However, this indication was not listed on the company's March 2005 pipeline [&lt;ulink linkID="587512" linkType="Reference"&gt;587512&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In July 2008, a decision on filing for depression was expected in mid-2009  following results of trials of saredutant in combination with SSRIs [&lt;ulink linkID="931778" linkType="Reference"&gt;931778&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Depression&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In February 2008, the 8-week, randomized, double-blind, 820-patient COMPASS study (NCT0062955) began in centrers around the world. It would evaluate two fixed doses of saredutant (100 and 30 mg) once daily in combination with 20 mg &lt;ulink linkID="8956" linkType="Drug"&gt;paroxetine&lt;/ulink&gt; compared to paroxetine alone in major depressive disorder [&lt;ulink linkID="936795" linkType="Reference"&gt;936795&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By February 2008, the phase III INDIGO study had been initiated in elderly patients [&lt;ulink linkID="876053" linkType="Reference"&gt;876053&lt;/ulink&gt;]. In April 2008, results were released, showing that the study did not reach significance compared to placebo. However, the company noted that a pooled analysis of all saredutant studies demonstrated a positive short-term benefit on patients with major depressive disorder [&lt;ulink linkID="900981" linkType="Reference"&gt;900981&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2007, two clinical studies treating depression patients with saredutant and an SSRI antidepressant had been initiated [&lt;ulink linkID="830743" linkType="Reference"&gt;830743&lt;/ulink&gt;]. This adjuvant trial was expected to comple in 1H09 [&lt;ulink linkID="875929" linkType="Reference"&gt;875929&lt;/ulink&gt;], [&lt;ulink linkID="989413" linkType="Reference"&gt;989413&lt;/ulink&gt;]. In September 2007, a phase III 8-week study (&lt;ulink linkID="7831" linkType="Protocol"&gt;NCT00531622&lt;/ulink&gt;) of 100 mg saredutant  plus &lt;ulink linkID="17518" linkType="Drug"&gt;escitalopram&lt;/ulink&gt; once daily began in 615 patients with major depressive disorder around the world [&lt;ulink linkID="936804" linkType="Reference"&gt;936804&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2007, a placebo-controlled, randomized, double-blind phase III trial (&lt;ulink linkID="35098" linkType="Protocol"&gt;NCT00429260&lt;/ulink&gt;, SFY6577) was initiated in subjects (expected n = 110) with depression in the US. The subjects were to receive placebo 100 mg/day saredutant for 8 weeks. The primary endpoint was change in daily number of discontinuation symptoms observed in the week after stopping treatment and secondary endpoints included the proportion of subjects experiencing discontinuation symptoms [&lt;ulink linkID="767979" linkType="Reference"&gt;767979&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, a placebo-controlled, randomized, double-blind phase III trial (EFC5574, &lt;ulink linkID="7832" linkType="Protocol"&gt;NCT00415142&lt;/ulink&gt;) was initiated in elderly subjects (n = 393) with major depressive disorder (MDD) in the US, Mexico, Russia, Turkey and Europe. The subjects were to receive placebo or 100 mg qd saredutant. In February 2008, the study was completed [&lt;ulink linkID="755870" linkType="Reference"&gt;755870&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2006, a US, 24- to 52-week, placebo controlled phase III study (NCT00336713, EFC5576, MAGENTA) began to assess the safety and efficacy of saredutant succinate (100 mg, qd) in preventing relapse of depressive symptoms in patients (expected enrollment n = 800) with MDD. The primary endpoint was timed to relapse and secondary endpoints related to MADRS, HAM-A and quality-of-life scores [&lt;ulink linkID="679575" linkType="Reference"&gt;679575&lt;/ulink&gt;]. In February 2008, results were expected in the second quarter of 2008 [&lt;ulink linkID="876053" linkType="Reference"&gt;876053&lt;/ulink&gt;]. In July 2008, results were released, showing that relapse was not significantly reduced compared to placebo when patients who had responded to saredutant after 3 months had their treatment extended to 12 months. However, the results confirmed the product's good long-term safety profile [&lt;ulink linkID="930012" linkType="Reference"&gt;930012&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2005, LTS5577 (NCT00250653), a US phase III study in adult and elderly depression patients, was initiated. Patients were to receive 100 mg/day saredutant succinate for 52 weeks and the primary endpoint was proportion experiencing treatment-emergent adverse events [&lt;ulink linkID="659599" linkType="Reference"&gt;659599&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2005, two US phase III placebo-controlled trials were initiated in patients with depression. EFC5571 (NCT00250601) and EFC5572 (NCT00250614) were each to recruit 450 patients and treat them with 100 mg saredutant succinate for 8 weeks. The primary endpoint was change in Hamilton Depression Rating Scale (HAM-D) score at day 56 [&lt;ulink linkID="659600" linkType="Reference"&gt;659600&lt;/ulink&gt;], [&lt;ulink linkID="659603" linkType="Reference"&gt;659603&lt;/ulink&gt;]. By March 2006, enrollment had been completed [&lt;ulink linkID="659452" linkType="Reference"&gt;659452&lt;/ulink&gt;]. By February 2007, results from EFC5575, EFC5573, EFC5571 and EFC5572 had shown significant efficacy for saredutant compared to placebo, with reduced loss of sexual function. Saredutant also showed similar rates of adverse events to the placebo group and these rates were significantly reduced compared to &lt;ulink linkID="8956" linkType="Drug"&gt;paroxetine&lt;/ulink&gt; [&lt;ulink linkID="765666" linkType="Reference"&gt;765666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2004, a French phase III study (EFC5575, NCT00256113) was initiated in an expected 450 patients with depression. The primary endpoint was to compare the efficacy of 100 mg saredutant to placebo. Secondary endpoints included safety and quality of life measures [&lt;ulink linkID="680294" linkType="Reference"&gt;680294&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2004, a US phase III study (EFC5573, NCT00250627) was initiated in an expected 450 patients with depression. The primary endpoint was to compare the efficacy of 100 mg saredutant to placebo. Secondary endpoints included safety and quality of life measures [&lt;ulink linkID="680295" linkType="Reference"&gt;680295&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In February 2004, Sanofi-Synthelabo reported data from DFI4381, a phase IIb study in patients with MDD. This trial was a double-blind, randomized, placebo- and &lt;ulink linkID="17558" linkType="Drug"&gt;fluoxetine&lt;/ulink&gt;-controlled multicenter trial in patients (n = 120 in each arm, aged 18 to 65) with recurrent, moderate-to-severe major depressive episodes (median HAM-D baseline score of 26). Patients were administered placebo for 1 week, then treated for a further 6 weeks. Saredutant showed a similar effect at 100 mg to fluoxetine 20 mg in reducing HAM-D and Hamilton-anxiety (HAM-A) scores (&amp;gt; -14 and -12, respectively). A greater number of patients taking saredutant exhibited a sustained response compared with fluoxetine (43.9 versus 37.5%, respectively). Saredutant also demonstrated an improved adverse event profile compared with fluoxetine for any class adverse events (33.6 and 38.3%, respectively, versus 27.3% for placebo), gastrointestinal disorders (13.6 and 18.8%, respectively, versus 7.4% for placebo) and nervous system disorders (14.4 and 20.3%, respectively, versus 9.1% for placebo) [&lt;ulink linkID="523363" linkType="Reference"&gt;523363&lt;/ulink&gt;], [&lt;ulink linkID="523368" linkType="Reference"&gt;523368&lt;/ulink&gt;], [&lt;ulink linkID="765666" linkType="Reference"&gt;765666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2000, phase IIa trials in CNS disorders, including depressive disorders, were ongoing [&lt;ulink linkID="359231" linkType="Reference"&gt;359231&lt;/ulink&gt;], [&lt;ulink linkID="413342" linkType="Reference"&gt;413342&lt;/ulink&gt;]. The drug was nearing completion of phase II trials for depression in November 2000, and it was anticipated at the time that complete clinical data would be available in 2001 [&lt;ulink linkID="389243" linkType="Reference"&gt;389243&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Generalized anxiety disorder&lt;/subtitle&gt;By February 2008, two studies examining saredutant as adjunctive therapy with standard therapies were initiated. Results were expected in 2009 [&lt;ulink linkID="875929" linkType="Reference"&gt;875929&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2007, two phase III GAD studies were planned for 2007. EFC6757 was to recruit 300 subjects and was to assess acute efficacy in the elderly. EFC5586 was to recruit 340 subjects and was to assess long-term efficacy [&lt;ulink linkID="765666" linkType="Reference"&gt;765666&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2006, a placebo-controlled, randomized, double-blind phase III trial (NCT00417118, EFC5583) was initiated in subjects (expected n = 360) with GAD in Europe, Canada and Turkey. The subjects were to receive placebo or 100 mg/day saredutant for 8 weeks. The primary endpoint was change in HAM-A score [&lt;ulink linkID="767980" linkType="Reference"&gt;767980&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2006, a placebo-controlled, randomized, double-blind phase III trial (EFC5582, NCT00390533) was initiated in subjects (expected n = 405) with GAD in the US and Australia. The subjects were to receive placebo or 30 or 100 mg qd saredutant. The primary endpoint was change from baseline in HAM-A total score at day 56 and secondary endpoints included change from baseline at day 56 in a quality-of-life score [&lt;ulink linkID="755864" linkType="Reference"&gt;755864&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2006, a placebo-controlled, randomized, double-blind phase III trial (EFC5581, NCT00390650) was initiated in subjects (expected n = 360) with GAD in the US and Canada. The subjects were to receive placebo or 100 mg qd saredutant. The primary endpoint was change from baseline in HAM-A total score at day 56 and secondary endpoints included change from baseline at day 56 in a quality-of-life score [&lt;ulink linkID="755865" linkType="Reference"&gt;755865&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Irritable bowel syndrome&lt;/subtitle&gt;The compound was under development for IBS in 1996 and had reached phase IIa trials by that time [&lt;ulink linkID="227792" linkType="Reference"&gt;227792&lt;/ulink&gt;]. No further development on the indication has been reported and it appeared that the company was no longer pursuing this indication. However, in September 2002, the company listed the compound as in phase IIa trials for the treatment of IBS again [&lt;ulink linkID="463211" linkType="Reference"&gt;463211&lt;/ulink&gt;]. Phase IIb trials had begun for this indication by February 2003 [&lt;ulink linkID="479170" linkType="Reference"&gt;479170&lt;/ulink&gt;] and were ongoing in February 2004 [&lt;ulink linkID="523368" linkType="Reference"&gt;523368&lt;/ulink&gt;]. However, this indication was not listed on the company's March 2005 pipeline [&lt;ulink linkID="587512" linkType="Reference"&gt;587512&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pain&lt;/subtitle&gt;By December 1998, phase IIa trials for analgesia were underway [&lt;ulink linkID="328910" linkType="Reference"&gt;328910&lt;/ulink&gt;]. However, the indication appeared to have been dropped from the company's pipeline by June 2001 [&lt;ulink linkID="413342" linkType="Reference"&gt;413342&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Asthma&lt;/subtitle&gt;Saredutant was reported to be under investigation for asthma. However, Sanofi-Synthelabo had not listed the compound for this indication on its pipeline by May 2000 [&lt;ulink linkID="367094" linkType="Reference"&gt;367094&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 1999, Saredutant had demonstrated inhibition of NK-A-induced bronchoconstriction in mild asthmatics. In a small trial, 100 mg or placebo was administered to 12 patients suffering from mild asthma, and the neurokinin A challenge performed at 1.5 and 24 h after dosing. The treated group reported a significant inhibition of bronchoconstriction [&lt;ulink linkID="323836" linkType="Reference"&gt;323836&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Urinary incontinence&lt;/subtitle&gt;By December 1998, phase IIa trials in urinary incontinence were underway [&lt;ulink linkID="328910" linkType="Reference"&gt;328910&lt;/ulink&gt;]. However, the indication was not mentioned in the company's pipeline disclosed in June 2001 [&lt;ulink linkID="413342" linkType="Reference"&gt;413342&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2008, preclinical data were presented at the 38th SFN conference in Washington, DC. Saredutant displayed anxiolytic- and antidepressant-like properties in rodent models of anxiety and depression [&lt;ulink linkID="955142" linkType="Reference"&gt;955142&lt;/ulink&gt;], [&lt;ulink linkID="955154" linkType="Reference"&gt;955154&lt;/ulink&gt;]. Moreover, saredutant did not produce deleterious effects on cognitive processes at therapeutic doses [&lt;ulink linkID="955144" linkType="Reference"&gt;955144&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2007, preclinical data on saredutant were presented at the 37th SFN meeting in San Diego, CA. In models of anxiety 30 mg/kg saredutant po produced significant anxiolytic effects in the hole board, stress-induced hyperthermic (SIH) response and four-plate tests; a significant effect was also observed with 18 mg/kg saredutant in the four-plate assay. Saredutant showed similar trends to chlordiazepoxide which had an effect in all three tests, without the same disinhibitory effect, while it differed from paroxetine which was ineffective in the SIH test [&lt;ulink linkID="847582" linkType="Reference"&gt;847582&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2006, preclinical data on saredutant were presented at the 36th Annual SFN Meeting in Atlanta, GA. In the distress vocalization test in rat pups, saredutant (3 and 10 mg/kg, sc) reduced ultrasonic calls in rat pups separated from their mother and littermates. After olfactory bulbectomy in rats, a deficit in the acquisition of passive avoidance (using the step-down procedure) was observed approximately 15 to 45 days after the lesion which was reversed by the acute administration of saredutant (10 to 30 mg/kg, ip). In male BALB/c mice subjected to a variety of mild stressors (eg, restraint, overnight illumination, forced swimming, pairing with an aggressive resident), treatment with saredutant (10 mg/kg, ip) administered once a day during 33 days (starting two weeks after the beginning of stress exposure) significantly improved the degradation of the physical state after 1 week of treatment and until the end of the chronic stress procedure [&lt;ulink linkID="731266" linkType="Reference"&gt;731266&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2002, preclinical data were presented at the 14th World Congress of Pharmacology in San Francisco, CA. The study presented sought to investigate the effects on airways of intraoesophageal HCl instillation in the rabbit and the role of tachykardins in these effects. HCl significantly increased the lung resistance, but this was significantly inhibited by nolpitanium and saredutant, but not by &lt;ulink linkID="8970" linkType="Drug"&gt;osanetant&lt;/ulink&gt;. Furthermore, intraoesophageal HCl instillation significantly increased plasma extravasation in trachea and main bronchi; the trachea effects were significantly inhibited by all of the tachykinin receptor antagonists used, while the main bronchi effect was elicited by nolpitanium only [&lt;ulink linkID="455709" linkType="Reference"&gt;455709&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2002, preclinical data on saredutant were presented at the Digestive Disease Week meeting in San Francisco, CA. TNBS-induced rectal allodynia in rats was reduced by 54% and 64% by 1 mg/kg ip saredutant and &lt;ulink linkID="8970" linkType="Drug"&gt;osanetant&lt;/ulink&gt;, respectively. Distension-induced pain was reduced by 34% with 1 mg/kg osanetant. Colonic retention time was not affected by either drug at doses up to 5 mg/kg. These data suggest that saredutant could be used to treat visceral pain without inducing constipation [&lt;ulink linkID="452023" linkType="Reference"&gt;452023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Clinical investigations presented at the American Society for Clinical Pharmacology and Therapeutics by 2000, discussed the effect of saredutant on acute pain and inflammation. As neurokinins are implicated in pain and inflammation, saredutant was investigated for analgesic and anti-inflammatory potential. Individuals received one of three treatments: 200 mg saredutant once daily starting 1 h prior to surgery, 200 mg after pain onset, or placebo. No analgesic effect was seen in either the preventative or curative treatments. The mean number of inflammatory cells observed (from tissue biopsies before and after surgery-different sites) increased significantly (P &amp;lt; 0.01) from the pre-operative biopsy to the postoperative biopsy. The data did not show any clinical utility for saredutant for acute pain and inflammation [&lt;ulink linkID="363193" linkType="Reference"&gt;363193&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Saredutant was the first neurokinin antagonist to be developed that belonged to the dichlorophenylalkylpiperidine series. Further investigation in 1997 led to the discovery of nolpitanium, an NK1 antagonist, and osanetant, an NK3 antagonist. Saredutant shows some affinity for the NK3 receptor, but none for the NK1 receptor. It has been shown in vitro that NK2-receptor-induced smooth muscle contraction is potently antagonized by saredutant, and in vivo studies have demonstrated that NKA-induced bronchoconstriction in the guinea pig is also antagonized [&lt;ulink linkID="275923" linkType="Reference"&gt;275923&lt;/ulink&gt;]. By 1998, modification of saredutant yielded a structurally divergent series of combined NK1/NK2 antagonists [&lt;ulink linkID="301472" linkType="Reference"&gt;301472&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2003, preclinical data on saredutant were presented at the 33rd Neuroscience meeting in New Orleans, LA. The effects of saredutant were investigated in male Long-Evans rats previously trained to make 80% correct choices in a T-maze. Subsequent injection of saredutant (50 nM/0.5 microl) into the ventral medial prefrontal cortex impaired performance of the rats to approaching chance levels [&lt;ulink linkID="512761" linkType="Reference"&gt;512761&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2000, in vivo data on saredutant were presented at the 30th Neuroscience meeting in New Orleans, LA. In mice, saredutant reduced immobility in the forced swimming test and decreased the amount of separation-induced vocalization in guinea-pig pups. It reduced the maternal separation-induced increase in the number of neurons displaying NK1 receptor internalization in the amygdala. Saredutant increased the expression of the cAMP response element binding protein (CREB) mRNA in the rat hippocampus after chronic but not acute administration [&lt;ulink linkID="390691" linkType="Reference"&gt;390691&lt;/ulink&gt;]. The administration of saredutant and antalarmin blocked an increase in extracellular NE levels in the prefrontal cortex after 15 min of tail-pinching awake rats. In anesthetized rats, the increase in NE levels in the PFc and also in LC neuronal firing evoked by the icbv administration of CRF, was abolished by administration of antalarmin and saredutant [&lt;ulink linkID="390698" linkType="Reference"&gt;390698&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;SK-48965 is the inactive enantiomer of saredutant [&lt;ulink linkID="288186" linkType="Reference"&gt;288186&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Evaluation prepared by Dr Peter Yu, &lt;ulink linkType="Company" linkID="20671"&gt;University of Saskatchewan&lt;/ulink&gt;&lt;/subtitle&gt;21 April 1997&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;SR-48968, (S)-N-methyl-N-(4-(4-acetylamino-4-phenyl piperidino)-2-(3,4-dichlorophenyl)butyl benzamide) has been synthesized by &lt;ulink linkType="Company" linkID="26495"&gt;Sanofi&lt;/ulink&gt; [&lt;ulink linkType="reference" linkID="235670"&gt;235670&lt;/ulink&gt;]. It has been widely used for the identification of the tachykinin NK2 receptor [&lt;ulink linkType="reference" linkID="57851"&gt;57851&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;The high potency and selectivity of SR-48968 as a tachykinin NK2 receptor antagonist has been confirmed in the respiratory, gastrointestinal and urinary systems in different laboratories [&lt;ulink linkType="reference" linkID="235480"&gt;235480&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="226850"&gt;226850&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="154416"&gt;154416&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="154177"&gt;154177&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="235657"&gt;235657&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;The principle metabolite in man is the inactive N-desmethyl SR-48968.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;SR-48968 is nontoxic in rodent and some non-rodent species. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;SR-48968 is currently in phase IIa clinical trials for incontinence and asthma [&lt;ulink linkType="reference" linkID="235502"&gt;235502&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="235576"&gt;235576&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion &lt;/subtitle&gt;Neurokinins, or tachykinins, which include substance P (SP), neurokinin A (NKA) and neurokinin B (NKB), are widely distributed in the peripheral and central nervous systems and exert various biological actions.  NKA induces the contraction of smooth muscles in various tissues and could be implicated as a neurotransmitter or neuromodulator in the central nervous system.  Three neurokinin receptors, NK1, NK2 and NK3, have been identified. SP, NKA and NKB preferentially bind to NK1, NK2 and NK3 receptors respectively. &lt;/para&gt;&lt;para&gt;SR-48968 is a highly potent and specific NK2 antagonist in various species , including humans, which blocks the NK2 receptor-mediated contractions of numerous isolated smooth muscles from the vascular respiratory, gastrointestinal, urinary and uterine systems [&lt;ulink linkType="reference" linkID="226850"&gt;226850&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="235486"&gt;235486&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="235660"&gt;235660&lt;/ulink&gt;]. SR-48968 also produces a dose-dependent inhibition of bronchoconstriction induced by inhaled citric acid, sodium metabisulfite, capsaicin, etc [&lt;ulink linkType="reference" linkID="235491"&gt;235491&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="235497"&gt;235497&lt;/ulink&gt;]. It is also effective in blocking the contraction of urinary bladder and intestines and it also exhibits antagonistic effects on NKA-induced contralateral rotations. Interestingly, the contraction of human bronchus has been reported to be primarily mediated via tachykinin receptors [&lt;ulink linkType="reference" linkID="235573"&gt;235573&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;The two main features of asthma are bronchial hyperresponsiveness and inflammation. The inflammatory response in asthma consists of the infiltration and activation of a variety of inflammatory cells.  Since nonpeptide tachykinin antagonists were discovered, interest in this area of research has increased markedly with several pharmaceutical companies actively patenting structures for a range of therapeutic applications. SR-48968 is a highly specific and potent NK2 antagonist with affinity (binding and in vitro study) for NK2 receptors in the subnanomolar range (pKi = 9 - 10) [&lt;ulink linkType="reference" linkID="196186"&gt;196186&lt;/ulink&gt;]. It does not affect non-cholinergic/non-adrenergic (NANC) receptors. SR-48968 is not only a useful tool for the study of the physiological or pathological role of neurokinin A, but also may be useful in the treatment of neurokinin A-dependent pathology [&lt;ulink linkType="reference" linkID="108989"&gt;108989&lt;/ulink&gt;]. This drug is currently in phase II clinical trials for the treatment of incontinence and asthma. It remains to be clarified whether or not this drug may cause any unwanted side-effects.  &lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>2009-04-29T00:00:00.000Z</StatusDate><Source id="1004352" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate>2009-04-29T00:00:00.000Z</StatusDate><Source id="1004352" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate>2009-04-29T00:00:00.000Z</StatusDate><Source id="1004352" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>2009-04-29T00:00:00.000Z</StatusDate><Source id="1004352" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>2009-04-29T00:00:00.000Z</StatusDate><Source id="1004352" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>2009-04-29T00:00:00.000Z</StatusDate><Source id="1004352" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate>2009-04-29T00:00:00.000Z</StatusDate><Source id="1004352" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>2009-04-29T00:00:00.000Z</StatusDate><Source id="1004352" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>2009-04-29T00:00:00.000Z</StatusDate><Source id="1004352" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><StatusDate>2001-11-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="192">Irritable bowel syndrome</Indication><StatusDate>2005-03-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2000-05-18T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2001-11-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>2000-11-10T00:00:00.000Z</StatusDate><Source id="367094" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2000-05-19T00:00:00.000Z</StatusDate><Source id="367094" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="192">Irritable bowel syndrome</Indication><StatusDate>2002-09-02T00:00:00.000Z</StatusDate><Source id="463211" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2000-11-10T00:00:00.000Z</StatusDate><Source id="367094" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2004-08-20T00:00:00.000Z</StatusDate><Source id="555709" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="192">Irritable bowel syndrome</Indication><StatusDate>2004-08-20T00:00:00.000Z</StatusDate><Source id="555709" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2006-12-31T00:00:00.000Z</StatusDate><Source id="755870" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2006-12-31T00:00:00.000Z</StatusDate><Source id="755870" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2006-12-31T00:00:00.000Z</StatusDate><Source id="755870" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2006-12-31T00:00:00.000Z</StatusDate><Source id="755870" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="680294" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2006-12-31T00:00:00.000Z</StatusDate><Source id="755870" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="755865" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="755865" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1937">Generalized anxiety disorder</Indication><StatusDate>2006-10-31T00:00:00.000Z</StatusDate><Source id="755864" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><StatusDate>1999-07-01T00:00:00.000Z</StatusDate><Source id="328910" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26494">Sanofi-Synthelabo</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>1999-07-01T00:00:00.000Z</StatusDate><Source id="328910" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="192">Irritable bowel syndrome</Indication><StatusDate>1996-12-19T00:00:00.000Z</StatusDate><Source id="227792" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>1996-12-19T00:00:00.000Z</StatusDate><Source id="227792" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>1995-06-01T00:00:00.000Z</StatusDate><Source id="176815" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>1995-06-01T00:00:00.000Z</StatusDate><Source id="176815" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26658">Sanofi Recherche SA</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>1995-06-01T00:00:00.000Z</StatusDate><Source id="176815" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01433"><Name>NK2 receptor</Name><SwissprotNumbers><Swissprot>P05363</Swissprot><Swissprot>P16610</Swissprot><Swissprot>P21452</Swissprot><Swissprot>P30549</Swissprot><Swissprot>P51144</Swissprot><Swissprot>P79218</Swissprot><Swissprot>Q5DUB2</Swissprot><Swissprot>Q64077</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1052493" number="EP-00474561" title="Arylalkylamines, process for their preparation and pharmaceutical compositions containing them."/><PatentFamily id="109111" number="WO-2008017753" title="Pharmaceutical composition containing saredutant and a selective inhibitor of serotonin recapture or an inhibitor of serotonin/norepinephrine recapture in combination"/><PatentFamily id="1112398" number="US-20090076083" title="Deuterium-enriched saredutant"/><PatentFamily id="2066989" number="CZ-200800598" title="Process for preparing (&lt;i&gt;S&lt;/i&gt;)-N-[4-(4-acetylamino-4-phenylpiperidin-1-yl)-2-(3,4-dichlorophenyl)-butyl]-N-methylbenzamide"/><PatentFamily id="2293766" number="WO-2008110697" title="Use of a compound antagonist to the NK2 receptors of a neurokinine for the preparation of drugs useful for preventing and treating sexual dysfunction"/><PatentFamily id="2575666" number="CN-103211817" title="A saredutant of neurokinin receptor is to use in cancer treatment"/><PatentFamily id="911875" number="WO-00064423" title="Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sanofi SA" id="1009547"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Zhejiang Sci-Tech University (ZSTU)" id="1039108"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protia LLC" id="1043660"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="51243"><DrugName>LY-2077855</DrugName><DrugSynonyms><Name><Value>LY-2077855</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>non-endocannabinoid related inhibitor (pain), Lilly</Value></Name></DrugSynonyms><CompanyOriginator id="17810">Eli Lilly &amp; Co</CompanyOriginator><CompaniesSecondary><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="51243" type="Drug"><TargetEntity id="384683" type="siDrug">LY-2077855</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="1551" type="Action"><TargetEntity id="102" type="Mechanism">Cannabinoid Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="7061" type="Action"><TargetEntity id="1501" type="Mechanism">Fatty Acid Amide Hydrolase (FAAH) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00730" type="ciTarget"><TargetEntity id="214331694921663" type="siTarget">Fatty-acid amide hydrolase 1</TargetEntity><TargetEntity id="-368513401" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="20">Pain</Indication></IndicationsSecondary><ActionsPrimary><Action id="1551">Cannabinoid receptor antagonist</Action><Action id="7061">Fatty acid amide hydrolase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2946">Analgesic</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2009-02-16T16:30:43.000Z</LastModificationDate><ChangeDateLast>2009-02-16T16:30:43.000Z</ChangeDateLast><AddedDate>2004-10-25T15:22:38.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="17810"&gt;Lilly&lt;/ulink&gt; was investigating LY-2077855, a non-endocannabinoid related inhibitor, for the potential treatment of pain [&lt;ulink linkType="Reference" linkID="566493"&gt;566493&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="565815"&gt;565815&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2004, preclinical data on LY-2077855 were presented at the 34th SFN meeting in San Diego, CA. This compound inhibited anandamide uptake in RBL-2H3 cells, and  inhibited fatty acid amide hydrolase (FAAH) hydrolysis of decanoyl-pNA, with an IC50 value of 41 nM. LY-2077855 had EC50 values at CB1 and CB2 receptors  greater than 10,000, and Kb values were greater than 4000 and greater than 7000. LY-2077855 dose-dependently increased brain concentrations of anandamide in the rat cerebellum, but had minimal effects on locomotion and anandamide-induced hypolocomotion in mice (30 mg/kg ip was the only dose to significantly increase ambulations; p &amp;lt; 0.05). The compound had an anticonvulsant effect in the mouse threshold electroshock seizures assay, and it potentiated the anticonvulsant effect of 30 mg/kg anandamide with an ED50 value of 0.9 mg/kg. LY-2077855 (30 mg/kg) was effective in a tail-flick model of acute nociceptive pain and an L5/L6 spinal nerve ligation model of neuropathic pain in rats, but showed no performance deficits in a rat rotarod test. Formalin-induced paw-licking pain behavior was significantly attenuated by 10 and 30 mg/kg of LY-2077855 (ED50 = 12.1 mg/kg), and an inactive dose potentiated the effects of anandamide on formalin-induced late phase pain behavior [&lt;ulink linkType="Reference" linkID="566493"&gt;566493&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2009-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate>2004-10-23T00:00:00.000Z</StatusDate><Source id="566493" type="CONFERENCE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00277"><Name>Cannabinoid receptor</Name><SwissprotNumbers/></Target><Target id="PTGT-00730"><Name>Fatty acid amide hydrolase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="51336"><DrugName>fospropofol</DrugName><DrugNamesKey><Name id="42841977">Aquavan</Name><Name id="42898722">Lusedra</Name><Name id="42841979">fospropofol</Name></DrugNamesKey><DrugSynonyms><Name><Value>GPI-15715</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>propofol prodrug, Guilford/ProQuest</Value></Name><Name><Value>PQ-1002</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Aquavan</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>fospropofol</Value><Types><Type>INN</Type></Types></Name><Name><Value>Lusedra</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>propofol prodrug, Eisai</Value></Name><Name><Value>258516-87-9</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>258516-89-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="27501">ProQuest Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="15872">Eisai Co Ltd</Company><Company id="16590">MGI GP Inc</Company><Company id="18203">MGI Pharma Inc</Company><Company id="27501">ProQuest Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="51336" type="Drug"><TargetEntity id="285963" type="siDrug">Fospropofol disodium</TargetEntity></SourceEntity><SourceEntity id="15872" type="Company"><TargetEntity id="4295876894" type="organizationId">Eisai Co Ltd</TargetEntity></SourceEntity><SourceEntity id="16590" type="Company"><TargetEntity id="4295906654" type="organizationId">Mgi Gp Inc</TargetEntity></SourceEntity><SourceEntity id="18203" type="Company"><TargetEntity id="4295907032" type="organizationId">MGI Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="27501" type="Company"><TargetEntity id="5000308345" type="organizationId">Proquest Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"/><TargetEntity id="D000758" type="MeSH"/><TargetEntity id="-564538434" type="omicsDisease"/><TargetEntity id="23" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="W">Withdrawn</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Anesthesia - US - Nov-2009</FirstLaunched></PhaseHighestDetailed><IndicationsSecondary><Indication id="19">Anesthesia</Indication></IndicationsSecondary><ActionsSecondary><Action id="2944">Hypnotic</Action><Action id="2942">Anxiolytic</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1652">Prodrug</Technology></Technologies><EphmraCodes><Ephmra><Code>N5C</Code><Name>TRANQUILLISERS</Name></Ephmra><Ephmra><Code>N5B</Code><Name>HYPNOTICS/SEDATIVES</Name></Ephmra></EphmraCodes><LastModificationDate>2019-04-22T08:45:02.000Z</LastModificationDate><ChangeDateLast>2019-04-16T00:00:00.000Z</ChangeDateLast><AddedDate>2004-11-11T16:20:12.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15872" linkType="Company"&gt;Eisai&lt;/ulink&gt;, following the acquisition of&lt;ulink linkID="18203" linkType="Company"&gt; MGI Pharma&lt;/ulink&gt; (formerly Guilford), had developed and launched fospropofol (Aquavan; GPI-15715; PQ-1002; Lusedra), a water-soluble prodrug of propofol licensed from &lt;ulink linkID="27501" linkType="Company"&gt;ProQuest&lt;/ulink&gt; [&lt;ulink linkID="358137" linkType="Reference"&gt;358137&lt;/ulink&gt;], [&lt;ulink linkID="626574" linkType="Reference"&gt;626574&lt;/ulink&gt;], [&lt;ulink linkID="871743" linkType="Reference"&gt;871743&lt;/ulink&gt;].  In November 2009, Eisai  launched  the drug in the US for monitored anesthesia care sedation [&lt;ulink linkID="1057275" linkType="Reference"&gt;1057275&lt;/ulink&gt;]. However, in June 2012, the FDA was notified that the product was no longer available due to a manufacturer shortage; no update was given regarding when the product would become available again [&lt;ulink linkID="1364590" linkType="Reference"&gt;1364590&lt;/ulink&gt;]; at that time, the product was  presumed to be withdrawn from the US market  [&lt;ulink linkID="1657962" linkType="Reference"&gt;1657962&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In March 2001, the USPTO issued the composition of matter patent, &lt;ulink linkID="PA2916837" linkType="Patent"&gt;US-06204257&lt;/ulink&gt;, entitled 'Water soluble prodrugs of hindered alcohols', covering fospropofol and other similar compounds [&lt;ulink linkID="409768" linkType="Reference"&gt;409768&lt;/ulink&gt;]. NCE exclusivity expires in the US in December 2013; &lt;ulink linkID="PA2958139" linkType="Patent"&gt;US-06872838&lt;/ulink&gt; and US-6204257  expire in August 2018 and July 2022, respectively [&lt;ulink linkID="1364870" linkType="Reference"&gt;1364870&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;In April 2019, &lt;ulink linkID="1099605" linkType="Company"&gt;Yingke Pharmaceutical&lt;/ulink&gt;  filed an ANDA  for its generic version in China [&lt;ulink linkID="2136406" linkType="Reference"&gt;2136406&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2019,&lt;ulink linkID="1039722" linkType="Company"&gt; Kelun Pharmaceutical&lt;/ulink&gt; filed an ANDA application for its generic version in China [&lt;ulink linkID="2136406" linkType="Reference"&gt;2136406&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In September 2007, MGI Pharma filed an NDA with the FDA  and, in December 2007, the NDA was accepted for review [&lt;ulink linkID="834035" linkType="Reference"&gt;834035&lt;/ulink&gt;], [&lt;ulink linkID="861655" linkType="Reference"&gt;861655&lt;/ulink&gt;]. In May 2008, an FDA advisory committee voted in favor of approval of the agent, but recommended that more studies be conducted in high-risk patients such as those with a low weight, the elderly and those with cardiopulmonary conditions. The panel was in agreement that the agent should only be used by healthcare professionals trained in airway management [&lt;ulink linkID="903708" linkType="Reference"&gt;903708&lt;/ulink&gt;], [&lt;ulink linkID="903652" linkType="Reference"&gt;903652&lt;/ulink&gt;]. However, in July 2008, the FDA issued a non-approvable letter. The FDA outlined a potential pathway for approval of the drug and the company planned to continue discussions with the agency [&lt;ulink linkID="928145" linkType="Reference"&gt;928145&lt;/ulink&gt;]. In December 2008, the FDA approved fospropofol for monitored anesthesia care sedation during diagnostic or therapeutic procedures. The FDA stipulated that the drug would only be used by people trained in administering general anesthesia, and that patients were continuously monitored by people not involved in conducting the procedure. It also recommended that the drug be classified as a controlled substance [&lt;ulink linkID="970866" linkType="Reference"&gt;970866&lt;/ulink&gt;]. In November 2009, Eisai announced it had launched fospropofol  [&lt;ulink linkID="1057275" linkType="Reference"&gt;1057275&lt;/ulink&gt;]. However, in June 2012, the FDA was notified that the product was no longer available due to a manufacturer shortage; no update was given regarding when the product would become available again  [&lt;ulink linkID="1364590" linkType="Reference"&gt;1364590&lt;/ulink&gt;] and the marketing status was subsequently listed as discontinued [&lt;ulink linkID="1657962" linkType="Reference"&gt;1657962&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2006, MGI began a pivotal trial program, comprising two randomized, double-blind, multicenter, phase III trials, one involving 300 colonoscopy patients (NCT00261599), and the other involving 250 bronchoscopy patients (NCT00306722). Both trials were designed to assess sedation and treatment success, patient and investigator satisfaction, sedation adequacy, recovery, clinical benefit and safety [&lt;ulink linkID="959492" linkType="Reference"&gt;959492&lt;/ulink&gt;], [&lt;ulink linkID="959494" linkType="Reference"&gt;959494&lt;/ulink&gt;]. The program also included a 150-patient safety study [&lt;ulink linkID="656684" linkType="Reference"&gt;656684&lt;/ulink&gt;]. By March 2007, all three trials were complete. They had been conducted without an anesthesiologist  present. In the 252-patient bronchoscopy trial, patients were randomized to receive a control dose of 2 mg/kg fospropofol, or 6.5 mg/kg fospropofol. The sedation success rate was 88.7% in patients who received an initial bolus dose of 6.5 mg/kg fospropofol compared to 27.5% of patients on control. The safety profile was similar on both arms, and the most frequent adverse event was transient hypoxemia. Around 91.3% of patients on the higher fospropofol dose completed the procedure without the use of alternative sedative medication or ventilation (secondary endpoint), compared to 41.2% for control. Patients also indicated high satisfaction with the treatment; 94.6% of patients would take the high dose again compared to 78.2% with the 2 mg/kg dose [&lt;ulink linkID="776822" linkType="Reference"&gt;776822&lt;/ulink&gt;]. In May 2007, at the 108th DDW meeting in WashingtonDC,  it was disclosed that 312 patients had been enrolled. At that time, 88% of patients  on the higher dose acheived the secondary endpoint, compared to 28% of subjects who were given the lower dose [&lt;ulink linkID="795657" linkType="Reference"&gt;795657&lt;/ulink&gt;]. Sub-analyses of this phase III trial showed that those on the 6.5 mg/kg dosing regimen had better satisfaction scores (from patient and physician  assessment)     [&lt;ulink linkID="795685" linkType="Reference"&gt;795685&lt;/ulink&gt;], and recovered quicker following a procedure [&lt;ulink linkID="795628" linkType="Reference"&gt;795628&lt;/ulink&gt;], [&lt;ulink linkID="798333" linkType="Reference"&gt;798333&lt;/ulink&gt;]. In October 2007, similar data from the 252-patient bronchoscopy trial were presented at the annual conference of the American  College of Chest  Physicians, Chicago, IL [&lt;ulink linkID="842069" linkType="Reference"&gt;842069&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2007, results were presented from the single-arm, open-label study in 123 patients undergoing a variety of minor surgical procedures to assess the safety and tolerability of fospropofol at a dose of 6.5 mg/kg in a variety of settings including arthroscopy, bunionectomy, dilation and curettage, endoscopy, hysteroscopy, lithroscopy, shunt placement and transesophageal echoes. The drug had a predictable safety profile, and the most frequently observed sedation-related adverse event was transient hypotension  [&lt;ulink linkID="776822" linkType="Reference"&gt;776822&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2004, a phase III trial with fospropofol was initiated. The company intended to conduct four phase III trials in patients undergoing colonoscopy, bronchoscopy, cardiac procedures and minor surgical procedures. A series of smaller studies were to be undertaken in specific patient populations such as burn patients, patients undergoing upper endoscopy prior to liver transplant and patients having an arterovenous shunt placed for renal dialysis. Approximately 900 patients were to be enrolled in the upcoming studies. The first two trials would be randomized comparisons with &lt;ulink linkID="44303" linkType="Drug"&gt;midazolam&lt;/ulink&gt; in which all patients were to receive fentanyl citrate for analgesia. The primary endpoint would be success of sedation, defined as a score &amp;lt; 4 on the modified observer's assessment of alertness/sedation (OAA/S) scale. Secondary endpoints would include the length of time until full alertness and full recovery, and the duration of sedation [&lt;ulink linkID="537564" linkType="Reference"&gt;537564&lt;/ulink&gt;]. In March 2005, results were published showing that the drug had met its primary efficacy endpoint, success of sedation, without any serious adverse events, in a phase III study in patients undergoing elective colonoscopy procedures. A total of 278 patients had enrolled in the randomized, open-label study assessing fospropofol versus midazolam HCl. Treatment with fospropofol resulted in a sedation success rate of 96% and patients experienced deeper levels of sedation for longer sustained periods. Patients treated with fospropofol showed a median time to sedation of 2 min and a median time to full recovery from the end of the procedure of 11 min. At that time, the company suspended enrollment in further studies of the drug in order to review dosing levels. Guilford believed that a lower dose than that used in the colonoscopy study would be more appropriate for procedural sedation [&lt;ulink linkID="591696" linkType="Reference"&gt;591696&lt;/ulink&gt;]. In April 2005, after meeting with the Division of Anesthetic, Critical Care and Addiction Drug Products of the FDA an agreement was concluded regarding a revised clinical development strategy and Guilford was to restart its previously planned studies for ICU sedation and potential drug interactions. This included the finalizing the design of adose-ranging study in colonscopy. On the basis of this study, Guilford expected to start two pivotal trials, one in colonoscopy and the other in minor surgical procedures and tofile an NDA during the second half of 2006 [&lt;ulink linkID="596803" linkType="Reference"&gt;596803&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2005, MGI reported results from a multicenter, double-blind, phase II, dose-ranging study in 127 colonoscopy patients. Volunteers received pretreatment with fentanyl, followed by a 2, 5, 6.5 or 8 mg/kg bolus injection of fospropofol or 0.2 mg/kg &lt;ulink linkID="44303" linkType="Drug"&gt;midazolam&lt;/ulink&gt;. A total of 92% of subjects in the 6.5 mg/kg group said they would choose fospropofol for procedures requiring moderate sedation, compared to 83% in the 8 mg/kg group; 77% of midazolam patients would choose that sedative again. Sedation success on the MOAA/S score was 24, 36, 75 and 95% in the 2, 5, 6.5 and 8 mg/kg group, respectively, and 75% for midazolam. Adequacy of sedation was 28, 50, 89 and 83% in the 2, 5, 6.5 and 8 mg/kg group, respectively, and 58% for midazolam. Patients receiving the 6.5 and 8 mg/kg fospropofol dose were able to resume normal activity 2 h sooner than midazolam patients and were able to eat 1 h sooner [&lt;ulink linkID="642319" linkType="Reference"&gt;642319&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2004, Guilford had held an end-of-phase II meeting with the FDA to discuss its proposed indication, clinical trial plan, and other requirements for a potential future NDA for fospropofol [&lt;ulink linkID="537564" linkType="Reference"&gt;537564&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2003, a second phase II trial in patients undergoing conscious sedation during colonoscopy was initiated in the US [&lt;ulink linkID="478654" linkType="Reference"&gt;478654&lt;/ulink&gt;], [&lt;ulink linkID="496628" linkType="Reference"&gt;496628&lt;/ulink&gt;]. The first part of the US phase II trial was to be a dose-ranging pilot study to determine the optimal iv dose of fospropofol necessary to achieve conscious sedation. The study was also to determine the safety and tolerability of fospropofol, as well as the safety and tolerability of pretreatment with fentanyl citrate or &lt;ulink linkID="12135" linkType="Drug"&gt;celecoxib&lt;/ulink&gt; in conjunction with fospropofol. Guilford then planned to compare fospropofol to midazolam HCl in patients undergoing colonoscopy. A total of 110 patients were to be enrolled and randomly assigned to receive either fospropofol or midazolam HCl in combination with fentanyl citrate or celecoxib. The primary objectives of the study were to determine the time to full recovery for patients receiving fospropofol, compared to midazolam HCl, and to determine the safety and tolerability of fospropofol following pretreatment with fentanyl citrate or celecoxib [&lt;ulink linkID="478654" linkType="Reference"&gt;478654&lt;/ulink&gt;]. In November 2003, preliminary results were released from the first part of the study. A total of 77 patients were randomized to one of the nine fospropofol/fentanyl dose groups. Three dose groups of fospropofol (7.5, 10 and 12.5 mg/kg) and three dose groups of fentanyl (0.5, 1.0 and 1.5 microg/kg) were studied. Following bolus administration of fospropofol, the median time to achieve sedation was 2 min. The median time to full alertness after removal of the colonoscope was 12 min and the median time to full recovery was 20 min. The most common adverse event seen in the study was parethesia, reported by 57% of patients. Brief episodes of apnea were reported in 4% of patients and were successfully treated with short-term supplemental oxygen [&lt;ulink linkID="511889" linkType="Reference"&gt;511889&lt;/ulink&gt;]. In June 2004, results were published from a related confirmatory study in 64 patients undergoing procedural sedation during colonoscopy. Following bolus administration of an unstated fixed dose of fospropofol, the median time to achieve sedation was 2 min. The median time to full alertness and was 12 min and the median time to full recovery was 20 min. Adequate sedated throughout the procedure was achieved in 94% of patients, as rated by gastroenterologists. The most common adverse events was a transitory itching or tingling sensation in 89% of patients, which was considered mild to moderate in 73%. The majority of patients and all physicians reported a high degree of satisfaction with fospropofol [&lt;ulink linkID="570559" linkType="Reference"&gt;570559&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2002, a phase II trial in cardiac surgery patients, designed to evaluate and compare the sedative/hypnotic efficacy and hemodynamic profiles of fospropofol and &lt;ulink linkID="44308" linkType="Drug"&gt;Diprivan&lt;/ulink&gt;, had begun in Europe. A total of 24 patients undergoing first time elective coronary artery surgery were to be randomized to receive either fospropofol or Diprivan as a component of their anesthetic regimen [&lt;ulink linkID="458045" linkType="Reference"&gt;458045&lt;/ulink&gt;]. In November 2003, preliminary results were released. For Diprivan, the average time to loss of consciousness was 2.6 min, while for fospropofol it was 3.1 min. The average time required for intubation was 9.9 min for Diprivan, compared to 9.5 min for fospropofol. The duration of the surgical procedure was 3.75 h for Diprivan, compared to 3.73 h for fospropofol. Postoperative sedation time was 2 h for both Diprivan and fospropofol. Adverse events considered to be drug-related were mild paresthesias in the fospropofol group and mild-to-moderate injection site pain in the Diprivan group [&lt;ulink linkID="511889" linkType="Reference"&gt;511889&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In April 2002,  data from a European, phase I, dose-escalation study of fospropofol were presented at the Annual Meeting of the European Society of Anesthesiology in Nice, France. Volunteers received &lt;ulink linkID="44308" linkType="Drug"&gt;Diprivan&lt;/ulink&gt; injectable emulsion as a target-controlled infusion to achieve three different plasma concentrations of propofol over a 60-min period. Two weeks later, the same volunteers received target-controlled infusions of fospropofol to achieve identical propofol concentrations. fospropofol induced and maintained stable levels of sedation and anesthesia and was more potent than propofol from Diprivan. Although comparable plasma concentrations of propofol were achieved in both groups, there was a greater decrease in the median EEG frequency for propofol from fospropofol (EC50 = 2 microg/ml), compared to Diprivan (EC50 = 3 microg/ml; p &amp;lt; 0.05) [&lt;ulink linkID="446843" linkType="Reference"&gt;446843&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002, data were reported from a phase I study of propofol derived from fospropofol, compared to &lt;ulink linkID="44308" linkType="Drug"&gt;Diprivan&lt;/ulink&gt;. Volunteers (n = 24) were randomized to receive a single bolus injection of fospropofol in doses ranging from 5 mg/kg to 25 mg/kg. One week later the same subjects received doses of Diprivan targeted to produce the same peak effect, and administered at a rate of 50 mg/min. Time to loss of consciousness was comparable between fospropofol 20 mg/kg (157 s) and Diprivan (184 s), and fospropofol 25 mg/kg (162 s) and Dirpirvan (208 s). Return of consciousness occurred significantly later and duration of unconsciousness was significantly longer with fospropofol than Diprivan (48 min with fospropofol 25 mg/kg compared to 16 min with Diprivan) [&lt;ulink linkID="448452" linkType="Reference"&gt;448452&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Phase I trials in the US were initiated in June 2002 [&lt;ulink linkID="453421" linkType="Reference"&gt;453421&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;Fospropofol was in late-stage preclinical evaluation in May 2000 and, at that time, phase I trials had been anticipated to begin before the end of 2000; however, in August 2000, Guilford was expecting to file to commence clinical trials in 2001 [&lt;ulink linkID="368798" linkType="Reference"&gt;368798&lt;/ulink&gt;], [&lt;ulink linkID="370758" linkType="Reference"&gt;370758&lt;/ulink&gt;], [&lt;ulink linkID="378404" linkType="Reference"&gt;378404&lt;/ulink&gt;], [&lt;ulink linkID="406529" linkType="Reference"&gt;406529&lt;/ulink&gt;]. In December 2000, Guilford filed an IND with the European authorities and anticipated initiating clinical studies in early 2001 [&lt;ulink linkID="393597" linkType="Reference"&gt;393597&lt;/ulink&gt;]. By May 2001, European phase I trials of fospropofol had been completed [&lt;ulink linkID="408168" linkType="Reference"&gt;408168&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By March 2000, preclinical studies had indicated that fospropofol may lack many of the side effects associated with the original propofol formulation. Specifically, fospropofol did not significantly affect cardiovascular function at doses that produced rapid and effective anesthesia and sedation. In addition, because a lipid emulsion is not required it may also avoid the hypertriglyceridemia associated with the original propofol formulation and may be less likely to cause bacterial contamination [&lt;ulink linkID="358137" linkType="Reference"&gt;358137&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Fospropofol is a water-soluble prodrug of propofol that is rapidly converted into propofol in the body after injection. It is formulated in a clear aqueous solution that does not contain a lipid emulsion [&lt;ulink linkID="358137" linkType="Reference"&gt;358137&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><ExpertReview>&lt;para&gt;Matthew D Krasowski, MD, PhD, Committee on Clinical Pharmacology &amp;amp; Pharmacogenomics and Department of Pathology, &lt;ulink linkType="Company" linkID="26013"&gt;University of Chicago&lt;/ulink&gt;, 5841 S Maryland Ave, MC 6101, P-615, Chicago, IL 60637, USA&lt;/para&gt;&lt;para&gt;Submission date: 11 November 2004&lt;br/&gt;Publication date: 13 December 2004&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;Propofol (2,6-diisopropylphenol) is a widely used general anesthetic agent that is effective for short surgical procedures and the induction and maintenance of anesthesia, when administered by intravenous infusion. Propofol is also used for sedation during radiological procedures and in the critical-care setting. The drug has a rapid onset and offset of action, and produces a low incidence of postoperative nausea and vomiting [&lt;ulink linkType="Reference" linkID="570628"&gt;570628&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="570630"&gt;570630&lt;/ulink&gt;]. Propofol is marketed by &lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca plc&lt;/ulink&gt; as Diprivan, and was the world's best selling general anesthetic agent until 2002 (reaching sales of $507 million in 2001) [&lt;ulink linkType="Reference" linkID="441975"&gt;441975&lt;/ulink&gt;], when revenues were surpassed by those of &lt;ulink linkType="Drug" linkID="5356"&gt;sevoflurane&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="562389"&gt;562389&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Propofol acts by allosterically enhancing the actions of gamma-aminobutyric acid (GABA) at GABA-A receptors, which serve as the major fast, inhibitory ion channels in the mammalian central nervous system [&lt;ulink linkType="Reference" linkID="496234"&gt;496234&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="496243"&gt;496243&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="496253"&gt;496253&lt;/ulink&gt;]. The action of propofol at GABA-A receptors is similar to that produced by sedative-hypnotic-anesthetic barbiturates, although these compounds bind to different sites on the GABA-A receptor. The binding site for propofol is separate from that of GABA itself, and of benzodiazepines, such as diazepam [&lt;ulink linkType="Reference" linkID="496234"&gt;496234&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="496243"&gt;496243&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="496253"&gt;496253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The limited aqueous solubility of propofol necessitates formulating an oil-in-water emulsion for intravenous infusions [&lt;ulink linkType="Reference" linkID="480696"&gt;480696&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="570628"&gt;570628&lt;/ulink&gt;]. Several adverse effects have been associated with such a propofol infusion, including pain on injection, bradycardia, hypotension and transient apnea [&lt;ulink linkType="Reference" linkID="570628"&gt;570628&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="570630"&gt;570630&lt;/ulink&gt;]. Some of these side effects (such as pain on injection) are likely to be associated with the soybean oil emulsion (Intralipid) formulation of Diprivan. In addition, intravenous line-clogging and rare cases of bacterial infection are known to be associated with Diprivan emulsion, following excessive lipid intake, particularly over extended infusions. Several strategies have been explored to overcome these lipid emulsion-associated adverse effects of Diprivan, including: i) additives to the Intralipid emulsion or use of alternative emulsions [&lt;ulink linkType="Reference" linkID="570632"&gt;570632&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="570633"&gt;570633&lt;/ulink&gt;]; ii) synthesis of water-soluble analogs of propofol [&lt;ulink linkType="Reference" linkID="421664"&gt;421664&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="426716"&gt;426716&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="484814"&gt;484814&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="518287"&gt;518287&lt;/ulink&gt;]; and iii) development of aqueous prodrugs of propofol [&lt;ulink linkType="Reference" linkID="521081"&gt;521081&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="570634"&gt;570634&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Historically, propofol has been formulated with a number of different emulsions [&lt;ulink linkType="Reference" linkID="480696"&gt;480696&lt;/ulink&gt;]. The original formulation, marketed by ICI Pharmaceuticals (and later acquired by &lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca&lt;/ulink&gt;), used the castor oil-based solubilizer and emulsifier Cremophor, which was subsequently withdrawn due to reports of severe histamine release and anaphylactic reactions. Propofol was then reformulated in Intralipid, a soybean oil emulsion. Reports of bacterial or fungal infections associated with the Intralipid formulation, particularly when open vials of the drug were stored at room temperature for extended periods, led &lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca&lt;/ulink&gt; to include EDTA as an antimicrobial agent. An alternative, commercially available formulation of propofol (from Gensia Sicor Pharmaceuticals) includes metabisulfite as a preservative. Other groups have studied other propofol formulations, including mixtures of medium- and long-chain triglycerides (Intralipid contains only long-chain triglycerides), cyclodextrins and nanoparticulates [&lt;ulink linkType="Reference" linkID="480696"&gt;480696&lt;/ulink&gt;], although none of these are yet clinically available.&lt;/para&gt;&lt;para&gt;A number of analogs of propofol with improved water solubility have been synthesized and evaluated [&lt;ulink linkType="Reference" linkID="421664"&gt;421664&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="426716"&gt;426716&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="518287"&gt;518287&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="570628"&gt;570628&lt;/ulink&gt;], but a limitation of this strategy is that modifications to the propofol structure that increase aqueous solubility have tended to reduce anesthetic potency and/or efficacy. This has been demonstrated for activity of analogs at GABA-A receptors, studied both in vitro and in vivo. Water-soluble analogs of propofol are also likely to have different pharmacokinetic properties from propofol [&lt;ulink linkType="Reference" linkID="426716"&gt;426716&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="496243"&gt;496243&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="496253"&gt;496253&lt;/ulink&gt;]. To date, no such water-soluble propofol analogs have been tested in humans.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="16590"&gt;Guilford Pharmaceuticals Inc&lt;/ulink&gt;'s &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; (Aquavan) is a water-soluble propofol prodrug which undergoes hydrolysis by phosphatases in vivo, to liberate propofol, formaldehyde and phosphate [&lt;ulink linkType="Reference" linkID="521070"&gt;521070&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; is formulated as a clear, sterile aqueous solution that is stable at ambient temperatures [&lt;ulink linkType="Reference" linkID="358137"&gt;358137&lt;/ulink&gt;]. To date, it is the only propofol prodrug to enter human trials. &lt;ulink linkType="Company" linkID="20779"&gt;Vyrex Corp&lt;/ulink&gt; had previously synthesized and performed preclinical animal studies with propofol phosphate, another water-soluble prodrug of propofol [&lt;ulink linkType="Reference" linkID="407066"&gt;407066&lt;/ulink&gt;]; however, this compound has not yet entered the clinic [&lt;ulink linkType="Reference" linkID="570634"&gt;570634&lt;/ulink&gt;]. Since hydrolysis of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; yields propofol, the pharmacodynamics, although not necessarily the pharmacokinetics, are expected to be the same as for administration of propofol [&lt;ulink linkType="Reference" linkID="521068"&gt;521068&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; was designed in a similar fashion to &lt;ulink linkType="Drug" linkID="3167"&gt;fosphenytoin&lt;/ulink&gt;, a water-soluble prodrug of the anticonvulsant drug phenytoin [&lt;ulink linkType="Reference" linkID="286768"&gt;286768&lt;/ulink&gt;], which eliminated some of the adverse effects associated with phenytoin injection, and has allowed for rapid intravenous or intramuscular administration in the emergency management of status epilepticus [&lt;ulink linkType="Reference" linkID="55857"&gt;55857&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="218259"&gt;218259&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="223446"&gt;223446&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;The synthesis of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; was detailed in patent US-06204257 [&lt;ulink linkType="Reference" linkID="409768"&gt;409768&lt;/ulink&gt;], and involves the reaction of propofol with sodium hydride, followed by chloromethyl methyl sulfide, with an 85% yield of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; [US-06204257].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical Development&lt;/subtitle&gt;The pharmacodynamics of propofol have been studied intensively [&lt;ulink linkType="Reference" linkID="496243"&gt;496243&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="496253"&gt;496253&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="570628"&gt;570628&lt;/ulink&gt;]. Most or all of the sedative-hypnotic-anesthetic effects of the drug are produced by interaction of the compound with a modulatory binding site (ie, one different from the GABA binding site) on the GABA-A receptor ion channel [&lt;ulink linkType="Reference" linkID="496243"&gt;496243&lt;/ulink&gt;]. Binding of propofol enhances the ability of GABA to activate GABA-A receptors, exerting a 'positive modulatory' or 'positive allosteric' effect. Enhancement of GABA-A receptor function throughout the CNS inhibits neurotransmission, leading to amnesia, disruption of movement and sensation, and unconsciousness [&lt;ulink linkType="Reference" linkID="570628"&gt;570628&lt;/ulink&gt;]. Although high-resolution structural data on the GABA-A receptor is lacking, current research suggests that propofol binds to the third (of four) transmembrane-spanning domain of the receptor ion channel, close to the ion channel pore, and distinct from the GABA and benzodiazepine binding sites, which are located in the extracellular domain [&lt;ulink linkType="Reference" linkID="496243"&gt;496243&lt;/ulink&gt;]. The major focus of studies on &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; have been on pharmacokinetic comparisons with formulations of propofol, and the pharmacodynamics of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; have not been investigated carefully. For example, there have been no reports of the effects of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; itself on GABA-A receptors.&lt;/para&gt;&lt;para&gt;One of the few published animal studies using &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; assessed its pharmacodynamic effect on EEG activity, following administration of a bolus injection of 40 mg to Sprague-Dawley rats [&lt;ulink linkType="Reference" linkID="521070"&gt;521070&lt;/ulink&gt;]. As is typically seen with propofol emulsions, the initial increase in spike activity was followed by suppression of EEG bursts when plasma propofol concentrations were &amp;gt; 5 microg/ml. The EEG returned to baseline ~ 40 min after dosing. The estimated EC50 value of propofol (released from &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;) for suppressing EEG bursts was 2.6 +/- 0.8 microg/ml. Mean arterial blood pressure in the rats decreased from an initial 147 +/- 7 mmHg, to a minimum of 113 +/- 18 mmHg, 20 min following bolus injection. The maximal decrease in mean arterial pressure of 27 +/- 17% with &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; compared favorably with the 33 +/- 7% decrease seen in a previous study with 20 microg propofol; however, in the latter study propofol was given as a 90-min continuous infusion, making comparison difficult [&lt;ulink linkType="Reference" linkID="521070"&gt;521070&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Some data are available from a study that compared 1-h infusions of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; and propofol (61.5 and 47.6 mg/kg, respectively, for 14 days) in beagle dogs. Mild-to-moderate anesthesia was induced by both drugs, but recovery took longer in the &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; group (41.8 compared with 28.7 min for propofol) [&lt;ulink linkType="Reference" linkID="521094"&gt;521094&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and Pharmacokinetics&lt;/subtitle&gt;After injection, &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; is rapidly hydrolyzed by alkaline phosphatases (most notably on endothelial cell surfaces) to produce the active metabolite propofol, along with formaldehyde and phosphate [&lt;ulink linkType="Reference" linkID="521070"&gt;521070&lt;/ulink&gt;]. Studies of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; in both humans and animals suggest that the formaldehyde and formate are rapidly cleared from the circulation, although no investigations of the possible effects of formaldehyde on proteins and cell surfaces have yet been published. Concentrations of formaldehyde and formate after a 48-h infusion in monkeys with a total dose of up to 2500 mg/kg &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; were not increased when compared with a control group anesthetized with propofol [&lt;ulink linkType="Reference" linkID="521070"&gt;521070&lt;/ulink&gt;]. The first study of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; in healthy volunteers (n = 9) showed no increases in plasma formate levels, following infusions of up to 1160 mg for 10 min [&lt;ulink linkType="Reference" linkID="521068"&gt;521068&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The pharmacokinetic parameters following an intravenous bolus injection of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; of 40 mg were assessed in Sprague-Dawley rats [&lt;ulink linkType="Reference" linkID="521070"&gt;521070&lt;/ulink&gt;]. The mean maximum concentration of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; (271 +/- 33 microg/ml) was detected 2 min after the bolus dose, while the mean maximum propofol concentration (7.1 +/- 1.6 microg/ml) was achieved 5 min after dosing, suggesting that metabolism of the prodrug takes ~ 3 min. The parent drug had a relatively fast distribution, with small volumes of distribution, and was efficiently converted to propofol. The liberated propofol then exhibited the expected lipophilic pharmacokinetics, with a large peripheral compartment. The observed biphasic decline in plasma concentrations of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; (mean t1/2s = 2.9 +/- 0.2 and 23.9 +/- 9.9 min), and the metabolite propofol (mean t1/2s = 1.9 +/- 0.1 and 45.0 +/- 7.3 min), were thus best described by coupled, linear two-compartment models [&lt;ulink linkType="Reference" linkID="521070"&gt;521070&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Nevertheless, some significant differences were seen when comparing the pharmacokinetics of propofol hydrolyzed from &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;, with those of Diprivan. The propofol liberated from &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; showed a significantly greater mean volume of distribution (Vdc = 2.3 l/kg; Vdss = 14.1 l/kg) and elimination clearance (Cl = 344 +/- 94 ml/kg/min), compared with several prior published studies describing propofol in the Diprivan formulation (Vdc = 0.3 to 0.9 l/kg; Vdss = 1.4 to 9.9 l/kg; Cl = 72 to 160 ml/kg/min). Overall, propofol from &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; showed a delayed onset, longer half-life, and longer duration of action, compared with known propofol emulsions [&lt;ulink linkType="Reference" linkID="521070"&gt;521070&lt;/ulink&gt;]. Such formulation-dependent differences in propofol pharmacokinetics have been described previously; &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; behaves much like the alcohol-based, lipid-free formulation of propofol studied by Dutta et al [&lt;ulink linkType="Reference" linkID="570635"&gt;570635&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The first study of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; in humans assessed its kinetics when infused (290, 580 or 1160 mg, iv) over 10 min in healthy volunteers (n = 9) [&lt;ulink linkType="Reference" linkID="521068"&gt;521068&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="521091"&gt;521091&lt;/ulink&gt;]. As in the rodent study, a relatively fast distribution and elimination and small volumes of distribution were seen with &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;, whereas the liberated propofol followed the expected pattern of lipophilic distribution, with large peripheral compartments. The hydrolysis half-life of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; was 7.2 +/- 1.1 min. The Cmax of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; was reached at the end of the infusion in the groups receiving 580 and 1160 mg doses. In individuals receiving 580 and 1160 mg &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;, mean Cmax was 71.6 +/- 3.0 and 133 +/- 12 microg/ml, respectively, and AUC was 1113 +/- 33 and 2334 +/- 480 microg/ml/min, respectively. In the same dose groups, the equivalent mean values for liberated propofol were Tmax of 13.3 +/- 1.2 and 12.0 +/- 0.0 min, Cmax of 1.87 +/- 0.26 and 3.08 +/- 0.18 microg/ml, and AUC of 89 +/- 21 and 182 +/- 37 microg/ml/min, respectively. The plasma t1/2 of propofol was ~ 10 to 20 min longer than for propofol formulated as a lipid emulsion. The most accurate description of these values was by a three-compartment model for both the parent drug and propofol, with a lag time of 1.15 +/- 0.4 min. Simulation experiments predicted that following a 1000-mg bolus injection of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;, a maximum propofol concentration of 3.3 +/- 0.6 microg/ml would be seen after 7.4 +/- 1.2 min [&lt;ulink linkType="Reference" linkID="521068"&gt;521068&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The only detailed comparison of Diprivan and &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; in the same subjects (nine healthy male volunteers) was reported in 2004 [&lt;ulink linkType="Reference" linkID="570571"&gt;570571&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="570627"&gt;570627&lt;/ulink&gt;]. Similar to previous human and animal studies, propofol liberated from &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; showed a significantly greater mean volume of distribution (Vdc = 0.55 +/- 0.14 l/kg; Vdss = 12.4 +/- 4.6 l/kg) and elimination clearance (Cl = 37.8 +/- 9.4 ml/kg/min), compared with the Diprivan formulation (Vdc = 0.23 +/- 0.03 l/kg; Vdss = 4.5 +/- 2.1 l/kg; Cl = 23.7 +/- 2.9 ml/kg/min) [&lt;ulink linkType="Reference" linkID="570571"&gt;570571&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="570627"&gt;570627&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;Detailed toxicity data were not presented in the only peer-reviewed study of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; in laboratory animals [&lt;ulink linkType="Reference" linkID="521070"&gt;521070&lt;/ulink&gt;]. However, this article states that in earlier studies in rats, mice, dogs and monkeys, no relevant toxicity concerns were noted, even in the case of longer administration of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;. In particular, concentrations of formaldehyde and formate after a drug infusion of 48 h in monkeys, for a total dose of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; of up to 2500 mg/kg, were not increased when compared to a control group anesthetized with propofol [&lt;ulink linkType="Reference" linkID="521070"&gt;521070&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A study in beagle dogs assessed the toxicity of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; and propofol (61.5 and 47.6 mg/kg, respectively) infused over 1 h daily for 14 days. Elevations in pulse and slight reductions in blood pressure were comparable between the two drugs. No effects on weight gain, food intake, eyes, or organ weights were seen with exposure to either drug [&lt;ulink linkType="Reference" linkID="521094"&gt;521094&lt;/ulink&gt;]. No long-term toxicity studies of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; are available. Given the release of formaldehyde and phosphate following hydrolysis of GTI-15715, these studies would be especially important if &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; were to be used in humans for extended periods, such as in intubated intensive care unit patients.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;Data from the first study of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; in humans was reported in abstract form in 2001 [&lt;ulink linkType="Reference" linkID="521091"&gt;521091&lt;/ulink&gt;], and in a peer-reviewed journal in 2003 [&lt;ulink linkType="Reference" linkID="521068"&gt;521068&lt;/ulink&gt;]. The drug was administered as an intravenous infusion, as it was in all subsequent human trials. Healthy male volunteers (n = 9) received &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; (290, 580 or 1160 mg iv) as a constant infusion over 10 min. The degree of sedation was assessed (on the observer's assessment of alertness/sedation scale; OAA/S), as were loss and recovery of consciousness (response to a loud verbal command) and corneal reflex. Loss of consciousness was achieved in 1/3 individuals at a dose of 580 mg, and in 3/3 subjects at a dose of 1160 mg. The plasma propofol EC50 value for achieving loss of consciousness was 2.2 +/- 0.4 microg/ml. Corneal reflex was lost in only one patient at the highest dose. The injections were well tolerated, without any pain on injection. The maximum decrease of blood pressure was 25% and the maximal increase in heart rate was ~ 35% [&lt;ulink linkType="Reference" linkID="521068"&gt;521068&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;An open-label, dose-escalation phase I study compared single bolus administration of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; and Diprivan in healthy individuals [&lt;ulink linkType="Reference" linkID="521081"&gt;521081&lt;/ulink&gt;]. Subjects (n = 24) rated I on the American Society of Anesthesiologists (ASA) scale (healthy and low risk) were randomized to receive a single bolus dose of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; (5, 10, 20 or 25 mg/kg), and the resulting degree of sedation was measured by an EEG-based monitoring device. One week after the &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; injection, individuals were administered a 50 mg/min dose of Diprivan to reach a similar bispectral index (BIS) level, a measure of consciousness and sedation. At doses of 5 and 10 mg/kg of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; no loss of consciousness was reached, although decreases in the BIS level were noted. All individuals achieved loss of consciousness after &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; was administered at 20 and 25 mg/kg doses. Compared with Diprivan, &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; treatment produced a comparable loss of consciousness, but with delayed peak sedation and a slower recovery time [&lt;ulink linkType="Reference" linkID="521081"&gt;521081&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A further study evaluated a 2-h controlled infusion of GPI-1571 in 12 human volunteers [&lt;ulink linkType="Reference" linkID="521086"&gt;521086&lt;/ulink&gt;]. Sedation was rated on the OAA/S, and BIS levels were determined. The target propofol concentration was 1.8 microg/ml. The amount of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; infused over 2 h to maintain adequate sedation (an OAA/S score of 2 to 3) was 2534 +/- 506 mg. To maintain the required sedation, at 60 min the doses of some subjects were increased to 2.4 or 3.0 microg/ml (n = 7 and 2). &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; was well tolerated and maintained adequate sedation for 2 h, and the mean recovery time was 18 +/- 3 min. Systolic blood pressure decreased by 21% on average, and heart rate increased by 13% [&lt;ulink linkType="Reference" linkID="521086"&gt;521086&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;More recently, a study was performed to compare in detail the pharmacokinetics and pharmacodynamics of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; and Diprivan in the same individuals [&lt;ulink linkType="Reference" linkID="570571"&gt;570571&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="570627"&gt;570627&lt;/ulink&gt;]. Healthy male volunteers (n = 9) first received a 60-min target controlled infusion of Diprivan, aiming for a target propofol concentration of 5 microg/ml in the first 20 min, 3 microg/ml in the next 20 min, and 1.5 mg/ml in the last 20 min. At least 14 days later, the same volunteers were administered &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; under a protocol designed to reach the same plasma propofol concentrations as for Diprivan. Sedation was rated on the OAA/S; EEG and BIS were also monitored. The plasma propofol EC50 value for reducing the median frequency of the EEG was 2.1 +/- 0.5 microg/ml for &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; and 3.0 +/- 0.7 microg/ml for Diprivan; the corresponding EC50 values for reducing the BIS were 2.9 +/- 0.8 microg/ml for &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; and 4.4 +/- 0.7 microg/ml for Diprivan [&lt;ulink linkType="Reference" linkID="570571"&gt;570571&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="570627"&gt;570627&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A phase II trial was recently completed in which &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; was compared to Diprivan in patients undergoing coronary artery surgery. Preliminary results indicated that a mean time to loss of consciousness with Diprivan was 2.6 min and with &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; was 3.1 min. The surgical procedure and postoperative sedation times were comparable between the two treatments [&lt;ulink linkType="Reference" linkID="458045"&gt;458045&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A second phase II trial was recently completed in patients undergoing conscious sedation during colonoscopy. The first part of the trial enrolled 91 patients in a dose-ranging study to both determine the optimal intravenous dose of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; necessary for conscious sedation, and assess the safety and efficacy of the drug alone and in combination with fentanyl citrate [&lt;ulink linkType="Reference" linkID="570559"&gt;570559&lt;/ulink&gt;]. A second part of the study was planned, in which the sedation provided by &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; will be compared to &lt;ulink linkType="Drug" linkID="44303"&gt;midazolam&lt;/ulink&gt; HCl [&lt;ulink linkType="Reference" linkID="478654"&gt;478654&lt;/ulink&gt;], although to date no results from this study are available.&lt;/para&gt;&lt;para&gt;Preliminary results were released by Guilford for 77 patients in the dose-ranging portion of the study. Patients were randomized to one of nine dose groups testing all combinations of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; (7.5, 10 and 12.5 mg/kg) and fentanyl citrate (0.5, 1.0 and 1.5 microg/kg). The median time to full alertness after removal of the colonoscope was 12 min, and median time to full recovery was 20 min. The most common adverse event was paresthesia, which was reported by 57% of patients. Brief episodes of apnea were reported in 4% of patients and were successfully treated by short-term supplemental oxygen [&lt;ulink linkType="Reference" linkID="511889"&gt;511889&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company later released further results from a confirmatory phase II trial, presumably from the same study, for 64 patients undergoing colonoscopy [&lt;ulink linkType="Reference" linkID="570559"&gt;570559&lt;/ulink&gt;]. Sedation was defined as a score of between 1 and 4 on the OAA/S scale. Following intravenous bolus administration of an unstated fixed dose of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;, the median time to achieve sedation was 2 min. The median time to full alertness was 12 min, and the median time to full recovery was 20 min. Adequate sedation throughout the procedure was achieved in 94% of patients, as rated by gastroenterologists. The most common adverse event was a transitory itching or tingling sensation (paresthesia) in 89% of patients, which was considered of mild-to-moderate severity in 73%. The majority of patients, and all physicians, reported a high degree of satisfaction with &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="570559"&gt;570559&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;Phase III trials of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; began in May 2004 [&lt;ulink linkType="Reference" linkID="537564"&gt;537564&lt;/ulink&gt;]. The phase III program is intended to involve four trials in patients undergoing cardiac procedures, minor surgical procedures, colonoscopy and bronchoscopy. The latter two trials will be randomized comparisons with &lt;ulink linkType="Drug" linkID="44303"&gt;midazolam&lt;/ulink&gt;. The primary endpoints are sedation as assessed by OAA/S, and secondary endpoints include duration of sedation, and time to full alertness and recovery. The FDA has also recommended smaller studies in special populations, such as burns patients, patients undergoing upper endoscopy prior to liver transplant and patients having an arterovenous shunt placed for renal dialysis. Guilford anticipates enrolling ~ 900 patients in the phase III trials, allowing for a total of 1200 patients in the NDA submission [&lt;ulink linkType="Reference" linkID="537564"&gt;537564&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side Effects and Contraindications&lt;/subtitle&gt;In contrast to Diprivan, individuals who took part in the first study of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; in healthy volunteers did not report pain on injection [&lt;ulink linkType="Reference" linkID="521068"&gt;521068&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="521091"&gt;521091&lt;/ulink&gt;]. However, 2/9 of them reported an unpleasant tingling sensation in the anal and genital area at the start of infusion. This lasted ~ 5 min in a patient receiving an infusion of 290 mg and 2 min in a patient receiving an infusion of 1160 mg. These sensations were accompanied by transient tachycardia to 100 bpm, and were completely resolved without intervention. The maximum decrease of blood pressure was 25% and a maximal increase in heart rate by ~ 35% was observed [&lt;ulink linkType="Reference" linkID="521068"&gt;521068&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="521091"&gt;521091&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The open-label comparison of single, bolus doses of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; (5, 10, 20 or 25 mg/kg) and equipotent doses of Diprivan in healthy individuals reported pain on injection in 10/24 individuals who had been administered Diprivan, but in none of those receiving &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="521081"&gt;521081&lt;/ulink&gt;]. However, all subjects receiving &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; experienced a dose-independent unpleasant tingling sensation, most severe in the perineal region, which generally subsided within 1 min of injection; this type of reaction has not been reported with Diprivan infusion. Dose-dependent apnea occurred in 10/24 subjects receiving Diprivan, compared with 7/24 of those treated with &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;. Both drugs produced comparable decreases in systolic and diastolic blood pressure, without clinically relevant hypotension [&lt;ulink linkType="Reference" linkID="521081"&gt;521081&lt;/ulink&gt;]. Subsequent phase II studies have demonstrated that these transient paresthesias, which are not seen with lipid-based formulations of propofol, are a common side effect of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; injection [&lt;ulink linkType="Reference" linkID="478654"&gt;478654&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="521086"&gt;521086&lt;/ulink&gt;]. The paresthesias are particularly severe in the perineal region, are dose-independent, and generally subside within several minutes following initial injection [&lt;ulink linkType="Reference" linkID="478654"&gt;478654&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="521086"&gt;521086&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Results from the most detailed study comparing &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; and Diprivan in the same individuals (nine healthy male volunteers) showed pain on injection in 3/9 of those receiving Diprivan and in none of those receiving &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="570571"&gt;570571&lt;/ulink&gt;]. All nine volunteers receiving &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; reported sensations of burning, heat, or tingling in the anal and genital region, beginning ~ 1 min after injusion and continuing for 1 to 2 min. Such paresthesias were not reported when the subjects received Diprivan. Decreases in blood pressure (of ~ 30%), increases in heart rate (of ~ 40%), and requirement for supplemental oxygen were similar whether the subjects received &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; or Diprivan [&lt;ulink linkType="Reference" linkID="570571"&gt;570571&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Paresthesias are the only adverse effect associated with &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; that are not seen with propofol formulations, and similar paresthesias have been observed following injection of the phenytoin prodrug &lt;ulink linkType="Drug" linkID="3167"&gt;fosphenytoin&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="55857"&gt;55857&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="218259"&gt;218259&lt;/ulink&gt;]. The paresthesias experienced with either &lt;ulink linkType="Drug" linkID="3167"&gt;fosphenytoin&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; are transient, and are apparently not associated with any other adverse effect. Given that both prodrugs release formaldehyde and phosphate upon hydrolysis in the body, liberation of these compounds (or their metabolites, such as formate) may underlie the paresthesias; however, the molecular mechanism of the paresthesias caused by either drug has not been investigated in any detail. The liberation of formaldehyde, which can be converted to toxic formate, and phosphate from the hydrolysis of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;, is a theoretical concern. The first study of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; in healthy volunteers showed no increases in plasma formate levels, following infusions of up to 1160 mg for 10 min [&lt;ulink linkType="Reference" linkID="521068"&gt;521068&lt;/ulink&gt;]; also, as mentioned above, results from a later study of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; also showed no increase in plasma formate levels [&lt;ulink linkType="Reference" linkID="570571"&gt;570571&lt;/ulink&gt;]. A study comparing &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; and Diprivan in healthy male volunteers showed no alterations in serum &lt;ulink linkType="Drug" linkID="52446"&gt;calcium&lt;/ulink&gt; or formate levels with either drug; however, inorganic phosphate was outside the normal range 20 and 60 min after infusion of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; (4.8 +/- 4.3 and 4.7 +/- 0.6 mg/dl, respectively; normal range reported as 2.5 to 4.5 mg/dl). The clinical significance of the temporary increases in serum inorganic phosphate following &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; is uncertain. &lt;/para&gt;&lt;para&gt;It should be pointed out that the phenytoin prodrug &lt;ulink linkType="Drug" linkID="3167"&gt;fosphenytoin&lt;/ulink&gt;, which also releases formaldehyde and phosphate following administration, has had a good safety record since being launched in 1996 in the US [&lt;ulink linkType="Reference" linkID="286768"&gt;286768&lt;/ulink&gt;]. Doses of &lt;ulink linkType="Drug" linkID="3167"&gt;fosphenytoin&lt;/ulink&gt; used for acute management of status epilepticus and doses of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; used to provide sedation for a medical or surgical procedure lasting 60 min or less will release similar amounts of formaldehyde and phosphate. For &lt;ulink linkType="Drug" linkID="3167"&gt;fosphenytoin&lt;/ulink&gt;, the upper end of the indicated dosage range for acute control of status epilepticus is 30 mg/kg or 2.1 g for a 70 kg individual [&lt;ulink linkType="Reference" linkID="22918"&gt;22918&lt;/ulink&gt;]. Given the molecular weight of 406.2 g/mol for &lt;ulink linkType="Drug" linkID="3167"&gt;fosphenytoin&lt;/ulink&gt;, this will release 5.2 mmol of phenytoin, formaldehyde, and phosphate, assuming complete hydrolysis. For comparison, the amount of GPI-15715 used to provide sedation under a 60 min target controlled infusion protocol in adult males was ~ 2.4 g [&lt;ulink linkType="Reference" linkID="570571"&gt;570571&lt;/ulink&gt;]. With a molecular weight for GPI-15715 of 332 g/mol and assuming complete hydrolysis, this will result in the release of 7.2 mmol of propofol, formaldehyde, and phosphate. However, if GPI-15715 is to be used for extended infusions or in patients with impaired hepatic and/or renal metabolism, the consequences of formaldehyde and phosphate release should be assessed by special studies. This especially applies to the potential use of GPI-15715 in intensive care unit patients, who often have abnormal liver and/or kidney function.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent Summary&lt;/subtitle&gt;The first patent that covered propofol was US-04056635, assigned in 1977 to ICI Ltd (the corporation from which Zeneca was de-merged, to later become &lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca&lt;/ulink&gt;). This patent expired in December 1996, following a two-year extension. Patent applications for alternative formulations of propofols have been published since by Zeneca/&lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca&lt;/ulink&gt;, including a formulation of Diprivan containing EDTA to retard growth of microorganisms and maintain sterility (1994 application WO-09629064). Various other companies have published PTC applications concerning the purification and re-formulation of propofol.&lt;/para&gt;&lt;para&gt;The first patent application claiming GPI-15715, which disclosed 'Water-soluble prodrugs of hindered alcohols or phenols', was WO-00008033, published in February 2000 by the originators at the &lt;ulink linkType="Company" linkID="20597"&gt;University of Kansas&lt;/ulink&gt;. This application also disclosed prodrugs for other drugs such as vitamin E, the immunosuppressant cyclosporine A, and the cancer chemotherapeutic agents etoposide and camptothecin. The application WO-00008033 was issued as US-06204257 to the &lt;ulink linkType="Company" linkID="20597"&gt;University of Kansas&lt;/ulink&gt; spin-off &lt;ulink linkType="Company" linkID="27501"&gt;ProQuest Pharmaceuticals Inc&lt;/ulink&gt; in March 2001, and later assigned to licensee Guilford Pharmaceuticals [&lt;ulink linkType="Reference" linkID="409768"&gt;409768&lt;/ulink&gt;]. Guilford published the application WO-03059255 in July 2003, which made similar claims surrounding the process of producing &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;. Guilford further claimed intravenous formulations of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; in WO-03057153 in July 2003. Most recently, in October 2003, Guilford claimed methods of administering propofol prodrugs and methods for maintaining sedation over extended periods in WO-03086413.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion &lt;/subtitle&gt;Development of a water-soluble prodrug of propofol is a logical strategy to circumvent many of the problems associated with lipid-based formulations of propofol. Clear advantages of this approach include the absence of pain on injection, the lack of risk of lipid overload with extended infusions, the improved storage stability and the lower risk of bacterial or fungal contamination. The prodrug approach avoids the difficulties associated with designing a water-soluble analog of propofol, which may have altered pharmacodynamics from the latter.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; produces loss of consciousness more slowly than Diprivan and with a slower offset of action, due to incompletely understood differences in pharmacokinetics between lipid-dissolved propofol (ie, Diprivan) and lipid-free propofol (as liberated from &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;). This slower offset of action may in some circumstances be an advantage, for example to allow for single bolus injection to provide sedation for a procedure such as colonoscopy. The real advantage of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; may well lie in conscious sedation for short medical or surgical procedures, such as colonoscopy and in anesthesia for cardiac surgeries. However, the slower onset and offset of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; compared to Diprivan also presents some potential problems. One of the major benefits of propofol over other intravenous anesthetics is short duration of action which allows for easy titration of the drug to achieve optimal sedation. In addition, the short duration of action of Diprivan provides some safety when relative overdoses are given and respiratory depression occurs. The use of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; will require modification of sedation and anesthesia protocols to account for the different pharmacokinetics of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; and maintain safety and adequate sedation/anesthesia. Clinicians will need to be aware of the extended duration of action of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; compared to Diprivan and provide adequate monitoring in case of respiratory depression. Target-controlled infusions will be beneficial in this effort.&lt;/para&gt;&lt;para&gt;Another potential use for &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; would be for more extended sedation, as in intubated intensive care unit patients, where the lack of lipid co-solvent would be particularly advantageous. However, the current published literature does not yet address the safety of such extended infusions. The hydrolysis of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; yields phosphate and formaldehyde in addition to propofol. Published data indicate no accumulation of formate during short-term infusions of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; in humans or in infusion over 48 h in monkeys; however, one study showed temporary increases in serum inorganic phosphate 20 and 60 min subsequent to &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; administration to humans. If &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; is to be used for extended sedation the risk of generating toxic levels of phosphate or formate in vivo may need to be evaluated in humans, perhaps by specifically designed studies. The only significant adverse effects unique to &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; are transient, dose-independent paresthesias, particularly involving the perineal region, that occur shortly after the start of infusion. Such paresthesias are also seen with the similarly-designed prodrug of phenytoin, &lt;ulink linkType="Drug" linkID="3167"&gt;fosphenytoin&lt;/ulink&gt;, and in that case do not appear to be associated with any other adverse effects. The published literature does not address whether the paresthesias resulting from &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; infusion are more distressing to patients than pain on injection following Diprivan injection or whether the paresthesias will be a hindrance to clinical acceptance of &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;. This will require more widespread clinical experience with &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;.&lt;/para&gt;&lt;para&gt;Other than &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt;, two other alternatives to the Diprivan formulation are presently in clinical trials. Propofol IDD-D (&lt;ulink linkType="Company" linkID="23151"&gt;SkyePharma plc&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="26192"&gt;Endo Pharmaceuticals Inc&lt;/ulink&gt;) is a formulation of propofol with a novel, proprietary solubilization system that has entered phase III trials [&lt;ulink linkType="Reference" linkID="572648"&gt;572648&lt;/ulink&gt;]. The pharmacokinetics and pharmacodynamics of Propofol IDD-D are very similar to Diprivan [&lt;ulink linkType="Reference" linkID="531293"&gt;531293&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="572648"&gt;572648&lt;/ulink&gt;]. SkyePharma is planning anNDA submission by mid-2006 [&lt;ulink linkType="Reference" linkID="533977"&gt;533977&lt;/ulink&gt;]. The second alternative formulation is a lingual spray of propofol in joint development by &lt;ulink linkType="Company" linkID="31093"&gt;Manhattan Pharmaceuticals Inc&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="27787"&gt;NovaDel Pharma Inc&lt;/ulink&gt;. This formulation has completed phase I trials in the UK [&lt;ulink linkType="Reference" linkID="548873"&gt;548873&lt;/ulink&gt;], and further studies are due to begin the US by the end of 2004 [&lt;ulink linkType="Reference" linkID="550795"&gt;550795&lt;/ulink&gt;]. The developers intend this lingual spray to be marketed as a pre-procedural sedative-hypnotic [&lt;ulink linkType="Reference" linkID="494094"&gt;494094&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="550795"&gt;550795&lt;/ulink&gt;]. To date, no water-soluble analogs of propofol (not including prodrugs) have entered human trials.&lt;/para&gt;&lt;para&gt;Overall, &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; has definite advantages over lipid-based formulations of propofol. The drug will be particularly useful for sedation and for surgeries in certain patient populations. However, the altered pharmacokinetics of this drug relative to propofol, particularly the slow onset and offset of action, will mean that this drug will not replace propofol, particularly as it will not be useful for rapid induction of general anesthesia. &lt;ulink linkType="Drug" linkID="51336"&gt;GPI-15715&lt;/ulink&gt; also does not have the easy titration and rapid recovery associated with propofol. Assuming the preparation is approved for clinical use, the cost of the marketed preparation and the effectiveness with which its advantages can be marketed will be key to commercial success.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2012-06-18T00:00:00.000Z</StatusDate><Source id="1364590" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="27501">ProQuest Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2000-03-02T00:00:00.000Z</StatusDate><Source id="358137" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2009-11-16T00:00:00.000Z</StatusDate><Source id="1057275" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2002-07-15T00:00:00.000Z</StatusDate><Source id="458045" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16590">MGI GP Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2004-05-10T00:00:00.000Z</StatusDate><Source id="537564" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18203">MGI Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2007-09-27T00:00:00.000Z</StatusDate><Source id="834035" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="27501">ProQuest Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2000-03-01T00:00:00.000Z</StatusDate><Source id="358137" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18203">MGI Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2005-12-21T00:00:00.000Z</StatusDate><Source id="642319" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18203">MGI Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2006-03-20T00:00:00.000Z</StatusDate><Source id="656684" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18203">MGI Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2008-12-14T00:00:00.000Z</StatusDate><Source id="970866" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2008-01-28T00:00:00.000Z</StatusDate><Source id="871743" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="15872">Eisai Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="116125" title="Guilford to develop ProQuest's fospropofol worldwide "/></Deals><PatentFamilies><PatentFamily id="1083891" number="WO-2009104054" title="Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration"/><PatentFamily id="1088916" number="WO-2008045189" title="Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol"/><PatentFamily id="1261348" number="WO-03057153" title="Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol"/><PatentFamily id="1309315" number="WO-2006033911" title="Methods of administering water-soluble prodrugs of propofol"/><PatentFamily id="1366411" number="WO-2007008869" title="Methods of dosing propofol prodrugs for inducing mild to moderate levels of sedation"/><PatentFamily id="1732771" number="WO-03059255" title="Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol"/><PatentFamily id="3549100" number="WO-2015120820" title="Class of carboxylic acid derivatives and use thereof in preparation of prodrugs"/><PatentFamily id="3647731" number="CN-106674270" title="A phosphorus third parking phenol sodium hydrate and crystal form and preparation method and use thereof"/><PatentFamily id="3647732" number="CN-106674269" title="Fospropofol disodium tetra-hydrate and crystal form and preparation method and use thereof"/><PatentFamily id="468311" number="WO-00008033" title="Water soluble prodrugs of hindered alcohols or phenols."/><PatentFamily id="474643" number="WO-03086413" title="Pharmaceutical compositions containing water-soluble prodrugs of propofol and methods of administering same"/><PatentFamily id="508750" number="WO-2005058250" title="Methods of administering water-soluble prodrugs of propofol for extended sedation"/><PatentFamily id="520095" number="US-20090075947" title="Deuterium-enriched fospropofol"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>8</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The University of Arkansas System" id="1018113"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Protia LLC" id="1043660"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Jiangsu Nhwa Pharmaceutical Group Co Ltd" id="1048457"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Shaanxi Synthetic Pharmaceutical Co Ltd" id="1074362"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eisai Co Ltd" id="15872"/><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Kansas" id="20597"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="53206"><DrugName>IMP-361</DrugName><DrugSynonyms><Name><Value>IMP-361</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>hLAG-3 + E7 fusion protein vaccine (ImmuCcine, human papilloma virus infection), Immutep</Value></Name></DrugSynonyms><CompanyOriginator id="1007701">Immutep SAS</CompanyOriginator><CompaniesSecondary><Company id="1007701">Immutep SAS</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1007701" type="Company"><TargetEntity id="4297120190" type="organizationId">Immutep SAS</TargetEntity></SourceEntity><SourceEntity id="396" type="ciIndication"><TargetEntity id="D030361" type="MeSH"/><TargetEntity id="-774172916" type="omicsDisease"/><TargetEntity id="865" type="siCondition"/></SourceEntity><SourceEntity id="427" type="ciIndication"><TargetEntity id="C53" type="ICD10"/><TargetEntity id="10008342" type="MEDDRA"/><TargetEntity id="D002583" type="MeSH"/><TargetEntity id="-837567682" type="omicsDisease"/><TargetEntity id="590" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="PTGT-09586" type="ciTarget"><TargetEntity id="33568801739023" type="siTarget">Lymphocyte activation gene 3 protein</TargetEntity><TargetEntity id="-584835448" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="396">Papillomavirus infection</Indication><Indication id="427">Uterine cervix tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="8411">CD223 modulator</Action><Action id="61725">Human papillomavirus E7 protein modulator</Action></ActionsPrimary><ActionsSecondary><Action id="12372">Protein subunit vaccine</Action><Action id="12378">Prophylactic vaccine</Action><Action id="12379">Therapeutic vaccine</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="84">Protein fusion</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2011-04-11T00:00:00.000Z</LastModificationDate><ChangeDateLast>2011-04-11T12:24:44.000Z</ChangeDateLast><AddedDate>2005-05-16T14:27:55.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1007701"&gt;Immutep SA &lt;/ulink&gt;was investigating IMP-361, a fusion protein consisting of the extra-cellular domains of hLAG-3 and the E7 oncoprotein of human papillomavirus-16 (HPV16), created using the company's ImmuCcine technology, as a potential  vaccine for the prevention and treatment of human papilloma virus infection-dependant cervical cancer. In May 2005, preclinical investigations were ongoing [&lt;ulink linkType="Reference" linkID="601367"&gt;601367&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1007701">Immutep SAS</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="427">Uterine cervix tumor</Indication><StatusDate>2010-09-23T00:00:00.000Z</StatusDate><Source id="533023" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1007701">Immutep SAS</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2010-09-23T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1007701">Immutep SAS</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="396">Papillomavirus infection</Indication><StatusDate>2004-04-15T00:00:00.000Z</StatusDate><Source id="533023" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-09586"><Name>CD223</Name><SwissprotNumbers><Swissprot>P18627</Swissprot><Swissprot>Q5BK54</Swissprot><Swissprot>Q61790</Swissprot></SwissprotNumbers></Target><Target id="PTGT-10963"><Name>Human papillomavirus E7 protein</Name><SwissprotNumbers><Swissprot>P03129</Swissprot><Swissprot>P06788</Swissprot><Swissprot>P06932</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="53603"><DrugName>TKM-ApoB</DrugName><DrugSynonyms><Name><Value>apolipoprotein B gene-silencing siRNAs (hypercholesterolemia), Alnylam</Value></Name><Name><Value>siRNA therapeutics (SNALP, hypercholesterolemia), Alnylam</Value></Name><Name><Value>siApo-B2</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>apoB stabilized nucleic acid lipid particles, Alnylam</Value></Name><Name><Value>Pro-B, Protiva</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>apolipoprotein B gene-silencing siRNAs (hypercholesterolemia), Tekmira</Value></Name><Name><Value>ApoB SNALP</Value></Name><Name><Value>PRO-040201</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>TKM-ApoB</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29927">Alnylam Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="1032153">Arbutus Biopharma Corp</Company><Company id="29927">Alnylam Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="53603" type="Drug"><TargetEntity id="423099" type="siDrug">TKM-ApoB</TargetEntity></SourceEntity><SourceEntity id="1032153" type="Company"><TargetEntity id="4295861697" type="organizationId">Arbutus Biopharma Corp (Pre-Merger)</TargetEntity></SourceEntity><SourceEntity id="29927" type="Company"><TargetEntity id="4295916167" type="organizationId">Alnylam Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="174" type="ciIndication"><TargetEntity id="10020603" type="MEDDRA"/><TargetEntity id="D006937" type="MeSH"/><TargetEntity id="-1478187279" type="omicsDisease"/><TargetEntity id="969" type="siCondition"/></SourceEntity><SourceEntity id="71" type="Action"><TargetEntity id="693" type="Mechanism">Cholesterol Absorption Inhibitors</TargetEntity></SourceEntity><SourceEntity id="26266" type="Action"><TargetEntity id="1418" type="Mechanism">APOB Expression Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="174">Hypercholesterolemia</Indication></IndicationsSecondary><ActionsPrimary><Action id="26266">APOB gene inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="71">Antihypercholesterolemic agent</Action><Action id="26035">siRNA agent</Action></ActionsSecondary><Technologies><Technology id="103">Oligonucleotide</Technology><Technology id="142">Liposome formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="599">Nanoparticle formulation injectable</Technology></Technologies><EphmraCodes><Ephmra><Code>C10A</Code><Name>CHOLESTEROL AND TRIGLYCERIDE REDUCTION PREPARATIONS</Name></Ephmra></EphmraCodes><LastModificationDate>2016-09-18T17:49:25.000Z</LastModificationDate><ChangeDateLast>2016-09-27T00:00:00.000Z</ChangeDateLast><AddedDate>2005-07-19T15:13:50.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1032153" linkType="Company"&gt;Tekmira Pharmaceuticals&lt;/ulink&gt; (following its merger with &lt;ulink linkID="28467" linkType="Company"&gt;Protiva&lt;/ulink&gt;), under license from &lt;ulink linkID="29927" linkType="Company"&gt;Alnylam Pharmaceuticals&lt;/ulink&gt;, was developing TKM-ApoB (ApoB SNAL; PRO-040201), a short interfering RNA (siRNAs) that silences the gene for apolipoprotein B (apoB), created using  the company's  lipid nanoparticle (LNP) delivery technology (previously known as stabilized nucleic acid lipid particles (SNALP) delivery system), for the potential iv treatment of hypercholesterolemia [&lt;ulink linkID="570315" linkType="Reference"&gt;570315&lt;/ulink&gt;], [&lt;ulink linkID="729294" linkType="Reference"&gt;729294&lt;/ulink&gt;], [&lt;ulink linkID="912282" linkType="Reference"&gt;912282&lt;/ulink&gt;], [&lt;ulink linkID="1249688" linkType="Reference"&gt;1249688&lt;/ulink&gt;]. In July 2009, a phase I trial began [&lt;ulink linkID="1023057" linkType="Reference"&gt;1023057&lt;/ulink&gt;]; by February 2010, a second generation candidate had been selected [&lt;ulink linkID="1076916" linkType="Reference"&gt;1076916&lt;/ulink&gt;]; in September 2010, reinitiation of a phase I/II study for the second generation candidate was to be delayed following unexpected findings regarding the lipid nanoparticle. At that time, clinical studies were to resume once an alternative formulation had been selected [&lt;ulink linkID="1130198" linkType="Reference"&gt;1130198&lt;/ulink&gt;]. In December 2011, the company was in a selection process of new siRNA payload and was evaluating a new LNP formulation of TKM-ApoB [&lt;ulink linkID="1249688" linkType="Reference"&gt;1249688&lt;/ulink&gt;]. By June 2011,  phase I trials were completed [&lt;ulink linkID="1305303" linkType="Reference"&gt;1305303&lt;/ulink&gt;].  In November 2011, the company was seeking to outlicense TKM-ApoB [&lt;ulink linkID="1249687" linkType="Reference"&gt;1249687&lt;/ulink&gt;]. However, in May 2013, the drug was no longer listed on the company's pipeline [&lt;ulink linkID="1426853" linkType="Reference"&gt;1426853&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In April 2009, the company filed an IND with the FDA for a phase I trial, which was expected to begin by mid-2009 [&lt;ulink linkID="1000011" linkType="Reference"&gt;1000011&lt;/ulink&gt;]. In May 2009, the FDA approved the IND. The escalating-single-dose, 30-patient study would assess the safety, tolerability and pharmacokinetics of the drug, as well as its effect on LDL cholesterol levels. At that time, the trial was to start before mid-2009, and data were expected in late 2009 or early 2010 [&lt;ulink linkID="1007299" linkType="Reference"&gt;1007299&lt;/ulink&gt;]. In July 2009, Tekmira started a phase I trial of ApoB SNALP. The placebo-controlled, escalating-single-dose trial (&lt;ulink linkID="59289" linkType="Protocol"&gt;NCT00927459&lt;/ulink&gt;; TKM-ApoB-001) would assess the safety, tolerability, pharmacokinetics and preliminary efficacy of the drug in an expected 32 subjects with elevated LDL cholesterol. Subjects who experienced a greater than 15% fall from baseline in LDL cholesterol levels would be followed until baseline cholesterol levels were achieved. At that time, results were expected in early 2010 [&lt;ulink linkID="1023057" linkType="Reference"&gt;1023057&lt;/ulink&gt;], [&lt;ulink linkID="1024821" linkType="Reference"&gt;1024821&lt;/ulink&gt;]. In January 2010, the trial was completed. A total of 23 subjects had received placebo or a single dose of ApoB SNALP at one of seven dose levels. Overall ApoB SNALP was well tolerated and there was no evidence of liver toxicity. Of two subjects dosed at the highest level, one experienced flu-like symptoms consistent with siRNA mediated immune stimulation. Due to this unexpected adverse event, the company decided to conclude the trial. The other two patients treated with the highest dose had an average transient reduction of ApoB protein and LDL cholesterol of 21.1 and 16.3%, respectively. At that time, the company planned to modify the drug to increase its potency and reduce immune stimulation. A new siRNA payload and SNALP formulation would be selected in the first quarter of 2010 and phase I trials would be re-initiated in 2010 [&lt;ulink linkID="1067319" linkType="Reference"&gt;1067319&lt;/ulink&gt;]. In  February 2010, a  trial of the reformulated drug was expected to  start in the second half of 2010 [&lt;ulink linkID="1074249" linkType="Reference"&gt;1074249&lt;/ulink&gt;]. By February 2010, the second generation candidate had been selected and a phase I/II study was expected to begin in the second half of 2010. Testing had shown the  reformulated drug inhibited the expression of ApoB without stimulating the immune system [&lt;ulink linkID="1076916" linkType="Reference"&gt;1076916&lt;/ulink&gt;]. In September 2010, initiation of the phase I/II study was to be delayed after non-clinical studies showed performance characteristics of the lipid nanoparticle had not met Tekmira's expectations. Several alternative formulations were being assessed [&lt;ulink linkID="1130198" linkType="Reference"&gt;1130198&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2009, data from non-human primates presented at the annual ASGT Meeting showed that a single dose of ApoB SNALP can reduce ApoB protein and LDL cholesterol for more than 1 month [&lt;ulink linkID="1033148" linkType="Reference"&gt;1033148&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2007, preclinical data were presented at the AHA Scientific Sessions in Orlando, FL. Systemic delivery of siRNAs was shown to down-regulate the disease targets apoB and proprotein convertase subtilisin kexin 9 (PCSK9), with over 90% silencing of apoB mRNA expression in the liver 48 h after administration, and reductions in apoB, cholesterol, and LDL that were sustained for at least 23 days. In mouse, humanized mouse, rat, and non-human primate models, RNAi was shown to down-regulate PCSK9 to a magnitude that decreased cholesterol levels by 20 to 60% [&lt;ulink linkID="849639" linkType="Reference"&gt;849639&lt;/ulink&gt;]. In May 2009, similar data showing over a 90% reduction in ApoB mRNA were presented at the 12th annual meeting of the American Society of Gene Therapy in San Diego, CA. Further data were also presented at the meeting demonstrating the a single dose of siRNAs to reduce ApoB protein and LDL cholesterol in non-human primates and repeat dosing prevented the formation of atherosclerotic plaques in blood vessels of rodents on a high fat diet. A new formulation resulted in a greater than 80% reduction of ApoB expression in rodents at doses of 0.1 mg/kg [&lt;ulink linkID="1013391" linkType="Reference"&gt;1013391&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2007, Alnylam and collaborators published data showing that in vivo, acute and repeated dosing of siRNAs achieved a specific and robust silencing of target genes without disruption of the endogenous microRNA pathway. Synthetic siRNAs were able to silence more than 80% of three distinct hepatocyte-expressed genes, apoB, factor VII, and SREBP cleavage-activating protein (SCAP), with single and repeat dose in rodents. The effects were well tolerated and with no detectable perturbations or off-target effects [&lt;ulink linkID="833815" linkType="Reference"&gt;833815&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Data published in March 2006, showed that siRNAs against apoB were efficacious in primate models. Liposome-formulated siRNAs were delivered to liver cells by single iv bolus doses of 1 to 2.5 mg/kg. The treatment dose-dependently reduced apoB mRNA by up to 90%. Plasma apoB, cholesterol and LDL levels were reduced by more than 75, 60 and 80%, respectively. Effects were seen within 24 h and persisted for at least 11 days at the highest dose used [&lt;ulink linkID="657921" linkType="Reference"&gt;657921&lt;/ulink&gt;], [&lt;ulink linkID="657897" linkType="Reference"&gt;657897&lt;/ulink&gt;]. Similar data were reported in March 2006 at the 231st ACS meeting in Atlanta, GA. In cynomolgus monkeys, the half-life of 2.5 mg/kg stable nucleic-acid-lipid particle (SNALP) siApo-B2 was 72 min, compared with 38 min in mice. After 2 days of treatment with siApo-B2 (n = 6), the RNA level reductions were 90 and 70% at the 2.5- and 1-mg/kg doses, respectively. By day 11, the reductions were 91 and 30% in the respective dose levels. These reductions were seen in the liver and not the jejunum. LDL levels dose-dependently reduced and HDL levels remained constant. The drug was well tolerated at both levels and there was no evidence for action of complement or cytokines, or delay in coagulation. There were no changes in hematology parameters and a transient elevation of liver enzymes was observed only in animals receiving the high dose  [&lt;ulink linkID="658172" linkType="Reference"&gt;658172&lt;/ulink&gt;], [&lt;ulink linkID="657096" linkType="Reference"&gt;657096&lt;/ulink&gt;]. Similar data were reported at the Fourth International RNAi-2006-Boston Meeting, MA [&lt;ulink linkID="668083" linkType="Reference"&gt;668083&lt;/ulink&gt;], and in August 2006 at the Cellular Delivery of Therapeutic Macromolecules meeting in Cardiff , UK [&lt;ulink linkID="689526" linkType="Reference"&gt;689526&lt;/ulink&gt;], and September 2006, at the third annual RNAi Europe meeting in Prague, Czech Republic [&lt;ulink linkID="729294" linkType="Reference"&gt;729294&lt;/ulink&gt;]. In October 2007, these data were also presented at the Fifth CHI Discovery on Target Conference in Boston, MA [&lt;ulink linkID="845431" linkType="Reference"&gt;845431&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2005, preclinical data on the  siRNAs were presented at the 2nd International Symposium on Triglycerides and HDL in New York City, NY. In mice, 5 mg/kg of the systemically delivered siRNA achieved 60% silencing of apoB in the target organ. Overall siRNA doses in this regimen were 6-fold lower than those used in a study which was published in November 2004 [&lt;ulink linkID="612799" linkType="Reference"&gt;612799&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2005, preclinical data on a siRNA were presented at the Keystone symposium on the Diverse roles of RNA in Gene Regulation in Breckenridge, CO. Silencing of the apoB gene by the siRNA was durable, lasting at least 7 days in the liver and 3 days in the intestine after a single systemic injection. In mice fed a high-fat, Western-type diet, the siRNA protected animals from developing elevated cholesterol, compared to mice treated with a saline control [&lt;ulink linkID="579030" linkType="Reference"&gt;579030&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2004, preclinical data on the siRNAs were published. The iv injection of the siRNAs into mice resulted in silencing of apoB mRNA in the liver and jejunum, and reduced blood levels of both apoB protein and total cholesterol. In a transgenic mouse model, the siRNA silenced the human apoB gene [&lt;ulink linkID="570315" linkType="Reference"&gt;570315&lt;/ulink&gt;], [&lt;ulink linkID="570640" linkType="Reference"&gt;570640&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In March 2008, as part of  Tekmira's' merger with Protiva,  Tekmira was granted the rights to develop seven RNAi therapeutic products based on &lt;ulink linkID="29927" linkType="Company"&gt;Alnylam&lt;/ulink&gt;'s intellectual property, including ApoB [&lt;ulink linkID="890658" linkType="Reference"&gt;890658&lt;/ulink&gt;]. Tekmira completed its merger with Protiva in June 2008 [&lt;ulink linkID="912282" linkType="Reference"&gt;912282&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2006, &lt;ulink linkID="16173" linkType="Company"&gt;Inex Pharmaceuticals&lt;/ulink&gt; agreed to evaluate its liposomal delivery technology with Alnylam's RNAi therapeutics, including apolipoprotein B for hypercholesterolemia [&lt;ulink linkID="657974" linkType="Reference"&gt;657974&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1032153">Arbutus Biopharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2013-05-23T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2008-06-02T00:00:00.000Z</StatusDate><Source id="912282" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1032153">Arbutus Biopharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2009-06-24T00:00:00.000Z</StatusDate><Source id="1024821" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29927">Alnylam Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2004-11-10T00:00:00.000Z</StatusDate><Source id="570315" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1032153">Arbutus Biopharma Corp</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2008-06-02T00:00:00.000Z</StatusDate><Source id="912282" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="GTGT-00149"><Name>APOB gene</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1032153">Arbutus Biopharma Corp</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="29927">Alnylam Pharmaceuticals Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="8">Technology - Delivery/Formulation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="113024" title="Tekmira to develop RNAi therapeutics under InterfeRx licenses from Alnylam "/><Deal id="115909" title="Inex to evaluate and apply its liposomal delivery technology Alnylam's RNAi therapeutics worldwide"/></Deals><PatentFamilies><PatentFamily id="1158327" number="US-08324366" title="Compositions and methods for delivering rnai using lipoproteins"/><PatentFamily id="1486652" number="US-08466122" title="Trialkyl cationic lipids and methods of use thereof"/><PatentFamily id="152979" number="WO-2011141705" title="Novel cationic lipids and methods of use thereof"/><PatentFamily id="1781505" number="WO-2011141703" title="Compositions and methods for silencing apolipoprotein B"/><PatentFamily id="2060770" number="US-20110071208" title="Lipid encapsulated dicer-substrate interfering RNA"/><PatentFamily id="2199374" number="WO-2006036916" title="RNAi modulation of ApoB and uses thereof"/><PatentFamily id="2492303" number="US-09126966" title="Cationic lipids and methods of use thereof"/><PatentFamily id="2581421" number="WO-2013126803" title="Trialkyl cationic lipids and methods of use thereof"/><PatentFamily id="3601886" number="WO-2016028649" title="Modified double-stranded RNA agents"/><PatentFamily id="449218" number="WO-2011141704" title="Novel cyclic cationic lipids and methods of use"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Arbutus Biopharma Corp" id="1032153"/><CountAsOwner>8</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>8</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Massachusetts Institute of Technology" id="18225"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="ETH Zurich" id="23144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Toyota Jidosha KK" id="25340"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alnylam Pharmaceuticals Inc" id="29927"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="55478"><DrugName>ASF-1085</DrugName><DrugSynonyms><Name><Value>ASF-1085</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="30636">Astion Pharma A/S</CompanyOriginator><CompaniesSecondary><Company id="30636">Astion Pharma A/S</Company></CompaniesSecondary><CrossReferences><SourceEntity id="30636" type="Company"><TargetEntity id="5001099228" type="organizationId">Henriksholm A/S</TargetEntity></SourceEntity><SourceEntity id="3040" type="ciIndication"><TargetEntity id="L70.0" type="ICD10"/><TargetEntity id="706.1" type="ICD9"/><TargetEntity id="D000152" type="MeSH"/><TargetEntity id="-1958569535" type="omicsDisease"/><TargetEntity id="3883" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="3040">Acne vulgaris</Indication></IndicationsSecondary><ActionsSecondary><Action id="1880">Dermatological agent</Action><Action id="2953">Anti-inflammatory</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2009-12-22T09:56:00.000Z</LastModificationDate><ChangeDateLast>2009-12-22T09:56:00.000Z</ChangeDateLast><AddedDate>2006-05-30T11:39:53.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="30636"&gt;Astion Pharma&lt;/ulink&gt; was investigating ASF-1085, an orally administered anti-inflammatory, for the potential treatment of acne vulgaris [&lt;ulink linkType="Reference" linkID="658018"&gt;658018&lt;/ulink&gt;].      &lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="30636">Astion Pharma A/S</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3040">Acne vulgaris</Indication><StatusDate>2009-12-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="30636">Astion Pharma A/S</Company><Country id="DK">Denmark</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3040">Acne vulgaris</Indication><StatusDate>2006-03-27T00:00:00.000Z</StatusDate><Source id="658018" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="59249"><DrugName>LX-2932</DrugName><DrugSynonyms><Name><Value>LX-2932</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>sphingosine-1-phosphate lyase inhibitor (autoimmune diseases), Lexicon</Value></Name><Name><Value>S1P lyase inhibitor (autoimmune diseases), Lexicon</Value></Name></DrugSynonyms><CompanyOriginator id="24887">Lexicon Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="24887">Lexicon Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="59249" type="Drug"><TargetEntity id="636284" type="siDrug">LX-2932</TargetEntity></SourceEntity><SourceEntity id="24887" type="Company"><TargetEntity id="4295914055" type="organizationId">Lexicon Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="36" type="ciIndication"><TargetEntity id="10061664" type="MEDDRA"/><TargetEntity id="D001327" type="MeSH"/><TargetEntity id="-2072222280" type="omicsDisease"/><TargetEntity id="729" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="39702" type="Action"><TargetEntity id="6195" type="Mechanism">Sphingosine-1-Phosphate Lyase 1 (S1PL; SGPL1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-07376" type="ciTarget"><TargetEntity id="100943588793" type="siTarget">Sphingosine-1-phosphate lyase 1</TargetEntity><TargetEntity id="4006" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="36">Autoimmune disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="39702">Sphingosine 1 phosphate lyase 1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="396">Immunosuppressant</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>L4</Code><Name>IMMUNOSUPPRESSIVE AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-01-21T08:56:33.000Z</LastModificationDate><ChangeDateLast>2019-01-21T00:00:00.000Z</ChangeDateLast><AddedDate>2008-01-22T11:49:15.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="24887" linkType="Company"&gt;Lexicon Pharmaceuticals&lt;/ulink&gt;  was investigating LX-2932 (structure shown), an orally available, small-molecule inhibitor of sphingosine-1-phosphate (S1P) lyase, for the potential treatment of  autoimmune diseases such as rheumatoid arthritis (RA) [&lt;ulink linkID="865820" linkType="Reference"&gt;865820&lt;/ulink&gt;], [&lt;ulink linkID="869165" linkType="Reference"&gt;869165&lt;/ulink&gt;].   By January 2008, preclinical development had begun [&lt;ulink linkID="865820" linkType="Reference"&gt;865820&lt;/ulink&gt;], [&lt;ulink linkID="869159" linkType="Reference"&gt;869159&lt;/ulink&gt;]. However, in January 2009, Lexicon restructured to focus on core programs, and the development of this program was presumed to be suspended [&lt;ulink linkID="978533" linkType="Reference"&gt;978533&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;LX-2932 is a chemically distinct back-up compound to &lt;ulink linkID="56264" linkType="Drug"&gt;LX-2931&lt;/ulink&gt; [&lt;ulink linkID="865820" linkType="Reference"&gt;865820&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By January 2008, studies had shown that LX-2932 reduces lymphocyte counts in multiple species. It also caused  S1P  levels  to increase in lymphoid tissues, thus retaining lymphocytes in the lymphoid tissues [&lt;ulink linkID="865820" linkType="Reference"&gt;865820&lt;/ulink&gt;]. In March 2010, similar data were presented at the 239th ACS meeting in San Francisco, CA [&lt;ulink linkID="1079557" linkType="Reference"&gt;1079557&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;LX-2932 inhibits sphingosine-1-phosphate (S1P) lyase, an enzyme associated with immune response and lymphocyte migration, and increases lymphoid S1P levels [&lt;ulink linkID="865820" linkType="Reference"&gt;865820&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24887">Lexicon Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>2009-01-22T00:00:00.000Z</StatusDate><Source id="978533" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24887">Lexicon Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>2007-06-30T00:00:00.000Z</StatusDate><Source id="869165" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-07376"><Name>Sphingosine 1 phosphate lyase 1</Name><SwissprotNumbers><Swissprot>O95470</Swissprot><Swissprot>Q5R4G0</Swissprot><Swissprot>Q8CHN6</Swissprot><Swissprot>Q8R0X7</Swissprot></SwissprotNumbers></Target></Targets><PatentFamilies><PatentFamily id="1602831" number="WO-2010008734" title="Methods of preparing imidazole-based bicyclic compounds"/><PatentFamily id="1781059" number="WO-2010022217" title="Combinations comprising bicyclic S-1P lyase inhibitors"/><PatentFamily id="1898294" number="WO-2010008733" title="Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use"/><PatentFamily id="775456" number="WO-2008109314" title="Heterocyclic compounds, compositions comprising them and methods of their use"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Lexicon Pharmaceuticals Inc" id="24887"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="59727"><DrugName>hPAM4-CL2A-SN-38</DrugName><DrugSynonyms><Name><Value>hPAM4-SN-38</Value></Name><Name><Value>hPAM4-CL2A-SN-38</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17204">Immunomedics Inc</CompanyOriginator><CompaniesSecondary><Company id="17204">Immunomedics Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17204" type="Company"><TargetEntity id="4295906779" type="organizationId">Immunomedics Inc</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="32078" type="Action"><TargetEntity id="1588" type="Mechanism">Anti-CD227 (MUC1)</TargetEntity><TargetEntity id="5011" type="Mechanism">Mucin-1 (MUC-1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="141" type="Action"><TargetEntity id="418" type="Mechanism">DNA Topoisomerase I Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01877" type="ciTarget"><TargetEntity id="133883360" type="siTarget">DNA topoisomerase</TargetEntity></SourceEntity><SourceEntity id="PTGT-06235" type="ciTarget"><TargetEntity id="181402999545823" type="siTarget">Mucin-1</TargetEntity><TargetEntity id="-1654932761" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="141">Topoisomerase I inhibitor</Action><Action id="32078">Mucin 1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="55685">Anticancer monoclonal antibody</Action></ActionsSecondary><Technologies><Technology id="171">Monoclonal antibody conjugated</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2015-06-12T07:56:09.000Z</LastModificationDate><ChangeDateLast>2012-09-13T00:00:00.000Z</ChangeDateLast><AddedDate>2008-03-25T13:43:07.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="17204"&gt;Immunomedics&lt;/ulink&gt; is investigating hPAM4-CL2A-SN-38 (hPAM4-SN-38), a &lt;ulink linkType="Drug" linkID="7035"/&gt;hPAM4 monoclonal antibody (mAb) with redesigned CL2A linker, conjugated to  the active metabolite of &lt;ulink linkType="Drug" linkID="2871"&gt;irinotecan&lt;/ulink&gt;, SN-38, to increase bioavailabilty and reduce toxicity, for the potential  treatment of cancer [&lt;ulink linkType="Reference" linkID="888830"&gt;888830&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1091884"&gt;1091884&lt;/ulink&gt;]. Preclinical data were reported in March 2008 [&lt;ulink linkType="Reference" linkID="888830"&gt;888830&lt;/ulink&gt;]; in April 2012, development was ongoing [&lt;ulink linkType="Reference" linkID="1299364"&gt;1299364&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company is also investigating SN-38 conjugated to &lt;ulink linkType="Drug" linkID="58504"&gt;hRS7&lt;/ulink&gt;,  &lt;ulink linkType="Drug" linkID="66267"&gt;epratuzumab&lt;/ulink&gt; and to &lt;ulink linkType="Drug" linkID="58503"&gt;labetuzumab&lt;/ulink&gt;.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2010, preclinical data were presented at the 101st AACR meeting in Washington DC.  hPAM4-CL2A-SN-38 was found to be equally as effective as its other SN-38-conjugates counterparts, hRS7, epratuzumab and labetuzumab in increasing the median survivial time (MST) of Capan-1 and BxPC-3 pancreatic carcinoma xenograft nude athymic mice   [&lt;ulink linkType="Reference" linkID="1089846"&gt;1089846&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1091884"&gt;1091884&lt;/ulink&gt;]. At the same meeting, data were presented from a study of hPAM4-CL2A-SN-38 compared to the hRS7-SN-38 conjugate in Capan-1 xenograft nude mice.     Results showed tumor growth was controlled for a longer time with hPAM4-CL2A-SN-38 [&lt;ulink linkType="Reference" linkID="1089977"&gt;1089977&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2008, preclinical data were reported  at the International Symposium on Targeted Anticancer Therapies meeting in Bethesda, MD. hPAM4-SN-38 produced 55% tumor inhiition in a pancreatic cancer model [&lt;ulink linkType="Reference" linkID="888830"&gt;888830&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By March 2008, this program was being funded by a SBIR grant from the NCI [&lt;ulink linkType="Reference" linkID="888830"&gt;888830&lt;/ulink&gt;].&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17204">Immunomedics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2015-06-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17204">Immunomedics Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-03-25T00:00:00.000Z</StatusDate><Source id="888830" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01877"><Name>Topoisomerase I</Name><SwissprotNumbers><Swissprot>O27661</Swissprot><Swissprot>O28469</Swissprot><Swissprot>O34204</Swissprot><Swissprot>O51768</Swissprot><Swissprot>O58356</Swissprot><Swissprot>O66893</Swissprot><Swissprot>O69548</Swissprot><Swissprot>O73954</Swissprot><Swissprot>O83409</Swissprot><Swissprot>P04786</Swissprot><Swissprot>P06612</Swissprot><Swissprot>P07799</Swissprot><Swissprot>P0A2I1</Swissprot><Swissprot>P0A2I2</Swissprot><Swissprot>P0A621</Swissprot><Swissprot>P11387</Swissprot><Swissprot>P16472</Swissprot><Swissprot>P30181</Swissprot><Swissprot>P30189</Swissprot><Swissprot>P32989</Swissprot><Swissprot>P34184</Swissprot><Swissprot>P34185</Swissprot><Swissprot>P39814</Swissprot><Swissprot>P40114</Swissprot><Swissprot>P41511</Swissprot><Swissprot>P41512</Swissprot><Swissprot>P43012</Swissprot><Swissprot>P46155</Swissprot><Swissprot>P46799</Swissprot><Swissprot>P47368</Swissprot><Swissprot>P55991</Swissprot><Swissprot>P57371</Swissprot><Swissprot>P68697</Swissprot><Swissprot>P68698</Swissprot><Swissprot>P73810</Swissprot><Swissprot>P78032</Swissprot><Swissprot>P83247</Swissprot><Swissprot>P93119</Swissprot><Swissprot>Q00313</Swissprot><Swissprot>Q04750</Swissprot><Swissprot>Q07050</Swissprot><Swissprot>Q1RIM1</Swissprot><Swissprot>Q4UM42</Swissprot><Swissprot>Q59046</Swissprot><Swissprot>Q68X45</Swissprot><Swissprot>Q76ZS7</Swissprot><Swissprot>Q7YR26</Swissprot><Swissprot>Q87AQ6</Swissprot><Swissprot>Q8K9P7</Swissprot><Swissprot>Q92IH1</Swissprot><Swissprot>Q9CG80</Swissprot><Swissprot>Q9CN30</Swissprot><Swissprot>Q9HM08</Swissprot><Swissprot>Q9HZJ5</Swissprot><Swissprot>Q9JN65</Swissprot><Swissprot>Q9KA23</Swissprot><Swissprot>Q9KRB2</Swissprot><Swissprot>Q9PEV8</Swissprot><Swissprot>Q9PLZ2</Swissprot><Swissprot>Q9UYS8</Swissprot><Swissprot>Q9WUL0</Swissprot><Swissprot>Q9X3X7</Swissprot><Swissprot>Q9X909</Swissprot><Swissprot>Q9YB01</Swissprot><Swissprot>Q9ZDK2</Swissprot><Swissprot>Q9ZMV7</Swissprot></SwissprotNumbers></Target><Target id="PTGT-06235"><Name>Mucin 1</Name><SwissprotNumbers><Swissprot>P08640</Swissprot><Swissprot>P15941</Swissprot><Swissprot>Q02496</Swissprot><Swissprot>Q29435</Swissprot><Swissprot>Q60528</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17204">Immunomedics Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="115902" title="NCI to support Immunomedics's development of antibody conjugates"/></Deals><PatentFamilies><PatentFamily id="1354053" number="US-08574575" title="RS7 antibodies"/><PatentFamily id="2474112" number="WO-03074566" title="RS7 antibodies"/><PatentFamily id="2481674" number="WO-2009079024" title="Improved methods and compositions for F-18 labeling of proteins, peptides and other molecules"/><PatentFamily id="2493704" number="WO-2009100194" title="Camptothecin-binding moiety conjugates"/><PatentFamily id="2494106" number="WO-2004054622" title="Immunoconjugates with an intracellularly-cleavable linkage"/><PatentFamily id="2497928" number="WO-2006107617" title="Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses"/><PatentFamily id="2497951" number="WO-2009126558" title="Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology"/><PatentFamily id="2497952" number="WO-2011068845" title="Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy"/><PatentFamily id="2504992" number="WO-2009135015" title="Improved methods and compositions for F-18 labeling of proteins, peptides and other molecules"/><PatentFamily id="2505148" number="WO-2007112193" title="Camptothecin-binding moiety conjugates"/><PatentFamily id="2505232" number="WO-2010093395" title="Immunoconjugates with an intracellularly-cleavable linkage"/><PatentFamily id="2505233" number="WO-2008088648" title="Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules"/><PatentFamily id="2505267" number="WO-03106495" title="Monoclonal antibody hPAM4"/><PatentFamily id="2505883" number="WO-2009055653" title="PEGylation by the dock and lock (DNL) technique"/><PatentFamily id="2755821" number="WO-2014092804" title="Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity"/><PatentFamily id="2913091" number="WO-2015047510" title="Anti-trop-2 antibody-drug conjugates and uses thereof"/><PatentFamily id="3435564" number="WO-2015012904" title="Antibody-SN-38 immunoconjugates with a CL2A linker"/><PatentFamily id="3499674" number="WO-2017004144" title="Antibody-sn-38 immunoconjugates with a cl2a linker"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>13</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>13</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>7</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>10</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alexis Biotech Ltd" id="1021386"/><CountAsOwner>13</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>13</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Immunomedics Inc" id="17204"/><CountAsOwner>18</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>18</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Center for Molecular Medicine &amp; Immunology" id="24272"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Garden State Cancer Center" id="28053"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="60409"><DrugName>GPR4 inverse agonists (inflammation), Kyowa Hakko Kirin</DrugName><DrugSynonyms><Name><Value>GPR4 inverse agonists (inflammation), Kyowa Hakko Kirin</Value></Name><Name><Value>K-285, Kyowa Hakko Kirin</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>K-924</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>K-992</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GPR4 inverse agonists (inflammation), Kyowa Hakko Kogyo</Value></Name><Name><Value>20153-98-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17724">Kyowa Hakko Kogyo Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Company id="17724">Kyowa Hakko Kogyo Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="60409" type="Drug"><TargetEntity id="477961" type="siDrug">K-285</TargetEntity></SourceEntity><SourceEntity id="1042596" type="Company"><TargetEntity id="4295877429" type="organizationId">Kyowa Kirin Co Ltd</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="40624" type="Action"><TargetEntity id="2817" type="Mechanism">G Protein-Coupled Receptor GPR4 Ligands</TargetEntity></SourceEntity><SourceEntity id="1887" type="Action"><TargetEntity id="3282" type="Mechanism">Chemokine Modulators</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-07523" type="ciTarget"><TargetEntity id="28280" type="siTarget">G-protein coupled receptor 4</TargetEntity><TargetEntity id="-578071210" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="40624">G protein coupled receptor 4 modulator</Action></ActionsPrimary><ActionsSecondary><Action id="1887">Chemokine modulator</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2016-10-12T15:39:16.000Z</LastModificationDate><ChangeDateLast>2016-10-27T00:00:00.000Z</ChangeDateLast><AddedDate>2008-06-06T12:34:45.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;It is presumed that  &lt;ulink linkID="1042596" linkType="Company"&gt;Kyowa Hakko Kirin&lt;/ulink&gt; (formerly  &lt;ulink linkID="17724" linkType="Company"&gt;Kyowa Hakko Kogyo&lt;/ulink&gt;), is investigating a series of G-protein-coupled receptor 4 (GPR4) inverse agonists, including  K-924, and K-992 (structure shown), for the potential treatment of inflammatory diseases, including chronic obstructive pulmonary disease (COPD) [&lt;ulink linkID="913869" linkType="Reference"&gt;913869&lt;/ulink&gt;], [&lt;ulink linkID="947785" linkType="Reference"&gt;947785&lt;/ulink&gt;]. In August 2014, preclinical data were presented [&lt;ulink linkID="1583927" linkType="Reference"&gt;1583927&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company was also investigating the neutrophil accumulation and CXCL2, CXCL1, MMP12 and EGR1 inhibitor, K-285,  from the series, however,  in May 2008, investigation of the compound  ceased due to concerns over its cardiotoxic potential [&lt;ulink linkID="913869" linkType="Reference"&gt;913869&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In August 2014, preclinical data were presented at the 248th ACS meeting in San Francisco, CA. K-992 had an IC50 value of 37 nM against human GPR4 reporter and a binding Ki value of 15 nM. K-992 was not neutrophilic and had normalized partial pressure of oxygen [&lt;ulink linkID="1583927" linkType="Reference"&gt;1583927&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2008, preclinical data were presented at the 2008 ATS Annual Meeting in Toronto, Canada. In a model of COPD it was found that K-285 had no effect on BAL total cell (at doses up to 30 mg/kg) but the drug did inhibit neutrophil accumulation (1.5 x 10(4) reduced to 0.4 x 10(4) with both 10 and 30mg/kg) and chemokines (CXCL2, CXCL1, MMP12 and EGR1 reduced by 50,  60,  50 and 75%, respectively).  K-285 was found to bind to HER2 in mice , however, K-924 and K-992 did not bind to HER2 and showed similar effects in a HCl installation model [&lt;ulink linkID="913869" linkType="Reference"&gt;913869&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2011-01-05T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17724">Kyowa Hakko Kogyo Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2008-05-16T00:00:00.000Z</StatusDate><Source id="947785" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1042596">Kyowa Hakko Kirin Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2008-10-01T00:00:00.000Z</StatusDate><Source id="947785" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-07523"><Name>G protein coupled receptor 4</Name><SwissprotNumbers><Swissprot>P46093</Swissprot><Swissprot>P50132</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="60911"><DrugName>cytochrome P450 3A inhibitors (pharmacokinetic boosters, HIV infection), Abbott</DrugName><DrugSynonyms><Name><Value>A-307701</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>cytochrome P450 3A inhibitors (pharmacokinetic boosters, HIV infection), Abbott</Value></Name><Name><Value>CYP3A inhibitors (pharmacokinetic boosters, HIV infection), Abbott</Value></Name></DrugSynonyms><CompanyOriginator id="13601">Abbott Laboratories</CompanyOriginator><CompaniesSecondary><Company id="13601">Abbott Laboratories</Company></CompaniesSecondary><CrossReferences><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"/><TargetEntity id="042" type="ICD9"/><TargetEntity id="10020161" type="MEDDRA"/><TargetEntity id="D015658" type="MeSH"/><TargetEntity id="-841965209" type="omicsDisease"/><TargetEntity id="862" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="158">HIV infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="7418">Cytochrome P450 3 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2012-11-16T16:57:36.000Z</LastModificationDate><ChangeDateLast>2012-11-16T00:00:00.000Z</ChangeDateLast><AddedDate>2008-07-31T13:53:31.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="13601"&gt;Abbott&lt;/ulink&gt; was investigating a series of cytochrome P450 3A (CYP3A) inhibitors for the potential pharmacokinetic boosting of HIV protease inhibitors such as &lt;ulink linkType="Drug" linkID="14681"&gt;lopinavir&lt;/ulink&gt; in the treatment of HIV infection [&lt;ulink linkType="Reference" linkID="901170"&gt;901170&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="930014"&gt;930014&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In August 2008, preclinical data on several inhibitors from the series were presented at the 236th ACS National Meeting in Philadelphia, PA. Three beagle dogs were administered 5 mg/kg CYP inhibitor in combination with &lt;ulink linkType="Drug" linkID="14681"&gt;lopinavir&lt;/ulink&gt;. One of the most active compounds  (structure shown) was found to enhance the plasma concentration of lopinavir by 22.95 microg.h/ml [&lt;ulink linkType="Reference" linkID="930014"&gt;930014&lt;/ulink&gt;]. Similar data were published in 2009, with the compound exhibiting a CYP3A4 IC50 value of 0.05 microM [&lt;ulink linkType="Reference" linkID="1088462"&gt;1088462&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data on A-307701 were presented at the Sixth SCI-RSC Proteinase Inhibitors Design Symposium in London, UK. A-307701 had an IC50 value of 140 nM against CYP3A4 [&lt;ulink linkType="Reference" linkID="901170"&gt;901170&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>2012-11-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>2008-04-22T00:00:00.000Z</StatusDate><Source id="901170" type="CONFERENCE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00560"><Name>Cytochrome P450 3</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="60929"><DrugName>resminostat</DrugName><DrugNamesKey><Name id="42912125">resminostat</Name></DrugNamesKey><DrugSynonyms><Name><Value>resminostat</Value><Types><Type>INN</Type></Types></Name><Name><Value>4SC-201</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BYK-408740</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>YHI-1001</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14069">Takeda GmbH</CompanyOriginator><CompaniesPrimary><Company id="20961">Yakult Honsha Co Ltd</Company><Company id="18053">The Menarini Group</Company><Company id="28108">4SC AG</Company></CompaniesPrimary><CompaniesSecondary><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Company id="14069">Takeda GmbH</Company></CompaniesSecondary><CrossReferences><SourceEntity id="60929" type="Drug"><TargetEntity id="635343" type="siDrug"></TargetEntity><TargetEntity id="450395" type="siDrug">Resminostat hydrobromide</TargetEntity><TargetEntity id="407946" type="siDrug">Resminostat hydrochloride</TargetEntity></SourceEntity><SourceEntity id="1002503" type="Company"><TargetEntity id="4297904097" type="organizationId">Takeda Pharmaceuticals International AG</TargetEntity></SourceEntity><SourceEntity id="14069" type="Company"><TargetEntity id="4296003739" type="organizationId">Altana Pharma AG</TargetEntity></SourceEntity><SourceEntity id="18053" type="Company"><TargetEntity id="4296446248" type="organizationId">A Menarini Industrie Farmaceutiche Riunite Srl</TargetEntity></SourceEntity><SourceEntity id="20961" type="Company"><TargetEntity id="4295878046" type="organizationId">Yakult Honsha Co Ltd</TargetEntity></SourceEntity><SourceEntity id="28108" type="Company"><TargetEntity id="4295870097" type="organizationId">4Sc AG</TargetEntity></SourceEntity><SourceEntity id="1115" type="ciIndication"><TargetEntity id="C84.0" type="ICD10"/><TargetEntity id="202.1" type="ICD9"/><TargetEntity id="10028483" type="MEDDRA"/><TargetEntity id="D009182" type="MeSH"/><TargetEntity id="-1091812760" type="omicsDisease"/><TargetEntity id="1748" type="siCondition"/></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"/><TargetEntity id="D002289" type="MeSH"/><TargetEntity id="-1730468577" type="omicsDisease"/><TargetEntity id="612" type="siCondition"/></SourceEntity><SourceEntity id="1515" type="ciIndication"><TargetEntity id="D001650" type="MeSH"/></SourceEntity><SourceEntity id="161" type="ciIndication"><TargetEntity id="C81" type="ICD10"/><TargetEntity id="201" type="ICD9"/><TargetEntity id="10020206" type="MEDDRA"/><TargetEntity id="D006689" type="MeSH"/><TargetEntity id="98293" type="ORPHANET"/><TargetEntity id="-1008729809" type="omicsDisease"/><TargetEntity id="701" type="siCondition"/></SourceEntity><SourceEntity id="1754" type="ciIndication"><TargetEntity id="D016410" type="MeSH"/><TargetEntity id="836" type="siCondition"/></SourceEntity><SourceEntity id="1756" type="ciIndication"><TargetEntity id="C84.1" type="ICD10"/><TargetEntity id="D012751" type="MeSH"/><TargetEntity id="3162" type="ORPHANET"/><TargetEntity id="-2115224942" type="omicsDisease"/><TargetEntity id="1341" type="siCondition"/></SourceEntity><SourceEntity id="1765" type="ciIndication"><TargetEntity id="D018281" type="MeSH"/><TargetEntity id="70567" type="ORPHANET"/><TargetEntity id="-2122101383" type="omicsDisease"/><TargetEntity id="1844" type="siCondition"/></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"/><TargetEntity id="88673" type="ORPHANET"/><TargetEntity id="-1116061312" type="omicsDisease"/><TargetEntity id="1973" type="siCondition"/></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"/><TargetEntity id="10033609" type="MEDDRA"/><TargetEntity id="D010190" type="MeSH"/><TargetEntity id="-670361033" type="omicsDisease"/><TargetEntity id="630" type="siCondition"/></SourceEntity><SourceEntity id="3146" type="ciIndication"><TargetEntity id="C23" type="ICD10"/><TargetEntity id="10017614" type="MEDDRA"/><TargetEntity id="D005706" type="MeSH"/><TargetEntity id="-1971138641" type="omicsDisease"/><TargetEntity id="601" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"/><TargetEntity id="D015179" type="MeSH"/><TargetEntity id="-1280257855" type="omicsDisease"/><TargetEntity id="594" type="siCondition"/></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2574" type="Action"><TargetEntity id="1213" type="Mechanism">Histone Deacetylase (HDAC) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7856" type="Action"><TargetEntity id="2266" type="Mechanism">Histone Deacetylase 6 (HDAC6) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7844" type="Action"><TargetEntity id="1915" type="Mechanism">Histone Deacetylase 2 (HDAC2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7841" type="Action"><TargetEntity id="1749" type="Mechanism">Histone Deacetylase 1 (HDAC1) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="7847" type="Action"><TargetEntity id="3062" type="Mechanism">Histone Deacetylase 3 (HDAC3) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00167" type="ciTarget"><TargetEntity id="19352042493833" type="siTarget">Arginase-1</TargetEntity><TargetEntity id="-375653545" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-00923" type="ciTarget"><TargetEntity id="205759791330653" type="siTarget">Histone deacetylase 1</TargetEntity><TargetEntity id="-1584981221" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-00924" type="ciTarget"><TargetEntity id="7769724330663" type="siTarget">Histone deacetylase 2</TargetEntity><TargetEntity id="-1539608840" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-00925" type="ciTarget"><TargetEntity id="198643746488413" type="siTarget">Histone deacetylase 3</TargetEntity><TargetEntity id="2539" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-00928" type="ciTarget"><TargetEntity id="1931963398100133" type="siTarget">Histone deacetylase 6</TargetEntity><TargetEntity id="2530" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1115">Mycosis fungoides</Indication><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="1515">Biliary tumor</Indication><Indication id="161">Hodgkins disease</Indication><Indication id="1756">Sezary syndrome</Indication><Indication id="1765">Cholangiocarcinoma</Indication><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="249">Pancreas tumor</Indication><Indication id="3146">Gallbladder tumor</Indication><Indication id="725">Solid tumor</Indication><Indication id="989">Colorectal tumor</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1754">Cutaneous T-cell lymphoma</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="7856">Histone deacetylase-6 inhibitor</Action><Action id="7841">Histone deacetylase-1 inhibitor</Action><Action id="2574">Histone deacetylase inhibitor</Action><Action id="7087">Arginase-I inhibitor</Action><Action id="7847">Histone deacetylase-3 inhibitor</Action><Action id="7844">Histone deacetylase-2 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1589">Apoptosis stimulator</Action><Action id="767">Cell cycle inhibitor</Action><Action id="7757">Natural killer cell stimulator</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-30T06:42:39.000Z</LastModificationDate><ChangeDateLast>2019-07-01T00:00:00.000Z</ChangeDateLast><AddedDate>2008-08-04T15:18:09.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28108" linkType="Company"&gt;4SC&lt;/ulink&gt;, following its acquisition of &lt;ulink linkID="1002503" linkType="Company"&gt;Nycomed&lt;/ulink&gt;'s oncology program&lt;ulink linkID="1002503" linkType="Company"&gt;&lt;/ulink&gt;s, is developing an oral pan-HDAC inhibitor, resminostat (4SC-201; BYK-408740; YHI-1001), which targets in particular HDAC 1, 2, 3 and 6, for the potential treatment of solid and hematological tumors, including hepatocellular carcinoma (HCC),  Hodgkin's lymphoma (HL), colorectal cancer (CRC) and cutaneous T-cell lymphoma (CTCL), such as advanced stage mycosis fungoides and  sezary syndrome [&lt;ulink linkID="931166" linkType="Reference"&gt;931166&lt;/ulink&gt;], [&lt;ulink linkID="1032344" linkType="Reference"&gt;1032344&lt;/ulink&gt;], [&lt;ulink linkID="1027818" linkType="Reference"&gt;1027818&lt;/ulink&gt;], [&lt;ulink linkID="1068219" linkType="Reference"&gt;1068219&lt;/ulink&gt;], [&lt;ulink linkID="1162426" linkType="Reference"&gt;1162426&lt;/ulink&gt;], [&lt;ulink linkID="1674637" linkType="Reference"&gt;1674637&lt;/ulink&gt;],  [&lt;ulink linkID="1872014" linkType="Reference"&gt;1872014&lt;/ulink&gt;]. In July 2009, a phase II trial began in patients with HCC in Italy and Germany  [&lt;ulink linkID="1027818" linkType="Reference"&gt;1027818&lt;/ulink&gt;]; in January 2012, positive data were reported and at that time, a pivotal trial for HCC was planned [&lt;ulink linkID="1256351" linkType="Reference"&gt;1256351&lt;/ulink&gt;].   In December 2009, a phase II HL trial  was initiated in Europe  [&lt;ulink linkID="1068219" linkType="Reference"&gt;1068219&lt;/ulink&gt;]; in May 2010,  data were reported from the first cohort and the company decided to expand the study with a second  cohort [&lt;ulink linkID="1103495" linkType="Reference"&gt;1103495&lt;/ulink&gt;]; in December 2011,  data were presented [&lt;ulink linkID="1243929" linkType="Reference"&gt;1243929&lt;/ulink&gt;]. In November 2016, a phase II study was initiated in patients with advanced stage mycosis fungoides or sezary syndrome [&lt;ulink linkID="1872014" linkType="Reference"&gt;1872014&lt;/ulink&gt;]; in November 2018, top-line data were expected in the first half of 2020 [&lt;ulink linkID="2115272" linkType="Reference"&gt;2115272&lt;/ulink&gt;]. In January 2011,  a phase I/II trial   was initiated for CRC in Germany [&lt;ulink linkID="1162426" linkType="Reference"&gt;1162426&lt;/ulink&gt;], [&lt;ulink linkID="1162530" linkType="Reference"&gt;1162530&lt;/ulink&gt;]; in December 2012, positive interim data were reported [&lt;ulink linkID="1349848" linkType="Reference"&gt;1349848&lt;/ulink&gt;]. In July 2015, phase II development for advanced CRC were ongoing [&lt;ulink linkID="1681522" linkType="Reference"&gt;1681522&lt;/ulink&gt;].  In February 2016, the US FDA approved an IND application to initiate a clinical trial in HCC patients [&lt;ulink linkID="1737438" linkType="Reference"&gt;1737438&lt;/ulink&gt;]. In September 2018, the drug was in phase II development for CTCL and bile duct cancer in Japan, and development was presumed to be ongoing for other indications [&lt;ulink linkID="2076919" linkType="Reference"&gt;2076919&lt;/ulink&gt;]. In December 2017, the company was planning to apply for marketing approval in the US and Europe for the treatment of CTCL [&lt;ulink linkID="1989353" linkType="Reference"&gt;1989353&lt;/ulink&gt;]. In September 2015, additional preclinical studies were planned to be initiated  [&lt;ulink linkID="1699030" linkType="Reference"&gt;1699030&lt;/ulink&gt;]. In September 2018, the drug was listed in phase II phase and development was presumed to be ongoing    [&lt;ulink linkID="2076919" linkType="Reference"&gt;2076919&lt;/ulink&gt;]. In February 2018, 4SC was seeking to outlicense the drug to development and marketing partners in the US and EU [&lt;ulink linkID="2011358" linkType="Reference"&gt;2011358&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Japanese licensee &lt;ulink linkID="20961" linkType="Company"&gt;Yakult Honsha&lt;/ulink&gt; is also developing  the drug for the potential treatment of HCC and non-small cell lung cancer (NSCLC) and biliary tract cancer (BTC) including cholangiocarcinoma, gallbladder cancer,  and investigating the drug for  CRC,  and other oncology indications [&lt;ulink linkID="1183842" linkType="Reference"&gt;1183842&lt;/ulink&gt;], [&lt;ulink linkID="2020387" linkType="Reference"&gt;2020387&lt;/ulink&gt;]. In March 2018, a phase II trial was initiated in patients with platinum-&lt;ulink linkID="3199" linkType="Drug"&gt;gemcitabine &lt;/ulink&gt;combination unresectable/recurrence BTC [&lt;ulink linkID="2020387" linkType="Reference"&gt;2020387&lt;/ulink&gt;]. In May 2013, a phase I/II trial in patients with HCC was initiated in Japan [&lt;ulink linkID="1428911" linkType="Reference"&gt;1428911&lt;/ulink&gt;]. In February 2016, data from the trial were expected later in 2016 [&lt;ulink linkID="1737438" linkType="Reference"&gt;1737438&lt;/ulink&gt;]. By May 2013, a phase I/II trial in non-small cell lung cancer patients had been ongoing in Japan [&lt;ulink linkID="1456987" linkType="Reference"&gt;1456987&lt;/ulink&gt;]; in October 2014, phase I part of the trial was completed and began the phase II part of the trial [&lt;ulink linkID="1600171" linkType="Reference"&gt;1600171&lt;/ulink&gt;]. In April 2015, a phase I study in patients with pancreatic or biliary tract cancer was initiated in Japan [&lt;ulink linkID="1673578" linkType="Reference"&gt;1673578&lt;/ulink&gt;], [&lt;ulink linkID="1676138" linkType="Reference"&gt;1676138&lt;/ulink&gt;]; in August 2018, final results were expected in mid-2020 [&lt;ulink linkID="2062018" linkType="Reference"&gt;2062018&lt;/ulink&gt;]. In March 2019, Yakult Honsha was planning to apply for marketing approval in Japan for resminostat for for  maintenance therapy in  CTCL  [&lt;ulink linkID="2132349" linkType="Reference"&gt;2132349&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Licensee &lt;ulink linkID="18053" linkType="Company"&gt;Menarini&lt;/ulink&gt; is developing the agent for the Asia Pacific market, excluding Japan [&lt;ulink linkID="1650569" linkType="Reference"&gt;1650569&lt;/ulink&gt;].  In March 2015, Yakult was conducting a phase II trial  in Korean patients with NSCLC and HCC [&lt;ulink linkID="1645172" linkType="Reference"&gt;1645172&lt;/ulink&gt;]. In April 2015, it was presumed that Menarini was to continue with development.&lt;/para&gt;&lt;para&gt;The compound is presumed to have derived from the  &lt;ulink linkID="54456" linkType="Drug"&gt;histone deacetylase-SAPHIRE1 inhibitors program&lt;/ulink&gt; of Nycomed's subsidiary &lt;ulink linkID="14069" linkType="Company"&gt;ALTANA&lt;/ulink&gt;. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In December 2017, the company was planning to apply for marketing approval in the US for resminostat for the treatment of CTCL [&lt;ulink linkID="1989353" linkType="Reference"&gt;1989353&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, the company aimed at obtaining market approval for resminostat as a personalized cancer therapy based on ZFP64 biomarker data [&lt;ulink linkID="1497448" linkType="Reference"&gt;1497448&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2011, the FDA granted Orphan Drug status to resminostat for HCC [&lt;ulink linkID="1206851" linkType="Reference"&gt;1206851&lt;/ulink&gt;]. In September 2011, the agency awarded  the drug Orphan status for Hodgkin's lymphoma [&lt;ulink linkID="1225473" linkType="Reference"&gt;1225473&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In December 2017, the company was planning to apply for marketing approval in Europe for resminostat for the treatment of CTCL [&lt;ulink linkID="1989353" linkType="Reference"&gt;1989353&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, 4SC expected to submit a filing for conditional approval of resminostat  for the treatment of CTCL in Europe based on data from the planned phase  II study for this indication [&lt;ulink linkID="1699030" linkType="Reference"&gt;1699030&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2011, the EMA's COMP adopted a positive opinion recommendingresminostat for Orphan Drugdesignation, for HCC [&lt;ulink linkID="1208834" linkType="Reference"&gt;1208834&lt;/ulink&gt;], [&lt;ulink linkID="1210023" linkType="Reference"&gt;1210023&lt;/ulink&gt;]; in September 2011, Orphan Drug status was granted [&lt;ulink linkID="1230604" linkType="Reference"&gt;1230604&lt;/ulink&gt;]. In October 2011, the EMA recommended   resminostat for    Orphan status for    the treatment of Hodgkin's lymphoma  [&lt;ulink linkID="1229948" linkType="Reference"&gt;1229948&lt;/ulink&gt;]; in December 2011, Orphan status was granted [&lt;ulink linkID="1255531" linkType="Reference"&gt;1255531&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;In March 2019, Yakult Honsha was planning to apply for marketing approval in Japan for resminostat for  maintenance therapy in  CTCL [&lt;ulink linkID="2132349" linkType="Reference"&gt;2132349&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Cutaneous T-cell lymphoma&lt;/subtitle&gt;In June 2015, a randomized, controlled phase II trial in  advanced CTCL was planned in Europe [&lt;ulink linkID="1673578" linkType="Reference"&gt;1673578&lt;/ulink&gt;]. [&lt;ulink linkID="1684264" linkType="Reference"&gt;1684264&lt;/ulink&gt;]. In August 2015, data from the placebo-controlled trial were expected in the second half of 2018 [&lt;ulink linkID="1684264" linkType="Reference"&gt;1684264&lt;/ulink&gt;]. In November 2015, the trial was expected to start in the second quarter of 2016 [&lt;ulink linkID="1712344" linkType="Reference"&gt;1712344&lt;/ulink&gt;]. In August 2016, the trial was expected to begin in the fourth quarter of 2016 [&lt;ulink linkID="1787402" linkType="Reference"&gt;1787402&lt;/ulink&gt;]. In November 2016, a multicenter, double-blind, randomized, placebo-controlled, phase II study (&lt;ulink linkID="278108" linkType="Protocol"&gt;NCT02953301&lt;/ulink&gt;; 4SC-201-6-2015 2016-000807-99) was initiated in Spain to assess the efficacy and safety of reminostat in patients (expected n = 150) with advanced stage mycosis fungoides or sezary syndrome. At that time, the study was expected to complete in February 2020 [&lt;ulink linkID="1872014" linkType="Reference"&gt;1872014&lt;/ulink&gt;]. In April 2017, top-line data were expected from the RESMAIN study in the first half of 2019 [&lt;ulink linkID="1922768" linkType="Reference"&gt;1922768&lt;/ulink&gt;]. In November 2017, one-third of patients in the RESMAIN trial had been recruited. At that time, the trial was ongoing in Austria, Belgium, Germany, France, Italy, the Netherlands, Spain, Switzerland and the UK [&lt;ulink linkID="1989353" linkType="Reference"&gt;1989353&lt;/ulink&gt;]. By October  2018,  100 patients had been recruited.  At that time,   top-line results were expected by the end of 2019 [&lt;ulink linkID="2087171" linkType="Reference"&gt;2087171&lt;/ulink&gt;]. In November 2018, top-line results were expected in the first half of 2020 [&lt;ulink linkID="2115272" linkType="Reference"&gt;2115272&lt;/ulink&gt;]. In January 2019, DSMB recommended to continue the trial without any modification for the study protocol. At tha time, enrollment was expected to complete 'later that year'  [&lt;ulink linkID="2115287" linkType="Reference"&gt;2115287&lt;/ulink&gt;]. In March 2019, more than two thirds of patients were enrolled in the study and positive safety outcome data were reported. At that time, the company expected to enroll sufficient patients in 2019 to observe the required 125 events to unblind the study [&lt;ulink linkID="2132349" linkType="Reference"&gt;2132349&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non small cell lung cancer&lt;/subtitle&gt;In March 2015, Yakult Honsha was developing the drug  in a randomized phase II trial in Korean patients with NSCLC [&lt;ulink linkID="1645172" linkType="Reference"&gt;1645172&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2013, a phase I/II trial (&lt;ulink linkID="132049" linkType="Protocol"&gt;JapicCTI-132123&lt;/ulink&gt;) of resminostat (as YHI-1001) in combination with docetaxel was ongoing in patients in Japan with advanced, metastatic or recurrent non-small cell lung cancer who had received platinum-based chemotherapy [&lt;ulink linkID="1423486" linkType="Reference"&gt;1423486&lt;/ulink&gt;]. In July 2013, the first patient (total n = 118) was treated in the randomized and multi-center study, conducted by Yakult Honsha, to assess the safety and efficacy of resminostat and &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; combination versus docetaxel alone [&lt;ulink linkID="1456987" linkType="Reference"&gt;1456987&lt;/ulink&gt;]. In October 2014, the dose escalation phase I part of the trial  was completed and demonstrated that combination of resminostat and docetaxel was found to be safe and well tolerated in patients (n = 9) with NSCLC. At that time, the randomised  phase II part of the trial was initiated to compare the efficacy of docetaxel alone, with the combination therapy of resminostat and docetaxel [&lt;ulink linkID="1600171" linkType="Reference"&gt;1600171&lt;/ulink&gt;]. In September 2015, further data were presented at the IASLC 16th World conference on Lung Cancer in Denver, CO. Partial response (maintained for 30 weeks) was observed in one patient in the resminostat 400 mg/day + docetaxel group and stable disease was observed in three patients in the resminostat 600 mg/day + docetaxel group. Resminostat 600 mg/day + docetaxel (75 mg/m2) was determined as the recommended dose for phase II study [&lt;ulink linkID="1693080" linkType="Reference"&gt;1693080&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hodgkin's lymphoma&lt;/subtitle&gt;In August 2009, a phase II Hodgkin's lymphoma trial was to start later in 2009 [&lt;ulink linkID="1032344" linkType="Reference"&gt;1032344&lt;/ulink&gt;]. In December 2009, an international, multi-center, open-label, single-arm, Simon-design, two-stage, phase II proof-of-concept trial (&lt;ulink linkID="62900" linkType="Protocol"&gt;NCT01037478&lt;/ulink&gt;; 4SC-201-2-2009; SAPHIRE) was initiated in patients (expected n = 33) with relapsed Hodgkin's lymphoma in Poland, Romania and the Czech Republic. Subjects would receive 600 mg of oral resminostat for 5 consecutive days followed by 9 treatment-free days (1 cycle) for 6 cycles. Disease would be assessed at the end of 3 and 6 cycles using computed tomography and positron emission tomography. Patients showing a response or stable disease at the end of the main treatment period would be eligible to continue in a follow-up phase for up to 1 year of treatment. The primary endpoint was to determine the objective overall response rate. The secondary endpoints included assessment of progression-free survival, time-to-progression, duration of response, overall survival, safety and tolerability. The trial was expected to complete in July 2011 [&lt;ulink linkID="1068219" linkType="Reference"&gt;1068219&lt;/ulink&gt;], [&lt;ulink linkID="1068057" linkType="Reference"&gt;1068057&lt;/ulink&gt;], [&lt;ulink linkID="1103495" linkType="Reference"&gt;1103495&lt;/ulink&gt;]. In January 2010, the first patient was treated [&lt;ulink linkID="1068057" linkType="Reference"&gt;1068057&lt;/ulink&gt;]. In May 2010, enrollment was ongoing, and radiological imaging data from first Simon stage patient cohort showed that the drug reached the predefined clinical activity and the company decided to advance the drug into second Simon stage of patient recruitment. At that time, final results were expected in the second half of 2011 [&lt;ulink linkID="1103495" linkType="Reference"&gt;1103495&lt;/ulink&gt;]. In October 2010, data from the first Simon stage cohort (n = 18 patients) were presented at the Eighth International Symposium on Hodgkin Lymphoma in Cologne, Germany. Two partial responses were seen, and eight patients had stable disease. At that time, the option of increasing the dose to 800 mg had been implemented [&lt;ulink linkID="1141993" linkType="Reference"&gt;1141993&lt;/ulink&gt;]. In November 2010, similar  clinical data were presented at the 22nd EORTC-NCI-AACR Symposium in Berlin, Germany [&lt;ulink linkID="1146092" linkType="Reference"&gt;1146092&lt;/ulink&gt;]. In April 2011, similar  clinical data were reported [&lt;ulink linkID="1183842" linkType="Reference"&gt;1183842&lt;/ulink&gt;]. In August 2011, results showed the trial had met its primary endpoint. The overall response rate was 33.3% and a clinical benefit was seen in 54.5% of 33 evaluable patients. At that time, two patients were continuing therapy beyond the 12 weeks [&lt;ulink linkID="1220026" linkType="Reference"&gt;1220026&lt;/ulink&gt;]. In September 2011, similar data were reported [&lt;ulink linkID="1225473" linkType="Reference"&gt;1225473&lt;/ulink&gt;]. In December 2011, further data were presented at the 53rd ASH meeting in San Diego, CA. In 600- (n = 19 ) and 800-mg (n = 18) dose cohorts, the peak plasma levels of resminostat were achieved at Tmax value of 2 h. The pharmacokinetic profiles were similar in both the dose cohorts, after the first and consecutive administrations of resminostat. Resminostat showed reversible and time-dependent inhibition of HDAC activity and reached maximum at 2 h. Of 34  evaluable patients for overall objective response rate, 19 (55.6%) achieved clinical benefit from resminostat treatment. Of 34 patients, 12 were responders and 7 had stable disease (SD); another patient was still under treatment with SD for 30 weeks. Reduction of target tumor lesion size and metabolic activity was observed in 22 and 24 patients, respectively. Almost all the responders obtained a reduction in target tumor lesion size and metabolic activity. The median progression-free survival for responders and for patients with stable disease was 16.1 and 8.9 weeks, respectively. The time to response was 6 weeks for 8 patients and 12 weeks for 4 patients, in the responder group [&lt;ulink linkID="1243929" linkType="Reference"&gt;1243929&lt;/ulink&gt;]. In June 2012, further data were presented at the 17th EHA Annual Congress in Amsterdam, the Netherlands.  A transient enzymatic HDAC activity inhibition was observed with a maximum median inhibition of up to 94% reached at 2 h post dose. A good correlation was observed between the resminostat pharmacokinetic and pharmacodynamic effects and the maximum inhibition of enzyme that corresponded to the median peak plasma levels of resminostat between 1 and 1.5 h. At that time, study of resminostat as monotherapy or as a sensitizing agent in combination with established treatment regimen in solid tumors was ongoing [&lt;ulink linkID="1301908" linkType="Reference"&gt;1301908&lt;/ulink&gt;]. In September  2013, data were presented at the ILCA and ECCO conferences in Washington, DC, and Amsterdam, Netherlands, respectively. Data from biomarker analysis  demonstrated that   patients with a high level of  ZFP64 biomarker  responded especially well to treatment with resminostat. Around two-thirds of patients had elevated ZFP64 blood levels before treatment commenced which translated into a statistically significant   doubling of overall survival for the patient group  [&lt;ulink linkID="1497448" linkType="Reference"&gt;1497448&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;HCC&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2012, discussions with regulatory authorities were underway for a registration HCC trial  [&lt;ulink linkID="1267924" linkType="Reference"&gt;1267924&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2015, Yakult Honsha was developing the drug  in a randomized phase II trial in Korean patients with HCC [&lt;ulink linkID="1645172" linkType="Reference"&gt;1645172&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, discussions with regulatory agencies and potential partners were ongoing to prepare the clinical steps to evaluate resminostat in combination with sorafenib in a pivotal trial for the treatment of first-line HCC towards market approval [&lt;ulink linkID="1456987" linkType="Reference"&gt;1456987&lt;/ulink&gt;].  In November 2013, the phase IIb/III registration  trial was expected to begin in mid-2014 [&lt;ulink linkID="1497448" linkType="Reference"&gt;1497448&lt;/ulink&gt;]. In February 2014, it was reported at the  21st Annual Molecular Medicine Tri-Conference in San Francisco, CA, that the expected enrollment was 270 and 380 patients for the phase II and III stages, respectively. The trial was to be an integrated study with an adaptive design that would include ZFP64 biomarker analysis [&lt;ulink linkID="1525483" linkType="Reference"&gt;1525483&lt;/ulink&gt;]; in August 2014, the company planned to file an IND with the FDA before the end of 2014 [&lt;ulink linkID="1583829" linkType="Reference"&gt;1583829&lt;/ulink&gt;]. In February 2016, the company received an IND approval from the US FDA [&lt;ulink linkID="1737438" linkType="Reference"&gt;1737438&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2012, the company had planned to initiate a pivotal  trial to evaluate resminostat in combination with &lt;ulink linkID="29831" linkType="Drug"&gt;sorafenib&lt;/ulink&gt; as a second line treatment in patients with advanced HCC, and at that time, discussions with regulatory authorities were underway   [&lt;ulink linkID="1267924" linkType="Reference"&gt;1267924&lt;/ulink&gt;]. By March 2012, the company expected to initiate the trial in the first half of 2013 [&lt;ulink linkID="1289459" linkType="Reference"&gt;1289459&lt;/ulink&gt;]; in September 2012, a phase III pivotal trial was expected to begin in mid-2013    [&lt;ulink linkID="1323697" linkType="Reference"&gt;1323697&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2013, the first patient was treated in a multi-center, dose-escalation, randomized, phase I/II trial in patients (expected n = 164) with  hepatocellular carcinoma (HCC) in Japan. The trial was to evaluate the safety, tolerability and pharmacokinetics with maximum tolerated dose (MTD) and potential dose-limiting toxicities (DLT) of the resminostat and &lt;ulink linkID="29831" linkType="Drug"&gt;sorafenib&lt;/ulink&gt; combination. The phase II part would compare the efficacy of sorafenib alone with the combination therapy of resminostat and sorafenib as a first-line treatment of patients with advanced HCC with a daily dose of 800 mg sorafenib as monotherapy in the control arm of the study or in combination with up to 600 mg/day resminostat in the second study arm [&lt;ulink linkID="1428911" linkType="Reference"&gt;1428911&lt;/ulink&gt;]. In September 2014, the phase I part of the trial was completed in  patients (n = 9) with advanced HCC . The drug was found to be safe and well tolerated. At that time, the randomised phase II part was initiated in patients (n = 140) with advanced HCC [&lt;ulink linkID="1596397" linkType="Reference"&gt;1596397&lt;/ulink&gt;]. In February 2016, data from the trial were expected later in 2016 [&lt;ulink linkID="1737438" linkType="Reference"&gt;1737438&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2009, a phase IIa, non-randomized, open-label, proof-of-concept study (&lt;ulink linkID="59008" linkType="Protocol"&gt;NCT00943449&lt;/ulink&gt;; 4SC-201-1-2009; SHELTER) was initiated in Germany and Italy to evaluate  safety, efficacy and pharmacokinetics. Patients (n = 62) with progressive, refractory hepatocellular carcinoma would receive repeated oral doses of resminostat alone or  in combination with sorafenib. The primary outcome measure was progression-free survival rate (PFSR) over 12 weeks, and the study was expected to be completed by December 2010 [&lt;ulink linkID="1027818" linkType="Reference"&gt;1027818&lt;/ulink&gt;], [&lt;ulink linkID="1603861" linkType="Reference"&gt;1603861&lt;/ulink&gt;]. In August 2009, patient dosing began in the two-arm trial of resminostat as a second-line treatment for HCC. The maximum tolerated dose (MTD) of resminostat would be determined by dose-escalation from 200 to 600 mg of resminostat in combination with sorafenib. The 15 patients in the first trial arm would receive the MTD of resminostat daily for the first 5 days of a 14-day cycle plus sorafenib every day for all 14 days. The 15 patients in the second arm would receive 600 mg of resminostat daily for the first 5 days of a 14-day cycle, after discontinuation of sorafenib at the start of the trial. Cycles would be repeated until disease progression. After 6 and 12 weeks, radiological tumor stagings would be performed. An extension phase would enroll ten extra patients into each arm, depending on data from the initial subjects. Secondary endpoints included time-to-progression, PFSR estimated at 6 weeks and beyond 12 weeks, overall survival, drug safety, tolerability, pharmacokinetics and biomarkers [&lt;ulink linkID="1034611" linkType="Reference"&gt;1034611&lt;/ulink&gt;]. An extension study of up to 10 additional patients per arm would be available [&lt;ulink linkID="1055354" linkType="Reference"&gt;1055354&lt;/ulink&gt;]. In September 2010, data from the first nine patients were presented at Viszeralmedizin 2010 Symposium in Stuttgart, Germany. Results after 6 weeks showed 6 of 9 patients had stable disease (SD), while 3 of 4 patients at 12 weeks also SD with 1 patient achieving SD for 36 weeks [&lt;ulink linkID="1131705" linkType="Reference"&gt;1131705&lt;/ulink&gt;]. In November 2010, similar data were presented at CHI's  Fourth Annual HDAC Inhibitors Conference in Boston, MA [&lt;ulink linkID="1149610" linkType="Reference"&gt;1149610&lt;/ulink&gt;]. In November 2010, similar  data were presented at the 22nd EORTC-NCI-AACR Symposium in Berlin, Germany [&lt;ulink linkID="1146092" linkType="Reference"&gt;1146092&lt;/ulink&gt;]. In April 2011, data from the first 13 patients were reported. Results after 6 weeks showed nine of the 13 patients had SD, while six of 11 patients at 12 weeks also displayed continued disease stabilization [&lt;ulink linkID="1183842" linkType="Reference"&gt;1183842&lt;/ulink&gt;]. In June 2011, interim data from the phase I/II trial in 72 patients were presented at the ESMO 13th World Congress on Gastrointestinal Cancer in Barcelona, Spain. Results after six weeks showed 11 out of 18 (61%) patients showed tumor stabilization, while eight out of 16 (50%) patients at 12 weeks displayed continuous SD either on sorafenib and resminostat or resminostat alone [&lt;ulink linkID="1203037" linkType="Reference"&gt;1203037&lt;/ulink&gt;], [&lt;ulink linkID="1203232" linkType="Reference"&gt;1203232&lt;/ulink&gt;]. Later that month, further data were presented at the 47th ASCO meeting in Chicago, IL. There was a dose-dependent increase in plasma exposure to resminostat on Day 1 (cycle 1) with mean AUC (0 to 6 h) value of 10.5 h.mg/l at 600 mg (monotherapy) and 9.01 h. mg/l at dose level 3. There was no major change in the pharmacokinetics of resminostat when administered with or without sorafenib. Stable disease was observed in 9 out of 14 patients examined after 6 weeks, and 7 out of 13 patients after 12 weeks [&lt;ulink linkID="1196589" linkType="Reference"&gt;1196589&lt;/ulink&gt;]. In January 2012, further data from the trial were reported from 15 evaluable patients demonstrating the drug to have met the primary endpoint of the study, halting of further progression in at least 20% of patients for at least 12 weeks, ahead of schedule. Resminostat plus sorafenib had a PFSR of 66.6% with a median progression-free survival (PFS) of 4.6 months after the 12 weeks. The PFSR for 9 evaluable patients treated with resminostat alone was 33.3% and PFS was 1.4 months [&lt;ulink linkID="1256351" linkType="Reference"&gt;1256351&lt;/ulink&gt;]. In the same month, further data were presented at the 2012 ASCO Gastrointestinal Cancer Symposium in San Francisco, CA. Interim results showed 15 out of 27 patients (56%) assessed after 6 weeks of treatment and 11 out of 24 assessed after 12 weeks displayed SD. One patient treated with 400 mg of resminostat had persistent SD  that lasted for more than one year and  good long-term tolerability was observed [&lt;ulink linkID="1261040" linkType="Reference"&gt;1261040&lt;/ulink&gt;].  In March 2012, further data were presented at Bio-Europe Spring 2012 in Amsterdam, the Netherlands. The PFSR at 20 weeks was 4 out of 11 (36.4%) and 4 out of 20 (20%) patients, excluding and including withdrawals, respectively, for the combination, compared with 0 out of 8 and 0 out 11, respectively, on resminostat alone  [&lt;ulink linkID="1274014" linkType="Reference"&gt;1274014&lt;/ulink&gt;]. Later that month, final data were expected in 2012 [&lt;ulink linkID="1289459" linkType="Reference"&gt;1289459&lt;/ulink&gt;]. In May 2012, results were published. The final PFSR was 70% after 12 weeks, which was a slight improvement on the data published in January 2012. The final analysis data showed the median PFS as 4.7 months in the combination treatment group. At that time, four patients were continuing the combination therapy and one patient was continuing the monotherapy beyond the first 12 weeks of treatment. For the monotherapy group, PFSR was 35.7% and PFS in five out of the 14 patients was found to be 2.2 months [&lt;ulink linkID="1296004" linkType="Reference"&gt;1296004&lt;/ulink&gt;]. These data were presented at the 48th ASCO meeting in Chicago, IL in June 2012 [&lt;ulink linkID="1299529" linkType="Reference"&gt;1299529&lt;/ulink&gt;]. In June 2012, further data were presented at the 14th World Congress of Gastrointestinal Cancer of the European Society for Medical Oncology (ESMO GI meeting) in Barcelona, Spain. Data showed that the combination of resminostat and sorafenib to be generally well tolerated in all the study groups, and no dose limiting toxicity was observed in the fourth study group (DL4), which had the highest dose of 600 mg resminostat    combined with the approved maximal 800 mgdose of sorafenib (n = 6). At that time, PFSR was calculated at 40% (not the final value) in the monotherapy group after 12 weeks, and the median PFS was expected to be in the range of 2.0 to 2.5 months finally [&lt;ulink linkID="1305044" linkType="Reference"&gt;1305044&lt;/ulink&gt;. In September 2012, data from the  trial were presented at the International Liver Cancer Association (ILCA) in Berlin, Germany and data demonstrated the significant median overall survival (OS) of 8.1 months in the resminostat/sorafenib combination ITT population (n=26) which was correlating to the previously obtained results that included a median PFS of 4.7 months [&lt;ulink linkID="1323697" linkType="Reference"&gt;1323697&lt;/ulink&gt;], [&lt;ulink linkID="1603861" linkType="Reference"&gt;1603861&lt;/ulink&gt;]; in May 2013, further analysis data were expected to be published later that year [&lt;ulink linkID="1422514" linkType="Reference"&gt;1422514&lt;/ulink&gt;]. In September  2013, data were presented at the ILCA and ECCO conferences in Washington, DC, and Amsterdam, Netherlands, respectively. Data from biomarker analysis  demonstrated that   patients with a high level of  ZFP64 biomarker  responded especially well to treatment with resminostat. Around two-thirds of patients had elevated ZFP64 blood levels before treatment commenced which translated into a statistically significant   doubling of overall survival for the patient group. Patient characteristics before the start of treatment with resminostat correlated with an extension of overall survival [&lt;ulink linkID="1497448" linkType="Reference"&gt;1497448&lt;/ulink&gt;]. In October 2014, the company reported that the median PFS was 5.4 months in the combination treatment group [&lt;ulink linkID="1603861" linkType="Reference"&gt;1603861&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;In March 2010, a phase I/II study of the drug in combination with FOLFIRI chemotherapy for the second-line treatment of colorectal tumors with KRAS mutations was expected to begin in 2010 [&lt;ulink linkID="1086499" linkType="Reference"&gt;1086499&lt;/ulink&gt;]. In January 2011, the randomized, open-label, multicenter, two-arm phase I/II SHORE study (&lt;ulink linkID="73773" linkType="Protocol"&gt;NCT01277406&lt;/ulink&gt;) was initiated in patients (expected n =  80) with advanced and metastatic colorectal cancer in Germany. An initial dose-escalation phase was to be conducted in 20 patients to determine the maximum tolerated dose of the drug in combination with FOLFIRI. At that time, the trial was estimated to  complete in June 2014  [&lt;ulink linkID="1162426" linkType="Reference"&gt;1162426&lt;/ulink&gt;], [&lt;ulink linkID="1162530" linkType="Reference"&gt;1162530&lt;/ulink&gt;]. In April 2011, it was reported that the first patient was dosed in January 2011 [&lt;ulink linkID="1183842" linkType="Reference"&gt;1183842&lt;/ulink&gt;].  In June 2011, data were presented at the ESMO 13th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The first dose level of 200 mg was completed in the dose escalation portion of the trial, with no observed toxicity and at that time dose-ranging part of the study was expected to complete in 2012 [&lt;ulink linkID="1203037" linkType="Reference"&gt;1203037&lt;/ulink&gt;], [&lt;ulink linkID="1203339" linkType="Reference"&gt;1203339&lt;/ulink&gt;]. In September 2011, initial results were expected in 2012 [&lt;ulink linkID="1225473" linkType="Reference"&gt;1225473&lt;/ulink&gt;]. In December 2012, positive interim results from the phase I part of the study conducted in 15 patients were reported. Data demonstrated that the combination therapy possessed a good safety, tolerability and pharmacokinetic profile. Data also showed that combination therapy would be administered for a long period of time (up to 33 weeks) with observed stabilization of tumor diseases. At that time, the company expected to initiate the phase II portion of the trial in 2013, to evaluate the progression free-survival and clinical efficacy of combination therapy in advanced CRC patients [&lt;ulink linkID="1349848" linkType="Reference"&gt;1349848&lt;/ulink&gt;]; in May 2013, data were expected to be reported in 12 to 18 months [&lt;ulink linkID="1422514" linkType="Reference"&gt;1422514&lt;/ulink&gt;]. In June 2013, data were presented at the 49th ASCO Meeting in Chicago, IL. The mean Cmax and AUC values of resminostat at 400 and 600 mg qd were 3.01 and 4.48 mg/l, respectively, and 6.94 and 11.8 h.mg/l, respectively. The mean t1/2 ranged from 1.6 to 2.2 h. Cmax and AUC of resminostat were found to increase dose-dependently.Stable disease was observed in 7 patients for 12 weeks. Stable disease for over 12 treatment cycles was observed in one patient treated with resminostat at 400 mg bid [&lt;ulink linkID="1427519" linkType="Reference"&gt;1427519&lt;/ulink&gt;]. In July 2015, further data were presented at the Sixth Annual EpiCongress Boston Conference, in Boston, MA, whereby   resminostat inhibited HDAC1/3/6 and was well tolerated when compared with other HDAC inhibitors [&lt;ulink linkID="1681522" linkType="Reference"&gt;1681522&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Biliary tract cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2017, Yakult was planning to initiate a phase II trial in patients with BTC in Japan [&lt;ulink linkID="1989353" linkType="Reference"&gt;1989353&lt;/ulink&gt;]; in March 2018, the randomized, double-blind,  interventional, multicenter, placebo-controlled trial (&lt;ulink linkID="312689" linkType="Protocol"&gt;JapicCTI-183883&lt;/ulink&gt;) was initiated in Japan to assess the efficacy of S-1 plus resminostat versus S-1 plus placebo in patients (expected n = 100) with platinum-gemcitabine combination unresectable/recurrence BTC (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or carcinoma of the ampulla of vater). The primary endpoint was progression free survival (PFS). At that time, the trial was expected to complete in May 2020 [&lt;ulink linkID="2020387" linkType="Reference"&gt;2020387&lt;/ulink&gt;]. In August 2018, final results were expected in mid-2020 [&lt;ulink linkID="2062018" linkType="Reference"&gt;2062018&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In April 2015, 4SC reported that Yakult Honsha treated the first patient in   a multicenter, open-label, two-part, safety, tolerability,pharmacokinetics and efficacy phase I trial (&lt;ulink linkID="232079" linkType="Protocol"&gt;JapicCTI-152864&lt;/ulink&gt;) of resminostat in combination with S-1 chemotherapy in Japan in advanced pancreatic (PC) and/or biliary tract (BTC) cancer patients (n = 44) to determine dose limiting toxicities of various dose regimens for potential   phase II trials. The trial was expected to complete in September 2016  [&lt;ulink linkID="1673578" linkType="Reference"&gt;1673578&lt;/ulink&gt;], [&lt;ulink linkID="1676138" linkType="Reference"&gt;1676138&lt;/ulink&gt;], [&lt;ulink linkID="1684264" linkType="Reference"&gt;1684264&lt;/ulink&gt;]. In September 2017, data from this trial were presented at the ESMO 2017 Congress in Madrid, Spain. In the first part of the study, 3 regimens were tested: daily resminostat (200 mg) on days 1 to 14 of 21 (n = 6); resminostat (200 mg qd) plus S-1 (80 to 120mg/day bid) both on days 1 to 14 of 21 (n = 5); and resminostat (200 mg qd) on days 1 to 5 and 8 to 12 plus S-1 (80 to 120 mg/day bid) on days 1 to 14 of 21 (n = 6). No DLTs were reported in regimen 1, with one DLT in each of regimens 2 and 3 of decreased appetite (grade 2) and stomatitis (grade 3), respectively. Early dose reduction occurred in 80 and 33% of the patients in regimens 2 and 3, respectively; thus, regimen 2 was judged not tolerable and regimen 3 was selected for use in the second part of the study. Across the entire trial, adverse events were reported in all patients dosed (total n = 27), with grade &amp;gt;/= 3 events reported in 1 and 7 patients in regimens 2 and 3, respectively. The most common adverse events were thrombocytopenia, decreased appetite and nausea. Of all patients who received regimen 3 (n = 16), one had a partial response and 12 had stable disease, with response (complete + partial response) and disease control (complete + partial response and stable disease) rates of 6.3 and 81.3%, respectively. The median progression-free and overall survival (PFS and OS) were 3.1 and 8 months, respectively. In BTC patients the response and disease control rates were 7.7 and 86.4%, respectively, compared with 0 and 66.7%, respectively, in PC patients. The median PFS was 5.5 versus 2.3 months in BTC and PC patients, respectively, and the OS was 10.2 versus 4.7 months, respectively. In all BTC patients who received second-line study treatment, tumor shrinkage or stabilization was observed [&lt;ulink linkID="1960346" linkType="Reference"&gt;1960346&lt;/ulink&gt;], [&lt;ulink linkID="1960305" linkType="Reference"&gt;1960305&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2012, 4SC reported that Yakult Honsha initiated an open-arm, dose-escalating, safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics  phase I trial of  resminostat in patients with advanced solid tumors, in Japan. At that time, the first patient was treated [&lt;ulink linkID="1291023" linkType="Reference"&gt;1291023&lt;/ulink&gt;]. In May 2014, the trial was completed. Data demonstrated that the drug was safe and well tolerated in all the doses and showed a clean safety profile in 12 Japanese patients. At that time, data from the trial were expected to be published [&lt;ulink linkID="1553424" linkType="Reference"&gt;1553424&lt;/ulink&gt;]. In July 2014,  data from the trial were presented at the 12th Annual JSMO Meeting in Fukuoka, Japan. Histone H4 acetylation was increased in all dose groups, indicating pharmacodynamic activity of the agent. No DLTs were reported and the MTD was not reached [&lt;ulink linkID="1608799" linkType="Reference"&gt;1608799&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2008, phase l trials were still ongoing [&lt;ulink linkID="931166" linkType="Reference"&gt;931166&lt;/ulink&gt;]. In October 2008, data from a dose-escalating, phase I trial, being conducted at the Royal Marsden Hospital in Sutton, England, were reported. In the study, 18 patients were treated with oral resminostat (100, 200, 400, 600 or 800 mg) once a day for 5 days, followed by a 9-day rest period. Resminostat demonstrated a good safety and tolerability profile and a beneficial pharmacological profile. Some cancer types stabilized toward the end of the study and in some cases therapy has been extended and reached up to 6 months. In the 600 mg dose group all patients achieved stable disease and the 800 mg arm was expected to conclude shortly. The drug's half-life was 3 to 4 h [&lt;ulink linkID="956489" linkType="Reference"&gt;956489&lt;/ulink&gt;]. In October 2008, similar clinical data were presented at the 20th EORTC-NCI-AACR meeting in Geneva, Switzerland [&lt;ulink linkID="951583" linkType="Reference"&gt;951583&lt;/ulink&gt;]. In December 2008, results showed the 800 mg dose was well tolerated. At that time, patient enrollment was concluded. Final data were expected in the first quarter of 2009 [&lt;ulink linkID="969764" linkType="Reference"&gt;969764&lt;/ulink&gt;]. In June 2009, positive results from the phase I trial were presented at the 45th ASCO meeting in Orlando, FL. Resminostat was generally well tolerated, and 11 of 18 patients exhibited stable disease after three or four cycles of treatment, including five of the six patients in the 800 mg cohort, with one patient remaining stable on a dose of 400 mg for more than 1 year. No dose limiting toxicities were observed, and the maximum tolerated dose was not reached. The optimal dose for future phase II trials was judged to be 600 mg [&lt;ulink linkID="1006615" linkType="Reference"&gt;1006615&lt;/ulink&gt;]. In September 2009, similar data were presented at the European Multidisciplinary Cancer conference ECCO 15 - ESMO 34, the joint congress of the European Cancer Organisation in Berlin, Germany [&lt;ulink linkID="1043077" linkType="Reference"&gt;1043077&lt;/ulink&gt;]. In November 2010, similar data were presented at CHI's  Fourth Annual HDAC Inhibitors Conference in Boston, MA. Additionally, pharmacokinetic data from these patients showed a Tmax of 2 h and a half-life of 3 h [&lt;ulink linkID="1149610" linkType="Reference"&gt;1149610&lt;/ulink&gt;]. In November 2010, similar data from the trial were presented at the 22nd EORTC-NCI-AACR Symposium in Berlin, Germany. An increase in heart rate was seen but no dose-limiting toxicities were seen with regard to cardiac safety in all dose cohorts and no severe cases of arrhythmias were observed [&lt;ulink linkID="1146089" linkType="Reference"&gt;1146089&lt;/ulink&gt;], [&lt;ulink linkID="1146092" linkType="Reference"&gt;1146092&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Other studies&lt;/subtitle&gt;In March 2015, it was observed that the drug improved the effect of checkpoint inhibitors (PD1/PDL1) and other  antibodies like &lt;ulink linkID="6736" linkType="Drug"&gt;rituximab&lt;/ulink&gt; or immunostimulating agents (e.g. TLR ligands), when applied in combination therapy with these drugs in the clinic [&lt;ulink linkID="1645172" linkType="Reference"&gt;1645172&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2018, in vitro data were presented at the 30th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. In CTCL cells, resminostat modulated progression-associated genes, represses skin-homing receptor genes; shifted expression from unfavorable Th2 to favorable Th1 genes; and also reduced expression of pruritus markers [&lt;ulink linkID="2094725" linkType="Reference"&gt;2094725&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2016, preclinical data were presented at the 28th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics in Munich, Germany. In CTCL cell lines (HH, HuT78, MyLa CD4+), resminostat (3 microM for 3 h) induced increase in protein acetylation. Resminostat displayed growth inhibitory potency in three CTCL cell lines and showed only moderate effect on cell cycle but apoptotic cell fraction was increased [&lt;ulink linkID="1878141" linkType="Reference"&gt;1878141&lt;/ulink&gt;]. Further preclinical data were presented at same conference. Resminostat in combination with rituximab efficiently killed B cell lymphoma and resulted in a strong increase of U2932 cell lysis [&lt;ulink linkID="1878156" linkType="Reference"&gt;1878156&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2016, data from cell culture studies   demonstrated that resminostat  enhanced the effect of immunotherapeutic anti-cancer compounds such as rituximab. Resminostat alone caused the natural killer cells of the immune system to better recognize cancer cells and fight them more effectively. Studies in non-Hodgkin's lymphoma cancer cell lines were planned with   resminostat and rituximab  as single agents and as a combination. At that time, data were expected to be presented at the Cancer Immonotherapy and Combinations Congressas part of the World Preclinical Congress, in Boston, MA [&lt;ulink linkID="1773717" linkType="Reference"&gt;1773717&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2015, additional preclinical studies were planned to be initiated. 4SC expected to initiate cell culture and animal model studies to investigate the properties of resminostat as immunomodulator, potential combination with immunotherapy agents, including checkpoint inhibitors, further research on its mechanism of action, potential combinations with other cancer therapies and other potential indications    [&lt;ulink linkID="1699030" linkType="Reference"&gt;1699030&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2015, resminostat had demonstrated efficacy in CTCL [&lt;ulink linkID="1684264" linkType="Reference"&gt;1684264&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By June 2015, the drug had shown positive results in pancreatic and  biliary tract cancer  in preclinical models [&lt;ulink linkID="1673578" linkType="Reference"&gt;1673578&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015 preclinical data were reported in hepatocellular HepG2, Huh7, and SNU475 and adenocarcinomic A549 cellular systems at  the ECCO ITOC conference 2015 in Munich, Germany. Data demonstrated that the  drug strongly reduced the expression of immunosuppression mediating enzymes, IDO1 and ARG1 thus rendered the tumor microenvironment sensitive against immune cell based anti tumor activities, and also enhanced the expression of several cancer antigens and MHC class I molecules, on several tumor cell lines thus making tumour cells more visible for recognition by the T cells of the immune system which in consequence leads to a more efficacious elimination of the tumor cells, also upregulation of NK cell ligands and a strong boost of NK cells  by resminostat was observed which effectively completes the new discoveries on epigenetic impact on immunotherapy [&lt;ulink linkID="1645172" linkType="Reference"&gt;1645172&lt;/ulink&gt;]. In July 2015,  further data were presented at the Sixth Annual EpiCongress Boston Conference, in Boston, MA. It blocked programmed cell death 1 (PD1)/PD-ligand (L)1  and enhanced expression of tumor-associated antigens, up-regulated MHC class II, and stimulated conversion of tumor cells to normal  [&lt;ulink linkID="1681522" linkType="Reference"&gt;1681522&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2015, preclinical data were reported. Data demonstrated that the resminostat had shown that it had effectively inhibited epithelial-mesenchymal transition (EMT) [&lt;ulink linkID="1645172" linkType="Reference"&gt;1645172&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2014, preclinical data were presented at the 105th AACR meeting in San Diego, CA. Resminostat induced G1 and G2/M phase arrest at lower and higher concentrations, respectively. Resminostat in combination with docetaxel showed synergistic/additive effects and also enhanced docetaxel-induced alpha-tubulin polymerization. In NCI-H460 tumor bearing mice, resminostat (90 mg/kg) increased levels of acetylated, histone h3 and alpha-tubulin, along with increase in p21 expression [&lt;ulink linkID="1540297" linkType="Reference"&gt;1540297&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2009, the drug was undergoing preclinical trials against various solid tumors in combination with different chemotherapeutic agents [&lt;ulink linkID="1055354" linkType="Reference"&gt;1055354&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2009, preclinical studies had demonstrated that the drug was a potent inhibitor  of  liver cancer cell growth, and that it synergized with sorafenib   against liver cancer cell growth  [&lt;ulink linkID="1034611" linkType="Reference"&gt;1034611&lt;/ulink&gt;]. In September 2009, similar data were presented at the European Multidisciplinary Cancer conference ECCO 15 - ESMO 34, the joint congress of the European Cancer Organisation in Berlin, Germany [&lt;ulink linkID="1043077" linkType="Reference"&gt;1043077&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In June 2008, 4SC planned to acquire all rights to eight of Nycomed's oncology programs [&lt;ulink linkID="931311" linkType="Reference"&gt;931311&lt;/ulink&gt;]. In July 2008, 4SC completed its acquisition of the programs. This included resminostat [&lt;ulink linkID="931166" linkType="Reference"&gt;931166&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28108">4SC AG</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-07-21T00:00:00.000Z</StatusDate><Source id="1027818" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3146">Gallbladder tumor</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate><Source id="2020387" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1765">Cholangiocarcinoma</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate><Source id="2020387" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2013-05-21T00:00:00.000Z</StatusDate><Source id="1428911" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28108">4SC AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="161">Hodgkins disease</Indication><StatusDate>2009-12-22T00:00:00.000Z</StatusDate><Source id="1068219" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28108">4SC AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1115">Mycosis fungoides</Indication><StatusDate>2016-11-30T00:00:00.000Z</StatusDate><Source id="1872014" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1515">Biliary tumor</Indication><StatusDate>2018-03-31T00:00:00.000Z</StatusDate><Source id="2020387" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28108">4SC AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-07-21T00:00:00.000Z</StatusDate><Source id="1027818" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28108">4SC AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2011-01-10T00:00:00.000Z</StatusDate><Source id="1162530" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2013-05-01T00:00:00.000Z</StatusDate><Source id="1423486" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2015-04-14T00:00:00.000Z</StatusDate><Source id="1650569" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18053">The Menarini Group</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2015-04-14T00:00:00.000Z</StatusDate><Source id="1650569" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28108">4SC AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1756">Sezary syndrome</Indication><StatusDate>2016-11-30T00:00:00.000Z</StatusDate><Source id="1872014" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2012-05-15T00:00:00.000Z</StatusDate><Source id="1291023" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="249">Pancreas tumor</Indication><StatusDate>2015-04-01T00:00:00.000Z</StatusDate><Source id="1676138" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2011-04-14T00:00:00.000Z</StatusDate><Source id="1183842" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28108">4SC AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="161">Hodgkins disease</Indication><StatusDate>2011-09-26T00:00:00.000Z</StatusDate><Source id="1225473" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28108">4SC AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2014-08-07T00:00:00.000Z</StatusDate><Source id="1583829" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2015-04-14T00:00:00.000Z</StatusDate><Source id="1650569" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2015-04-14T00:00:00.000Z</StatusDate><Source id="1650569" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-07-31T00:00:00.000Z</StatusDate><Source id="931166" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2011-04-14T00:00:00.000Z</StatusDate><Source id="1183842" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2015-03-26T00:00:00.000Z</StatusDate><Source id="1645172" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2015-03-26T00:00:00.000Z</StatusDate><Source id="1645172" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28108">4SC AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1754">Cutaneous T-cell lymphoma</Indication><StatusDate>2015-06-26T00:00:00.000Z</StatusDate><Source id="1673578" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20961">Yakult Honsha Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1515">Biliary tumor</Indication><StatusDate>2015-04-01T00:00:00.000Z</StatusDate><Source id="1676138" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14069">Takeda GmbH</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-10-12T00:00:00.000Z</StatusDate><Source id="635353" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1002503">Takeda Pharmaceuticals International GmbH</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2007-01-16T00:00:00.000Z</StatusDate><Source id="758163" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28108">4SC AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-07-31T00:00:00.000Z</StatusDate><Source id="931166" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28108">4SC AG</OwnerCompany><Country id="EU">EU</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2016-07-15T00:00:00.000Z</MileStoneDate><Source id="1208834" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28108">4SC AG</OwnerCompany><Country id="EU">EU</Country><Indication id="161">Hodgkins disease</Indication><AwardedIndication>Treatment of Hodgkins lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2011-12-09T00:00:00.000Z</MileStoneDate><Source id="1255531" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28108">4SC AG</OwnerCompany><Country id="EU">EU</Country><Indication id="161">Hodgkins disease</Indication><AwardedIndication>Treatment of Hodgkins lymphoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2011-10-07T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28108">4SC AG</OwnerCompany><Country id="EU">EU</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2011-09-27T00:00:00.000Z</MileStoneDate><Source id="1230604" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28108">4SC AG</OwnerCompany><Country id="US">US</Country><Indication id="161">Hodgkins disease</Indication><AwardedIndication>Treatment of Hodgkin's lymphoma.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2011-09-16T00:00:00.000Z</MileStoneDate><Source id="1225473" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="28108">4SC AG</OwnerCompany><Country id="US">US</Country><Indication id="1767">Hepatocellular carcinoma</Indication><AwardedIndication>Treatment of hepatocellular carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2011-06-29T00:00:00.000Z</MileStoneDate><Source id="1206851" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00167"><Name>Arginase-I</Name><SwissprotNumbers><Swissprot>P05089</Swissprot><Swissprot>P07824</Swissprot><Swissprot>P30759</Swissprot><Swissprot>P37818</Swissprot><Swissprot>Q61176</Swissprot><Swissprot>Q95JC8</Swissprot><Swissprot>Q95KM0</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00922"><Name>Histone deacetylase</Name><SwissprotNumbers><Swissprot>O22446</Swissprot><Swissprot>P56521</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00923"><Name>Histone deacetylase-1</Name><SwissprotNumbers><Swissprot>O09106</Swissprot><Swissprot>O42227</Swissprot><Swissprot>P56517</Swissprot><Swissprot>P56518</Swissprot><Swissprot>Q13547</Swissprot><Swissprot>Q91695</Swissprot><Swissprot>Q94517</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00924"><Name>Histone deacetylase-2</Name><SwissprotNumbers><Swissprot>P56519</Swissprot><Swissprot>P70288</Swissprot><Swissprot>Q92769</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00925"><Name>Histone deacetylase-3</Name><SwissprotNumbers><Swissprot>O15379</Swissprot><Swissprot>O88895</Swissprot><Swissprot>P56520</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00928"><Name>Histone deacetylase-6</Name><SwissprotNumbers><Swissprot>Q9UBN7</Swissprot><Swissprot>Q9Z2V5</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2167964" linkType="reference" linkID="2167964"&gt;2167964&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="18053">The Menarini Group</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20961">Yakult Honsha Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24293">German Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28108">4SC AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>4</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="114380" title="4SC acquires eight oncology programs from Nycomed"/><Deal id="134523" title="Yakult Honsha to develop and commercialize 4SC's resminostat for HL, CRC, HCC and other selected cancer indications in Japan"/><Deal id="153994" title="Menarini AP to develop and market 4SC's resminostat against cancer in APAC regions excluding Japan "/><Deal id="156484" title="German Federal Ministry of Education and Research to award 4SC funding for preclinical research on resminostat and 4SC-202 against cancer     "/></Deals><PatentFamilies><PatentFamily id="1689251" number="WO-2005087724" title="Novel amido-substituted hydroxy-6-phenylphenanthridines"/><PatentFamily id="1944355" number="WO-2009112529" title="Novel method for the production of sulphonylpyrroles as HDAC inhibitors"/><PatentFamily id="2125538" number="WO-2007039403" title="Sulphonylpyrrole hydrochloride salts as histone deacetylases inhibitors"/><PatentFamily id="2834563" number="WO-2014187894" title="Gene expression biomarkers and their use for diagnostic and prognostic application in patients potentially in need of HDAC inhibitor treatment"/><PatentFamily id="3820810" number="WO-2017178577" title="Medical application of resminostat in asian patients"/><PatentFamily id="4221186" number="WO-2018184678" title="Hdac inhibitor in combination with vegf / vegfr interaction inhibitor for cancer therapy based on platelet count"/><PatentFamily id="4419512" number="WO-2019043176" title="HDAC Inhibitor in combination with antimetabolite agent for cancer therapy"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Menarini Group" id="18053"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Yakult Honsha Co Ltd" id="20961"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="4SC AG" id="28108"/><CountAsOwner>7</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>7</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="61129"><DrugName>aurora kinase inhibitors (cancer), Amgen</DrugName><DrugSynonyms><Name><Value>aurora kinase inhibitors (cancer), Amgen</Value></Name></DrugSynonyms><CompanyOriginator id="14109">Amgen Inc</CompanyOriginator><CompaniesSecondary><Company id="14109">Amgen Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="14109" type="Company"><TargetEntity id="4295905537" type="organizationId">Amgen Inc</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="4420" type="Action"><TargetEntity id="1798" type="Mechanism">Aurora-A (ARK1) Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4418" type="Action"><TargetEntity id="1386" type="Mechanism">Aurora-B (ARK2) Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00183" type="ciTarget"><TargetEntity id="100768792123" type="siTarget">Aurora kinase B</TargetEntity><TargetEntity id="-624614447" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-00184" type="ciTarget"><TargetEntity id="100768367903" type="siTarget">Aurora kinase A</TargetEntity><TargetEntity id="-2076917160" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="4420">Aurora protein kinase 2 inhibitor</Action><Action id="4418">Aurora protein kinase 1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2012-11-16T15:48:10.000Z</LastModificationDate><ChangeDateLast>2016-05-27T00:00:00.000Z</ChangeDateLast><AddedDate>2008-08-28T12:09:16.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="14109"&gt;Amgen&lt;/ulink&gt; was investigating a series of aurora  kinase inhibitors for the potential treatment of cancer [&lt;ulink linkType="Reference" linkID="930446"&gt;930446&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2010, preclinical data were presented at the 239th ACS meeting in San Francisco, CA. A series of aminopyrimidines were found to be potent and highly selective for both aurora A and B kinases. When administered po to rats, the lead compound (structure shown) had a Cmax of 1367 ng/ml, AUC(0 to inf) of 1294 ng/h/ml, and an oral bioavailability of 65% [&lt;ulink linkType="Reference" linkID="1081008"&gt;1081008&lt;/ulink&gt;]. By that time, other compounds from the same series had been synthesized. One of the compounds exhibited IC50 values of 41 nM and 15 nM for aurora A and B respectively and demonstrated significant reduction in tumor p-histone H3 for at least 6 h in a xenograft mice model (50 mg/kg, po) [&lt;ulink linkType="Reference" linkID="1145278"&gt;1145278&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2008, preclinical data on a series of aminobenzimidazole derivatives were presented at the 236th ACS National Meeting in Philadelphia, PA.  A lead compound was shown to have favorable pharmacokinetics in rat for future use in tumor pharmacodynamic and disease models [&lt;ulink linkType="Reference" linkID="930446"&gt;930446&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2012-11-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-08-20T00:00:00.000Z</StatusDate><Source id="930446" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00183"><Name>Aurora protein kinase 2</Name><SwissprotNumbers><Swissprot>O14965</Swissprot><Swissprot>P59241</Swissprot><Swissprot>P97477</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00184"><Name>Aurora protein kinase 1</Name><SwissprotNumbers><Swissprot>O55099</Swissprot><Swissprot>O70126</Swissprot><Swissprot>Q96GD4</Swissprot><Swissprot>Q9N0X0</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="6150"><DrugName>eperisone</DrugName><DrugNamesKey><Name id="42757599">Myonal</Name><Name id="42769341">Myorelark</Name><Name id="42757596">eperisone</Name></DrugNamesKey><DrugSynonyms><Name><Value>eperisone</Value><Types><Type>INN</Type></Types></Name><Name><Value>E-0646</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>EMPP</Value></Name><Name><Value>Myonal</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>E-646</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>E-2000</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Myorelark</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>E-2000 (oral), Eisai</Value></Name><Name><Value>eperisone (oral), Eisai</Value></Name><Name><Value>64840-90-0</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>56839-43-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15872">Eisai Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="15872">Eisai Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="21017">Zambon Italia Srl</Company><Company id="22348">Bracco Eisai</Company></CompaniesSecondary><CrossReferences><SourceEntity id="6150" type="Drug"><TargetEntity id="91067" type="siDrug">Eperisone hydrochloride</TargetEntity></SourceEntity><SourceEntity id="15872" type="Company"><TargetEntity id="4295876894" type="organizationId">Eisai Co Ltd</TargetEntity></SourceEntity><SourceEntity id="21017" type="Company"><TargetEntity id="4298232311" type="organizationId">Zambon Company SpA</TargetEntity></SourceEntity><SourceEntity id="22348" type="Company"><TargetEntity id="5000600118" type="organizationId">Bracco-Eisai Co Ltd</TargetEntity></SourceEntity><SourceEntity id="358" type="ciIndication"><TargetEntity id="M62.83" type="ICD10"/><TargetEntity id="10028334" type="MEDDRA"/><TargetEntity id="D013035" type="MeSH"/><TargetEntity id="-323136046" type="omicsDisease"/><TargetEntity id="154" type="siCondition"/></SourceEntity><SourceEntity id="913" type="ciIndication"><TargetEntity id="10028335" type="MEDDRA"/><TargetEntity id="D009122" type="MeSH"/><TargetEntity id="-702772965" type="omicsDisease"/><TargetEntity id="175" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Muscle hypertonia - Japan - May-1983</FirstLaunched><FirstLaunched>Muscle spasm - Japan - May-1983</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="358">Muscle spasm</Indication><Indication id="913">Muscle hypertonia</Indication></IndicationsPrimary><ActionsSecondary><Action id="652">Centrally-acting muscle relaxant</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>M3B</Code><Name>MUSCLE RELAXANTS, CENTRALLY ACTING</Name></Ephmra></EphmraCodes><LastModificationDate>2017-05-08T12:12:23.000Z</LastModificationDate><ChangeDateLast>2016-10-27T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="15872" linkType="Company"&gt;Eisai&lt;/ulink&gt; has developed and launched eperisone (Myonal), a centrally acting muscle relaxant. The product is indicated in  markets outside the US for the treatment of spastic paralysis caused by cerebrovascular disorders, spastic spinal paralysis, cervical spondylosis, sequela of surgical trauma, spinal injury and head injury, amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute myelo-optico neuropathy or other encephalomyelopathies, and for the improvement of myotonic conditions caused by neck-shoulder-arm syndrome, scapulohumeral periarthritis or low back pain [&lt;ulink linkID="1114158" linkType="Reference"&gt;1114158&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The drug was first launched in Japan in May 1983 [&lt;ulink linkID="1114158" linkType="Reference"&gt;1114158&lt;/ulink&gt;], and by September 1999, eperisone had been launched throughout Central and South America, the Middle East and South East Asia [&lt;ulink linkID="341988" linkType="reference"&gt;341988&lt;/ulink&gt;]. By 2003, the drug was marketed in South Korea by licensee &lt;ulink linkID="30057" linkType="Company"&gt;LG Life Sciences&lt;/ulink&gt; [&lt;ulink linkID="504474" linkType="reference"&gt;504474&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2008, a phase III trial for muscular spasm associated with low back pain had been completed in India [&lt;ulink linkID="677431" linkType="Reference"&gt;677431&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Eisai had been developing a &lt;ulink linkID="47642" linkType="Drug"&gt;transdermal patch formulation&lt;/ulink&gt;, but  the company withdrew its Japanese NDA as the formulation had not demonstrated sufficient efficacy in clinical trials [&lt;ulink linkID="523046" linkType="reference"&gt;523046&lt;/ulink&gt;], [&lt;ulink linkID="525073" linkType="reference"&gt;525073&lt;/ulink&gt;]. By 1994, the drug had been filed for approval in Italy by &lt;ulink linkID="20999" linkType="Company"&gt;Zambon&lt;/ulink&gt; and &lt;ulink linkID="22348" linkType="Company"&gt;Bracco Eisai&lt;/ulink&gt; [&lt;ulink linkID="165734" linkType="reference"&gt;165734&lt;/ulink&gt;], but there is no evidence it was ever approved. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;By 1994, eperisone had been filed for approval in Italy [&lt;ulink linkID="165734" linkType="reference"&gt;165734&lt;/ulink&gt;], with a Turkish submission having taken place by December 1999 [&lt;ulink linkID="351999" linkType="reference"&gt;351999&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Japan&lt;/subtitle&gt;By 1995, a tablet formulation of eperisone had been launched in Japan [&lt;ulink linkID="189449" linkType="reference"&gt;189449&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;China&lt;/subtitle&gt;It was assumed that the drug was launched in China shortly after its approval in October 1999 [&lt;ulink linkID="1281583" linkType="Reference"&gt;1281583&lt;/ulink&gt;], [&lt;ulink linkID="1281584" linkType="Reference"&gt;1281584&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Latin America&lt;/subtitle&gt;By September 1999, eperisone had been launched throughout Central and South America [&lt;ulink linkID="341988" linkType="reference"&gt;341988&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Middle East and Africa&lt;/subtitle&gt;By September 1999, eperisone had been launched throughout  the Middle East  [&lt;ulink linkID="341988" linkType="reference"&gt;341988&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;South Asia&lt;/subtitle&gt;By September 1999, eperisone had been launched throughout  the South East Asia [&lt;ulink linkID="341988" linkType="reference"&gt;341988&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In May 2006, a multicenter, randomized, double-blind, placebo-controlled phase III study began in India in patients (expected enrollment n = 240) with acute musculoskeletal spasm associated with low back pain. The total duration of treatment with eperisone, or placebo, was to be 14 days, and outcomes were to be efficacy and tolerability.  By September 2008, the study had been completed [&lt;ulink linkID="677431" linkType="Reference"&gt;677431&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>1999-09-21T00:00:00.000Z</StatusDate><Source id="341988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1999-12-31T00:00:00.000Z</StatusDate><Source id="1281584" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="XF">Central America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>1999-09-21T00:00:00.000Z</StatusDate><Source id="341988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1983-05-10T00:00:00.000Z</StatusDate><Source id="1114158" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="XJ">Middle East</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1999-09-21T00:00:00.000Z</StatusDate><Source id="341988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1999-09-21T00:00:00.000Z</StatusDate><Source id="341988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="XI">South East Asia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1999-09-21T00:00:00.000Z</StatusDate><Source id="341988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>1983-05-10T00:00:00.000Z</StatusDate><Source id="1114158" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="XE">South America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>1999-09-21T00:00:00.000Z</StatusDate><Source id="341988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="XF">Central America</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1999-09-21T00:00:00.000Z</StatusDate><Source id="341988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="XI">South East Asia</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="913">Muscle hypertonia</Indication><StatusDate>1999-09-21T00:00:00.000Z</StatusDate><Source id="341988" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21017">Zambon Italia Srl</Company><Country id="IT">Italy</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1994-08-26T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="22348">Bracco Eisai</Company><Country id="IT">Italy</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1994-08-26T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15872">Eisai Co Ltd</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>2008-09-05T00:00:00.000Z</StatusDate><Source id="677431" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="21017">Zambon Italia Srl</Company><Country id="IT">Italy</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1994-08-26T00:00:00.000Z</StatusDate><Source id="165734" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="22348">Bracco Eisai</Company><Country id="IT">Italy</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1994-08-26T00:00:00.000Z</StatusDate><Source id="165734" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1999-10-29T00:00:00.000Z</StatusDate><Source id="1281583" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>1998-06-01T00:00:00.000Z</StatusDate><Source id="307737" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15872">Eisai Co Ltd</Company><Country id="IN">India</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="358">Muscle spasm</Indication><StatusDate>2006-05-16T00:00:00.000Z</StatusDate><Source id="677431" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="15872">Eisai Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="20999">Zambon Co SpA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22235">LG Chem Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="24368">Bracco SpA</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="116662" title="Bracco Eisai to develop Eisai's eperisone in italy"/><Deal id="116663" title="Zambon Italia to develop Eisai's eperisone in Italy"/><Deal id="116664" title="LG to market Eisai's eperisone in South Korea"/></Deals><PatentFamilies><PatentFamily id="1054377" number="JP-03525225" title="An eperisone or tolperisone percutaneously absorbing tape agent or a patch agent, and its manufacturing method"/><PatentFamily id="1127550" number="EP-00295411" title="Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or a salt thereof."/><PatentFamily id="1146853" number="JP-2001064205" title="Preparation composition"/><PatentFamily id="1195085" number="KR-2012103521" title="Film-coated tablet comprising eperisone, and method of preparation for the same."/><PatentFamily id="1199345" number="JP-04066580" title="Production Of Piperidinopropiophenone Derivative"/><PatentFamily id="1496354" number="EP-00310259" title="Eperisone as a hypotensive agent"/><PatentFamily id="1497999" number="JP-04182424" title="Plaster Containing Eperisone"/><PatentFamily id="1499364" number="JP-08291068" title="Eperisone Plaster For External Use"/><PatentFamily id="1530790" number="WO-2010081070" title="Novel forms of eperisone"/><PatentFamily id="1572789" number="JP-03277239" title="An eperisone or a tolperisone external-use patch"/><PatentFamily id="1577908" number="JP-2000143510" title="External composition"/><PatentFamily id="1577909" number="JP-2000143513" title="External composition"/><PatentFamily id="1590908" number="JP-2001019640" title="External composition"/><PatentFamily id="1602967" number="WO-2010017135" title="Novel forms of eperisone"/><PatentFamily id="1710725" number="KR-01151342" title="Film-coated tablet comprising eperisone, and method of preparation for the same."/><PatentFamily id="18658" number="JP-08291067" title="Eperisone Plaster For External Use"/><PatentFamily id="1868086" number="JP-06024986" title="Composition For Percutaneous Absorption Preparation Containing Eperisone Or Its Salt And Percutaneous Absorption Preparation"/><PatentFamily id="1868816" number="JP-07267860" title="Dermatological preparations containing eperisone or tolperisone."/><PatentFamily id="2150105" number="WO-2013058450" title="Stabilized eperisone medical composition, and sustained-release preparation containing same"/><PatentFamily id="2230880" number="KR-2012052080" title="Eperisone containing releasing tablet and a manufacturing method thereof."/><PatentFamily id="2275373" number="WO-2004032927" title="Transdermal preparations comprising eperisone, tolperisone or salts thereof"/><PatentFamily id="2435106" number="WO-2012172413" title="Pharmaceutical composition comprising a combination of eperisone and diclofenac and process for preparing thereof"/><PatentFamily id="2563138" number="WO-2013105819" title="Stable pharmaceutical composition comprising eperisone or a pharmaceutically acceptable salt thereof and an acidifying agent"/><PatentFamily id="2564155" number="KR-2013078123" title="Method for preparing a stable pharmaceutical composition comprising eperisone or a pharmaceutically acceptable salt thereof"/><PatentFamily id="2607682" number="KR-01565505" title="The new drug delivery system containing the eperisone."/><PatentFamily id="2632741" number="CN-103232415" title="A method for producing hydrochloric acid eperisone."/><PatentFamily id="2755495" number="KR-01462468" title="The manufacturing method of the hydrochloric acid eperisone."/><PatentFamily id="2806851" number="WO-2014157851" title="Eperisone pharmaceutical composition having improved preservability and pH stability"/><PatentFamily id="2807074" number="WO-2014156196" title="Therapeutic agent for type 2 diabetes"/><PatentFamily id="2807879" number="WO-2014157852" title="Sustained-release medicinal composition containing eperisone as active ingredient"/><PatentFamily id="314638" number="JP-06040917" title="Cataplasm containing tolperisone or eperisone"/><PatentFamily id="3747377" number="WO-2018044020" title="Method for preparing eperisone sustained release microsphere, and composite preparation of eperisone sustained release microsphere and aceclofenac"/><PatentFamily id="3829843" number="JP-2017193505" title="Type-2 diabetes therapeutic agent"/><PatentFamily id="393355" number="US-03995047" title="Propiophenone derivatives in the treatment of pathological muscular conditions"/><PatentFamily id="608547" number="EP-00454089" title="Percutaneously Absorbable Eperisone Or Tolperisone Preparation"/><PatentFamily id="684397" number="JP-06256330" title="Production of propiophenone derivative."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>6</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="4">Delivery device</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>21</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AmorePacific Corp" id="1006313"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Enzychem Lifesciences Corp" id="1016849"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Daiichi Sankyo Co Ltd" id="1017506"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bionevia Pharmaceuticals Inc" id="1048711"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kumamoto Health Science University" id="1051861"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Korea Prime Pharm Co Ltd" id="1054436"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Navipharm Co Ltd" id="1056771"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hanmi Holdings Co Ltd" id="1060189"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Chodang Pharm Co Ltd" id="1062748"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Withus Pharmaceutical Co Ltd" id="1071459"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Og Giken Co Ltd" id="1083252"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="General Inc Association Pharma Valley Project Supporting Organization" id="1087596"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Intro Pharm &amp;Tech" id="1087801"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hunan Asia Pharmaceutical Co Ltd" id="1095257"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eisai Co Ltd" id="15872"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nichiban Co Ltd" id="18510"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nitto Denko Corp" id="18574"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ohara Chemical Industries Ltd" id="18640"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sansho Seiyaku Co Ltd" id="19668"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sekisui Chemical Co Ltd" id="19851"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Taisho Pharmaceutical Co Ltd" id="20289"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Kumamoto University" id="21328"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sansei Seiyaku KK" id="29759"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Nipro Corp" id="30972"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="61707"><DrugName>CDK9 inhibitors (oral, cancer), Exelixis</DrugName><DrugSynonyms><Name><Value>CDK9 inhibitors (oral, cancer), Exelixis</Value></Name></DrugSynonyms><CompanyOriginator id="22676">Exelixis Inc</CompanyOriginator><CompaniesSecondary><Company id="22676">Exelixis Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="22676" type="Company"><TargetEntity id="4295915832" type="organizationId">Exelixis Inc</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="8110" type="Action"><TargetEntity id="1904" type="Mechanism">CDK9 Inhibitors</TargetEntity><TargetEntity id="2305" type="Mechanism">CDK9/Cyclin T1 Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00533" type="ciTarget"><TargetEntity id="93365695410253" type="siTarget">Cyclin-dependent kinase 9</TargetEntity><TargetEntity id="2229" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="8110">Cyclin-dependent kinase-9 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2010-08-10T06:16:56.000Z</LastModificationDate><ChangeDateLast>2010-08-10T06:16:56.000Z</ChangeDateLast><AddedDate>2008-10-28T17:36:34.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="22676"&gt;Exelixis&lt;/ulink&gt; was investigating a series of oral cyclin-dependent kinase-9 (CDK9) inhibitors for the potential treatment of cancer [&lt;ulink linkType="Reference" linkID="950612"&gt;950612&lt;/ulink&gt;].  In October 2008, lead optimization was ongoing [&lt;ulink linkType="Reference" linkID="950612"&gt;950612&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2009, preclinical data were presented at the 100th AACR meeting in Denver, CO. In mouse xenograft tumor models, oral administration of the inhibitors induced potent and dose-dependent inhibition of CDK9 markers [&lt;ulink linkType="Reference" linkID="994303"&gt;994303&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2008,  preclinical data  were presented at the 20th EORTC-NCI-AACR symposium in Geneva, Switzerland.  Biochemical and cell-based assays identified CDK9 inhibitors. Oral administration of  the inhibitors in mouse xenograft tumor models showed potent and dose-dependent inhibition of RNAPII CTD SER2 phosphorylation, as well as reductions in protein levels of Myc, cyclin D1 and  MCL-1 [&lt;ulink linkType="Reference" linkID="950612"&gt;950612&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="22676">Exelixis Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2010-08-09T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="22676">Exelixis Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-10-23T00:00:00.000Z</StatusDate><Source id="950612" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00533"><Name>Cyclin-dependent kinase-9</Name><SwissprotNumbers><Swissprot>P46551</Swissprot><Swissprot>P50750</Swissprot><Swissprot>Q641Z4</Swissprot><Swissprot>Q96WV9</Swissprot><Swissprot>Q99J95</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="62034"><DrugName>V-1810</DrugName><DrugSynonyms><Name><Value>V-1810</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="28108">4SC AG</CompanyOriginator><CompaniesSecondary><Company id="28108">4SC AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="62034" type="Drug"><TargetEntity id="646820" type="siDrug"></TargetEntity><TargetEntity id="468279" type="siDrug">SC-75741</TargetEntity></SourceEntity><SourceEntity id="28108" type="Company"><TargetEntity id="4295870097" type="organizationId">4Sc AG</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="2653" type="Action"><TargetEntity id="945" type="Mechanism">NF-kappaB (NFKB) Activation Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="2653">Nuclear factor kappa B inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1589">Apoptosis stimulator</Action><Action id="767">Cell cycle inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2015-08-14T16:54:50.000Z</LastModificationDate><ChangeDateLast>2013-07-19T00:00:00.000Z</ChangeDateLast><AddedDate>2008-12-11T11:25:59.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="28108" linkType="Company"&gt;4SC&lt;/ulink&gt; was investigating V-1810, an NFkappa B inhibitor, for the potential treatment of cancer [&lt;ulink linkID="967199" linkType="Reference"&gt;967199&lt;/ulink&gt;]. In December 2008, V-1810 was in preclinical development [&lt;ulink linkID="967199" linkType="Reference"&gt;967199&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In February 2010, preclinical data on V-1810 were published demonstrating the drug to induce apoptosis and cell cycle arrest in four multiple myeloma cell lines and primary multiple myeloma cells. The drug was also shown to reverse NFkappa B activation induced by melphalan and doxorubicin [&lt;ulink linkID="1116873" linkType="Reference"&gt;1116873&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, preclinical data were presented at the 50th annual meeting of ASH in San Francisco, CA.  V-1810 was found to induce apoptosis in multiple myeloma cells in mice [&lt;ulink linkID="967199" linkType="Reference"&gt;967199&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In December 2008, 4SC was collaborating with &lt;ulink linkID="22137" linkType="Company"&gt;LMU&lt;/ulink&gt;, Munich, Germany, on the investigation of V-1810 [&lt;ulink linkID="967199" linkType="Reference"&gt;967199&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28108">4SC AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2013-07-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28108">4SC AG</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-12-06T00:00:00.000Z</StatusDate><Source id="967199" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01442"><Name>Nuclear factor kappa B</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Deal Summary Added/Updated</Reason><Description>Deal summary added/updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="22137">Ludwig-Maximilians University of Munich</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28108">4SC AG</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="140781" title="4SC to collaborate with LMU Munchen for the research on V-1810"/></Deals><hasSWOTs>N</hasSWOTs></Drug><Drug id="65014"><DrugName>TT-124</DrugName><DrugSynonyms><Name><Value>TT-124</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>C03/TT-124</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1042818">Thrombotargets Corp</CompanyOriginator><CompaniesSecondary><Company id="1042818">Thrombotargets Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1042818" type="Company"><TargetEntity id="5000644434" type="organizationId">Thrombotargets Corp</TargetEntity></SourceEntity><SourceEntity id="75" type="ciIndication"><TargetEntity id="10009802" type="MEDDRA"/><TargetEntity id="D001778" type="MeSH"/><TargetEntity id="-1078043666" type="omicsDisease"/><TargetEntity id="1254" type="siCondition"/></SourceEntity><SourceEntity id="659" type="Action"><TargetEntity id="3176" type="Mechanism">Inhibitors of Blood Coagulation Pathways</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="75">Blood clotting disorder</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="659">Coagulation inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2011-12-30T09:07:29.000Z</LastModificationDate><ChangeDateLast>2011-12-31T04:24:37.000Z</ChangeDateLast><AddedDate>2009-11-27T04:06:31.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1042818"&gt;Thrombotargets&lt;/ulink&gt; was investigating TT-124 (C03/TT-124), a small molecule anticoagulant, for the potential treatment of coagulation disorders [&lt;ulink linkType="Reference" linkID="952157"&gt;952157&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1060266"&gt;1060266&lt;/ulink&gt;]. In November 2009, the program was listed as having completed the lead generation stage and  ready to enter lead optimization [&lt;ulink linkType="Reference" linkID="1060266"&gt;1060266&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2008, the program was at the discovery stage [&lt;ulink linkType="Reference" linkID="952157"&gt;952157&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1042818">Thrombotargets Corp</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="75">Blood clotting disorder</Indication><StatusDate>2011-12-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1042818">Thrombotargets Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="75">Blood clotting disorder</Indication><StatusDate>2008-10-14T00:00:00.000Z</StatusDate><Source id="952157" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="65247"><DrugName>PP-9706642</DrugName><DrugNamesKey><Name id="42981437">Viracure</Name></DrugNamesKey><DrugSynonyms><Name><Value>anti-HSV2 agent, Piramal</Value></Name><Name><Value>PP-9706642</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Viracure</Value><Types><Type>Trade Name</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1037717">Piramal Phytocare Ltd</CompanyOriginator><CompaniesSecondary><Company id="1006437">Life Molecular Imaging</Company><Company id="1037717">Piramal Phytocare Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="65247" type="Drug"><TargetEntity id="665096" type="siDrug">PP-9706642</TargetEntity></SourceEntity><SourceEntity id="1006437" type="Company"><TargetEntity id="4295872692" type="organizationId">Piramal Enterprises Ltd</TargetEntity></SourceEntity><SourceEntity id="1037717" type="Company"><TargetEntity id="4295872368" type="organizationId">Piramal Phytocare Ltd</TargetEntity></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="165">HSV-2 infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="1647">Natural product</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-28T09:00:59.000Z</LastModificationDate><ChangeDateLast>2014-12-06T00:00:00.000Z</ChangeDateLast><AddedDate>2010-01-04T16:04:19.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1006437" linkType="Company"&gt;Piramal Enterprises&lt;/ulink&gt; (formerly Piramal Healthcare), following the acquisition of the NCE research unit of its former spin-off &lt;ulink linkID="1037717" linkType="Company"&gt;Piramal Life Sciences&lt;/ulink&gt; (PLS) in May 2011 [&lt;ulink linkID="1276010" linkType="Reference"&gt;1276010&lt;/ulink&gt;], was developing the phytopharmaceutical PP-9706642 (Viracure) for the potential topical treatment and prevention of herpes simplex virus-2 (HSV-2) infection  [&lt;ulink linkID="1066341" linkType="Reference"&gt;1066341&lt;/ulink&gt;]. By May 2011, the drug was in phase II trials [&lt;ulink linkID="1213283" linkType="Reference"&gt;1213283&lt;/ulink&gt;]. In May 2013, the drug was still listed as being in phase II development for HSV-2 infection [&lt;ulink linkID="1424850" linkType="Reference"&gt;1424850&lt;/ulink&gt;]. However, in August 2014, it was reported that the company had ceased drug discovery to focus on generics and manufacturing [&lt;ulink linkID="1617347" linkType="Reference"&gt;1617347&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;By June 2011, the drug was in phase II trials in India [&lt;ulink linkID="1213283" linkType="Reference"&gt;1213283&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In September 2010, preclinical data on PP-9706642 were presented at the 50th ICAAC meeting in Boston, MA. In MTT and plaque reduction assays, PP-9706642 dose-dependently suppressed HSV-2 multiplication, with an IC50 value of 33.5 microg/ml. PP-9706642 showed no activity against HSV-1 and CMV. The survival rate of female BALB/c mice challenged with lethal HSV-2 and then treated with PP-9706642 (1500 and 375 mg/kg/day) was 100%. PP-9706642 was effective when used both prophylactically and therapeutically [&lt;ulink linkID="1126332" linkType="Reference"&gt;1126332&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1006437">Life Molecular Imaging</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="165">HSV-2 infection</Indication><StatusDate>2014-08-27T00:00:00.000Z</StatusDate><Source id="1617347" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1037717">Piramal Phytocare Ltd</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="165">HSV-2 infection</Indication><StatusDate>2011-05-01T00:00:00.000Z</StatusDate><Source id="1213283" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1006437">Life Molecular Imaging</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="165">HSV-2 infection</Indication><StatusDate>2011-05-06T00:00:00.000Z</StatusDate><Source id="1276010" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1037717">Piramal Phytocare Ltd</Company><Country id="IN">India</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="165">HSV-2 infection</Indication><StatusDate>2010-01-04T00:00:00.000Z</StatusDate><Source id="1066341" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="6602"><DrugName>NSC-361456</DrugName><DrugSynonyms><Name><Value>NSC-361456</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>pyrazine diazohydroxide</Value></Name><Name><Value>103829-46-5</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20518">National Institutes of Health</CompanyOriginator><CompaniesSecondary><Company id="20518">National Institutes of Health</Company></CompaniesSecondary><CrossReferences><SourceEntity id="6602" type="Drug"><TargetEntity id="124144" type="siDrug">NSC-361456</TargetEntity></SourceEntity><SourceEntity id="20518" type="Company"><TargetEntity id="5001347606" type="organizationId">National Institutes of Health</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"/><TargetEntity id="D015179" type="MeSH"/><TargetEntity id="-1280257855" type="omicsDisease"/><TargetEntity id="594" type="siCondition"/></SourceEntity><SourceEntity id="999" type="ciIndication"><TargetEntity id="C64" type="ICD10"/><TargetEntity id="10038389" type="MEDDRA"/><TargetEntity id="D007680" type="MeSH"/><TargetEntity id="-1866040075" type="omicsDisease"/><TargetEntity id="607" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication><Indication id="989">Colorectal tumor</Indication><Indication id="999">Renal tumor</Indication></IndicationsSecondary><ActionsSecondary><Action id="140">DNA synthesis inhibitor</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2009-12-29T08:41:14.000Z</LastModificationDate><ChangeDateLast>2009-12-29T08:41:14.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="20518"&gt;National Institutes of Health&lt;/ulink&gt; was developing NSC-361456,  a DNA synthesis inhibitor  which was in  in phase II trials as a potential treatment for renal and colorectal cancer [&lt;ulink linkType="reference" linkID="293597"&gt;293597&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2009-12-29T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="999">Renal tumor</Indication><StatusDate>2009-12-29T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>1993-12-01T00:00:00.000Z</StatusDate><Source id="153976" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>1998-08-07T00:00:00.000Z</StatusDate><Source id="293597" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="999">Renal tumor</Indication><StatusDate>1998-08-07T00:00:00.000Z</StatusDate><Source id="293597" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="67350"><DrugName>EC-70124</DrugName><DrugSynonyms><Name><Value>EC-70124</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>I-kappa kinase beta inhibitor (solid tumor), Entrechem</Value></Name><Name><Value>staurosporine analogue (solid tumor), Entrechem</Value></Name><Name><Value>staurosporine-rebeccamycin analog (solid tumor/inflammation), Entrechem</Value></Name></DrugSynonyms><CompanyOriginator id="1032000">Entrechem</CompanyOriginator><CompaniesPrimary><Company id="1032000">Entrechem</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1032000" type="Company"><TargetEntity id="5035525159" type="organizationId">EntreChem SL</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity><SourceEntity id="4480" type="Action"><TargetEntity id="1315" type="Mechanism">IKK-2 (IKK-beta) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="2653" type="Action"><TargetEntity id="945" type="Mechanism">NF-kappaB (NFKB) Activation Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="PTGT-00980" type="ciTarget"><TargetEntity id="18165806835513" type="siTarget">Inhibitor of nuclear factor kappa-B kinase subunit beta</TargetEntity><TargetEntity id="9158" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><IndicationsPrimary><Indication id="188">Inflammatory disease</Indication><Indication id="725">Solid tumor</Indication></IndicationsPrimary><ActionsPrimary><Action id="2653">Nuclear factor kappa B inhibitor</Action><Action id="4480">I-kappa B kinase beta inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="1589">Apoptosis stimulator</Action><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="767">Cell cycle inhibitor</Action><Action id="7293">Synergist</Action></ActionsSecondary><Technologies><Technology id="1647">Natural product</Technology><Technology id="585">Oral formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-05-30T04:54:56.000Z</LastModificationDate><ChangeDateLast>2018-07-31T00:00:00.000Z</ChangeDateLast><AddedDate>2010-07-16T07:55:21.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1032000" linkType="Company"&gt;Entrechem&lt;/ulink&gt;,a spin-off of  &lt;ulink linkID="20655" linkType="Company"&gt;University of Oviedo&lt;/ulink&gt;, is investigating EC-70124, a staurosporine-rebeccamycin  analogue, the lead from the series of I-kappa B kinase beta inhibitors, for the potential oral and iv treatment of solid tumors and inflammation  [&lt;ulink linkID="1116535" linkType="Reference"&gt;1116535&lt;/ulink&gt;],  [&lt;ulink linkID="1108130" linkType="Reference"&gt;1108130&lt;/ulink&gt;], [&lt;ulink linkID="1504576" linkType="Reference"&gt;1504576&lt;/ulink&gt;], [&lt;ulink linkID="1553868" linkType="Reference"&gt;1553868&lt;/ulink&gt;]. In June 2011,  in vitro target validation and in vivo proof-of-concept studies were ongoing [&lt;ulink linkID="1198443" linkType="Reference"&gt;1198443&lt;/ulink&gt;]. In September 2012, the drug was listed as being in preclinical development [&lt;ulink linkID="1327009" linkType="Reference"&gt;1327009&lt;/ulink&gt;];   in March 2018, this was still the case [&lt;ulink linkID="2016727" linkType="Reference"&gt;2016727&lt;/ulink&gt;]. In December  2015, preclinical data were presented [&lt;ulink linkID="1597742" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1721689" linkType="Reference"&gt;1721689&lt;/ulink&gt;]. In September 2012, the company was seeking to outlicense the drug [&lt;ulink linkID="1327009" linkType="Reference"&gt;1327009&lt;/ulink&gt;]; in November 2013, this was still the case [&lt;ulink linkID="1504576" linkType="Reference"&gt;1504576&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In July 2018, preclinical data were presented at the 25th Biennial EACR Meeting in Amsterdam, the Netherlands. EC-70124 in combination with doxorubicin (0.1 microM) produced a synergistic decrease of cell viability (&amp;gt; 2 microM in hMSC and 0.128 microM in T-5H-FC) and a reduction in tumor growth (93.66% of tumor growth inhibition), while EC-70124 alone showed a small effect in vivo (27.22% of tumor growth inhibition) [&lt;ulink linkID="2050577" linkType="Reference"&gt;2050577&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2015, preclinical data were presented at the 38th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. In a panel of triple negative cell lines including HS578T, BT549, MDA-MB231 and HCC3153, doses of EC-70124 in the nM range reduced proliferation and cell growth. EC-70124 showed activity in xenografted animals. EC-70124 inhibited PI3K/mTOR pathway both in vitro and in vivo [&lt;ulink linkID="1721689" linkType="Reference"&gt;1721689&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2014, preclinical data were presented at the 26th EORTC-NCI-AACR Symposium in Barcelona, Spain. In human prostate cancer cells (DU145 cells), treatment with EC-70124 (250 nM) inhibited the NF-kappaB and STAT3 transcriptional activities. In DU145 tumor bearing nude mice xenograft models, treatment with EC-70124  inhibited NF-kB activity, growth of DU145 tumor xenografts, decreased IkB and STAT3 phosphorylation, reduced NF-kB and STAT3 target genes  in cancer stem cell  compartment  [&lt;ulink linkID="1613538" linkType="Reference"&gt;1613538&lt;/ulink&gt;]. In March 2017, similar data were presented at the 32nd Annual EAU Congress in London, UK [&lt;ulink linkID="1910251" linkType="Reference"&gt;1910251&lt;/ulink&gt;], [&lt;ulink linkID="1911692" linkType="Reference"&gt;1911692&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, preclinical data were presented at the 39th ESMO congrss in Madrid, Spain. In the SW 620 colon cancer cell line, AKT, pS6 and Sre were strongly inhibited by treatment with EC-70124 at 6 and 12h. In the HT 29 colon cancer cell line,  EC-70124 showed Sre and pS6  inhibition at 6h. EC-70124 had a strong antiproliferative effect compared with other inhibitors and it reached a half-maximal inhibitory effect in the nM range [&lt;ulink linkID="1597742" linkType="Reference"&gt;1597742&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In June 2014, preclinical data were presented at the 50th ASCO meeting in Chicago, IL. In mice sc injected with MDA-MB-231 cells, EC-70124 reduced tumor volume with no effect on body weight when compared with control.  EC-70124 in combination with &lt;ulink linkID="2953" linkType="Drug"&gt;docetaxel&lt;/ulink&gt; and &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; synergistically increased apoptosis and also induced DNA damage [&lt;ulink linkID="1562592" linkType="Reference"&gt;1562592&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, in vitro target validation and in vivo proof-of-concept studies in a human cancer model were ongoing  [&lt;ulink linkID="1198443" linkType="Reference"&gt;1198443&lt;/ulink&gt;]. In May 2014, preclinical data were reported. In mice models of human cancer, EC-70124 was found to be effective in ESE1/ELF3overexpressed tumors with NF-kappaB activation. Pharmacokinetic data from the dose range finding studies in rats and dogs showed higher circulating plasma levels [&lt;ulink linkID="1553868" linkType="Reference"&gt;1553868&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1032000">Entrechem</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2008-12-16T00:00:00.000Z</StatusDate><Source id="1116535" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1032000">Entrechem</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2014-05-07T00:00:00.000Z</StatusDate><Source id="1553868" type="CORPORATE"/></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-00980"><Name>I-kappa B kinase beta</Name><SwissprotNumbers><Swissprot>O14920</Swissprot><Swissprot>O88351</Swissprot><Swissprot>Q9QY78</Swissprot><Swissprot>Q9VEZ5</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01442"><Name>Nuclear factor kappa B</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1086746" number="WO-2009125042" title="Glycosylated indolecarbazoles, method for obtaining same and uses thereof"/><PatentFamily id="3078814" number="WO-2015181201" title="Antitumor activity of multi-kinase inhibitors in triple negative breast cancer"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Entrechem" id="1032000"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Universidad de Oviedo" id="20655"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="68731"><DrugName>telratolimod</DrugName><DrugNamesKey><Name id="43118988">telratolimod</Name></DrugNamesKey><DrugSynonyms><Name><Value>TLR 7/8 agonists (vaccination), 3M</Value></Name><Name><Value>S-36862</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>3M-052</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>S-33080</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MEDI-9197</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>telratolimod</Value><Types><Type>INN</Type></Types></Name><Name><Value>1359993-59-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="25630">3M Drug Delivery Systems</CompanyOriginator><CompaniesSecondary><Company id="18008">MedImmune LLC</Company><Company id="25630">3M Drug Delivery Systems</Company></CompaniesSecondary><CrossReferences><SourceEntity id="68731" type="Drug"><TargetEntity id="751501" type="siDrug">Telratolimod</TargetEntity></SourceEntity><SourceEntity id="18008" type="Company"><TargetEntity id="4295907119" type="organizationId">Medimmune LLC</TargetEntity></SourceEntity><SourceEntity id="25630" type="Company"><TargetEntity id="4296677382" type="organizationId">3M Drug Delivery Systems</TargetEntity></SourceEntity><SourceEntity id="384" type="ciIndication"><TargetEntity id="D014611" type="MeSH"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="7821" type="Action"><TargetEntity id="2313" type="Mechanism">Toll-Like Receptor 7 (TLR7) Agonists</TargetEntity></SourceEntity><SourceEntity id="7824" type="Action"><TargetEntity id="2435" type="Mechanism">Toll-Like Receptor 8 (TLR8) Agonists</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity><SourceEntity id="PTGT-01870" type="ciTarget"><TargetEntity id="1906540745512843" type="siTarget">Toll-like receptor 7</TargetEntity><TargetEntity id="9178" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-01871" type="ciTarget"><TargetEntity id="1156808663513113" type="siTarget">Toll-like receptor 8</TargetEntity><TargetEntity id="-847770258" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="384">Vaccination</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="7821">TLR-7 agonist</Action><Action id="7824">TLR-8 agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="393">Immunostimulant</Action><Action id="524">Adjuvant</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="347">Intratumoral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-03-12T09:50:46.000Z</LastModificationDate><ChangeDateLast>2018-03-28T00:00:00.000Z</ChangeDateLast><AddedDate>2010-10-26T17:13:25.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="18008" linkType="Company"&gt;MedImmune&lt;/ulink&gt;, under license from  &lt;ulink linkID="25630" linkType="Company"&gt;3M Drug Delivery System&lt;/ulink&gt;, was developing  telratolimod (MEDI-9197, 3M-052), a TLR 7/8 agonist, for the potential injectable treatment of cancer, including solid tumors [&lt;ulink linkID="1453962" linkType="Reference"&gt;1453962&lt;/ulink&gt;], [&lt;ulink linkID="1520686" linkType="Reference"&gt;1520686&lt;/ulink&gt;], [&lt;ulink linkID="1549488" linkType="Reference"&gt;1549488&lt;/ulink&gt;]. In September 2015, a phase I study for solid tumors was initiated in the US [&lt;ulink linkID="1698159" linkType="Reference"&gt;1698159&lt;/ulink&gt;]. In April 2017,   phase I  data   were presented [&lt;ulink linkID="1914209" linkType="Reference"&gt;1914209&lt;/ulink&gt;]. However, in February 2019, telratolimod was listed as discontinued on the AstraZeneca pipeline [&lt;ulink linkID="2120373" linkType="Reference"&gt;2120373&lt;/ulink&gt;].   &lt;/para&gt;&lt;para&gt;3M Drug Delivery System  is also investigating the agent as potential vaccine adjuvant    [&lt;ulink linkID="1549488" linkType="Reference"&gt;1549488&lt;/ulink&gt;],  [&lt;ulink linkID="1698159" linkType="Reference"&gt;1698159&lt;/ulink&gt;]. In June 2017, 3M was seeking to outlicense rights to telratolimod as  a vaccine adjuvant. At that time, it was presumed that  development  had been discontinued  [&lt;ulink linkID="1957839" linkType="Reference"&gt;1957839&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;   Telratolimod is a lead from a program of TLR 7/8 agonists that included S-36862 and S-33080 [&lt;ulink linkID="1142208" linkType="Reference"&gt;1142208&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In April 2017, clinical data from an ongoing, multicenter, open-label, dose escalation, first-in-human, phase I study in 23 subjects with solid tumors were presented at the 108th AACR Annual Meeting in Washington DC. Subjects received telratolimod (0.05, 0.012, 0.037 and 0.55 mg, intratumoral (IT)) in cohort 2, -1, -1, and -0.5 cohorts, respectively, for every 28 days. The MTD of telratolimod was 0.037 mg. Grade 3 cytokine release syndrome and grade 4 CRS were the dose-limiting toxicities reported by each one patient at 0.037 and 0.055 mg of telratolimod, respectively. Overall, telratolimod was generally well-tolerated up to 0.05 to 0.037 mg (q4w) [&lt;ulink linkID="1914209" linkType="Reference"&gt;1914209&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2015, an IND had been filed for a phase I study (&lt;ulink linkID="241107" linkType="Protocol"&gt;NCT02556463&lt;/ulink&gt;; D6410C00001) to evaluate the safety and tolerability of telratolimod in combination with &lt;ulink linkID="81193" linkType="Drug"&gt;durvalumab&lt;/ulink&gt; in patients (expected n = 45) with solid tumors;  at that time, the FDA had accepted it. Later that month, the open-label, single group assignment trial was initiated and at that time, the trial was expected to be completed in June 2020 [&lt;ulink linkID="1698159" linkType="Reference"&gt;1698159&lt;/ulink&gt;], [&lt;ulink linkID="1699498" linkType="Reference"&gt;1699498&lt;/ulink&gt;]. In January 2016, the trial was ongoing and at that time, the trial was expected to be completed in October 2018 [&lt;ulink linkID="1699498" linkType="Reference"&gt;1699498&lt;/ulink&gt;]. In November 2017, further data were presented at the 32nd SITC Annual Meeting 2017 in National Harbor, MD. Majority of patients who received treatment with 0.037 mg telratolimod achieved &amp;gt;/= 2 fold increase in CD8, CD40, CD56, or programmed death-ligand 1 (tumor and immune cells) markers according to immunohistochemistry  assessment of local pharmacodynamic effects in longitudinal biopsies. Across all three telratolimod doses of 0.005, 0.012, and 0.037 mg, patients achieved increase in peripheral levels of IFN-gamma, CXCL10 and CXCL11. The median peak values of IFN-gamma, CXCL10, and CXCL11 within 24 h of intratumoral administration of 0.037 mg telratolimod was 236, 9286, and 558 picog/ml, respectively [&lt;ulink linkID="1984144" linkType="Reference"&gt;1984144&lt;/ulink&gt;]. In December 2017, the protocol was approved in  South Korea [&lt;ulink linkID="1923602" linkType="Reference"&gt;1923602&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2017, preclinical data were presented at the 108th AACR Annual Meeting in Washington DC. Treatment with a single intratumoral injection of telratolimod (20 microg) modulated immune-related genes at 7 days following dosing. C57BL/6 mice, telratolimod (0.4 microg/25 microl, ip) in combination with immune checkpoint inhibitors (10 mg/kg Ab) led to increased survival (p &amp;lt; 0.0005 and p &amp;lt; 0.05) [&lt;ulink linkID="1913779" linkType="Reference"&gt;1913779&lt;/ulink&gt;]. Further in vitro data were presented at the same conference. In human PBMCS (59 ng/ml), cytokines were induced at minimal effective concentration of telratolimod and approximately 600-fold higher than plasma levels observed after telratolimod IT treatment. Treatment with telratolimod induced type 2 and 2-IFN and TH1 responses and within 24 h of administration increased peripheral levels of IFN gamma, CXCL-10 and -11 [&lt;ulink linkID="1914209" linkType="Reference"&gt;1914209&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2016, preclinical data were presented at the 31st SITC Annual Meeting in National Harbor, MD. In B16F10 luc, B16-OVA, 4 T1, and CT-26 mouse syngeneic tumor models, telratolimod mediated antitumor activity (tumor growth inhibition and enhanced survival). Enhanced efficacy was observed in syngeneic mouse tumor models treated with telratolimod + CTLA-4 and PD-L1 antibodies [&lt;ulink linkID="1883950" linkType="Reference"&gt;1883950&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  April 2016, preclinical data were presented at the 107th AACR Annual Meeting in New Orleans, LA, USA. Intratumoral administration of telratolimod induced a local immune response. The local stimulation of immune cells with telratolimod resulted in tumor growth inhibition in B16F10 luc syngeneic mouse tumor model. Telratolimod when combined with immune checkpoint inhibitors enhanced the efficacy in syngeneic mouse tumor models [&lt;ulink linkID="1753978" linkType="Reference"&gt;1753978&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, preclinical data were presented at the 54th Society of Toxicology Annual Meeting in San Diego, CA. In mice and monkey, the serum telratolimod levels were low, but increased over four doses.   In monkeys, inappetence, reduced weight gain, reduced RBC, reduced hemoglobin and increased post-dose body temperatures were observed [&lt;ulink linkID="1651801" linkType="Reference"&gt;1651801&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2014, data shown that telratolimod had more efficacy than resiquimod in stimulating immune responses for a multiple range of doses. Also, the drug was active in both mouse and non-human primate models [&lt;ulink linkID="1549488" linkType="Reference"&gt;1549488&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2013, preclinical data were presented at the 28th Annual Scientific Meeting of the Society for Immunotherapy of Cancer in National Habor, MD. In mice and rats, telratolimod was retained at the injection site and direct activation of innate immune cells with antitumor activities was observed. Telratolimod was found to induce antitumor activity when injected directly into tumors but not when injected distal to them [&lt;ulink linkID="1520686" linkType="Reference"&gt;1520686&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, preclinical data were presented for  telratolimod at GTCbio's 11th Annual Vaccines Research and Development Conference in Boston, MA. Preclinical proof of concept was demonstrated In animal models of influenza, HBV, HPV and tuberculosis, as measured by enhanced antigen-specific immune responses (both functional antibodies and Th1-type T-cells) [&lt;ulink linkID="1453962" linkType="Reference"&gt;1453962&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In July 2013, animal toxicology studies were ongoing in preparation for clinical studies [&lt;ulink linkID="1453962" linkType="Reference"&gt;1453962&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2010, preclinical data on several compounds were presented at the Third International Conference on Modern Vaccines and Adjuvant Formulation in Cannes, France. S-36862 was found to have low systemic exposure. Telratolimod was well tolerated and a good adjuvant when tested with influenza hemagglutinin in mice and also induced low serum cytokines. S-33080 when conjugated to a gag protein was found to induce high T-cell responses in small animals [&lt;ulink linkID="1142208" linkType="Reference"&gt;1142208&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25630">3M Drug Delivery Systems</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="384">Vaccination</Indication><StatusDate>2017-06-04T00:00:00.000Z</StatusDate><Source id="1957839" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2019-02-14T00:00:00.000Z</StatusDate><Source id="2120373" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18008">MedImmune LLC</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate>2019-02-14T00:00:00.000Z</StatusDate><Source id="2120373" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="25630">3M Drug Delivery Systems</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2015-09-25T00:00:00.000Z</StatusDate><Source id="1698159" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25630">3M Drug Delivery Systems</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2013-11-07T00:00:00.000Z</StatusDate><Source id="1520686" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2015-09-25T00:00:00.000Z</StatusDate><Source id="1698159" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="25630">3M Drug Delivery Systems</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="384">Vaccination</Indication><StatusDate>2010-10-26T00:00:00.000Z</StatusDate><Source id="1142208" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2015-09-30T00:00:00.000Z</StatusDate><Source id="1699498" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18008">MedImmune LLC</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2017-12-29T00:00:00.000Z</StatusDate><Source id="1923602" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01870"><Name>TLR-7</Name><SwissprotNumbers><Swissprot>P58681</Swissprot><Swissprot>Q9NYK1</Swissprot></SwissprotNumbers></Target><Target id="PTGT-01871"><Name>TLR-8</Name><SwissprotNumbers><Swissprot>P58682</Swissprot><Swissprot>Q9NR97</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2120373" linkType="reference" linkID="2120373"&gt;2120373&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14190">AstraZeneca plc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18239">3M Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="156433" title="3M Drug Delivery Systems and MedImmune to develop next generation toll-like receptor (TLR) agonists for cancer "/></Deals><PatentFamilies><PatentFamily id="2846403" number="WO-2014201245" title="TLR-9 Agonist with TLR-7 and/or TLR-8 agonist for treating tumors"/><PatentFamily id="3368931" number="WO-2012024284" title="Lipidated immune response modifier compound compositions, formulations, and methods"/><PatentFamily id="3445007" number="WO-2016183371" title="Methods for the treatment or prevention of ischemic tissue damage"/><PatentFamily id="3855841" number="WO-2017200852" title="Formulation containing TLR agonist and methods of use"/><PatentFamily id="3855870" number="WO-2017200957" title="PEGylated liposomes and methods of use"/><PatentFamily id="3979593" number="WO-2018049017" title="Block copolymer systems for local administration of toll-like receptor agonists"/><PatentFamily id="4126435" number="WO-2018132539" title="Safety and pharmacodynamic activity of a toll-like receptor 7/8 agonist"/><PatentFamily id="4205456" number="WO-2018175854" title="Methods and compositions relating to adjuvants"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>4</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="G1 Therapeutics Inc" id="1054091"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AstraZeneca plc" id="14190"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="3M Co" id="18239"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="US Government" id="20516"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Virginia" id="20695"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Washington" id="20701"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Montana University" id="22253"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Boston Children's Hospital" id="24334"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Infectious Disease Research Institute" id="27376"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="72274"><DrugName>adenosine A2b antagonists, Hoffman-La Roche</DrugName><DrugSynonyms><Name><Value>adenosine A2b antagonists, Hoffman-La Roche</Value></Name></DrugSynonyms><CompanyOriginator id="19446">Roche Holding AG</CompanyOriginator><CompaniesSecondary><Company id="19446">Roche Holding AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="72274" type="Drug"><TargetEntity id="734957" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="283" type="ciIndication"><TargetEntity id="10025082" type="MEDDRA"/><TargetEntity id="D008171" type="MeSH"/><TargetEntity id="-1582153652" type="omicsDisease"/><TargetEntity id="3451" type="siCondition"/></SourceEntity><SourceEntity id="31" type="ciIndication"><TargetEntity id="J45" type="ICD10"/><TargetEntity id="493" type="ICD9"/><TargetEntity id="10003553" type="MEDDRA"/><TargetEntity id="D001249" type="MeSH"/><TargetEntity id="-1473716268" type="omicsDisease"/><TargetEntity id="270" type="siCondition"/></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"/><TargetEntity id="10067585" type="MEDDRA"/><TargetEntity id="D003924" type="MeSH"/><TargetEntity id="-1888632793" type="omicsDisease"/><TargetEntity id="509" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="598" type="Action"><TargetEntity id="25" type="Mechanism">Adenosine A2B Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00058" type="ciTarget"><TargetEntity id="11753131001363" type="siTarget">Adenosine receptor A2b</TargetEntity><TargetEntity id="19" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="283">Lung disease</Indication><Indication id="31">Asthma</Indication><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsSecondary><ActionsPrimary><Action id="598">Adenosine A2b receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="399">Hypoglycemic agent</Action><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2013-09-27T06:00:53.000Z</LastModificationDate><ChangeDateLast>2013-09-27T00:00:00.000Z</ChangeDateLast><AddedDate>2011-07-05T13:34:17.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="19446"&gt;Hoffmann-La Roche&lt;/ulink&gt; was investigating   adenosine A2b receptor antagonists for the potential treatment of type 2 diabetes, asthma and pulmonary diseases [&lt;ulink linkType="Reference" linkID="1205490"&gt;1205490&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By April 2010, a series of 2-aminobenzothiazoles had been synthesized and tested as adenosine A2b receptor antagonists. One of the best compounds exhibited an IC50 value of 21 nM and Ki value of 8 nM against A2b receptor, was selective over A1 and A2a receptors with Ki values of 100 nM and 51 nM, respectively and displayed good rodent PK properties [&lt;ulink linkType="Reference" linkID="1205490"&gt;1205490&lt;/ulink&gt;]. By January 2011, further optimization had led to a compound (structure shown) with improved A2a and A1 selectivities (Ki values of 530 nM and 690 nM, respectively) and excellent A2b potency (IC50 value of 20 nM) [&lt;ulink linkType="Reference" linkID="1205493"&gt;1205493&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2013-09-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2013-09-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="283">Lung disease</Indication><StatusDate>2013-09-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="31">Asthma</Indication><StatusDate>2010-04-12T00:00:00.000Z</StatusDate><Source id="1205490" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="283">Lung disease</Indication><StatusDate>2010-04-12T00:00:00.000Z</StatusDate><Source id="1205490" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="19446">Roche Holding AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate>2010-04-12T00:00:00.000Z</StatusDate><Source id="1205490" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00058"><Name>Adenosine A2b receptor</Name><SwissprotNumbers><Swissprot>O13076</Swissprot><Swissprot>P29275</Swissprot><Swissprot>P29276</Swissprot><Swissprot>Q60614</Swissprot><Swissprot>Q6W3F4</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="7238"><DrugName>HIV-IT(V)</DrugName><DrugSynonyms><Name><Value>HIV-IT(V)</Value></Name><Name><Value>HIV ImmunoTherapeutic, Viagene</Value></Name><Name><Value>HIV gene therapy, Chiron Viagene</Value></Name></DrugSynonyms><CompanyOriginator id="23146">Chiron Viagene Inc</CompanyOriginator><CompaniesSecondary><Company id="23146">Chiron Viagene Inc</Company><Company id="25607">The Green Cross Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="7238" type="Drug"><TargetEntity id="214471" type="siDrug">HIV ImmunoTherapeutic</TargetEntity></SourceEntity><SourceEntity id="23146" type="Company"><TargetEntity id="5035523783" type="organizationId">Chiron Viagene Inc</TargetEntity></SourceEntity><SourceEntity id="25607" type="Company"><TargetEntity id="4295876882" type="organizationId">Green Cross Corp</TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"/><TargetEntity id="042" type="ICD9"/><TargetEntity id="10020161" type="MEDDRA"/><TargetEntity id="D015658" type="MeSH"/><TargetEntity id="-841965209" type="omicsDisease"/><TargetEntity id="862" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="158">HIV infection</Indication></IndicationsSecondary><ActionsSecondary><Action id="12370">Recombinant viral vector vaccine</Action><Action id="12379">Therapeutic vaccine</Action><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-23T05:38:01.000Z</LastModificationDate><ChangeDateLast>2017-07-17T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="7238" linkType="Drug"&gt;HIV-IT(V)&lt;/ulink&gt; is a gene therapy that was under development by Chiron and Green Cross for the potential treatment of HIV infection. It had completed a phase II study in the US and following results that suggested that the treatment had limited efficacy, Green Cross decided to abandon its Japanese clinical program. The companies reported that they would continue to investigate &lt;ulink linkID="7238" linkType="Drug"&gt;HIV-IT(V)&lt;/ulink&gt; using a new trial protocol involving such measures as changing administration conditions [&lt;ulink linkID="277991" linkType="reference"&gt;277991&lt;/ulink&gt;], [&lt;ulink linkID="277228" linkType="reference"&gt;277228&lt;/ulink&gt;]; however, no development has been reported since 1998.&lt;/para&gt;&lt;para&gt;The therapy involves the intramuscular injection of a retroviral vector encoding the genes for the HIV env and rev proteins [&lt;ulink linkID="161512" linkType="reference"&gt;161512&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkID="7238" linkType="Drug"&gt;HIV-IT(V)&lt;/ulink&gt; entered the US phase II trials in December 1994 [&lt;ulink linkID="169961" linkType="reference"&gt;169961&lt;/ulink&gt;]. The 2-year, placebo-controlled, triple-blinded study was conducted at 16 centers and involved up to 190 HIV-positive patients. The trial tested single dose levels of &lt;ulink linkID="7238" linkType="Drug"&gt;HIV-IT(V)&lt;/ulink&gt; administered intramuscularly. Patients were split into three strata according to CD4 counts. Each course of treatment involved three biweekly injections given every 4 months, initially for 2 years. Patients were monitored for changes in CD4 cell counts, HIV virus levels, clinical endpoints and safety parameters [&lt;ulink linkID="175409" linkType="reference"&gt;175409&lt;/ulink&gt;]. Following results that suggested that this treatment had limited efficacy, initiation of planned Japanese clinical trials were halted [&lt;ulink linkID="277228" linkType="reference"&gt;277228&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 1997, Chiron and Green Cross announced that they had agreed to expand clinical studies of the jointly developed &lt;ulink linkID="7238" linkType="Drug"&gt;HIV-IT(V)&lt;/ulink&gt;. Green Cross provided an additional $4 million for the year to conduct phase II testing in combination with new antiretroviral protease inhibitors, in approximately 200 HIV-positive patients [&lt;ulink linkID="234037" linkType="reference"&gt;234037&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The product initially entered phase I trials in August 1993 [&lt;ulink linkID="170245" linkType="reference"&gt;170245&lt;/ulink&gt;]. In November 1994 it was reported to be in three ongoing phase I trials involving more than 60 patients [&lt;ulink linkID="168582" linkType="reference"&gt;168582&lt;/ulink&gt;]. In one trial an enhanced cytotoxic T lymphocyte response with an intramuscular injection of &lt;ulink linkID="7238" linkType="Drug"&gt;HIV-IT(V)&lt;/ulink&gt; was seen in 21 asymptomatic HIV-1 subjects [&lt;ulink linkID="168582" linkType="reference"&gt;168582&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Development is being conducted in collaboration with Green Cross, under an agreement that began in 1991 [&lt;ulink linkID="161561" linkType="reference"&gt;161561&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="25607">The Green Cross Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="158">HIV infection</Indication><StatusDate>1998-03-01T00:00:00.000Z</StatusDate><Source id="277228" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23146">Chiron Viagene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="158">HIV infection</Indication><Source id="277228" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="25607">The Green Cross Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="158">HIV infection</Indication><StatusDate>1997-04-01T00:00:00.000Z</StatusDate><Source id="239826" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23146">Chiron Viagene Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="158">HIV infection</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1022450">Mitsubishi Chemical Holdings Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="118448" title="Green Cross to develop Viagene's HIV ImmunoTherapeutic drug in Japan"/></Deals><hasSWOTs>N</hasSWOTs></Drug><Drug id="72847"><DrugName>PP-4001</DrugName><DrugSynonyms><Name><Value>PP-4001</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>phenazopyridine analogs (bladder pain/urinary urgency), Pinnacle</Value></Name></DrugSynonyms><CompanyOriginator id="1018517">Pinnacle Pharmaceuticals</CompanyOriginator><CompaniesSecondary><Company id="1018517">Pinnacle Pharmaceuticals</Company></CompaniesSecondary><CrossReferences><SourceEntity id="72847" type="Drug"><TargetEntity id="741781" type="siDrug">PP-4001</TargetEntity></SourceEntity><SourceEntity id="1018517" type="Company"><TargetEntity id="4296358033" type="organizationId">Pinnacle Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="403" type="ciIndication"><TargetEntity id="N30" type="ICD10"/><TargetEntity id="10011781" type="MEDDRA"/><TargetEntity id="D003556" type="MeSH"/><TargetEntity id="-1776447469" type="omicsDisease"/><TargetEntity id="941" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="403">Cystitis</Indication></IndicationsSecondary><ActionsSecondary><Action id="2946">Analgesic</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-29T12:17:43.000Z</LastModificationDate><ChangeDateLast>2017-04-18T00:00:00.000Z</ChangeDateLast><AddedDate>2011-08-03T12:19:40.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1018517" linkType="Company"&gt;Pinnacle Pharmaceuticals&lt;/ulink&gt; was developing the urinary analgesic PP-4001, a  phenazopyridine analog, for the potential oral treatment of bladder symptoms associated with uncomplicated urinary tract infections (UTIs), including burning sensation, pain and urination frequency  [&lt;ulink linkID="1212087" linkType="Reference"&gt;1212087&lt;/ulink&gt;], [&lt;ulink linkID="1212058" linkType="Reference"&gt;1212058&lt;/ulink&gt;]. In July 2011, a phase II trial began [&lt;ulink linkID="1212087" linkType="Reference"&gt;1212087&lt;/ulink&gt;]. However, by September 2013, the company had   purged and all development by the company has been assumed to be discontinued [&lt;ulink linkID="1481123" linkType="Reference"&gt;1481123&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In July 2011, a randomized, double-blind, placebo-controlled, phase II study (&lt;ulink linkID="79686" linkType="Protocol"&gt;NCT01406587&lt;/ulink&gt;; PP4001.301) was initiated in patients with uncomplicated UTIs (expected n = 256) in the US, to assess the safety and efficacy of PP-4001. The study was expected to be complete by November that year [&lt;ulink linkID="1212087" linkType="Reference"&gt;1212087&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1018517">Pinnacle Pharmaceuticals</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="403">Cystitis</Indication><StatusDate>2013-09-26T00:00:00.000Z</StatusDate><Source id="1481123" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1018517">Pinnacle Pharmaceuticals</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="403">Cystitis</Indication><StatusDate>2011-07-29T00:00:00.000Z</StatusDate><Source id="1212087" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="447718" number="WO-2010071878" title="Phenazopyridine compounds"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Pinnacle Pharmaceuticals" id="1018517"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug><Drug id="72973"><DrugName>ETV-001</DrugName><DrugSynonyms><Name><Value>ETV-001</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1062945">ET Vaccine Technology Inc</CompanyOriginator><CompaniesSecondary><Company id="1062945">ET Vaccine Technology Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1062945" type="Company"><TargetEntity id="5036215380" type="organizationId">Etvaccine Technology Inc</TargetEntity></SourceEntity><SourceEntity id="3455" type="ciIndication"><TargetEntity id="J09.X" type="ICD10"/><TargetEntity id="863" type="siCondition"/></SourceEntity><SourceEntity id="991" type="Action"><TargetEntity id="3051" type="Mechanism">Viral Attachment Inhibitors</TargetEntity><TargetEntity id="1307" type="Mechanism">Viral Fusion Inhibitors</TargetEntity><TargetEntity id="4886" type="Mechanism">Drugs Targeting Hepatitis C Virus (HCV) Proteins</TargetEntity><TargetEntity id="3482" type="Mechanism">UL37 Expression Inhibitors</TargetEntity><TargetEntity id="2436" type="Mechanism">Viral Maturation Inhibitors</TargetEntity><TargetEntity id="1376" type="Mechanism">BR1 Expression Inhibitors</TargetEntity><TargetEntity id="5304" type="Mechanism">Drugs Targeting Rabies Virus Proteins</TargetEntity><TargetEntity id="3371" type="Mechanism">Drugs Acting on Influenza Virus Proton Channels</TargetEntity><TargetEntity id="3759" type="Mechanism">L Expression Inhibitors</TargetEntity><TargetEntity id="3481" type="Mechanism">UL36 Expression Inhibitors</TargetEntity><TargetEntity id="3235" type="Mechanism">UL29 Expression Inhibitors</TargetEntity><TargetEntity id="4479" type="Mechanism">Drugs Targeting JC Polyomavirus Proteins</TargetEntity><TargetEntity id="3575" type="Mechanism">Orthopoxvirus Egress Inhibitors</TargetEntity><TargetEntity id="4476" type="Mechanism">Anti-JC Polyomavirus Capsid Protein</TargetEntity><TargetEntity id="4612" type="Mechanism">Drugs Targeting Human Immunodeficiency Virus 1 (HIV-1) Proteins</TargetEntity><TargetEntity id="2893" type="Mechanism">Human T-Cell Leukemia Virus Type I (HTLV-I) Protease Inhibitors</TargetEntity><TargetEntity id="4128" type="Mechanism">Flavivirus Guanylyl Transferase (NS5) Inhibitors</TargetEntity><TargetEntity id="5287" type="Mechanism">Drugs Targeting Influenza Virus Proteins</TargetEntity></SourceEntity><SourceEntity id="12905" type="Action"><TargetEntity id="3089" type="Mechanism">Anti-Complement Factor D</TargetEntity><TargetEntity id="4809" type="Mechanism">Complement Factor D Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-03257" type="ciTarget"><TargetEntity id="135958241416753" type="siTarget">Complement factor D</TargetEntity><TargetEntity id="2836" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-05421" type="ciTarget"><TargetEntity id="80087185930753" type="siTarget">Complement factor H</TargetEntity><TargetEntity id="2856" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="3455">Influenza virus A infection</Indication></IndicationsSecondary><ActionsPrimary><Action id="12905">Complement factor D inhibitor</Action><Action id="26227">Complement Factor H inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="991">Antiviral</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="777">Nasal formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>J5</Code><Name>ANTIVIRALS FOR SYSTEMIC USE</Name></Ephmra></EphmraCodes><LastModificationDate>2014-08-22T06:08:57.000Z</LastModificationDate><ChangeDateLast>2014-08-22T00:00:00.000Z</ChangeDateLast><AddedDate>2011-08-11T10:29:34.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1062945"&gt;ET Vaccine Technology&lt;/ulink&gt;, a spin-off of &lt;ulink linkType="Company" linkID="1062937"&gt;Endocrine Technology&lt;/ulink&gt;,  was investigating a nasal formulation of ETV-001, a small molecule inhibitor of factor H and D,  based on the company's ETBOND technology, for the potential prevention of influenza A. In August 2011, the drug was listed as being in preclinical development [&lt;ulink linkType="Reference" linkID="1214270"&gt;1214270&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1215192"&gt;1215192&lt;/ulink&gt;]; in January 2013, this was still the case [&lt;ulink linkType="Reference" linkID="1368496"&gt;1368496&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;ETBOND technology enables the development of products that act to balance modulation of complement system and thereby immune system to reduce host inflammation and tilt the survival and therapeutic advantage to host in many life threatening diseases [&lt;ulink linkType="Reference" linkID="1214270"&gt;1214270&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1062945">ET Vaccine Technology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2014-08-14T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1062945">ET Vaccine Technology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3455">Influenza virus A infection</Indication><StatusDate>2011-08-11T00:00:00.000Z</StatusDate><Source id="1214270" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-03257"><Name>Complement factor D</Name><SwissprotNumbers><Swissprot>P00746</Swissprot><Swissprot>P03953</Swissprot><Swissprot>P32038</Swissprot><Swissprot>P51779</Swissprot></SwissprotNumbers></Target><Target id="PTGT-05421"><Name>Complement Factor H</Name><SwissprotNumbers><Swissprot>P06909</Swissprot><Swissprot>P08603</Swissprot><Swissprot>Q28085</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="7436"><DrugName>Shigistat-G</DrugName><DrugSynonyms><Name><Value>Shigistat-G</Value></Name></DrugSynonyms><CompanyOriginator id="16263">Let's Talk Recovery Inc</CompanyOriginator><CompaniesSecondary><Company id="16263">Let's Talk Recovery Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="16263" type="Company"><TargetEntity id="4295906559" type="organizationId">Cornwall Resources Inc</TargetEntity></SourceEntity><SourceEntity id="102" type="ciIndication"><TargetEntity id="10012735" type="MEDDRA"/><TargetEntity id="D003967" type="MeSH"/><TargetEntity id="-957779542" type="omicsDisease"/><TargetEntity id="380" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C1">Phase 1 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="102">Diarrhea</Indication></IndicationsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="1">Antibody</Technology></Technologies><LastModificationDate>2017-09-02T05:24:43.000Z</LastModificationDate><ChangeDateLast>1999-01-22T16:05:50.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="7436" linkType="Drug"&gt;Shigistat-G&lt;/ulink&gt;, along with the rest of GalaGen pharmaceutical development projects was terminated in 1998, following a company decision to focus its resources in the field of nutritional foods [&lt;ulink linkID="312321" linkType="reference"&gt;312321&lt;/ulink&gt;].GalaGen was developing &lt;ulink linkID="7436" linkType="Drug"&gt;Shigistat-G&lt;/ulink&gt; to prevent symptoms of Shigella dysentery which are fever, nausea, vomiting and bloody diarrhea. &lt;/para&gt;&lt;para&gt; &lt;ulink linkID="7436" linkType="Drug"&gt;Shigistat-G&lt;/ulink&gt; would target the Shigella bacteria leaving the normal bacterial flora of the gastrointestinal tract unaffected. In a phase I trial, &lt;ulink linkID="7436" linkType="Drug"&gt;Shigistat-G&lt;/ulink&gt; provided 100% protection in normal volunteers challenged with live Shigella flexneri organisms [&lt;ulink linkID="169677" linkType="reference"&gt;169677&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="16263">Let's Talk Recovery Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="102">Diarrhea</Indication><StatusDate>1999-01-22T00:00:00.000Z</StatusDate><Source id="312321" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="16263">Let's Talk Recovery Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="102">Diarrhea</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="75597"><DrugName>O-GlcNAcase inhibitors (Alzheimers disease), University of Dundee/AquaPharm</DrugName><DrugSynonyms><Name><Value>O-GlcNAcase inhibitors (Alzheimers disease), University of Dundee/AquaPharm</Value></Name><Name><Value>GlcNAcstatin (Alzheimers disease), University of Dundee/Aquapharm Biodiscovery</Value></Name></DrugSynonyms><CompanyOriginator id="20568">University of Dundee</CompanyOriginator><CompaniesSecondary><Company id="1008577">Aquapharm Biodiscovery Ltd</Company><Company id="20568">University of Dundee</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1008577" type="Company"><TargetEntity id="4297749462" type="organizationId">Aquapharm Bio Discovery Ltd</TargetEntity></SourceEntity><SourceEntity id="20568" type="Company"><TargetEntity id="4296535706" type="organizationId">University of DundeeThe</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"/><TargetEntity id="331.0" type="ICD9"/><TargetEntity id="10012271" type="MEDDRA"/><TargetEntity id="D000544" type="MeSH"/><TargetEntity id="-1268969445" type="omicsDisease"/><TargetEntity id="101" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="14">Alzheimers disease</Indication></IndicationsSecondary><ActionsSecondary><Action id="1615">Neuroprotectant</Action><Action id="284">Nootropic agent</Action></ActionsSecondary><Technologies><Technology id="1647">Natural product</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>N6D</Code><Name>NOOTROPICS</Name></Ephmra></EphmraCodes><LastModificationDate>2014-06-11T12:11:47.000Z</LastModificationDate><ChangeDateLast>2014-06-11T00:00:00.000Z</ChangeDateLast><AddedDate>2012-01-20T04:29:24.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="20568"&gt;University of Dundee&lt;/ulink&gt; in collaboration with &lt;ulink linkType="Company" linkID="1008577"&gt;Aquapharm Biodiscovery&lt;/ulink&gt;, was investigating O-GlcNAcase inhibitors including GlcNAcstatin based on  marine natural products for the potential treatment of Alzheimers disease [&lt;ulink linkType="Reference" linkID="1251447"&gt;1251447&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1255301"&gt;1255301&lt;/ulink&gt;]. In January 2012, development was ongoing [&lt;ulink linkType="Reference" linkID="1255311"&gt;1255311&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By December 2009, data had shown that GlcNAcstatin effectively modulates intracellular O-GlcNAc levels through the inhibition of O-GlcNAcase at low nanomolar concentrations [&lt;ulink linkType="Reference" linkID="1255302"&gt;1255302&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By December 2006, data had  shown that GlcNAcstatin raised O-GlcNAc levels in   human HEK 293 and SH-SY5Y cell lines (neuroblastoma) [&lt;ulink linkType="Reference" linkID="1255301"&gt;1255301&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20568">University of Dundee</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2014-06-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1008577">Aquapharm Biodiscovery Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2014-06-06T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1008577">Aquapharm Biodiscovery Ltd</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2010-09-20T00:00:00.000Z</StatusDate><Source id="1251447" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20568">University of Dundee</Company><Country id="GB">UK</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2006-09-22T00:00:00.000Z</StatusDate><Source id="1255301" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1008577">Aquapharm Biodiscovery Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20568">University of Dundee</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="1">Drug - Discovery/Design</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="137503" title="Aquapharm and Dundee University to discover marine natural product inhibitors of O-GlcNAcase for Alzheimer's disease "/></Deals><hasSWOTs>N</hasSWOTs></Drug><Drug id="7627"><DrugName>Ki-1769</DrugName><DrugSynonyms><Name><Value>Ki-1769</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>133300-00-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17661">Kirin Brewery Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="17661">Kirin Brewery Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="7627" type="Drug"><TargetEntity id="182931" type="siDrug">Ki-1769</TargetEntity></SourceEntity><SourceEntity id="17661" type="Company"><TargetEntity id="5000075410" type="organizationId">Kirin Brewery Co Ltd</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"/><TargetEntity id="D006973" type="MeSH"/><TargetEntity id="-369992864" type="omicsDisease"/><TargetEntity id="240" type="siCondition"/></SourceEntity><SourceEntity id="313" type="Action"><TargetEntity id="1644" type="Mechanism">Calcium-Activated K(Ca) Channel Activators</TargetEntity><TargetEntity id="364" type="Mechanism">Potassium Channel Activators</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><IndicationsSecondary><Indication id="178">Hypertension</Indication></IndicationsSecondary><ActionsPrimary><Action id="313">Potassium channel stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="388">Vasodilator</Action><Action id="2657">Antihypertensive</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>C2</Code><Name>ANTIHYPERTENSIVES</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-04T06:29:22.000Z</LastModificationDate><ChangeDateLast>2002-03-21T16:25:48.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="7627" linkType="Drug"&gt;Ki-1769&lt;/ulink&gt; is a potassium channel activator, which Kirin Brewery has discontinued from development as a potential treatment for hypertension [&lt;ulink linkID="160787" linkType="reference"&gt;160787&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17661">Kirin Brewery Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="178">Hypertension</Indication></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-01591"><Name>Potassium channel</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1ccc(cc1)CCN/C(=N\C#N)/c2cccnc2</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></Drug><Drug id="77213"><DrugName>SAR-305801</DrugName><DrugSynonyms><Name><Value>SAR-305801</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>MDM2-p53 inhibitor (cancer), Sanofi</Value></Name></DrugSynonyms><CompanyOriginator id="1009547">Sanofi SA</CompanyOriginator><CompaniesSecondary><Company id="1009547">Sanofi SA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="77213" type="Drug"><TargetEntity id="776603" type="siDrug">SAR-305801</TargetEntity></SourceEntity><SourceEntity id="1009547" type="Company"><TargetEntity id="4295868215" type="organizationId">Sanofi SA</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="17120" type="Action"><TargetEntity id="5158" type="Mechanism">Cellular Tumor Antigen p53 (TP53) Activators</TargetEntity></SourceEntity><SourceEntity id="10391" type="Action"><TargetEntity id="2194" type="Mechanism">MDM2 (hdm2) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-02463" type="ciTarget"><TargetEntity id="27085270853" type="siTarget">Mdm2-binding protein</TargetEntity><TargetEntity id="6247" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="10391">Mdm2 p53-binding protein inhibitor</Action><Action id="17120">p53 tumor suppressor protein stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2014-10-27T06:10:33.000Z</LastModificationDate><ChangeDateLast>2018-11-13T00:00:00.000Z</ChangeDateLast><AddedDate>2012-04-12T05:03:04.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1009547" linkType="Company"&gt;Sanofi&lt;/ulink&gt; was investigating SAR-305801,  a selective inhibitor of the MDM2-p53 interaction, for the potential treatment of cancer. By April 2012, preclinical studies had begun  [&lt;ulink linkID="1276828" linkType="Reference"&gt;&lt;/ulink&gt;&lt;ulink linkID="1275888" linkType="Reference"&gt;1275888&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The company is also investigating a second MDM2-p53 inhibitor &lt;ulink linkID="76986" linkType="Drug"&gt;SAR-299155&lt;/ulink&gt; for cancer [&lt;ulink linkID="1275888" linkType="Reference"&gt;1275888&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2013, preclinical data were presented at the 11th International TAT Congress in Paris, France. In  liposarcoma xenografted mice, SAR-299155 greatly enhanced the expression of p53 and its transcriptional targets, decreased BrdU incorporation and induced apoptosis. Complete and durable elimination of the xeongrafts was seen after 3 weeks of treatment; mouse survival was significantly extended [&lt;ulink linkID="1391568" linkType="Reference"&gt;1391568&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, preclinical data were presented at the 103rd AACR annual meeting in Chicago, IL. Characterization of the antitumor effects of SAR-305801 and SAR-299155 showed that in liposarcoma cells with wild-type p53, both compounds increased the protein levels of p53, MDM2 and p21, decreased cell viability, and induced cell cycle arrest and apoptosis in a dose-dependent manner. Additionally, both compounds were approximately 5-fold more potent than the MDM2 inhibitor &lt;ulink linkID="52556" linkType="Drug"&gt;Nutlin-3&lt;/ulink&gt;, and complete responses were achieved in 100% of primary human liposarcoma tumor xenografts following treatment with SAR-299155 [&lt;ulink linkID="1275888" linkType="Reference"&gt;1275888&lt;/ulink&gt;]. In further preclinical data presented at the 103rd AACR meeting in Chicago, IL, SAR-305801 demonstrated pharmacological properties favorable for clinical testing, including  binding affinity for human MDM2 that was greater than for &lt;ulink url="MI-219"&gt;MI-219&lt;/ulink&gt; and &lt;ulink linkID="52556" linkType="Drug"&gt;Nutlin-3&lt;/ulink&gt;, with representative  Kd values in a fluorescence polarization displacement assay of 7.9 nM compared with 94 and 127 nM,  respectively [&lt;ulink linkID="1275338" linkType="Reference"&gt;1275338&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2014-10-23T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1009547">Sanofi SA</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2012-04-02T00:00:00.000Z</StatusDate><Source id="1275888" type="OTHER"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-02463"><Name>Mdm2 p53-binding protein</Name><SwissprotNumbers><Swissprot>O42354</Swissprot><Swissprot>P22717</Swissprot><Swissprot>P23804</Swissprot><Swissprot>P56950</Swissprot><Swissprot>P56951</Swissprot><Swissprot>Q00987</Swissprot><Swissprot>Q60524</Swissprot><Swissprot>Q7YRZ8</Swissprot></SwissprotNumbers></Target><Target id="PTGT-04229"><Name>p53 tumor suppressor protein</Name><SwissprotNumbers><Swissprot>P04637</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="79241"><DrugName>IL-1 beta inhibitors (inflammatory/immune disease), Swedish Orphan Biovitrum</DrugName><DrugSynonyms><Name><Value>IL-1 beta inhibitors (inflammatory/immune disease), Affibody/Swedish Orphan Biovitrum</Value></Name><Name><Value>IL-1 beta inhibitors (inflammatory/immune disease), Swedish Orphan Biovitrum</Value></Name></DrugSynonyms><CompanyOriginator id="1005215">Affibody AB</CompanyOriginator><CompaniesPrimary><Company id="28921">Swedish Orphan Biovitrum AB</Company></CompaniesPrimary><CompaniesSecondary><Company id="1005215">Affibody AB</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1005215" type="Company"><TargetEntity id="5035524419" type="organizationId">Affibody Medical AB</TargetEntity></SourceEntity><SourceEntity id="28921" type="Company"><TargetEntity id="4295889856" type="organizationId">Swedish Orphan Biovitrum AB (publ)</TargetEntity></SourceEntity><SourceEntity id="185" type="ciIndication"><TargetEntity id="10021428" type="MEDDRA"/><TargetEntity id="D007154" type="MeSH"/><TargetEntity id="-155407498" type="omicsDisease"/><TargetEntity id="1128" type="siCondition"/></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="12479" type="Action"><TargetEntity id="873" type="Mechanism">IL-1beta Inhibitors</TargetEntity><TargetEntity id="1559" type="Mechanism">Anti-IL-1beta</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-03143" type="ciTarget"><TargetEntity id="22280137135533" type="siTarget">Interleukin-1 beta</TargetEntity><TargetEntity id="391" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><IndicationsPrimary><Indication id="185">Immune disorder</Indication><Indication id="188">Inflammatory disease</Indication></IndicationsPrimary><ActionsPrimary><Action id="12479">Interleukin-1 beta ligand inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2016-08-24T06:53:15.000Z</LastModificationDate><ChangeDateLast>2016-08-31T00:00:00.000Z</ChangeDateLast><AddedDate>2012-07-10T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28921" linkType="Company"&gt;Swedish Orphan Biovitrum&lt;/ulink&gt; (Sobi), under license from &lt;ulink linkID="1005215" linkType="Company"&gt;Affibody&lt;/ulink&gt;, is investigating a program of IL-1 beta inhibitors, for the potential treatment of immune and inflammatory diseases [&lt;ulink linkID="1307216" linkType="Reference"&gt;1307216&lt;/ulink&gt;], [&lt;ulink linkID="1471582" linkType="Reference"&gt;1471582&lt;/ulink&gt;], [&lt;ulink linkID="1754584" linkType="Reference"&gt;1754584&lt;/ulink&gt;]. By July 2012, the program had been  in lead optimization  [&lt;ulink linkID="1307216" linkType="Reference"&gt;1307216&lt;/ulink&gt;], [&lt;ulink linkID="1307325" linkType="Reference"&gt;1307325&lt;/ulink&gt;]. In September 2013, the program was listed as being in preclinical research [&lt;ulink linkID="1471893" linkType="Reference"&gt;1471893&lt;/ulink&gt;]; in May 2015, the program was listed as being in preclinical development [&lt;ulink linkID="1656226" linkType="Reference"&gt;1656226&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="185">Immune disorder</Indication><StatusDate>2012-07-10T00:00:00.000Z</StatusDate><Source id="1307216" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28921">Swedish Orphan Biovitrum AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2012-07-10T00:00:00.000Z</StatusDate><Source id="1307216" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005215">Affibody AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2016-04-22T00:00:00.000Z</StatusDate><Source id="1754584" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005215">Affibody AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="185">Immune disorder</Indication><StatusDate>2016-04-22T00:00:00.000Z</StatusDate><Source id="1754584" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1005215">Affibody AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><StatusDate>2012-07-10T00:00:00.000Z</StatusDate><Source id="1307216" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1005215">Affibody AB</Company><Country id="SE">Sweden</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="185">Immune disorder</Indication><StatusDate>2012-07-10T00:00:00.000Z</StatusDate><Source id="1307216" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-03143"><Name>Interleukin-1 beta ligand</Name><SwissprotNumbers><Swissprot>P01584</Swissprot><Swissprot>P09428</Swissprot><Swissprot>P10749</Swissprot><Swissprot>P14628</Swissprot><Swissprot>P21621</Swissprot><Swissprot>P26889</Swissprot><Swissprot>P41687</Swissprot><Swissprot>P46648</Swissprot><Swissprot>P48090</Swissprot><Swissprot>P51493</Swissprot><Swissprot>P51745</Swissprot><Swissprot>P79162</Swissprot><Swissprot>P79182</Swissprot><Swissprot>Q28292</Swissprot><Swissprot>Q28386</Swissprot><Swissprot>Q63264</Swissprot><Swissprot>Q6R2X3</Swissprot><Swissprot>Q865X8</Swissprot><Swissprot>Q8WNR2</Swissprot><Swissprot>Q9WVG1</Swissprot><Swissprot>Q9XS77</Swissprot><Swissprot>Q9YGD3</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1790501" linkType="reference" linkID="1790501"&gt;1790501&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1005215">Affibody AB</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28921">Swedish Orphan Biovitrum AB</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="121873" title="Biovitrum to use Affibody technology to develop therapeutics for inflammatory and autoimmune diseases  "/></Deals><hasSWOTs>N</hasSWOTs></Drug><Drug id="79982"><DrugName>darbepoetin alfa follow-on biologic, Zenotech</DrugName><DrugNamesKey><Name id="42758175">darbepoetin alfa</Name></DrugNamesKey><DrugSynonyms><Name><Value>darbepoetin alfa</Value><Types><Type>INN</Type></Types></Name><Name><Value>darbepoetin alfa follow-on biologic, Zenotech</Value></Name></DrugSynonyms><CompanyOriginator id="1021416">Zenotech Laboratories Ltd</CompanyOriginator><CompaniesSecondary><Company id="1021416">Zenotech Laboratories Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1021416" type="Company"><TargetEntity id="4295874017" type="organizationId">Zenotech Laboratories Ltd</TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"/><TargetEntity id="D000740" type="MeSH"/><TargetEntity id="-201701473" type="omicsDisease"/><TargetEntity id="988" type="siCondition"/></SourceEntity><SourceEntity id="2501" type="Action"><TargetEntity id="2583" type="Mechanism">Erythropoietin Receptor (EpoR) Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00688" type="ciTarget"><TargetEntity id="50345408320573" type="siTarget">Erythropoietin receptor</TargetEntity><TargetEntity id="246" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-03045" type="ciTarget"><TargetEntity id="92553377420563" type="siTarget">Erythropoietin</TargetEntity><TargetEntity id="245" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="17">Anemia</Indication></IndicationsSecondary><ActionsPrimary><Action id="12162">Erythropoietin ligand</Action><Action id="2501">Erythropoietin receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="610">Hematopoietic stimulator</Action></ActionsSecondary><Technologies><Technology id="74">Glycoprotein</Technology><Technology id="85">Protein recombinant</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="961">Follow on biological product</Technology></Technologies><LastModificationDate>2012-08-14T06:07:05.000Z</LastModificationDate><ChangeDateLast>2012-11-06T00:00:00.000Z</ChangeDateLast><AddedDate>2012-08-10T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1021416"&gt;Zenotech&lt;/ulink&gt; was investigating a follow-on biologic version of   &lt;ulink linkType="Drug" linkID="7413"&gt;darbepoetin alfa&lt;/ulink&gt;, for the potential treatment of anemia related to chronic renal failure [&lt;ulink linkType="Reference" linkID="1313300"&gt;1313300&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1312731"&gt;1312731&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By March 2008, the drug was entering toxicity studies [&lt;ulink linkType="Reference" linkID="1313300"&gt;1313300&lt;/ulink&gt;].&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1021416">Zenotech Laboratories Ltd</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2012-08-10T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1021416">Zenotech Laboratories Ltd</Company><Country id="IN">India</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2008-03-31T00:00:00.000Z</StatusDate><Source id="1313300" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00688"><Name>Erythropoietin receptor</Name><SwissprotNumbers><Swissprot>P14753</Swissprot><Swissprot>P19235</Swissprot><Swissprot>Q07303</Swissprot><Swissprot>Q9MYZ9</Swissprot></SwissprotNumbers></Target><Target id="PTGT-03045"><Name>Erythropoietin ligand</Name><SwissprotNumbers><Swissprot>P01588</Swissprot><Swissprot>P07321</Swissprot><Swissprot>P07865</Swissprot><Swissprot>P29676</Swissprot><Swissprot>P33707</Swissprot><Swissprot>P33708</Swissprot><Swissprot>P33709</Swissprot><Swissprot>P48617</Swissprot><Swissprot>P49157</Swissprot><Swissprot>Q28513</Swissprot><Swissprot>Q867B1</Swissprot><Swissprot>Q9GKA2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="81420"><DrugName>lenaldekar</DrugName><DrugSynonyms><Name><Value>lenaldekar</Value></Name></DrugSynonyms><CompanyOriginator id="20690">University of Utah</CompanyOriginator><CompaniesSecondary><Company id="20690">University of Utah</Company></CompaniesSecondary><CrossReferences><SourceEntity id="20690" type="Company"><TargetEntity id="4296025726" type="organizationId">University of Utah</TargetEntity></SourceEntity><SourceEntity id="199" type="ciIndication"><TargetEntity id="10024288" type="MEDDRA"/><TargetEntity id="D007938" type="MeSH"/><TargetEntity id="-609576380" type="omicsDisease"/><TargetEntity id="683" type="siCondition"/></SourceEntity><SourceEntity id="36" type="ciIndication"><TargetEntity id="10061664" type="MEDDRA"/><TargetEntity id="D001327" type="MeSH"/><TargetEntity id="-2072222280" type="omicsDisease"/><TargetEntity id="729" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="199">Leukemia</Indication><Indication id="36">Autoimmune disease</Indication></IndicationsSecondary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1596">Immunomodulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2014-10-22T11:35:53.000Z</LastModificationDate><ChangeDateLast>2014-10-22T00:00:00.000Z</ChangeDateLast><AddedDate>2012-10-12T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;The &lt;ulink linkType="Company" linkID="20690"&gt;University of Utah&lt;/ulink&gt; was investigating lenaldekar for the potential treatment of diseases associated with T-cell expansion, including T-cell-mediated autoimmune diseases and    leukemia[&lt;ulink linkType="Reference" linkID="1331218"&gt;1331218&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1331222"&gt;1331222&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2012, preclinical data published showed that lenaldekar selectively affected the survival of malignant hematopoietic cell lines and primary human leukemia cells, including therapy-refractory B-cell acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia samples, without causing major toxicity to other cell types, and inhibited the growth of human T-cell ALL xenografts [&lt;ulink linkType="Reference" linkID="1278470"&gt;1278470&lt;/ulink&gt;],  [&lt;ulink linkType="Reference" linkID="1331226"&gt;1331226&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1331222"&gt;1331222&lt;/ulink&gt;]. In October 2012, similar preclinical data were presented at CHI's Third Annual Advances in Targeting the PI3K Pathway Meeting, Boston, MA [&lt;ulink linkType="Reference" linkID="1330517"&gt;1330517&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, preclinical data were published  showing that lenaldekar was identified as an inhibitor of immature T-cell expansion in a zebrafish screen. In an experimental autoimmune encephalomyelitis model, the worsening of multiple sclerosis symptoms were prevented in lenaldekar-treated animals [&lt;ulink linkType="Reference" linkID="1331218"&gt;1331218&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20690">University of Utah</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate>2014-10-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20690">University of Utah</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>2014-10-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20690">University of Utah</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="36">Autoimmune disease</Indication><StatusDate>2012-01-14T00:00:00.000Z</StatusDate><Source id="1331218" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20690">University of Utah</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="199">Leukemia</Indication><StatusDate>2012-04-09T00:00:00.000Z</StatusDate><Source id="1278470" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="84411"><DrugName>human interferon inducible protein 10 (angiogenesis related diseases), NCI</DrugName><DrugSynonyms><Name><Value>human interferon inducible protein 10 (angiogenesis related diseases), NCI</Value></Name></DrugSynonyms><CompanyOriginator id="20519">National Cancer Institute</CompanyOriginator><CompaniesSecondary><Company id="20518">National Institutes of Health</Company><Company id="20519">National Cancer Institute</Company></CompaniesSecondary><CrossReferences><SourceEntity id="20518" type="Company"><TargetEntity id="5001347606" type="organizationId">National Institutes of Health</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="422" type="ciIndication"><TargetEntity id="D009389" type="MeSH"/></SourceEntity><SourceEntity id="24261" type="Action"><TargetEntity id="6898" type="Mechanism">Drugs Acting on C-X-C Motif Chemokine 10 (CXCL10)</TargetEntity></SourceEntity><SourceEntity id="PTGT-05151" type="ciTarget"><TargetEntity id="130748275936273" type="siTarget">C-X-C motif chemokine 10</TargetEntity><TargetEntity id="-2038694811" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="422">Angiogenesis disorder</Indication></IndicationsSecondary><ActionsPrimary><Action id="24261">CXC10 chemokine ligand modulator</Action></ActionsPrimary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="766">Parenteral formulation unspecified</Technology></Technologies><LastModificationDate>2015-09-25T13:30:37.000Z</LastModificationDate><ChangeDateLast>2015-09-29T00:00:00.000Z</ChangeDateLast><AddedDate>2013-04-10T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="20519"&gt;National Cancer Institute&lt;/ulink&gt; is investigating human interferon inducible protein 10 (IP-10; CXCL-10), for the potential treatment of angiogenesisrelated diseases including arthritis, psoriasis, hemangiomas, diabetic retinopathy, and retrolental fibroplasia. In April 1996, development was ongoing; in March 2013, this was still the case. In April 1996, the NCI was seeking to outlicense rights to the program through &lt;ulink linkType="Company" linkID="20518"&gt;National Institutes of Health Office of Technology Transfer&lt;/ulink&gt;; in March 2013, this was still the case [&lt;ulink linkType="Reference" linkID="1395222"&gt;1395222&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="422">Angiogenesis disorder</Indication><StatusDate>2015-09-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="422">Angiogenesis disorder</Indication><StatusDate>2015-09-25T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20519">National Cancer Institute</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="422">Angiogenesis disorder</Indication><StatusDate>1996-04-30T00:00:00.000Z</StatusDate><Source id="1395222" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20518">National Institutes of Health</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="422">Angiogenesis disorder</Indication><StatusDate>1996-04-30T00:00:00.000Z</StatusDate><Source id="1395222" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-05151"><Name>CXC10 chemokine ligand</Name><SwissprotNumbers><Swissprot>P02778</Swissprot><Swissprot>P17515</Swissprot><Swissprot>P48973</Swissprot><Swissprot>Q5KSV9</Swissprot><Swissprot>Q865F5</Swissprot><Swissprot>Q8MIZ1</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="9244"><DrugName>TEI-4463</DrugName><DrugSynonyms><Name><Value>TEI-4463</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20331">Teijin Ltd</CompanyOriginator><CompaniesSecondary><Company id="20331">Teijin Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="9244" type="Drug"><TargetEntity id="212517" type="siDrug">TEI-4463</TargetEntity></SourceEntity><SourceEntity id="20331" type="Company"><TargetEntity id="4295877394" type="organizationId">Teijin Ltd</TargetEntity></SourceEntity><SourceEntity id="711" type="ciIndication"><TargetEntity id="J98.9" type="ICD10"/><TargetEntity id="10038683" type="MEDDRA"/><TargetEntity id="D012140" type="MeSH"/><TargetEntity id="-2143937119" type="omicsDisease"/><TargetEntity id="269" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="711">Respiratory disease</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action><Action id="646">Bronchodilator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2000-04-07T13:07:14.000Z</LastModificationDate><ChangeDateLast>2000-04-07T13:07:14.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="9244"&gt;TEI-4463&lt;/ulink&gt;, an antihypoxemic compound, was under investigation by Teijin for the potential treatment of hypoxic pulmonary vasoconstriction and respiratory disease [&lt;ulink linkType="reference" linkID="161181"&gt;161181&lt;/ulink&gt;]; however, no development has been reported since 1994.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="711">Respiratory disease</Indication><StatusDate>2000-04-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="711">Respiratory disease</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="9256"><DrugName>Mer-W8020</DrugName><DrugSynonyms><Name><Value>Mer-W8020</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="18076">Mercian Corp</CompanyOriginator><CompaniesSecondary><Company id="18076">Mercian Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="9256" type="Drug"><TargetEntity id="212544" type="siDrug">Mer-W8020</TargetEntity></SourceEntity><SourceEntity id="18076" type="Company"><TargetEntity id="4295877910" type="organizationId">Mercian Corp</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"/><TargetEntity id="D001172" type="MeSH"/><TargetEntity id="-1391695545" type="omicsDisease"/><TargetEntity id="749" type="siCondition"/></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="188">Inflammatory disease</Indication><Indication id="291">Rheumatoid arthritis</Indication></IndicationsSecondary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2002-05-29T11:21:31.000Z</LastModificationDate><ChangeDateLast>2002-05-29T11:21:31.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Drug" linkID="9256"&gt;Mer-W8020&lt;/ulink&gt; is an anti-inflammatory compound that was in development by Mercian for the treatment of rheumatoid arthritis [&lt;ulink linkType="reference" linkID="170241"&gt;170241&lt;/ulink&gt;]. However, no development has been reported since 1994.&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="18076">Mercian Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="170241" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18076">Mercian Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><Source id="170241" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="18076">Mercian Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><Source id="170241" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18076">Mercian Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="188">Inflammatory disease</Indication><Source id="170241" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="93773"><DrugName>incrementally modified drug (mental disorder), Handok</DrugName><DrugSynonyms><Name><Value>incrementally modified drug (mental disorder), Handok</Value></Name></DrugSynonyms><CompanyOriginator id="19986">Handok Inc</CompanyOriginator><CompaniesSecondary><Company id="19986">Handok Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="19986" type="Company"><TargetEntity id="4295881029" type="organizationId">Handok Inc</TargetEntity></SourceEntity><SourceEntity id="207" type="ciIndication"><TargetEntity id="10061284" type="MEDDRA"/><TargetEntity id="D001523" type="MeSH"/><TargetEntity id="-1461364818" type="omicsDisease"/><TargetEntity id="29" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="207">Psychiatric disorder</Indication></IndicationsSecondary><ActionsSecondary><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2018-02-16T06:56:34.000Z</LastModificationDate><ChangeDateLast>2018-02-16T00:00:00.000Z</ChangeDateLast><AddedDate>2014-11-25T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="19986" linkType="Company"&gt;Handok&lt;/ulink&gt; was investigating an undisclosed incrementally modified drug, for the potential treatment of mental disorders [&lt;ulink linkID="1614229" linkType="Reference"&gt;1614229&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="19986">Handok Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="207">Psychiatric disorder</Indication><StatusDate>2018-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="19986">Handok Inc</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="207">Psychiatric disorder</Indication><StatusDate>2014-11-05T00:00:00.000Z</StatusDate><Source id="1614229" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1614229" linkType="reference" linkID="1614229"&gt;1614229&lt;/ulink&gt;]							</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug><Drug id="96253"><DrugName>cancer immunotherapy, Apellis</DrugName><DrugSynonyms><Name><Value>cancer immunotherapy, Apellis</Value></Name></DrugSynonyms><CompanyOriginator id="1063900">Apellis Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="1063900">Apellis Pharmaceuticals Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1063900" type="Company"><TargetEntity id="5000744891" type="organizationId">Apellis Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="1596">Immunomodulator</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-02-05T17:34:49.000Z</LastModificationDate><ChangeDateLast>2019-02-06T00:00:00.000Z</ChangeDateLast><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1063900" linkType="Company"&gt;Apellis Pharmaceuticals&lt;/ulink&gt; was investigating an immunotherapy for the potential treatment of cancer [&lt;ulink linkID="1647304" linkType="Reference"&gt;1647304&lt;/ulink&gt;], [&lt;ulink linkID="1617161" linkType="Reference"&gt;1617161&lt;/ulink&gt;]. In April 2015, the  drug was listed as being in preclinical development [&lt;ulink linkID="1647304" linkType="Reference"&gt;1647304&lt;/ulink&gt;]. In May 2016, this was still the case [&lt;ulink linkID="1768175" linkType="Reference"&gt;1768175&lt;/ulink&gt;]. However by January 2019, the drug was no longer listed on the company's pipeline [&lt;ulink linkID="2116920" linkType="Reference"&gt;2116920&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1063900">Apellis Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2019-01-22T00:00:00.000Z</StatusDate><Source id="2116920" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1063900">Apellis Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2014-12-02T00:00:00.000Z</StatusDate><Source id="1617161" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=1768175" linkType="reference" linkID="1768175"&gt;1768175&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>